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ABSTRACT 
 
Background:  Misuse of drugs is a public health problem which can lead to poor 
health outcomes.  Drug use during pregnancy could potentially harm the unborn 
baby.  Pregnancy usually triggers women to visit their general practitioner (GP) 
which may provide an opportunity for drug use to be raised and recorded.  To 
date, there are no UK studies with large sample sizes to estimate the burden of 
drug use during pregnancy.  Therefore, my aim was to describe and understand 
drug use and opioid substitution treatment in and around pregnancy using 
electronic health records.   
Methods:  Using a mixed methods design, I firstly, utilized The Health 
Improvement Network (THIN) to estimate GP recording rates of individuals who 
use drugs and/or are prescribed opioid substitution treatment in the general 
population, of women in and around pregnancy and infants with neonatal 
abstinence syndrome (NAS).  Next, I compared rates with national surveys and 
hospital birth data.  Finally, I conducted qualitative interviews to gain GPs’ 
perspectives regarding their decisions about recording drug-use.  
Results:  GP recording trends for the general population were in keeping with 
national surveys, but with lower rates.  Recording was relatively low in and 
around pregnancy.  GP recording of NAS was similar to hospital data, however 
rates were lower.  Finally, qualitative interview analysis identified that influences 
on recording drug use were complex and related to pressures at the individual as 
well as organisational (general practices, Clinical Commissioning Groups) and 
governmental levels in the shape of government policies.   
Conclusion:  In conclusion, evidence from the thesis supports the use of THIN 
as a suitable tool for monitoring trends but not rates of problem drug use in the 
general population.  Electronic primary health records could potentially be used to 
monitor the impact of problematic drug use in and around pregnancy.  The thesis 
also supports utilising THIN for researching drug use and opioid substitution 
treatment in the general population. 
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 INTRODUCTION AND LITERATURE 
REVIEW 
1.1 Content and Structure of Chapter 1 
In this chapter, I firstly present an overview of the thesis, followed by the 
background of the dissertation which is based on previous literature and policy 
documents.  The chapter ends with a review of literature that has previously 
explored recording of drug use and opioid substitution treatment in electronic 
health records and drug use during pregnancy. 
 
1.2 Overview of Thesis 
The main focus of the PhD was to explore the level of burden of drug use in and 
around pregnancy in England and Wales by examining General Practitioner (GP) 
recording of drug use and opioid substitution treatment in individuals’ electronic 
health records.  The two main research questions of the thesis were to establish 
if a primary care database could be used as i) a surveillance and ii) a research 
tool for drug use and opioid substitution treatment in and around pregnancy.  In 
order to increase my understanding of pregnant women who use drugs and/or 
opioid substitution treatment, I first examined electronic health records of the 
general population and subsequently focused on women in and around 
pregnancy and infants with neonatal abstinence syndrome (a symptom of 
maternal drug use).  I used a mixed methods approach to answer the research 
questions, consequently the first three studies are quantitative and the fourth 
qualitative.   
 
The thesis comprises of nine chapters, which all begin with the content and 
structure of each chapter and conclude with how the chapter supports the thesis.  
The first chapter begins with descriptions and definitions of drug use, opioid 
substitution treatment and recording in electronic health records.  I then evaluate 
the burden of drug use globally and describe the history of drug policy in the UK.  
After which, I review previous literature examining recording of drug use and 
opioid substitution treatment in primary care and conclude this chapter with the 
rationale for undertaking my PhD.  In the second chapter I describe the overall 
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aim, objectives and research questions of the thesis, followed by short 
summaries of chapters 3-8.  The third chapter includes a description of the two 
large databases that I used for my epidemiological studies (The Health 
Improvement Network (used in studies 1-3) and Hospital Episode Statistics (used 
in study 3)) and I discuss qualitative methodologies (used in study 4).  The fourth 
chapter covers the first quantitative study in which I focus on GP recording of 
those in the general population who use drugs and/or opioid substitution 
treatment.  This leads onto the fifth chapter, which examines women identified in 
chapter 4 who are also pregnant.  The focus of this chapter is on GP recording of 
women who use drugs and/or opioid substitution treatment in and around 
pregnancy.  Following this, chapter six presents the third and final quantitative 
study, which concentrates on GP recording of neonatal abstinence syndrome in 
infants.  The seventh chapter describes the analysis and findings of the 
qualitative study in which I interviewed GPs to gain a deeper understanding of 
factors that influence recording of drugs use and/or opioid substitution treatment 
in electronic health records.  The penultimate chapter synthesises the results 
from both the quantitative and qualitative studies.  Finally, in the last chapter, I 
present and overview of the thesis and discuss how the thesis brings new 
knowledge and improves method, I discuss the reason for choosing the Crime 
Survey for England and Wales over the Offending Crime and Justice Survey, I 
present the overarching strengths and limitations, support the argument for the 
thesis, discuss the contribution of the thesis to the field of research, the clinical 
and research implications and the overall conclusion of the thesis.  
1.3 Background 
1.3.1 Classification of controlled drugs in the United Kingdom 
A drug is defined as controlled if it has the potential for abuse or addiction 
(Drugscope, 2015a).  This can include both illicit drugs and prescribed 
medications under the United Kingdom Misuse of drugs Act, passed in 1971 (see 
section 1.3.8 for details) (Drugscope, 2015a).  There are four categories of 
controlled drugs; sedatives, stimulants, opioids and hallucinogens which are 
categorised into classes and schedules (Home office, 2013).  Penalties for 
production, supply and possession are highest for Class A drugs and lowest for 
Class C drugs (Table 1.1) (Drugscope, 2015a; Home office, 2013).  Each drug is 
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also classified into a schedule, which relates to the control of supply of the drug 
(Drugscope, 2015a; Home office, 2013).  Schedule 1 is the most rigorous and 
these drugs can only be administered under exceptional circumstances with a 
license from the home office (Drugscope, 2015a; Home office, 2013).  Whilst 
schedule 5 can be bought over the counter but the drug has to be supplied by a 
pharmacist (Table 1.1) (Drugscope, 2015a; Home office, 2013).  
Table 1.1: Classes and schedules of the most common drugs used in the United 
Kingdom (Drugscope, 2015a; Home office, 2013) 
Drug Class Schedule Type 
Amphetamine  A 2 Stimulant 
Benzodiazepine C 3/4 Sedative 
Buprenorphine C 3 Opiate 
Cannabis B 1 Sedative 
Cocaine/ Crack cocaine A 2 Stimulant 
Ecstasy/MDMA* A 1 Stimulant 
Heroin A 2 Opiate 
Lysergic Acid 
Diethylamide/LSD 
A 1 Hallucinogenic 
Methadone C 2 Opiate 
*MDMA=methylenedioxy methamphetamine 
1.3.2 Definitions of individuals who use drugs 
In the next section, I define drug dependence, addiction, recreational drug use, 
problematic drug use, substance use disorder, people who use drugs and 
diagnosis of substance misuse disorder 
 
1.3.2.1 Drug dependence 
Drug dependence is defined as a physical dependence to a drug (National 
Institute of Drug Abuse, 2015).  An individual adapts to the drug both 
physiologically and psychologically leading to them developing a tolerance to the 
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drug (National Institute of Drug Abuse, 2015).  Consequently, if the same 
individual stops taking the drug, withdrawal symptoms can occur (National 
Institute of Drug Abuse, 2015).  A person is not necessarily addicted to a drug if 
they are physically dependant, however, a person who is addicted, is usually 
physically dependant on the drug (National Institute of Drug Abuse, 2015). 
 
1.3.2.2 Drug addiction 
Drug addiction is defined as a condition where an individual develops a 
compulsive craving for the pleasurable effects induced by a specific drug 
(National Institute of Drug Abuse, 2015).  This harmful behaviour can interfere 
with normal life responsibilities, and despite the negative consequences of the 
behaviour, the individual continues to take the drug (National Institute of Drug 
Abuse, 2015).   
 
1.3.2.3 Recreational drug use 
Recreational drug use is when an individual uses a drug to alter their state of 
consciousness rather than for medical reasons (Drugscope, 2015b).  The 
individual uses the drug occasionally and usually perceives that the drug is not 
addictive (Drugscope, 2015b).  However, recreational drug use can lead to 
problem drug use (Drugscope, 2015b). 
 
1.3.2.4 Problem drug use 
Problem drug use can arise in those individuals who become dependent on or 
addicted to the recreational drug (Drugscope, 2015c).  Drugs induce different 
effects on the user and these effects are seen as more problematic than how 
often the drug is used (Drugscope, 2015c).  Consequences of problematic drug 
use can include difficulties with relationships, financial and legal problems and 
imbalance with physical and mental health (Drugscope, 2015c). 
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An individual can seek specific treatment (see sections 1.3.3 for details) for 
problem drug use.  However, both recreational drug users and problem drug 
users may also seek help for other symptoms and co-morbidities occurring due to 
the drug use. 
 
1.3.2.5  People who use drugs  
People who use drugs are defined as individuals who use illegal drugs , other 
“club-drugs” or abuse prescription drugs (National Institute of Drug Abuse, 2014).  
It is difficult to distinguish between recreational and problem drug users when 
looking at primary care records and I will therefore be using the term, ‘people 
who use drugs’ (see section 1.3.2.5 for details) when describing the individuals 
who have a recording for any illicit drug use, controlled drug dependence and 
“opioid substitution treatment” if they have a prescription or Read code for 
treatment.   
 
1.3.2.6 Clinical diagnosis of Substance Use Disorder 
The Diagnostic and Statistical Manual for Mental disorders (DSM) is available for 
clinicians to diagnose and classify mental disorders (American Psychiatric 
Association, 2013).  The DSM-V was published, in April 2013 and changes were 
made to the Substance-Related and Addictive Disorders chapter (See Appendix 
1) (American Psychiatric Association, 2013).  One of the main changes was that 
the chapter in the DSM-IV was divided into two parts; “substance abuse” and 
“substance dependence” (American Psychiatric Association, 2013).  Whereas, 
the DSM-V has incorporated these two and relabelled them “substance use 
disorder” (American Psychiatric Association, 2013).  Another of the main changes 
was that in the DSM-V, an individual had to have a threshold of at least two 
criteria to be diagnosed with “substance use disorder” as opposed to at least one 
and two criteria for “substance abuse” and “substance dependence” respectively 
in the DSM-IV.  The criteria for diagnosis are laid out in Table 1.2. 
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Table 1.2: DSM-V Substance use disorder chapter (American Psychiatric Association, 
2013)  
DSM-V- Substance use disorders (2 or more criteria in the last year)  
Impaired control over substance use (1-4) 
A. the individual may take the substance in larger amounts or over a longer period than was originally 
intended 
B. the individual may express a persistent desire to cut down or regulate substance use and may 
report multiple unsuccessful efforts to decrease or discontinue use 
C. the individual may spend a great deal of time obtaining the substance, using the substance, or 
recovering from its effects 
D. craving, or a strong desire or urge to use the substance  
Social impairment (5-8) 
E. recurrent substance use may result in a failure to fulfil major role obligations at work, school, or 
home. 
F. the individual may continue substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the substance 
G. important social, occupational, or recreational activities may be given up or reduced because of 
substance use.  The individual may withdraw from family activities and hobbies in order to use the 
substance 
H. this may take the form of recurrent substance use in situations in which it is physically hazardous 
Risky use of the substance (8-9) 
I. the individual may continue substance use despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or exacerbated by the 
substance 
Pharmacological grouping (10-11) 
J. tolerance, as defined by either of the following: 
a) a need for markedly increased dose of the substance to achieve the desired effect or a markedly 
reduced effect when the usual dose is consumed.  
b) a markedly diminished effect with continued use of the same dose of the substance 
K. withdrawal 
a) characteristic withdrawal syndrome for the substance 
b) the substance is taken to relieve or avoid withdrawal symptoms 
 
There are different sections for each type of drug in the DSM-V, and the same 11 
criteria seen in Table 1.2 are included in each of these sections (American 
Psychiatric Association, 2013).  The DSM-V is used to ascertain if individuals 
have certain criteria to be formally diagnosed.  I will be examining all records 
between 1994-2012 in the first study (Chapter 4) and I will therefore incorporate 
diagnoses from both the DSM-IV and DSM-V when looking for possible Read 
codes that GPs could be using to record drug use in electronic health records. 
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GPs may however not always adhere to the detail of the DSM-V diagnoses.  For 
example Rait et al found that GPs increasingly record a mixture of symptoms and 
definitions for depression rather than a formal diagnosis in electronic health 
records (Rait et al., 2009).  I therefore need to also include Read codes other 
than formal DSM diagnoses when examining electronic health records for drug 
use. 
 
If an individual in the UK is diagnosed with one of the following; “substance 
dependence”, “substance abuse” or “substance use disorder”; various treatments 
should be offered to the individual from either a general practice, a hospital 
inpatient setting or a community drug clinic.  I will discuss the treatments 
available in the next section. 
  
1.3.3 Treatments available in the UK 
In this section I describe the different treatments available for both opioid and 
non-opioid dependence available in the UK 
 
1.3.3.1 Treatments for problematic opioid use in the UK (see Appendix 2 for 
details of dose and cost of different treatments) 
The National Institute for Health and Care Excellence (NICE), the Royal College 
of General Practitioners (RCGP) and the British Association for 
Psychopharmacology have published guidelines for pharmaceutical treatment for 
problematic opioid use (Lingford-Hughes et al., 2012; National Institute for 
Clinical Excellence, 2010a; Royal College of General Practitioners, 2011).  Both 
methadone and buprenorphine are synthetic opioid derivatives and are the first 
line treatment for opioid addiction in the UK (Lingford-Hughes et al., 2012; 
National Institute for Clinical Excellence, 2010a; Royal College of General 
Practitioners, 2011). 
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Opioids produce pain relief and mood enhancing effects (Al-Hasani and Bruchas, 
2011).  Four opioid receptors are widely dispersed in the brain, spinal cord and 
digestive tract (Al-Hasani and Bruchas, 2011).  These receptors are classified 
into four subtypes; delta (δ), kappa (κ), mu (µ) an opioid receptor like-1 (ORL 1) 
(Al-Hasani and Bruchas, 2011).  Methadone is a full opioid agonist and it 
produces its effects until either it fills and activates all the µ opioid receptors 
(located on nerve synapses) or reaches its maximum effect and therefore 
induces a heightened state through the same mechanism as illicit opioids 
(Whelan and Remski, 2012).  Methadone comes in various forms and it is up to 
the GP which form to prescribe (Ford et al., 2013; National Institute for Clinical 
Excellence, 2010a).  Oral liquid methadone is most commonly prescribed, 
however injectable forms of methadone are also licenced for treatment (Ford et 
al., 2013; National Institute for Clinical Excellence, 2010a).  Methadone alleviates 
cravings, withdrawal symptoms and blocks other opioids from entering the µ 
opioid receptors (Whelan and Remski, 2012). 
 
Buprenorphine (Subutex®) was licensed in the UK in 1999 (Ford et al., 2013).  It 
has both agonist and antagonist properties (Rothman et al., 2000).  Its main 
effects are acting as a partial µ opioid receptor agonist and a κ opioid receptor 
antagonist (Rothman et al., 2000).  It has a plateau effect which is reached at a 
moderate dose and increasing the dose should not increase the euphoric effect 
(Mégarbane et al., 2006; Rothman et al., 2000).  Buprenorphine is not as potent 
as methadone and it has fewer side effects such as withdrawal, addiction, 
respiratory distress and risk of overdose. (Mégarbane et al., 2006; Whelan and 
Remski, 2012).  However, buprenorphine does have a harmful interaction with 
benzodiazepine and other analgesics and it is more expensive than methadone 
(Appendix 2) (Whelan and Remski, 2012).  Buprenorphine is usually prescribed 
as a sublingual table for opioid substitution treatment (Ford et al., 2013). 
 
Naloxone is usually prescribed in combination with buprenorphine 
(Suboxone®1:4 ratio) (Ford et al., 2013).  Suboxone® was licensed in the UK in 
2007 and is also prescribed as a sublingual tablet (Ford et al., 2013).  Naloxone 
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reduces the opioid-effects if an individual tries to inject the buprenorphine rather 
than taking it as sub-lingual tablet (Ford et al., 2013).  There is evidence that 
patients can be safely changed from Subutex® to Suboxone® in a community 
setting (Bell et al., 2004; Daulouède et al., 2010).  Naloxone is also used in high 
doses for individuals who have taken an opioid-overdose (Ford et al., 2013). 
 
Naltrexone is an opioid antagonist which blocks opioid receptors (National 
Institute for Clinical Excellence, 2007a).  It is licensed to be used for 7-10 days 
after completion of detox from methadone or buprenorphine (National Institute for 
Clinical Excellence, 2007a).  It should be prescribed as oral tablets and should be 
combined with psychological support (Ford et al., 2013; National Institute for 
Clinical Excellence, 2007a).  
 
Lofexidine is a non-opioid alpha-adrenergic agonist (Ford et al., 2013).  It is rarely 
prescribed, however it can be used to manage opioid withdrawal and is usually 
prescribed to individuals who use smaller amounts of opioids (Gowing et al., 
1996).   
 
Dihydrocodeine is not licensed for opioid substitution treatment in the UK (Ford et 
al., 2013).  However, some GPs do prescribe it in tablet form for opioid 
dependence and there is some evidence indicating that it is as effective as 
methadone (Ford et al., 2013; Robertson et al., 2006).  It is shorter acting than 
methadone and therefore requires a higher dose (Ford et al., 2013).   
 
There is ongoing discussion as to which medication is the most effective for 
individuals requiring treatment, and it is recommended that treatment is usually 
selected on a case-by-case basis (Lingford-Hughes et al., 2012; Whelan and 
Remski, 2012).  As stated previously, GPs have recommended guidelines for 
prescribing opioid substitution treatment.  When GPs prescribe a drug for 
substance misuse, they record it as a drug code (prescription) in the individual’s 
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electronic health care record and should report it to the National Drug Treatment 
Monitoring System (Public Health England, 2013a).  However, some people who 
use drugs, but do not receive treatment or who have been referred for treatment 
elsewhere, may still have some notes in their electronic health records.  I will 
therefore be examining prescriptions and Read codes used by GPs for 
prescribing and recording opioid substitution treatment in the first study (Chapter 
4).   
 
1.3.3.2 Treatment for non-opioid drug dependence 
There are no pharmacological treatments for non-opioid substance misuse 
(Public Health England, 2015).  Patient-centred and evidence based 
psychosocial interventions, such as cognitive behavioural therapy are not 
commonly available at GP practices, but are available in some other NHS and 
voluntary services (National Institute for Clinical Excellence, 2007b).  Day and 
residential rehabilitation treatment centres are available and charities and non-
profit organizations (such as Cocaine and Narcotics Anonymous) offer informal 
treatment which have been recommended for recovery (Drugscope, 2015d; 
Public Health England, 2015).  GPs can directly refer or guide individuals to self-
refer to the appropriate treatment (Drugscope, 2015d; Public Health England, 
2015).  Unlike pharmacological treatment, it is not mandatory to record non-
pharmacological treatment in a patient’s electronic health record, nor is it 
mandatory to report the treatment to the National Drug Treatment Monitoring 
Agency (Public Health England, 2013a).  I will however include referrals for drug 
use in the electronic health records in the first study (Chapter 4).  
 
1.3.4 Health records in general practice 
In this section I will describe health records and focus on electronic health 
records used in the UK 
 
1.3.4.1 Electronic Health records 
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Health records play an important role in documenting an individual’s clinical 
information (National Archives, 2015; Royal College of General Practitioners 
Informatics Group, 2009).  There has been a staggered transition from paper 
records to electronic records in the UK (Freeman and Hughes, 2010).  Electronic 
health records can contribute to a longitudinal view and help with continuous care 
of the individual, especially if the individual is not always seeing the same GP 
(Freeman and Hughes, 2010).  The benefits of good record-keeping in general 
practice are summarised by the Department of Health’s good practice guidelines 
for electronic patient records (Royal College of General Practitioners, 2011b).   
 “The primary purpose of the GP record is to aid the clinical care of individual patients by: 
assisting the health professional to structure their thoughts and make appropriate 
decisions; acting as an aide memoir during subsequent consultations; making 
information available to others with access to the record system who are involved in the 
care of the same patient (including electronic transfer of records when the patient moves 
practice); providing information for inclusion in other documents (e.g. case conference 
reports or referrals); and storing information received from other parties or organisations 
(e.g. discharge letters from maternity services). The records can also assist in the clinical 
care of the practice population by facilitating needs assessments of the population; 
identifying target groups; and supporting audit and improvement need to put in own 
words.“ 
 
The primary purpose of the electronic health record is to support the care of the 
patient.  In order to achieve this, recommendations in the guidelines include the 
following: 
 All health professionals within the practice are responsible for ensuring 
complete, accurate and comprehensible record keeping. 
 All records should be recorded electronically and the use of paper records 
should be discontinued in order to avoid confusion of patient care. 
 Every clinical consultation with the patient should be recorded 
electronically. 
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 All prescriptions should be chronologically and correctly entered into the 
electronic records. 
 All practices should have agreed coding standards.  The general practices 
should agree as to which information is recorded in a systematic way, 
which codes or groups of codes are used to record and what is the best 
way to enter the data.  The recording standards will be based on priorities, 
practice populations, special interests within the practices and secondary 
use of the electronic records. 
 Practices are encouraged to use templates or recording protocols to 
standardise coding. 
 Practices should update and refine their recording policies and should be 
able to use the electronic records to review their own data or external 
analysis by large electronic database. 
Health professionals can utilize electronic health records to structure their 
thoughts and make suitable decisions in order to ensure patient-centred care 
(Freeman and Hughes, 2010).  The electronic health record can be shared 
amongst other health professionals who are involved in the same patient’s care 
and include other documentations such as discharge letters from the midwifery 
services (Freeman and Hughes, 2010).  Although the primary purpose of the 
record is for patient care, they have also been used for clinical audit, research, 
education, service planning and contract delivery (Royal College of General 
Practitioners, 2011b).   
 
Electronic health records are a more efficient way of sharing patient information 
compared to paper records (Royal College of General Practitioners Informatics 
Group, 2009).  There may be a number of GPs and allied health professionals 
involved in an individual’s care and the health records allow access to important 
information and continuity of care.  Electronic health records can therefore be 
accessed in order to monitor, assess and treat an individual appropriately 
(Medical Protection Society, 2015).  However, access to the health records can 
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sometimes be limited to the general practice and there may be variation within 
practices (Royal College of General Practitioners Informatics Group, 2009).  
Health records with removal of identities (such as name and address) can also be 
used for public health research, although patients can opt out of their records 
being used for research (Medical Protection Society, 2015; Royal College of 
General Practitioners Informatics Group, 2009).  Since 1990, an individual has 
the right to request access to their records (National Archives, 2015; Royal 
College of General Practitioners Informatics Group, 2009).  GPs can record 
medical symptoms, diagnoses, prescriptions, additional health records and 
referrals in the health records (Medical Protection Society, 2015).  GPs use drug 
codes for prescriptions and Read codes and/or free-text for symptoms, diagnoses 
and care pathways (Davé and Petersen, 2009).  I will describe these coding 
systems in more detail in the next section. 
 
1.3.5 Coding in general practice 
In this section, I will explain specific coding systems GPs use to record and 
document patient consultations.  
A classification and coding system is important for recording and retrieving 
information for individual patients, analysing data for audit and research and 
electronic communication of data between computers (Chisholm, 1990).  The first 
coding system used in the UK was Oxford Medical Information System codes 
(OXMIS codes) (Benson, 2011).  OXMIS was developed by Dr J Perry and was 
based on the international classification of diseases Eighth Revision (ICD-8) 
(Benson, 2011).  This coding system was used throughout the 1980s in general 
practice (Benson, 2011).  
 
Read codes were subsequently developed as a thesaurus of medical terms by 
James Read between 1981 to 1986 (Benson, 2011).  They are a hierarchical 
classification system mapped to the International Classification of Diseases Ninth 
Revision (ICD-9) (Benson, 2011; Chisholm, 1990; Davé and Petersen, 2009).  
Family, social and medical history, presenting medical symptoms, diagnoses, 
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additional health records, procedures referrals and administration (Benson, 2011; 
Chisholm, 1990; Davé and Petersen, 2009).  The NHS introduced the Read 
codes in 1990 and implemented them as standard coding practice (Benson, 
2011; Chisholm, 1990; Davé and Petersen, 2009).  Read codes were originally 
designed for general practice, but the NHS has extended to all areas of clinical 
practice (Benson, 2011; Chisholm, 1990; Davé and Petersen, 2009).  When a 
Read code is used, the code is flagged up on the computer screen when the 
individual’s record is opened (Davé and Petersen, 2009; Medical Protection 
Society, 2015).  GPs can also choose to use free-text when recording.  I will 
explain Read codes in more detail in section 3.4.1.  
 
Read codes are rarely used outside the UK, most other countries use the WHO 
International Classification of Primary Care (ICPC) (World Health Organisation, 
2003).  However, Chisholm argues that the Read code system is the most 
comprehensive coding system, as it also includes patient history, and occupation 
and social information (Chisholm, 1990). 
1.3.6 Primary Care Databases 
In this section, I will describe two of the primary care databases available in the 
UK; the General Practice Research Database (GPRD) and The Health 
Improvement Network (THIN).  The majority of the UK population is registered 
with a GP (Lis et al., 1995) (see section 3.4.2 for details).  General practices can 
choose to contribute electronic health records to different primary care 
databases.  GPRD became the Clinical Practice Research Datalink (CPRD) in 
March 2012 (Clinical Practice Research Datalink, 2013).  CPRD represents 
approximately 8% of the UK population and uses both OXMIS (restricted to older 
records) and Read codes (Clinical Practice Research Datalink, 2013).  Whilst 
THIN represents about 6% of the UK population and only uses Read codes (CSD 
health research, 2015; Davé and Petersen, 2009).  There is approximately an 
overlap of 60% of the general practices in both these primary care databases 
(CSD health research, 2015).  Since 2013, the UK government have encouraged 
research in academia to use patient electronic health records in the form of 
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primary care databases (Callaway, 2013).  I will describe THIN in more detail in 
section 3.4. 
I will now describe and discuss the problem of drug use worldwide and compare 
this to the problem in the UK. 
1.3.7 How big is the problem? 
Illicit drug use and misuse of controlled drugs is a public-health problem with 
potentially serious impacts on both mental (depression, anxiety, psychosis and 
personality disorder) and physical health (liver and lung damage, cardiovascular 
disease, muscular and skeletal problems and poor vein health) (Madgula et al., 
2011a; Public Health England, 2015).  In 2012, between approximately 162-324 
million people had used an illicit drug globally (United Nations Office on Drugs 
and Crime, 2014).  Approximately 20 million disability adjusted life years is due to 
illicit drug dependence (Degenhardt et al., 2013).  It is estimated that £2.50 could 
be saved in costs to society for every £1 invested in drug treatment (National 
Treatment Agency for Substance Misuse, 2012a).  The prevalence of illicit drug 
use and misuse of controlled drugs is greater in high income countries, but this 
may reflect low ascertainment of data in low income countries (United Nations 
Office on Drugs and Crime, 2014).  The UK, together with the USA, Russia and 
Australia had the highest rate of global disease burden due to illicit drug intake in 
2010 (Degenhardt et al., 2013).  The prevalence of illicit drug use in the UK is one 
of the highest in Europe with the UK also having the second highest number of 
illicit drug confiscations by police in Europe in 2012 (European Monitoring Centre 
for Drugs and Drug Addiction, 2014a).  Table 1.3 illustrates the percentage of the 
adult population who reported using drugs in England, Wales, Scotland and 
Northern Ireland between 2002/03 to 2011/12.  
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Table 1.3: Percentage of adults using drugs ever, in the last year and last month in 
England, Wales, Scotland and Northern Ireland 
 England and Wales* 
(Adults aged 16/59 
years) 
Scotland** (Adults 
aged 16/59 years) 
Northern Ireland*** 
(Adults aged 16/64 
years) 
% Adults 2002/03 2011/12 2004 2010/11 2002/03 2010/11 
Ever used a drug 35.6 36.5 24.8 23.7 18.5 27.2 
Used drugs in last year 12.3   8.9   8.0   6.6   5.6   7.0 
Used drugs in last 
month 
  7.5   5.2   4.0   3.5   3.0   3.2 
*British Crime Survey (2002/03), Crime Survey for England and Wales (2011/12)                                                                                                    
**Scottish Crime Survey (2002/03), Scottish Crime and Justice Survey (2010/11) ***Northern Irish Crime Survey 
The proportion of adults who used drugs in the last year and last month have 
decreased over a ten year period in England, Wales and Scotland (Condon and 
Smith, 2003; Office for National Statistics, 2012; Scottish Government, 2011, 
2004).  Whilst the proportions have risen in Northern Ireland between 2002/03 to 
2010/11 (Northern Ireland Executive, 2013).  Higgens et al. suggested that one of 
the reasons for the increase in Northern Ireland is due to the decrease in political 
conflict and therefore easier access to drugs. (Higgins et al., 2004).  It may be 
difficult to directly compare the three crime surveys as the scope and timing is not 
consistent.  For this reason, I will be focusing on drug use and treatment in 
England and Wales rather than for the whole of the UK in the thesis. 
 
According to the Crime survey for England and Wales, there has been a 
reduction in reported drug use from 12.3% in 2002/03 to 8.9% (±3 million people) 
in 2011/12 (Office for National Statistics, 2012).  Furthermore, there has also 
been a reduction in problem drug users in treatment from 210,815 in 2008/09 to 
193,575 in 2012/13 and a reduction of heroin and crack cocaine users from 
332,090 in 2005/06 to 298,752 in 2010/11 (Hay et al., 2013, 2011, 2006; Public 
Health England, 2015).  These estimates are based on self-reports and hence 
may be subject to reporting bias. (Degenhardt et al., 2013; Health Protection 
Agency, 2012; Office for National Statistics, 2013a).  Additionally, Frischer et al. 
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argued that the estimates of drug use from household surveys may be 
conservative (Frischer et al., 2001).  Moreover, they exclude population groups 
who may have a higher prevalence of drug use, these groups include; prisoners, 
homeless people and students living in halls of residence (Degenhardt et al., 
2013; Health Protection Agency, 2012; Office for National Statistics, 2013a).  
 
Although, overall declared drug use seems to have decreased in England and 
Wales, there has been a change in trend of particular drugs used between 1996 
and 2013 (Figure 1:1).  By 2012/13, the main illicit drugs that were used in the UK 
population (16-59 years old) were cannabis (6.4%), cocaine (1.9%), crack 
cocaine (0.2%), amphetamine (0.8%), ecstasy (1.3%) and heroin (0.12%) (Office 
for National Statistics, 2013a).  The overall trend of recorded drug use has 
decreased with heroin remaining relatively stable whilst cannabis has routinely 
been the highest contributor for recorded drug use (Office for National Statistics, 
2013a).  Cannabis was classified as a class B drug until 2004, it was reclassified 
to a class C drug between 2004 and 2009 and then reverted back to class B. 
(see section 1.3 for more details).  The increase of reported cannabis use in 
2003/04 and the subsequent reduction in 2012/13 could be due to the change in 
class classification and the change in willingness of individuals to report cannabis 
use. 
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Figure 1:1: Trends in illicit drugs used among adults aged 16-59 years (1996, 2003/4, 
2012/13) (Chivite-Matthew et al., 2005, Office for National Statistics, 2013a) 
 
Men consistently have higher recording for drug use, however women of potential 
childbearing age contribute to the majority of recording in females (Office for 
National Statistics, 2013a).  Drug use during pregnancy impacts the mother, 
foetus and the subsequent development of the child (Madgula et al., 2011a).  
Accurately estimating the prevalence of drug use during pregnancy is difficult as 
examining women during pregnancy can be complex (Gyarmathy et al., 2009; 
O’Donnell et al., 2009; Office for National Statistics, 2013a; Public Health 
England, 2015).  Estimates of drug use during pregnancy vary by country ranging 
from 5-8% of pregnant women (Gyarmathy et al., 2009; O’Donnell et al., 2009; 
van Gelder et al., 2009).  Information about drug use during pregnancy is 
collected as part of the National Drug Strategy Household Survey in Australia 
(every three years) and the annual National Survey on Drug Use and Health in 
the United States (Australian government, 2010; Substance Abuse and Mental 
Health Services Administration, 2012).  The results from the surveys are subject 
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to limitations such as response bias which makes estimates of drug use during 
pregnancy more uncertain than in the general population.  The prevalence of 
drug use during pregnancy has been difficult to ascertain in Europe, as data is 
not available for most European countries (European Monitoring Centre for Drugs 
and Drug Addiction, 2014b).  Estimates reported by The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) are based on various 
approximations, rather than actual measures (European Monitoring Centre for 
Drugs and Drug Addiction, 2014b).  The EMCDDA estimates that 20% of women 
entering drug treatment and 34% of opioid users are women, of which the 
majority are of child bearing age (Gyarmathy et al., 2009).  They also suggested 
that there may be approximately 30,000 pregnant women using opioids in Europe 
and that a similar number of pregnant women are using drugs other than opioids 
(Gyarmathy et al., 2009).  The EMCDDA estimates of drug use in the general UK 
population are based on the Crime Survey for England and Wales, the Scottish 
Crime and Justice Survey and the Northern Irish Crime Survey (see section 
1.3.8), which currently do not include questions on drug use specifically during 
pregnancy (European Monitoring Centre for Drugs and Drug Addiction, 2013; 
Office for National Statistics, 2013b).  Findings from Scottish hospital births 
reported that drug use during pregnancy had increased from 9 to 11 per 1000 
women given birth between 2003 and 2010 (National Statistics Scotland, 2012).  
It was however suggested that caution should be taken when comparing 
prevalence over time as recording of drug use during pregnancy has improved 
over the last 5 years in Scotland (National Statistics Scotland, 2012).  Based on 
the limited studies in England and Wales, approximately a third of people who 
use drugs are female, with 90% being of potential childbearing age (Ed Day and 
George, 2005).  It is evident that large gaps still exist in epidemiological research 
regarding the prevalence and burden drug use during pregnancy in England and 
Wales (Madgula et al., 2011a).   
 
1.3.8 Policies influencing recording of drug use and treatment of 
opioid substitution treatment 
In this section, I will describe how present policy influences GP recording of drug 
use and opioid substitution treatment. 
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1.3.8.1 Quality Outcomes Framework and Payment-by-Results  
The Quality and Outcomes Framework (QOF) which was implemented in 2004, 
remunerates general practices for providing clinical quality indicators of certain 
diseases and outcomes (Department of Health, 2003).  Maisey et al. suggested 
that if a disease is included in QOF and the general practice receives a financial 
incentive for treating the individual it is more likely that the disease, treatment and 
outcome will be recorded systematically and regularly (Maisey et al., 2008).  The 
general practice may also develop a recording protocol to ensure recording 
quality assurance (Maisey et al., 2008).  Dixon et al. examined whether or not 
QOF helped reduce health inequalities using both quantitative and qualitative 
methods (Dixon et al., 2010).  They conducted 33 semi-structured interviews with 
GPs and practice managers in primary care (Dixon et al., 2010).  Their findings 
echoed the study by Maisey et al. as they found that practices responded to QOF 
incentive outcomes by re-organising and making their approach more systematic, 
however some GPs perceived that QOF was not addressing the challenges of 
serving individuals with complex and social needs (Dixon et al., 2010).  Examples 
of challenging individuals were refugees, homeless, or drug-and alcohol-
dependent patients (Dixon et al., 2010).  The findings suggested that other pay-
for-performance indicators may need to be developed to remunerate and 
incentivise practices who deliver care to challenging individuals (Dixon et al., 
2010).  Consequently a pilot study is investigating how a different incentive 
scheme, Payment-by-Results, could be used to incentivise delivery for recovery 
for drugs and alcohol in primary care (Department of Health, 2012).  The pilot 
took place across eight sites for two years and started in April 2012, however the 
final results have not been published yet (Department of Health, 2012).  The 
RCGP argued that although not everyone agrees with Payment-by-Results for 
the treatment of recovery for drugs and alcohol, Payment-by-Results may be 
incorporated into primary care in the future (Harris and Halliday, 2013).   
 
There are currently no specific QOF indicators for recording drug use (NHS 
Employers, 2013).  There are however general NICE guidelines recommending 
39 
 
that GPs should discuss drug use in conjunction with mental health and the 
implications of drug use should be discussed with the individual during pregnancy 
(National Institute for Clinical Excellence, 2014).  Consequently, there are no 
financial incentives for recording drug use, unless a Local Enhanced Service 
(LES) has been commissioned in the area (see section 1.3.8.2) (NHS 
Commissioning Board, 2015) 
 
1.3.8.2 Clinical Commissioning Groups, Local Enhanced Services and the 
Localism Act (2011) 
Clinical Commissioning Groups (CCGs) became responsible for commissioning 
hospital and community services in their area in April 2013 (NHS Clinical 
Commissioners, 2015).  CCGs determine which services are required in the area 
and are also responsible for providing these services, which includes drug and 
alcohol services (NHS Clinical Commissioners, 2015).  General practices are 
incorporated into the applicable CCG (NHS Clinical Commissioners, 2015).  
Therefore decisions and services provided by the CCG could indirectly influence 
GP recording of drug use in electronic health records.  
 
Local Enhanced Services are agreed by CCGs and local authorities in response 
to local needs and priorities in the specific area (Department of Health, 2003; 
NHS Commissioning Board, 2015).  Furthermore, the Localism Act, 2011 is an 
Act of Parliament to facilitate the transfer of decision-making powers from central 
government to individuals and communities (Harris and Halliday, 2013; Localism 
Act, 2011).  The General Medical Services (GMS) contract, introduced in 2003, is 
the contractual agreement between NHS England and General Practices stating 
the core requirements of GPs in General Practices (Department of Health, 2003).  
Whilst opioid substitution treatment and treatment for non-opioid problem drug 
use is not incorporated in this GMS contract, specific Local Enhanced Services 
have been commission in various areas to treat drug use (National Treatment 
Agency for Substance Misuse, 2006).  Together with the Localism Act, 2011, the 
model of shared care has been implemented whereby general practices work 
together with statutory NHS and voluntary drug treatment services.(National 
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Treatment Agency for Substance Misuse, 2006).  The individual can therefore 
either receive treatment at a specific general practice, be referred or they can 
self-refer to the drug treatment services (National Treatment Agency for 
Substance Misuse, 2006).  As mentioned previously in section 1.3.3.1, if the 
individual receives opioid substitution treatment from the GP, it should be 
recorded in the electronic health record. 
 
1.3.9 History of drug policy in the UK 
In order to contextualise the role of GPs with people who use drugs, I describe 
the history of UK drug policies with a focus on how policy has impacted the 
involvement of GPs. 
 
An increase in drug use for non-medical purposes in the late eighteenth and early 
nineteenth centuries was attributed to the improvement in production, increase in 
supply, promotion, distribution and reduced prices of drugs (Courtwright, 2012a, 
2012b).  In the early nineteenth century, the increase in drug use led to the 
concept of addiction (Courtwright, 2012a).  Before 1916, there was little 
regulation over the use of drugs of dependence in the UK (Reuter and Stevens, 
2007).  However, the concept of addiction influenced the formation of the 
“temperance movement” which influenced a change in societal attitudes towards 
the regulation of drugs (Courtwright, 2012a).  During 1870-1930, anti-vice 
activism rose in North America and Europe and campaigns for the prohibition of 
non-medical use of drugs and other substances such as alcohol, were launched 
(Courtwright, 2012a). 
 
During and after World War I, there was an increase in the use of both cocaine 
and heroin which together with anti-vice activism, led to the criminalisation of 
these drugs by the UK government between 1916-1928 (Reuter and Stevens, 
2007).  During this time, GPs could legally prescribe illicit drugs to the relatively 
small and stable number of known addicts who were predominantly from a middle 
class background (Reuter and Stevens, 2007).  In 1924, the Rolleston committee 
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was established to advise on the supply of morphine and heroin to addicts 
(Strang and Gossop, 2005).  This led to the publication of the Rolleston report in 
1926, which recommended that GPs gradually reduce the amount of addictive 
drugs prescribed (Strang and Gossop, 2005).  The ‘British system’ of controlling 
illicit drugs was developed and GPs were still allowed to prescribe these addictive 
drugs in a controlled manner, but with the aim of weaning the individual off the 
drug or to maintain them on a small amount (Strang and Gossop, 2005).  
 
During 1958, the Interdepartmental Committee on drug addiction (also known as 
the Brain Committee) was established by the Home Office (Reuter and Stevens, 
2007).  The Committee was responsible for assessing the potential harmful 
effects of certain drugs and whether or not some of the drugs needed to be 
prescribed for medicinal purposes (Reuter and Stevens, 2007).  The first Brain 
report (published in 1961), stated that problem drug use was small in the UK, 
however by the time the second ‘Brain’ report was published in 1964, there was 
an increase in the use of cannabis, amphetamines and Lysergic Acid 
Diethylamide (LSD) and concurrently GP prescribing (Interdepartmental committe 
on drug addiction, 1965; Interdepartmental committee on drug addiction, 1961).  
This increase in drug use was the driving force for the establishment of the 
Dangerous Drugs Act, 1967 and the Home Office Addicts Index in 1968 (Reuter 
and Stevens, 2007).  This legislative Act required doctors to notify the Home 
Office of any confirmed and suspected addicts (Corkery, 2002).  It also restricted 
the prescription of heroin and cocaine by GPs and the first drug treatment centres 
were set up (Corkery, 2002).  There was often a delay from dependence to 
notification, but individuals who became dependent were more likely to come into 
contact with a GP (Figure 1:2) (Millar et al., 2004).  
 
The Misuse of Drugs Act was introduced in 1971, to classify drugs according to 
the potential harm they could cause and penalties for possession, producing and 
selling them (Misuse of Drugs Act, 1971) (see section 1.3 for details).  More 
serious penalties were created for trafficking and supplying drugs (Reuter and 
Stevens, 2007).  The Advisory Council on the Misuse of Drugs was created under 
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this Act and continues to advise the UK government on the control of illicit drugs 
(Figure 1:2) (Reuter and Stevens, 2007).  
 
Monitoring of drug misuse has its challenges.  The first British Crime Survey was 
conducted in 1983; it incorporated crimes that had not been reported to police 
and included drug misuse (Office for National Statistics, 2013b).  The survey was 
replaced by the Crime Survey for Britain and Wales in 1993 and there are similar 
surveys conducted in Scotland and Northern Ireland (Department of Justice, 
2014; Office for National Statistics, 2013b; The Scottish Government, 2013).  As 
mentioned in the previous section, the crime surveys do not include information 
regarding drug use specifically during pregnancy.  The European Monitoring 
Centre for Drugs and Drug Addiction argues that using population surveys for 
estimating problematic drug use may be underestimated as most surveys are 
self-reports and not representative of homeless and prisons (European 
Monitoring Centre for Drugs and Drug Addiction, 2007).  However, in the UK the 
national surveys are the best population estimates for surveillance of drug use.  
As mentioned in the previous section I will be comparing results of recording drug 
use in general practice to the Crime Survey for England and Wales in the first 
study (Chapter 4) 
 
Monitoring of opioid substitution treatment (see section 1.3.3.1 for details) for 
drug misuse is more accurate as recording of treatment is mandatory, initially the 
Home Office Addicts Index monitored individuals accessing services for drug 
misuse treatment.  In 1997, the Regional Drug Misuse Database replaced the 
Addicts index.  Subsequently, the National Treatment Agency and the Welsh 
National Database for Substance misuse replaced the Regional Drug Misuse 
Database in 2001 for recording treatment in England and Wales respectively. 
(Public Health England, 2015; Welsh Government, 2015).   
 
The National Treatment Agency became part of Public Health England in 2013 
(Public Health England, 2015).  The National Drug Treatment Monitoring System 
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monitors over 1500 community treatment centres which includes inpatient, 
outpatient and GP practices in England (Public Health England, 2015).  Most of 
the drug treatment services in England and Wales are accessed via self-referral 
and other referral sources including the NHS, the criminal justice system and 
GPs (Figure 1:2) (Public Health England, 2015; Welsh Government, 2015).  The 
reports from the monitoring systems regarding treatment produce more reliable 
surveillance results compared to the national surveys for drug use and can be 
used more credibly to compare treatment occurring in general practice.   
 
Figure 1:2: Graphical representation of the history of drug policy in the United Kingdom 
(1968-present) 
 
In 1998, a 10 year Drug strategy (Tackling Drugs to Build a Better Britain) was 
implemented in the UK (Home office, 1998).  The main focus of this strategy was 
on providing and improving treatment services, reducing drug-related crime, 
raising public awareness and engaging with the community (Howard, 2007).  This 
strategy was revised in 2002 and 2008 (Howard, 2007).  Coinciding with the 
change in government, a revised version was implemented in 2010 (Reducing 
1968                                                                                                         1997            
Home Office Addicts Index
1989                             
Regional Drug Misuse Database
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Misuse of Drugs Act
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National Treatment Agency
1982                                                             1993
British Crime Survey     → Crime survey for England and Wales
1998 2010                              2015
UK Drug Strategy  →  UK Drug Policy
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Demand, Restricting Supply, Building Recovery: Supporting People to Live a 
Drug-Free Life) (Home office, 2010).  One of the main aims of this strategy was 
to help people to live a drug-free life and focus on complete withdrawal rather 
than maintenance (Home office, 2010).  There are criticisms of the impact that 
the 1998 strategy made, which included the fact that not enough money was 
provided for the purpose of research (Howard, 2007).  Policies were, therefore, 
developed without understanding of the underlying causes of the problem 
(Howard, 2007).  However, prevention and recovery of drug dependency has 
been recently incorporated in one of the top five health priorities for Public Health 
England 2013/14 (Public Health England, 2013b). 
 
I will now describe previous quantitative and qualitative studies that have 
examined GP recording of drug use and opioid substitution treatment. 
 
1.3.10 Search methods for identification of studies 
I used the following search engines to search for relevant primary, review and 
meta-analysis studies regarding recording of drug use in primary care up to April, 
2013: PubMed, Web of Science, CINAHL, EMBASE (Search terms can be seen 
in Appendix 3).  Once I found relevant studies, I also examined their reference 
lists in order to find additional relevant articles.  I will briefly describe the various 
studies in this section and discuss them in more detail in Chapters 4-7. 
 
1.3.11 Quantitative studies examining recording of drug use and 
opioid substitution treatment in primary care 
Up to April, 2013, there were five studies that had used a primary care database 
to identify individuals with a recording of drug misuse and one study identifying 
individuals with prescriptions for opioid substitution treatment.  I will describe the 
aims and main findings of these studies in this section, and I will describe and 
discuss the studies in more detail in section 4.2. 
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All five of the cohort studies by Frischer et al. used the General Practice 
Research Database (GPRD) to identify individuals recorded (using either Read or 
OXMIS codes) with drug misuse (Frischer et al., 2000; 2001, 2004, 2005, 2009).  
The first study’s aim was to ascertain if the GPRD could be used as a 
surveillance tool for monitoring problematic drug use, whilst the second (pilot), 
third and fourth studies examined co-morbid psychiatric illness and substance 
misuse and the fourth focused on the time-trends of recorded drug misuse.   
 
The main findings from the study published in 2000 were firstly that GPRD had a 
significantly higher number of individuals recorded with drug use (n=6574) (In the 
West Midlands, between 1993-1997) compared with an existing surveillance tool, 
the Regional Drug Misuse Database (n=3643).  The authors suggested that the 
discrepancy could be attributed to the decrease in mandatory reported cases 
from GPs and other sources in RDMD and the increase in treatment in primary 
care (Frischer et al., 2000).  Over half of the individuals with a recording for drug 
misuse also had a psychiatric co-morbidity (Frischer et al., 2000).  The authors 
concluded that although GPs did not record the specific drug used, the GPRD 
may be a good contributor to overall drug misuse trends (Frischer et al., 2000). 
 
The second study was a pilot study examining the prevalence of co-morbid 
mental illness and drug use recorded in GPRD (Frischer and Akram, 2001).  A 
patient was defined as having a co-morbidity if they had both a mental illness and 
drug use diagnosis in their medical records between January 1993 until 
December 1997 in the West Midlands (Frischer and Akram, 2001).  The main 
findings showed that 0.25% of the cohort had a recorded for drug use, 11.26% a 
recording for mental illness and 0.12% had a recording for both (Frischer and 
Akram, 2001).  The authors concluded the GPRD may be suitable for identifying 
and analysing individuals with a co-morbidity of mental illness and drug misuse 
(Frischer and Akram, 2001). 
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The third study published in 2004, found that GPs were seeing more co-morbid 
(psychiatric illness and drug misuse) patients each year (1993-1998 in England 
and Wales), additionally the annual prevalence of recorded drug misuse 
increased in all age-groups except for individuals aged between 65-74 years.  
The ratio of males to females also increased from 1.1:1 to 1.37:1 (Frischer et al., 
2004).   
Findings from the fourth study published in 2005, indicated that 15.1% (936,128) 
of individuals had a code for psychiatric illness, 0.37% (22,904) had a code for 
substance misuse and 3969 individuals had codes for both (between 1993 and 
1998 in England and Wales).  They estimated that individuals who were coded 
with substance misuse first were 1.54 times more likely to develop a psychiatric 
illness, whilst those with a psychiatric illness were 2.09 times more likely to have 
a code for substance misuse (Frischer et al., 2005).   
 
The main findings from the final study published in 2009, showed that the 
prevalence and incidence for drug misuse decreased for the 16-24 age-group 
and increased or remained the same for the older age-groups (between 1998 and 
2005 in the UK) (Frischer et al., 2009).  The authors suggested a decline in 
recording which could be due to a decrease in overall drug use especially in the 
16-24 year age-group as a result of the 1998 drug policy (see section 1.3.8 for 
details) (Frischer et al., 2009).  The authors suggested that individuals who had a 
diagnostic or prescription code had a serious enough problem to warrant a 
recording (Frischer et al., 2009). 
 
GPRD has also been used to identify individuals who have been diagnosed with 
substance misuse and prescribed opioid substitution treatment.  Cornish et al. 
examined prescribing patterns of opiate substitution treatment and the risk of 
death between 1990 and 2005 in the UK (Cornish et al., 2010).  The main 
outcome of the study was comparing mortality rates with the timing of starting 
and discontinuing opioid substitution treatment (Cornish et al., 2010).  The study 
highlighted that mortality risk of opioid users in treatment increased at the start of 
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treatment (14-28 days) and the month after treatment has discontinued (Cornish 
et al., 2010).   
 
I will now describe the qualitative studies which have examined recording in 
primary care. 
 
1.3.12 Qualitative studies examining recording in primary care 
Up to April, 2013, there were no qualitative studies exploring GP recording of 
drug use and opioid substitution treatment in primary care in the UK in the 
general population or during pregnancy.  There were however two UK studies 
exploring recording of two other sensitive issues; alcohol misuse and child 
maltreatment.   
 
Firstly, the Alcohol Needs Assessment Research Project included the exploration 
of recording of alcohol misuse using both quantitative and qualitatively methods 
in England (Department of Health, 2005).  Alcohol misuse recording was 
examined using GPRD (see section 1.3.6) and telephone interviews with GPs 
across the country, in addition six focus groups were conducted (Department of 
Health, 2005).  Five times more individuals were reported with alcohol misuse in 
the telephone interviews compared with those recorded in GPRD (Department of 
Health, 2005).  This indicated that GPs were aware of people who misused 
alcohol but did not record it (Department of Health, 2005).  The following reasons 
for not recording and referring were highlighted in focus groups; GPs were 
reluctant to record and refer due to limited access of overstretched services and 
the lack of patient engagement with the services (Department of Health, 2005).   
 
Secondly, Woodman et al. used both quantitative and qualitative methods to 
examine recording and responses to child maltreatment in primary care 
(Woodman et al., 2013, 2012).  As with drug use, child maltreatment is an 
example of a stigmatised and sensitive issue managed in primary care.  The 
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Health Improvement Network was firstly used to examine the variation of 
recording of child maltreatment in the UK (Woodman et al., 2012).  The results 
showed that 1% of child maltreatment was recorded in primary care and they 
acknowledged that this was an underestimate (Woodman et al., 2012).  
Subsequently, they conducted in-depth qualitative interviews with GPs and 
practice nurses in England to understand the response and action taken by 
health professionals with regards to child maltreatment (Woodman et al., 2013).  
The findings suggested that GPs used core skills for long term management of 
families who prompted concerns about child maltreatment and that general 
practices who displayed exemplar practice (example: conducting regular practice 
meetings regarding vulnerable families) should be evaluated with a view to being 
rolled out nationally (Woodman et al., 2013).  Woodman et al. did not explicitly 
explore GP recording of child maltreatment, however, they went a step further to 
ascertain an understanding of the response and actions of the health 
professionals regarding a very sensitive issue (Woodman et al., 2013).   
 
Although both studies explored recording of other concerns, the issues of alcohol 
misuse and child maltreatment are also examples of stigmatised and sensitive 
issues that may have repercussions if recorded in the electronic health records, 
as with recording of drug use (Department of Health, 2005; Woodman et al., 
2013, 2012).  
 
1.3.13 Quantitative studies estimating drug use during 
pregnancy and outcomes of drug use during pregnancy 
Up until April, 2013, there have been no studies examining the recording of drug 
use during pregnancy using primary care databases in England and Wales.  
Accurately estimating the burden of drug use during pregnancy is complex.  
Likely reasons for inaccurate data are underreporting due to the stigma of drug 
use during pregnancy, unawareness of the pregnancy due to amenorrhoea, fear 
of the newborn being taken away and no, late or default attendance to the GP 
and antenatal clinics (Centre for Maternal and Child Enquiries, 2011).   
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There have been four studies within the England, but none in Wales that have 
examined drug use during pregnancy.  In this section I will describe these studies 
briefly and discuss them in more detail in section 5.2.  The aims of all four studies 
were to ascertain an estimate of women who use drugs during pregnancy in 
secondary care.   
 
The first two cross-sectional studies by Farkas et al. (n=1000) and Sherwood et 
al. (n=807), were conducted in East and South London respectively and both 
tested anonymous urine samples of pregnant women during the first trimester for 
drug use.  Ten percent (Farkas et al.) and 15.6% (Sherwood et al.) of the 
samples tested positively for drug use with cannabis being the most common 
drug used in both studies.   
 
The third study involved analysis of the Avon Longitudinal Study of Parents and 
Children Study (ALSPAC) (Fergusson et al., 2002).  Pregnant women (n=12,000) 
enrolled on the ALSPAC study were given a self-reported questionnaire which 
included questions on cannabis use between 18-20 weeks gestation and a 
question on whether or not the woman used drugs during pregnancy.  The 
authors reported that 5% of women in their study smoked cannabis during 
pregnancy, whilst 6.8% reported using other hard drugs.   
 
The final study was conducted by The Advisory Council on the Misuse of Drugs 
prevention working group in June, 2011, which produced the Hidden Harm report 
in response to the needs of children of problem drug users (Advisory Council on 
the Misuse of Drugs, 2011).  The findings estimated that between 200,000-
300,000 (2-3% of children under 16 years) of children in England and Wales, 
have at least one parent who uses drugs (Advisory Council on the Misuse of 
Drugs, 2011).  A questionnaire was sent to 423 maternity units in Sheffield and 
Glasgow for health professionals to complete.  Ninety percent (92%, 238/259) of 
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the responding units said that they frequently asked pregnant women about drug 
and alcohol use and a mean of 1% (24/2407, range 0-172) of women who gave 
birth in the maternity units disclosed their drug use during pregnancy (Advisory 
Council on the Misuse of Drugs, 2011).   
 
It was evident that evidence of the burden of drug use during pregnancy in the 
England and Wales is inconsistent.  Since the Crime Survey for England and 
Wales does not currently include questions on drug use during pregnancy, a 
primary care database may be a potential tool for examining this problem.  
Alternatively, another method of estimating the burden of drug use during 
pregnancy is to examine adverse outcomes and symptoms due to drug use in 
infants’ electronic health records.  I will discuss the potential adverse outcomes 
and symptoms in the next section. 
 
1.3.13.1 Potential adverse outcomes of drug use during pregnancy 
Madgula et al. conducted a review on adverse outcomes due to drug use during 
pregnancy (Madgula et al., 2011a).  The review reported that previous studies 
examining the adverse effects of drug use during pregnancy have had relatively 
small sample sizes and utilised different methodologies (Madgula et al., 2011a).  
The review concluded that there is no conclusive evidence for adverse birth 
outcomes due to drug use during pregnancy except for neonatal abstinence 
syndrome (NAS).  Infants have a higher risk of developing NAS if a mother uses 
either opioids, barbiturate or benzodiazepine during pregnancy (Madgula et al., 
2011a; O’Donnell et al., 2009; Winklbaur et al., 2008).  Following this, NAS could 
potentially be used as indirect measure of specific drug use during pregnancy. 
 
1.4 Rationale for Thesis 
As previously mentioned in section 1.3.7, the scope and timing of the three 
different crime-surveys (England and Wales, Scotland and Northern Ireland) is 
not consistent and therefore it may be difficult to directly compare them.  
Additionally, the burden of drug use during pregnancy has been examined more 
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in Scotland hospital births (National Statistics Scotland, 2012).  Therefore this 
thesis will focus on drug use and opioid substitution treatment in England and 
Wales, rather than for the whole of the UK. 
 
It is evident to date, that there is little evidence of the burden of drug use and 
opioid substitution treatment during pregnancy in England and Wales.  
Pregnancy usually triggers women to visit their general practitioner (GP) which 
may provide an opportunity for drug-use to be raised and recorded.  All women 
residing in the UK have the opportunity to be registered with a GP and receive 
free antenatal care (National Institute for Clinical Excellence, 2010b).  Women 
are recommended to visit either their GP or midwife once they know they are 
pregnant (National Institute for Clinical Excellence, 2010b).  A 2010 survey found 
that for 77% of women, a GP was the first healthcare practitioner they saw and 
that 45% of antenatal appointments occurred in general practice (Redshaw and 
Heikkila, 2010).  Antenatal care is usually transferred to the midwifery service, 
and transferred back to the GP when a woman visits her GP six weeks after the 
birth of her baby (National Institute for Clinical Excellence, 2010b).  If a woman 
chooses to consult her GP after giving birth, this timely appointment may lend 
itself as an opportunity for a GP to enquire about drug use together with other 
health related behaviours.  If a woman discloses that she uses drugs, the GP is in 
a better position to offer long term support for both mother and child.  GPs may 
also record information regarding drug use during and after pregnancy as a Read 
code in a woman’s electronic health record.  Data from the electronic health 
record could be viewed as an approach to monitoring women who use drugs.   
 
Various methods were used in studies examining drug use during pregnancy and 
the results are conflicting (Advisory Council on the Misuse of Drugs, 2011; Farkas 
et al., 1995; Fergusson et al., 2002; Sherwood et al., 1999).  Pregnancy could be 
an opportune time for a GP to ask about drug use and therefore a primary care 
database may have the potential to assess the level of burden of drug use in and 
around pregnancy.  In order to increase my understanding of pregnant women 
who use drugs, I will initially examine recording of drug use and opioid 
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substitution treatment in electronic health records of the general population.  
Following this, I will compare the results to national surveys conducted in 
England and Wales to ascertain that it is a suitable surveillance tool.  
Subsequently, I will focus on women in and around pregnancy and also examine 
infants’ electronic health records for an indirect measure of drug use and/ or 
opioid substitution treatment during pregnancy.  
 
1.5 How Does This Chapter Support My Thesis? 
In the first chapter, I have set the scene and context and explained the rationale 
for the thesis, I will describe and discuss the research questions, aims and 
objectives in the next chapter (Chapter 2), followed by a short summary of each 
chapter. 
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  SUMMARY OF CHAPTERS 
2.1 Content and Structure of Chapter 2 
In this chapter, I describe the overall aim, objectives and research questions of 
the thesis, followed by short summaries of chapters 3-8.  
 
2.2 Overall Aim  
The overall aim of the thesis was to explore the level of burden of drug use and 
opioid substitution treatment in and around pregnancy in England and Wales by 
examining GP recording in individuals’ electronic health records. 
2.3 Research Questions 
The two main research questions are: 
1. Can a large primary care database (The Health Improvement 
Network (THIN)) be used as a surveillance tool for understanding 
drug use and opioid substitution treatment in the general population 
and specifically during pregnancy (in England and Wales)? 
2. Can a large primary care database (THIN) be used as a tool to 
research drug use and opioid substitution treatment in general 
practice in the general population and specifically during pregnancy 
(in England and Wales)? 
2.4 Overall Objectives 
The main objectives of the PhD are to: 
1. Further investigate GP recording of drug use (including recreational drug 
use) and opioid substitution treatment and compare results to national 
surveys and reports 
2. Examine GP recording of drug use and opioid substitution treatment in and 
around pregnancy  
3. Examine GP recording of neonatal abstinence syndrome, an indirect 
measure of drug use and opioid substitution treatment during pregnancy  
4. Explore why, how and in which circumstances GPs record drug use in 
primary care. 
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2.5 Chapter Summaries 
Chapter 3: METHODS 
In Chapter 3, I justify why I decided to use mixed methods to answer the research 
questions.  I describe the two large databases (The Health Improvement Network 
(THIN) and Hospital Episode Statistics (HES)) used in the quantitative studies 
and the qualitative interview methods 
 
Chapter 4: Study 1: GP recording in the general population 
In Chapter 4, I describe and examine GP recording of drug use and opioid 
substitution treatment in the general population using electronic health records 
from THIN.  In order to achieve the main aim of the thesis (section 2.2), I first had 
to ascertain if THIN was a suitable tool to examine GP recording of drug use 
and/or opioid substitution treatment in the general population.   
Aims of Study 1: 
To describe and examine GP recording of drug use and opioid substitution 
treatment in the general population, using electronic health records 
Objectives of Study 1: 
Using data from the period between 1994-2012 in England and Wales, I sought 
to: 
1. Explore the level of entry of different codes available for GPs to 
record drug use and opioid substitution treatment 
2. Identify new records (first recording) of drug use and opioid 
substitution treatment in primary care 
3. Examine recording rate ratios for new records of drug use and opioid 
substitution treatment 
4. Estimate the period prevalence (2010/11 to 2012/13) of recorded 
drug use and opioid substitution treatment 
5. Compare GP recording of drug use and opioid substitution treatment 
with national surveys 
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Chapter 5: Study two: GP recording in and around pregnancy 
In the fifth chapter, I describe and discuss the second study, which focuses on 
recording of drug use and opioid substitution treatment in women in and around 
during pregnancy, using THIN.  I use the females obtained in study 1 and women 
from a pre-existing pregnancy cohort to examine the number of women who have 
a GP recording before (36 months), during and after (36 months) pregnancy.   
 
Aims of Study 2: 
To describe GP recording of drug use and/or opioid substitution treatment in and 
around pregnancy. 
Objectives of Study 2: 
Using data for women residing in England and Wales in the time-periods in and 
around pregnancy, I sought to:  
1. Examine the parity and demographics for women with and without 
recordings for drug use and/or prescriptions for opioid substitution 
treatment  
2. Examine the timing of recordings for drug use and/or prescriptions for 
opioid substitution treatment  
3. Explore the frequency of Read and/or prescription codes entered for each 
woman during specific time periods  
 
Chapter 6: Study three: GP recording of Neonatal Abstinence 
Syndrome  
In Chapter 6, I describe and discuss the third study, which focuses on GP 
recording of an outcome of drug use during pregnancy, neonatal drug withdrawal 
syndrome (NAS), in primary care.  I discuss how I obtained a cohort of all infants 
registered between birth and 6 months and examined both infant and mother’s 
records for a recording of NAS, using THIN.  I calculate the recording rate per 
calendar year and I describe how I calculated the birth prevalence of NAS in 
secondary care, using HES.  Finally, I assess how much of the discharge 
information (regarding NAS) from HES is entered onto the GP records in THIN.   
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Aims of Study 3: 
To explore recording of NAS, a symptom of drug use during pregnancy in primary 
and secondary care. 
Objectives of Study 3: 
1. Develop a list of Read codes for NAS in primary care 
2. Identify infants who have a Read code indicated for NAS and 
examine the demographics and other factors of infants with and 
without a recording  for NAS in primary care 
3. Calculate the recording rate of NAS per 1,000 live births in primary 
care 
4. Calculate the recording rate of NAS per 1,000 live births in 
secondary care and compare how much of this information is 
entered in primary care electronic health records 
 
Chapter 7: Study four: Factors influencing recording of drug use – a 
qualitative study 
In this chapter, I describe and discuss the qualitative study which was essential 
for helping to understand the results from the previous three chapters.  I explain 
how I conducted and analysed 12 semi-structured interviews with GPs.  Finally, I 
discuss how I interpreted the qualitative data. 
 
Aims of Study 4: 
To understand GP recording of drug use and opioid substitution treatment and to 
use existing literature to contextualise my findings. 
Objectives of Study 4: 
1. To explore and generate an understanding of the factors determining 
GP recording of people who use drugs and/or receive opioid 
substitution treatment in primary care. 
2. To examine if GPs use any specific protocols or codes for recording 
drug use and/or opioid substitution treatment 
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3. To examine and generate an understanding of the similarities and 
differences of recording drug use and/or opioid substitution treatment 
between the general population and pregnant women 
4. To examine if GPs use any specific protocols or codes for referring 
individuals for treatment of drug use and/or opioid substitution 
treatment 
 
Chapter 8: Summary and synthesis of results of quantitative and 
qualitative studies 
In the penultimate chapter, I summarize and synthesize the results of the four 
studies.  I consider how the studies support each other and support my findings.   
 
Chapter 9: Discussion 
In this final chapter, I will firstly present an overview of the thesis and summary of 
the findings.  I will then present the following: 
1. Illustrate how the thesis brings new knowledge and/or improves 
method. 
2. Discuss the value of the Offending Crime and Justice Survey as a 
measure of drug use in the population. 
3. Describe the overarching strengths and limitations of the thesis 
4. Discuss what I have learnt during the thesis and what I might have 
done differently 
5. Discuss if THIN is sufficient to address the hypothesis concerning drug 
use during pregnancy or the consequences of NAS? 
6. Consider both the clinical and research implications of the thesis 
7. Present the conclusions of the thesis 
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 METHODS 
3.1 Content and Structure of Chapter 3 
In this chapter, I begin by describing the differences between quantitative and 
qualitative methodologies.  Secondly, I discuss and justify why I chose to use 
mixed methods for the thesis.  Finally, I provide a description of and discussion 
about; The Health Improvement Network (THIN) primary care database (used in 
studies 1-3, Chapter 4-6), Hospital Episode Statistics (HES) secondary care 
database (used in study 3, Chapter 6) and qualitative interview methods (used in 
study 4,Chapter 7).   
 
3.2 Quantitative and Qualitative Methodologies  
Methodology is the strategic approach to gaining knowledge and conducting 
research (Green and Thorogood, 2004).  Two principal methodologies are the 
deductive and inductive approaches (Pope and Mays, 2000).  Furthermore, the 
two most common procedures in acquiring knowledge are quantitative and 
qualitative methods (Pope and Mays, 2000).  Figure 3:1 illustrates the 
fundamental differences between quantitative and qualitative research.  I will now 
discuss the two methodologies in more detail and how I applied these in my 
research design. 
 
59 
 
 
Figure 3:1: An illustration of the main differences between quantitative and qualitative research methodologies:
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3.2.1 Quantitative methodologies 
Quantitative methodologies attempt to answer the following questions; what and 
how much?  There are different study designs used to conduct quantitative 
epidemiological research which include; randomised controlled trials, meta-
analyses and observational studies (cohort, case-control and cross-sectional 
studies) (Green and Thorogood, 2004).  Quantitative research is generally a 
deductive approach and hypotheses are tested to answer research questions 
(Pope and Mays, 2000).  Research questions and hypotheses are generated 
from existing literature and theory (Green and Thorogood, 2004).  The 
researcher needs to use statistical methods to analyse the data (collected or 
observed) in order to test hypotheses and answer specific research questions.   
In the thesis, I initially developed my two main research questions from existing 
literature and theory: 
1. Can a large primary care database (The Health Improvement 
Network (THIN)) be used as a surveillance tool for understanding 
drug use and opioid substitution treatment in the general 
population and specifically during pregnancy (in England and 
Wales)? 
2. Can a large primary care database (THIN) be used as a tool to 
research drug use and opioid substitution treatment in general 
practice in the general population and specifically during 
pregnancy (in England and Wales)? 
 
I then conducted three epidemiological studies and applied statistical methods 
in order to test the hypotheses and answer the research questions.  The results 
from this work could then contribute to the existing landscape of literature 
(Figure 3:1). 
 
3.2.2 Qualitative methodologies 
Qualitative methodologies endeavour to answer questions such as why and 
how something occurs (Pope and Mays, 1995).  There are various qualitative 
 61 
 
methodologies applied to answer different qualitative research questions (this 
will be discussed in more detail in section 3.6).  Qualitative research is 
characterised by researchers’ interpretation of the results (Pope and Mays, 
1995).  It is also imperative that the researcher understands and reflects on 
his/her own views and incorporates this when interpreting the data (Green and 
Thorogood, 2004).  Qualitative research is more likely to be associated with an 
inductive approach (Green and Thorogood, 2004).  Although the sample size is 
generally smaller, the qualitative exploration usually generates richer and more 
in-depth data (Figure 3:1) (Green and Thorogood, 2004).   
 
Once I had conducted my quantitative studies, I conducted a qualitative study in 
which I conducted semi-structured interviews with GPs regarding their 
behaviour of recording patients that use drugs and/or are prescribed opioid 
substitution treatment.  I then analysed and interpreted the qualitative data in 
order to understand the patterns generated. The new hypotheses generated 
could then contribute to the existing landscape of literature (Figure 3:1).  
 
I will now discuss and justify why I used mixed methods to answer my research 
questions. 
 
3.3 Why I Used Mixed Methods  
Mixed methods research comprises the use of using both quantitative and 
qualitative research methods (Brannen, 2005).  Mixed methods research is 
defined as adopting more than one strategy to answer the research question 
and it is used more in medical and health research (Brannen, 2005). The mixed 
methods approach has been used in clinical trials with surveys of attitudes and 
beliefs, and epidemiological measures to improve understanding of health 
problems (Plano Clark, 2010). 
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My initial research experience involved generating data through experiments or 
observation and testing a hypothesis.  Consequently, I was initially guided by 
quantitative methodologies to answer my two main research questions.  
However, it soon became evident that there were more questions that needed 
to be answered in terms of how and why the data was recorded.  I therefore 
decided to take a different approach to acquiring knowledge in order to answer 
these new questions.  It was essential to answer questions regarding the social 
context of how and why the data was recorded and it was therefore necessary 
that I also use qualitative methodologies to help interpret and understand my 
quantitative results and optimally answer my research questions (Pope et al., 
2014).  I chose to take a pragmatic approach and used both quantitative and 
qualitative methods, as one methodological approach could not answer all my 
research questions.   
 
The increased use of mixed methods has led to the development of its own 
terminology, and techniques (Tashakkori and Teddlie, 2003).  Denscome 
argued that whilst pragmatism is used for the philosophical understanding of 
mixed methods, mixed methods itself could be a distinct paradigm for social 
research (Denscombe, 2008).  Triangulation of two methods helps achieve 
comprehensive understanding (Hammersley, 2005).  However, the data 
collected cannot simply be added together to produce one answer and the 
methods should not be used to check or verify each other, but rather to 
complement each other and use each other as a critical lens (Hammersley, 
2005).  The deductive approach can help the qualitative analysis be more 
systematic and rigorous, whilst the inductive approach can aid in increased 
knowledge and understanding of empirical data. 
 
Hammersley describes four ways of combining data analysis from two different 
research methods: expansion or elaboration, initiation, complementarity, and 
contradictions (Hammersley, 2005).  I decided to use a combination of two of 
these methods of combining data; expansion and complementarity.  Expansion 
describes how one type of data analysis can add to the understanding of the 
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other type of data analysis (Hammersley, 2005).  Complementarity treats 
quantitative and qualitative differently, but uses the results in conjunction with 
each other to contrast and compare in order to enhance and build a greater 
understanding of the data (Hammersley, 2005).  I will use both of these 
methods of combining data as my three quantitative studies (Studies 1-3, 
Chapters 4-6) focus on GP recording of drug use in electronic health records 
and the qualitative study (Study 4, Chapter 7) involves interviewing GPs who 
routinely enter data into patient’s electronic health records.  The qualitative 
findings should therefore add to the understanding and complement the three 
quantitative studies.  Methodological triangulation could therefore strengthen 
the evidence of my quantitative work.  
 
3.3.1 The design of the mixed method study and integrating the 
studies 
The thesis developed into a mixed methods study and I therefore chose to use 
the explanatory sequential method, as I conducted the quantitative studies first, 
followed by the qualitative study and then analysed and interpreted all four 
studies (Figure 3:2) (Cresswell and Plano Clark, 2007). 
 
Figure 3:2: Explanatory sequential mixed methods design (Cresswell and Plano Clark, 2007) 
 
Quantitative work Qualitative work
Interpretation 
of both
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I kept the analysis of the two different methodologies distinct until the 
interpretation phase of my thesis.  I used a cohort design for studies 1-3 
(described in sections 4.7.3, 5.6.5 and 6.6.3) and thematic analysis to analyse 
study 4. (described in section in 7.5.7).  I then synthesised and integrated the 
results from all four studies at the interpretation stage. 
 
I have justified why I used mixed methods in the thesis. I will now describe the 
two large databases that I used for my epidemiological studies 1-3, THIN and 
HES.   
 
3.4 The Health Improvement Network  
The Health Improvement Network (THIN) is a primary care database of 
anonymised patient electronic records.  The database is based on practice staff 
(GP, nurses and administrative staff) recording information from consultations 
and other information about the patient using Vision software in the form of 
Read codes, prescriptions and/or free-text (see section 1.3.5 for details).  The 
primary purpose of electronic health records is not for research, but rather to 
record consultations which provides a clinical window of primary care (CSD 
health research, 2015).  
 
3.4.1 History of THIN 
Dr John Preece was the first GP to use a computer to record patient 
consultations in 1960 (Benson, 2011).  His work resulted in the computer-
printed prescription form still currently used by GPs (Benson, 2011).  
Subsequently Dr John Perry worked on the Oxford GP record linkage project 
and developed OXMIS codes (see section 1.3.5 for details) (Benson, 2011).  
These codes were used by many GPs in the 1980’s, however, the death of Dr 
Perry meant these codes were not developed and their usage was 
subsequently discontinued (Benson, 2011). 
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Abie Informatics Limited was founded in 1980 (Benson, 2011).  The Abie 
medical dictionary was developed by Dr James Read, together with Abie 
Informatics (Benson, 2011).  It was later renamed the Read code classification 
system (Benson, 2011; Chisholm, 1990).  The system was constructed to be 
comprehensive, hierarchical, coded, computerised, cross-referenced and 
dynamic (Chisholm, 1990).  The Read codes are a hierarchical classification 
system and each code has four digits (letters/numbers/baseline dot) (Chisholm, 
1990).  The codes were divided into sections and either based on pre-existing 
classification systems, or were newly developed (Chisholm, 1990).  The Royal 
College of General Practitioners and British Medical Association recommended 
using Read codes as a national clinical coding system in 1988 (Benson, 2011).  
 
Read codes are structured into hierarchical groups and divided into specific 
sections (Appendix 4).  A Read code is made up of a code (medcode) and a 
description.  The medcode is 7 characters which is case sensitive, whilst the 
description can have up to 60 characters (Table 3.1).  There are common 
abbreviations used in Read codes, examples of these include H/O (history of), 
NOS (not otherwise specified) and F/H (family history) (CSD health research, 
2015). 
 
Table 3.1: Example of Read code (medcode) and description (CSD health research, 2015) 
Medcode (7 characters, case sensitive) Description (up to 60 characters) 
1V22.00  Age at starting drug misuse 
E242100 Cocaine dependence, continuous 
1V0C.00 Drug addict 
 
VAMP (Value Added Medical Products) health specialised in developing 
software for GPs to use for electronic health recording  (García Rodríguez and 
Pérez Gutthann, 1998; Walley and Mantgani, 1997).  VAMP health installed 
computer systems and software in GP practices in the UK.  If a GP practice 
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joined VAMP, they received free computers, VAMP software and 12 months 
training (García Rodríguez and Pérez Gutthann, 1998; Hall, 1992; Walley and 
Mantgani, 1997).  The practices’ data was only included in the VAMP Research 
Database after the quality of their data reached a specific standard (García 
Rodríguez and Pérez Gutthann, 1998; Lis Y and Mann RD, 1995).  In 1993, due 
to financial problems, the VAMP Research Database was taken over by 
Reuters Health Information, who donated the database a year later to the 
Department of Health.  It was then renamed the General Practice Research 
Database (GPRD) and managed until 1999 by the Office for National Statistics.  
Subsequently, the Medicines and Healthcare Products Regulatory Agency 
(MHRA) (previously called the Medical Control Agency (MCA)) took it over.  The 
GPRD is now a sub-division of the MHRA.  GPRD changed name to Clinical 
Practice Research Datalink (CPRD) in 2012 (Clinical Practice Research 
Datalink, 2013).   
 
After the closure of VAMP Research Database, some employees of VAMP 
formed EPIC, a non-profit organisation in 1995 (García Rodríguez and Pérez 
Gutthann, 1998; Lis Y and Mann RD, 1995).  EPIC held an exclusive license to 
provide information on patient records (in GPRD) for medical research between 
1995-2002 (García Rodríguez and Pérez Gutthann, 1998; Lis Y and Mann RD, 
1995).  Once the license expired, THIN (see section 1.3.6 for details) was 
formed by EPIC and Cegedim Strategic Data Medical Research (CSD; a 
European software company) (CSD health research, 2015).  Subsequently CSD 
acquired EPIC and collaborated with In Practice Systems (INPS) who supplied 
a particular software, Vision, to 1800 general practices across the UK (CSD 
health research, 2015).  Some general practices contribute data to both THIN 
and CPRD (Lewis et al., 2007).  There is approximately a 60% overlap of 
practices between the two databases (Cai et al., 2012).  As of April 2015, CSD 
became part of IMS Health Real World Evidence Solutions (IMS Health, 2015) 
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3.4.2 Description of THIN 
The data is collected weekly by THIN and consolidated by CSD (CSD health 
research, 2015).  The data is anonymised and contains information about 
patients registered in the particular general practices (Table 3.2) (CSD health 
research, 2015).  Each patient’s electronic records are linked by a unique 
patient id (patid) to the specific general practice (CSD health research, 2015). 
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Table 3.2: Content of THIN data (CSD health research, 2015) 
Anonymised patient level 
information 
Files in which the 
information is catalogued  
Codes used 
Demographic Patient records Field and description 
Medical Medical records Field, description and 
medcodes 
Prescribing Therapy records Field, description and 
Multilex/drug codes 
Referral to specialists Additional Health Data Field, description, 
ahdcode and/or medcode 
Diagnostic laboratory results Additional Health Data Field, description, 
ahdcode and/or medcode 
Lifestyle characteristics Additional Health Data Field, description, 
ahdcode and/or medcode 
Other measurements Additional Health Data Field, description, 
ahdcode and/or medcode 
Postcode variable indicators (to 
classify deprivation) 
PVI record PVI 
Data on the practices *Practice file records  
Information on consultation date, 
time and length 
*Consult file records  
Staff roles *Staff file records  
Anonymised free-text comments *Practice file records Textid 
*Additional data files the information is catalogued in 
In the UK the majority of individuals are registered with a GP (Lis Y and Mann 
RD, 1995).  By 2012, there were 570 general practices in the UK (England, 
Scotland, Northern Ireland and Wales) which contributed data to THIN covering 
approximately 6% of the population (CSD health research, 2015).  During 
consultations, clinical information is entered in the form of standardised Read 
codes together with drugs prescribed onto a computer using Vision software 
(Chisholm, 1990).  More information about the consultation can be entered as 
free-text during the consultation.  Over 313, 000 comments have been 
anonymised and are available for a researcher with a THIN license (CSD health 
research, 2015).  This amounts to approximately 35% of all the free-text-
comments (CSD health research, 2015).  If a comment is anonymised, a 7 
character numeric identifier (textid) will be linked to a unique comment (CSD 
health research, 2015).  Letters and discharge notes from secondary care and 
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other primary care services (e.g. midwives) are often scanned and not coded as 
Read codes or free-text comments.  Sometimes GPs may highlight the scanned 
letters and enter Read codes for important symptoms and diagnoses.  I will 
discuss in detail how I examined free-text comments in the electronic health 
records in section 4.7.5.2. 
 
3.4.3 Validity of THIN 
THIN is comparable to the general UK population in terms of demographics, 
mortality and prevalence of chronic and acute diseases, although under 25s, 
males and less affluent individuals are slightly underrepresented compared to  
national statistics (Blak et al., 2011).  Individuals in the armed forces and 
prisoners are not included in THIN (this is discussed in more detail in section 
3.4.4).  Social deprivation is recorded in THIN as quintiles of Townsend scores, 
which is a measure of deprivation in the UK (Townsend, 1987).  The score is 
created by measuring four variables; the number of individuals per household, 
employment, ownership of car and home to create a single measure of 
deprivation (Townsend et al., 1986).  A higher scores indicate more deprived 
areas (Townsend et al., 1986).  The region of the general practice is divided into 
regions equivalent to the former Strategic Health Authorities (SHA) for England 
and countries for Scotland, Wales and Northern Ireland (Health and Social Care 
Information Centre, 2013a).   
 
There are certain recording issues in primary care databases, and in order to 
reduce this, two quality markers have been developed: the acceptable mortality 
rate date (AMR) and the acceptable computer usage date (ACU). 
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3.4.3.1 Acceptable mortality rate date (AMR) 
Mortality is an important outcome measure when using a database for 
epidemiological research.  However, as some practices have changed from one 
software to another, they would only have transferred individuals who were alive 
at the time they changed software and hence the overall mortality rate would 
have been too low in these practices (Hollowell, 1997; Maguire et al., 2009).  
Therefore, a data quality marker, Acceptable Mortality Ratio (AMR), was 
developed to ensure recording of death are comparable to expected national 
mortality figures (Hollowell, 1997; Maguire et al., 2009).  The expected mortality 
rate is derived from the Office of National Statistics (ONS) for a particular 
practice based on the demographics.  The AMR year for a practice is then 
determined, when the observed mortality rate of the practice is reporting a 
mortality rate which is comparable with the ONS mortality rate (Maguire et al., 
2009).  
 
3.4.3.2 Acceptable computer usage date (ACU) 
In the 1990’s some practices did not use their computer system completely and 
therefore another data quality marker for computer usage, Acceptable 
Computer Usage (ACU) date was developed by the electronic health records 
research team at UCL (Horsfall et al., 2013).  This is a marker for when 
practices appear to be using their computer system rather than paper records.  
An ACU date would be assigned to each practice, on average, they have at 
least two therapy records, one medical records and an additional health data 
record per patient per year (Horsfall et al., 2013).  The ACU year is on average 
approximately 3.3 years after the AMR year of a practice (Horsfall et al., 
2013).The reliability of using THIN is improved if a combination ACU and AMR 
years are used instead of practice registration or computerisation (Horsfall et 
al., 2013).  
 
 71 
 
3.4.4 Strengths and limitations of THIN 
The main strength of using THIN, is that it provides a large amount of data from 
real life UK primary care.  It also provides access to information on vulnerable 
and difficult groups to study or access such as pregnant women and individuals 
with mental health diagnoses.  Furthermore, the database lends itself to 
research regarding rare exposures and outcomes. 
 
There are various limitations to using THIN.  Firstly only information about 
individuals who are registered with a general practice is included in THIN.  GPs 
also needs to record specific aspects of the consultation using Read and/or 
drug codes and/or free-text.  Read codes are not always specific to the 
symptom or diagnosis.  Prescriptions may be more specific, but assumptions 
are made as to whether individual actually take the prescribed medication or 
not.  As mentioned previously, free-text is available for some consultations, but 
not all free-text are anonymised and it may be costly to apply for access to the 
free-text.  Referral letters that have been scanned into the clinical records and 
discharge letters may not be coded.   
 
Another identified limitation is that the number of patients registered with an 
NHS number is higher than the registered population (Audit commission, 2012).  
In 2012, 53,493,729 individuals were living in the UK, however 55,724,785 
people were registered with a GP (Audit commission, 2012).  There have been 
several audit commission reports to evaluate this issue (Audit commission, 
2006, 2012).  These individuals fall into two categories: 
1) Individuals who may have two NHS numbers  
a. Students who are registered both at their home and university resident 
address (Audit commission, 2006) 
b. Individuals who register with a new practice and do not inform their old 
general practice (Audit commission, 2006).   
2) Individuals who have a single NHS number, but have left the general practice 
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a. Individuals who immigrate but choose not to de-register.  They therefore 
remain on the practice register, but not on the resident population 
register (Audit commission, 2006). 
b. Individuals who work and/or study in the UK short term, may also register 
with a general practice, but not be included in the resident population 
(Audit commission, 2006). 
c. Asylum seekers who are no longer living in the UK may still be registered 
with a general practice (Audit commission, 2006). 
Some GPs may intentionally not remove patients and are still receiving money 
for each of these patients (Audit commission, 2006).   
 
There may also be individuals who register twice with intention, using their own 
and false identity in order to gain access to more prescriptions for either 
personal use or to sell (NHS Counter fraud services, 2011). This group includes 
individuals who use drugs and/or are receiving treatment for opioid substitution 
treatment (NHS Counter fraud services, 2011).  However, the audit commission 
report in 2009 shows that there is an overall improvement in duplicate 
registrations from 185, 000 (2006) to 93, 000 (2009).  The deceased and 
duplicate categories remain relatively high, and the removed asylum seekers 
category has increased by 10% (Table 3.3) (Audit commission, 2006, 2012).  
 
Table 3.3: Comparison of results from duplicate audit commission reports in 2006 and 
2009 (Audit commission, 2006, 2012) 
Categories Figures from 2006 audit 
commission report (%) 
Figures from 2009 audit 
commission report (%) 
Age reports (patients > 90 
years old) 
8 4 
Temporary NHS number 7 N/A 
Deceased 22 34 
Duplicates 34 31 
Gone away 28 N/A 
Multiple occupancy 24 21 
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Categories Figures from 2006 audit 
commission report (%) 
Figures from 2009 audit 
commission report (%) 
Removed asylum seekers 1 10 
 
There are some groups of individuals who may be registered as residents, but 
not be registered with a practice.  These groups include, the armed forces 
(0.3%), prisoners (0.2%) and non-registered immigrants (1%) (NHS England, 
2013; UK Government, 2014).  All armed forces service personnel, mobilised 
reservists and service family are registered with a defence medical services 
general practice, whilst prisoners are deregistered from their GP and registered 
with a prison GP (NHS England, 2013).  Prisoners may have difficulty 
registering with a GP once they leave prison (UK Government, 2014).  
Homeless people may also not know how or have difficulty registering with a 
general practice, however the RCGP advise general practices to register 
homeless individuals (Royal College of General Practitioners, 2002).   
 
Finally, it should be mentioned that data from primary care databases may not 
represent community incidence of conditions/diseases as some individuals may 
not present to the GP.  If the individual does present, they may not be 
diagnosed or they may not disclose an issue and therefore symptoms and 
diagnoses may not be recorded in their electronic primary care health record.  
As illustrated in Figure 3:3, the proportion of individuals in the community who 
present to their general practice when they get ill is a sub-sample of those 
registered with a GP.  An even smaller proportion of individual consultations will 
be recorded and/or coded electronically (Figure 3:3) (Huxley and Goldberg, 
1993; Public Health England, 2015).  
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Figure 3:3: The pyramid illustrates that it is only a subset of individuals with a specific 
condition who present in general practice and of these it is only a smaller proportion 
who are recognised by general practice and an even smaller proportion have an entry 
made into their electronic health records. Adaption of Access to Health Care Pyramid 
(Huxley and Goldberg, 1993) 
 
3.4.5 Reasons for using THIN in thesis 
I decided to a primary care databases for my epidemiological studies as to date 
there are no large studies examining drug use and opioid substitution treatment 
in and around pregnancy in England and Wales.  The Research Department of 
Primary Care and Population Health, UCL currently holds a license to use THIN 
and I therefore chose to use this database over GPRD.  It is challenging to 
obtain information about such a sensitive and stigmatised issue, especially 
during pregnancy.  As drug use had not been previously examined in THIN, it 
was necessary that I firstly identified a cohort of people who were recorded as 
using drugs and/or opioid substitution treatment.  Following this, I would use a 
pre-existing cohort of women who had at least one pregnancy to identify 
pregnant women who were also recorded with drug use and/or opioid 
substitution treatment.  Other methods of obtaining information about drug use 
and or opioid substitution treatment, such as a questionnaire, may be more 
costly and time intensive to obtain a large sample size and self-reporting may 
introduce response bias.  THIN will allow me access to real life data from 
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primary care, information on a relatively rare exposure (drug use and/or opioid 
substitution treatment) and provide a large sample size. 
 
My third epidemiological study was examining recording of Neonatal Abstinence 
Syndrome using THIN.  There are however currently no studies looking at the 
birth prevalence of neonatal abstinence syndrome in England.  Therefore, I 
examined the birth prevalence using data from Hospital Episode Statistics to 
compare with the results from THIN.  I will now describe the hospital database 
that I will use for part of the third study. 
 
3.5 Hospital Episode Statistics  
3.5.1 Description of HES 
Hospital Episode Statistics (HES) is a data repository for all admissions to the 
NHS hospitals in England (Health and Social Care Information Centre, 2012).  
Initially, only 10 percent of hospital data was collected and used nationally 
(Health and Social Care Information Centre, 2012).  The concept of HES 
originated after 1987, following a report on collecting and using routine hospital 
data (Health and Social Care Information Centre, 2012).  The aim of HES was 
to collect detailed information of all patient episodes occurring in NHS hospitals 
and sectors commissioned by the NHS (Health and Social Care Information 
Centre, 2012).  All patients recorded in HES have their identifiers 
pseudonymised and replaced by a unique patient identifier; HESID (Health and 
Social Care Information Centre, 2012).  The HESID is based on the patient’s 
NHS number, date of birth, sex and postcode, it is unique and cannot be traced 
back to the patient (Health and Social Care Information Centre, 2012).   
 
The length of stay from admission to discharge is called a ‘spell’ (Figure 3:4) 
(Health and Social Care Information Centre, 2013b).  During a spell a patient 
can have one or more ‘episodes’ (Health and Social Care Information Centre, 
2013b).  Admission diagnoses are coded according to the International Coding 
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for Disease-10 (ICD-10) (Health and Social Care Information Centre, 2012).  
ICD-10 is a diagnostic tool which is used for epidemiology, health management 
and clinical reasons (World Health Organisation, 2010).  The ICD-10 codes 
assist in monitoring incidence and prevalence rates of specific symptoms and 
diseases (World Health Organisation, 2010).  ICD-10 replaced ICD-9 in 1994 
and a revised version, ICD-11, will be implemented in 2017 (World Health 
Organisation, 2010).  In HES, a four digit code is used to identify diagnoses for 
each episode (Murray et al., 2013).  A patient can have up to 20 diagnoses per 
episode (Figure 3:4) (Health and Social Care Information Centre, 2013b).  
 
 
Figure 3:4: Admission and episodes in Hospital Episode Statistics (Health and Social 
Care Information Centre, 2013b) 
 
In order for a diagnosis to be entered as an ICD-10 code, the doctor needs to 
highlight the diagnoses of interest in the patient’s paper records or discharge 
notes (Department of Health, 2013).  Both the records and notes are sent to 
hospital coders once the patients are discharged (Department of Health, 2013).  
The coders will then work systematically to determine the appropriate ICD-10 
code to use and should contact the doctors if there are any queries (Department 
of Health, 2013).  The correct coding is important, as diagnoses are mapped to 
payment to the NHS trust (Department of Health, 2013).  An example of this is 
that if an individual has angina they will get one code, but if they have angina 
plus hypertension, they will receive a different code and they will receive a 
 77 
 
higher payment (Department of Health, 2013).  HES data is collected on a 
monthly basis and annual reports are produced for each financial year (1 April-
31 March).  HES data are derived from routinely collected administrative data 
which were pseudonymised before I received them, and therefore I did not 
require Research Ethics Committee approval (Health Research Authority, NHS, 
2010). 
 
3.5.2 Mother and baby records in HES 
When a pregnant woman is admitted into hospital, she will have an inpatient 
record and once she gives birth she will have a maternity record.  A maternity 
record consists of two parts; the delivery and birth records.  The delivery record 
contains general information about the mother and a baby, which includes 
information about the delivery.  Whilst the birth record is for the baby and 
contains some of the same information as the mother’s record, as well as 
general information regarding the baby.  The diagnostic information for the baby 
will not necessarily be in the mother’s records as mother and baby records are 
not linked.  If there are multiple births, each baby will have a unique baby record 
but the same delivery record (Figure 3:5) (Murray et al., 2013).  
 
Figure 3:5: Structure of mother and child records in hospital episode statistics.  This 
example illustrates a situation where the pregnancy resulted in twin births (Health and 
Social Care Information Centre, 2013b) 
Mother's inpatient record
Mother record Baby record 2Baby record 1
Delivery record
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3.5.3 Validity, quality, strength and limitations of HES 
The quality of data coded and sent to HES is of varying quality, but a report by 
Knight et al. showed how the number of hospitals providing good quality 
maternity data has improved over the years (Knight et al., 2013a).  The quality 
of baby data is still relatively poor, especially with regards to missing data and 
social deprivation.  In HES, social deprivation is measured by the index of 
multiple deprivation (IMD) which is based on postcode of residence 
(Department for Communities and Local Government, 2015).  Due to a data 
extraction error by the data provider, IMD is only available for babies in HES 
who were readmitted in the first 6 months of life and not from the delivery record 
(Health and Social Care Information Centre, 2012).  Therefore, currently IMD 
cannot be included when analysing neonatal HES data. 
 
HES is a key resource for monitoring health outcomes and assisting in 
epidemiological research (Morleo et al., 2011; Murray et al., 2013; Royal 
College of Obstetricians and Gynaecologists, 2014).  The database is an 
extensive electronic resource which is cost-effective, and can compare 
outcomes between hospitals and trusts (Health and Social Care Information 
Centre, 2012; Morleo et al., 2011).  The unique HESID, allows longitudinal 
analysis of each individual patient.  HES includes approximately 96% of births in 
England (Birthplace in England Collaborative Group et al., 2011).  HES was 
therefore an appropriate database to examine the birth prevalence of infants 
recorded with NAS in England.  
 
Limitations of HES relate to the quality of hospital administrative data.  Firstly, 
using HES can lead to systematic error, either because of incorrect recognition 
of symptoms and/or disease, recording by the doctor and/or coding by the 
hospital coder.  The quality of data varies across NHS hospital trusts.  
Secondly, the mother and baby identities are not linked in HES.  Information 
regarding the mother may not be in the baby record.  An example of this is if the 
type of opioid drug used by the mother is recorded, it may not be in the baby 
record.  However there is not at present, a gold standard method to examine 
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NAS and therefore HES is the most appropriate database to obtain the birth 
prevalence of NAS. 
 
3.5.4 Reasons for using HES in thesis 
To date there have been no large epidemiological studies looking at an indirect 
measure of drug use during pregnancy, specifically NAS.  My aim is to therefore 
compare recording of NAS in both primary and secondary care by using 
electronic health records from both.  I can then assess how much of the 
maternity discharge information is entered onto the baby’s electronic primary 
care records.  HES has previously been used to calculate prevalence rates of 
foetal alcohol spectrum disorders in England (Morleo et al., 2011) and I 
therefore wanted to explore its use for obtaining estimates of the prevalence of 
NAS in England. 
I will now describe and discuss different qualitative methods available for my 
fourth study. 
 
3.6 Qualitative Data Collection, Sampling and Analysis 
Techniques  
Qualitative research is generally interested in depth and/or understanding 
(Green and Thorogood, 2004).  I will describe and justify why I decided to use 
particular methods for data collection, sampling and analysis for my qualitative 
study.  Additionally, I will discuss rigor, data quality and the ethics of qualitative 
research methods.   
 
3.6.1 Qualitative interviews for generating data 
There are three common methods used to collect qualitative data; interviews, 
focus groups and participant observation (ethnography).  The methods aid in 
generating and shaping the data.   
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Interviews are well established as the most common qualitative method used for 
health research (Green and Thorogood, 2004).  An interview is a guided 
conversation between interviewer and interviewee (Ritchie and Lewis, 2003).  
The interview relies on the interview skills of the interviewer (Clough and 
Nutbrown, 2002).  A good interviewer tries to develop a rapport with the 
interviewee by asking questions clearly, listening actively, pausing correctly and 
exploring the answers aptly (Ritchie and Lewis, 2003).  The interviews can be 
conducted face-to-face, by telephone or using internet video-conferencing to 
gain insight and understanding (Ritchie and Lewis, 2003).  Opdenakker argues 
that telephone and video-conference interviews will have a different interaction 
between researcher and interviewee compared with face-to-face interviews 
(Opdenakker, 2006).  I therefore decided to conduct face-to-face interviews with 
all the participants, to help reduce the difference in interviewer-interviewee-
interaction between interviews.   
 
Semi-structured interviews, are based on a less formal structure and 
incorporate open-ended questions (Ritchie and Lewis, 2003).  The reseracher 
develops an interview schedule in order to set the agenda and aims to cover 
specific topics (Cohen and Manion, 2011).  The conversation may deviate due 
to the participant’s response and both researcher and participant can pursue 
the response or idea in more detail (Ritchie and Lewis, 2003). The order of 
questions may vary in interviews and some questions may not be asked 
(Newton, 2010).   
 
The main advantages of semi-structured interviews is that the researcher can 
prepare the questions ahead of time, yet the process and social cues still allow 
room for the participant to express their opinions and discuss a particular topic 
in more detail.  They can also provide reliable data that can be contrasted and 
compared to other interviews (Opdenakker, 2006).  Sensitive questions can 
also be asked in a relaxed environment, interviews can be recorded and there is 
less interactional difficulties which can be caused by an interview that is not 
face-to-face (Opdenakker, 2006).  The limitations of using semi-strucutred 
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interviews are that they can be time-intensive (but not as long as in-depth 
interviews), the interviewer may be less inclined to take notes if the interview is 
being recorded and the interviewer needs to be actively listening and 
concentrating for the duration of the interview (Green and Thorogood, 2004).  
Transcription of the interview is time-consuming and/or expensive and travelling 
to and from interviews can be costly (Green and Thorogood, 2004; Opdenakker, 
2006).  
 
After careful consideration and discussion amongst my supervisors and 
collegues, I decided to use face-to-face semi-structured interviews for my 
qualitative study with GPs.  I aimed to gain a deeper understanding of their 
perceptions, context and process of their recording practice of drug use.  I 
specifically chose semi-structured interviews as there were some specific 
questions I needed to ask at the beginning of the interview, followed by more 
open-ended questions.  I was aware of the importance of GP time and I 
intended to interview GPs from a range of locations, I therefore decided to 
conduct semi-structured rather than in-depth interviews or focus groups.  I will 
discuss how I iteratively developed my topic guide for my face-to-face 
interviews in section 7.5.3. 
 
3.6.2 Sampling techniques 
Sampling techniques depend on the purpose of the qualitative study (Al-
Busaidi, 2008).  The aim of sampling is to identify people who have particular 
characteristics or live in specific circumstances that are important to answering 
the research question (Al-Busaidi, 2008).  Unlike quantitative research, 
generalisability is not the main aim of the qualitative study sample (Green and 
Thorogood, 2004).  It is also not necessary to have a large sample, as the focus 
is on the quality of the insights not if they are made by a representative sample 
of people (Green and Thorogood, 2004).  There are no strict rules for deciding 
the sample size in qualitative research, it depends on the aim of the study and 
the feasibility in terms of costs and resources (Patton, 2002).  It is difficult to 
pre-determine the sample size for qualitative research, and this is often needed 
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for research grants and ethics applications (Green and Thorogood, 2004).  It is 
suggested that the researcher keeps sampling and analysing until there are no 
new themes arising, this is called ‘sampling to saturation’ (Patton, 2002).  
However, Patton argued that a researcher may run out of time and/or money 
before true saturation occurs (Patton, 2002).   
 
There are many sampling techniques used in qualitative research.  The main 
techniques are; convenience, snowballing, purposive and theoretical sampling.  
There are no superior sampling techniques and it depends on the research 
question, population, researcher and feasibility.  I initially decided to use 
purposive sampling as it is a technique that involves selecting participants from 
a particular group who are likely to generate useful and appropriate data 
(Coyne, 1997).  A researcher can select participants according to age, gender, 
status, profession, experience or location (Coyne, 1997).  I chose to interview 
GPs who had a special interest in patients who use drugs.  The clinical director 
of Substance Misuse Management in General Practice agreed to contact GPs 
who had completed the RCGP Certificate in the Management of Drug Misuse 
(see section 7.5.2 for details)  (Royal College of General Practitioners, 2015a). 
However, after initial interviews and analysis, I decided to also use theoretical 
sampling which originated with the grounded theory approach (Coyne, 1997).  
The researcher simultaneously collects and analyses data in order to establish 
emerging ideas and theories and to guide their upcoming sampling (Coyne, 
1997).  I will discuss my sampling process in more detail in section 7.5.2. 
 
3.6.3 Transcription and qualitative analysis methods 
The data was transcribed to prove a record of the words without linguistic 
features such as pauses and stresses which I judged to be sufficient to answer 
the research questions.  I will describe my transcription process in more detail in 
section 7.5.4.  
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I decided to use thematic analysis as it can be both an inductive and deductive 
approach (Joffe and Yardley, 2004).  It is a method used to describe and 
interpret generated themes from the data (Joffe and Yardley, 2004).  It can be 
very complex or simple, depending on the researcher’s aims.  The researcher 
can establish relationships between concepts and compare and contrast these 
with the rest of the data (Joffe and Yardley, 2004).  The main advantage of 
thematic analysis is that it can be flexible, however the analysis can either be 
very robust or lack depth or in between (Green and Thorogood, 2004).  
 
Thematic network analysis is a tool used to organise data and themes arising 
from thematic analysis (Attride-Stirling, 2001).  This organising technique is 
practical, systematic, rigorous and sensitive (Attride-Stirling, 2001).  As 
discussed earlier, thematic analysis aims to explore and gain insight into a 
phenomenon or idea from the text.  A conceptual diagram can then be 
produced and this allows the researcher to conceptualise the themes (Figure 
3:6) (Attride-Stirling, 2001).  I reasoned that this step-by-step methodical 
approach would be the most appropriate technique for organising my themes.  I 
will discuss in more detail how I thematically analysed my interviews in section 
7.5.7. 
 
 
Basic theme
Basic theme
Basic theme
Basic theme
Organising theme 1
Organising theme 2
GLOBAL THEME 1
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Figure 3:6: Thematic network analysis for organising themes arising from thematic 
analysis (Figure adapted from Attride-Stirling, 2001) 
 
3.6.4 Improving rigour of qualitative analysis 
3.6.4.1  Transparency of analysis 
In order for the collection and analysis of interviews to be transparent, a clear 
record needs to be kept and reported (Green and Thorogood, 2004).  It should 
also be reported in a way that non-qualitative researchers can understand 
(Clough and Nutbrown, 2002).  I will endeavour to show transparency of how I 
analysed my data in chapter 7 (see section 7.5.7). 
 
3.6.4.2 Improving validity 
In order to improve validity, the researcher needs to provide enough evidence 
and context from the data in order for the reader to judge the interpretation of 
the text (Clough and Nutbrown, 2002).  The researcher also needs to analyse 
any deviant cases that may occur (Green and Thorogood, 2004).  I will provide 
appropriate evidence in order for the reader to interpret the findings in (see 
section 7.5.7). 
 
3.6.4.3 Improving reliability 
In order to improve reliability of my analysis, qualitative researchers can set up 
a data clinic.  This clinic consists of other researchers analysing a sample of 
transcripts and then meeting to discuss similarity and differences in 
interpretation.  A data clinic is a good method to improve the rigour of qualitative 
analysis (Bergman and Coxon, 2005).  I will describe the data clinic that I 
conducted for study 4 later (Chapter 7 in section 7.5.5). 
 
3.6.4.4 Comparative 
The researcher needs to compare different interviews within the study (Green 
and Thorogood, 2004).  They also need to compare these results with previous 
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studies (Green and Thorogood, 2004).  I will compare my data within and with 
other studies in (see section 7.5.7). 
 
3.6.4.5 Reflexivity 
The researcher acts as the research instrument in qualitative research and 
therefore needs to monitor and critique their opinions, attitudes and interview 
techniques (Green and Thorogood, 2004).  The researcher should be aware 
that they are integral to developing and shaping the data (Pope and Mays, 
2000).  It is therefore good reflexive practice to be aware of their own opinions, 
attitudes and social context, keep detailed field notes, listen to the interview 
shortly after it has taken place and reflect on good and poor aspects of their 
interviewing technique (Green and Thorogood, 2004; Pope and Mays, 2000).  I 
will discuss how I addressed reflexivity throughout my qualitative study in 
section 7.5.6. 
 
3.6.5 Ethical considerations for qualitative research 
Most qualitative research does not involve direct impact/intervention, however 
there can be an emotional consequence when a participant is telling their story, 
such as having to live with ill health, reliving a traumatic event or discussing 
private and sensitive issues.  The researcher needs to respect the participant’s 
time and conversation and not focus soley on their research agenda.  The 
researcher also needs to gain a sense of rapport before asking potentially 
sensitive questions and be empathetic and actively listen to the participant.  
Green described how she felt misunderstood and rushed when she was a 
participant during an interview and found that there was little opportunity for her 
to ask questions (Green and Thorogood, 2004).  The participant needs to give 
informed consent before the interview process, and they should also be given 
the opportunity to refuse to give information or to withdraw from the study at any 
point.  If a one-to-one interview may be too intimidating, a focus group may be a 
more appropriate method to use.  I will discuss how I addressed ethical issues 
in my qualitative study in sections 7.5.1 and 7.5.3. 
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I have now described and justified the methods that I will be using for studies 1-
4.  I will now discuss how this chapter supports the thesis. 
 
3.7 How Does This Chapter Support My Thesis? 
I have described and discussed THIN database, which I will be using for all 
three epidemiological studies (Chapters 4-6).  I have also described and 
discussed HES, which I will be using in Chapter 6.  Finally, I have described 
and discussed qualitative methods that I will be using for the qualitative study 
(chapter 7).  I will now introduce the first study: GP recording in the general 
population. 
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 STUDY 1: GP RECORDING IN THE 
GENERAL POPULATION  
4.1 Content and Structure of Chapter 4 
The main aim of the thesis was to understand drug use and opioid substitution 
treatment in and around pregnancy.  However, in order to do this, I first had to 
ascertain if The Health Improvement Network (THIN) was a suitable 
surveillance tool for the general population.  This chapter therefore covers a 
description and discussion of my first study which examines GP recording of 
drug use and opioid substitution treatment of both males and females in THIN.  I 
also explored different codes available for GPs to use to record drug use and 
explain how annual recording rates (between 1994 and 2012), prevalence rates 
(between 2009 and 2012) and rate ratios were calculated.  As previously 
mentioned in section 1.3.7, there are different crime surveys and treatment 
monitoring databases for England and Wales, Scotland and Northern Ireland.  It 
is difficult to directly compare the three surveys as the scope and timing is not 
consistent.  For this reason, I will be focusing on drug use and treatment in 
England and Wales rather than for the whole of the UK.  This chapter contains 
the introduction, aim, specific objectives, methods, results and discussion for 
the first study. 
 
This study addresses the first objective of my PhD (see section 2.4 for details) 
and will also contribute to answering part of my main research questions 
(section 2.3):  
1. Can a large primary care database (The Health Improvement 
Network (THIN)) be used as a surveillance tool for understanding 
drug use and opioid substitution treatment in the general 
population and specifically during pregnancy (in England and 
Wales)? 
2. Can a large primary care database (THIN) be used as a tool to 
research drug use and opioid substitution treatment in general 
practice in the general population and specifically during 
pregnancy (in England and Wales)? 
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Part of this chapter has been published in the Plos One Journal, 2015 (Journal 
article is included in Appendix 11) 
4.2 Introduction 
As mentioned previously in the Chapter 1, illicit drug use and misuse of 
controlled drugs is a public health problem with serious impacts on both mental 
and physical health (Madgula et al., 2011a).  In 2012, between 162 and 324 
million people had used an illegal drug globally (United Nations Office on Drugs 
and Crime, 2014).  The prevalence of drug use in the United Kingdom (UK) is 
one of the highest in Europe, furthermore, the UK had the second highest 
number of illegal drug seizures in Europe in 2012 (European Monitoring Centre 
for Drugs and Drug Addiction, 2014a).  According to the Crime survey for 
England and Wales, there has been a reduction in reported drug use from 11% 
in 2001/02 to 8.2% in 2012/13 (Office for National Statistics, 2013a).  
Approximately one-third (35.9%) of individuals aged between 16-59 years have 
taken an illicit drug and/or 15% have used a class A drug at least once in their 
life (Office for National Statistics, 2013a).  The proportion of individuals who 
were classified as frequent drug users has decreased from 3.3% in 2011/12 to 
2.8% in 2012/13 (Office for National Statistics, 2013a).  These values may be 
underestimates as they are based on self-reports and hence may be subject to 
response bias (Office for National Statistics, 2013a, Frischer et al., 2001).  
Moreover, the surveys exclude groups of individuals who may be more likely to 
use drugs; prisoners, homeless people and students living in halls of residence 
(Degenhardt et al., 2013; Health Protection Agency, 2012; Office for National 
Statistics, 2013a).  
 
The majority of people who use drugs do so for recreational use and a small 
proportion become problem drug users and require treatment (see section 
1.3.2) (Public Health England, 2015).  As with recreational drug use, there has 
also been a reduction in problem drug users in treatment and the use of heroin 
and crack cocaine between 2005 and 2011 (Public Health England, 2015).  In 
England and Wales, opioid substitution prescribing is controlled and therefore 
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more effectively monitored than drug use (Public Health England, 2015).  
Consequently, the National Treatment Agency monitors problem drug use in 
England, whilst the Welsh drug misuse database monitors in Wales (Public 
Health England, 2015, Welsh Government, 2015).  The National Treatment 
Agency was established as a special health authority in 2001 and became part 
of Public Health England (PHE) in April 2013, which has incorporated 
prevention and recovery of drug dependency as one of the top five health 
priorities for 2013/2014 (Public Health England, 2015).  The National Drug 
Treatment Monitoring System monitors over 1,500 community treatment centres 
which includes inpatient, outpatient and GP practices in England (Public Health 
England, 2015).  Most of the National Treatment Agency services are accessed 
via self-referral and other referral sources including the NHS, the criminal justice 
system and GPs (Public Health England, 2015).  As with recreational drug use, 
more males from deprived areas are in treatment for problematic drug use 
(Public Health England, 2015).   
 
As previously mentioned in section 1.3.11, up to April, 2013 there were five 
studies that had used a primary care database to identify individuals with a 
recording of drug misuse and one study identifying individuals with prescriptions 
for opioid substitution treatment.  All five of the cohort studies by Frischer et al., 
used the General Practice Research Database (GPRD) to identify individuals 
recorded with drug misuse (Frischer et al., 2000; 2001, 2004, 2005, 2009).  The 
first study’s aim was to ascertain if the GPRD could be used as a surveillance 
tool for monitoring problematic drug use, whilst the second (pilot), third and 
fourth studies examined the prevalence of comorbid psychiatric illness and 
substance misuse and the fourth focused on the time-trends of recorded drug 
misuse 
 
The first study, published in 2000, aimed to see if the GPRD (in West Midlands, 
between January 1993 until December 1997) could be used as a surveillance 
tool and supplement an existing reporting system for problematic drug use, the 
Regional Drug Misuse Database (RDMD) (see section 1.3.8 for details) 
 90 
 
(Frischer et al., 2000).  As there were no specific OXMIS codes (see section 
1.3.5 for details) for problematic drug use or validation studies at this time, the 
authors identified and included all possible codes for drug misuse or 
dependence and drug overdose.  In total, forty OXMIS codes were identified as 
codes that GPs could use to record problematic drug use, however codes for 
referral to drug treatment were not included and the authors did not 
acknowledge that GPs may not record the drug use using OXMIS codes and 
may either record it in the free-text or not record it at all (Frischer et al., 2000).  
Individuals who had one of these codes in their electronic health records were 
identified and examined to see if they also had a diagnosis for a psychiatric 
morbidity and/or a hospital referral (Frischer et al., 2000).  The main findings 
were that recording trends were higher in the GPRD (n=6,574) compared with 
the RDMD (n=3,643).  The authors suggested that the discrepancy in number 
could be attributed to the decrease in mandatory reported cases to the RDMD 
and more individuals receiving treatment for problem drug use in primary care 
(Frischer et al., 2000).  Additionally, over half of the recorded cases in GPRD 
had a psychiatric co-morbidity and ten percent had a hospital referral.  The 
authors concluded that although GPs did not record the specific drug used, the 
GPRD may be a good contributor to overall drug misuse trends (Frischer et al., 
2000). 
 
Frischer et al. published preliminary findings from a pilot study examining the 
prevalence of comorbid mental illness and drug use recorded in GPRD 
(Frischer and Akram, 2001).  A patient was defined as having a comorbidity if 
they had both a mental illness and drug use diagnosis in their medical records 
(between January 1993 until December 1997) in the West Midlands.  The 
authors identified 40 and 369 OXMIS codes that GPs could use to record drug 
use and mental illness respectively.  They divided the drug use codes into three 
categories (based on ICD-9 codes), “non-dependent abuse of illicit drugs”, 
“dependence on/or addiction to illicit drugs” and “abuse of prescribed drugs”.  
The main findings showed that 0.25% of the cohort had a recorded for drug use, 
11.26% a recording for mental illness and 0.12% had a recording for both.  The 
authors concluded that the GPRD may be suitable for identifying and analysing 
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individuals with a comorbidity of mental illness and drug misuse (Frischer and 
Akram, 2001). 
 
The same authors published another study in 2004 to examine the prevalence 
of comorbid psychiatric illness and substance misuse between January 1993 
until December 1998 in England and Wales (Frischer et al., 2004).  They initially 
conducted a small validation study with a random sample (they did not present 
the actual number) and found that 92% of patients being treated for substance 
misuse in secondary care also had a diagnosis of substance misuse in their 
electronic health record.  They identified 258 possible Read and OXMIS codes 
for substance misuse disorder, however, they recognised that the codes were 
broad and most were not specific for the drug used.  Similarly to the study they 
conducted in 2000, they also did not include referral for drug treatment (Frischer 
et al., 2000).  They used results from their pilot study published in 2001, and 
substance misuse recordings into three groups; “drug misuse”, “drug 
dependence” and “licit drug dependence” (Frischer and Akram, 2001).  
Additionally, they included previously validated codes for psychiatric illness 
(divided into 6 groups).  Annual prevalence, incidence rates, continued 
prevalent and chronic cases for individuals with a comorbidity aged between 16-
84 years were calculated.  The annual prevalence increased in all age-groups 
except for individuals aged between 65-74 years; the ratio of males to females 
increased from 1.1:1 to 1.37:1.  The proportion of individuals from two of the 
substance misuse categories; (“drug misuse” and “drug dependence”) 
increased, whilst those in the category, “licit drug dependence” decreased.  
Additionally, the mean age in all three substance misuse categories differed 
(“drug misuse”; 30.2 years, “drug dependence”; 33.4 years and “licit drug 
dependence”; 45.3 years).  The authors emphasized that GPs are seeing more 
comorbid patients in primary care and that GPs are often the first point of 
contact for drug misusers (Frischer et al., 2004).   
 
A study published in 2005 by the same authors, aimed to examine the 
relationship between substance misuse and psychiatric illness in England and 
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Wales (Frischer et al., 2005).  They used the same OXMIS and Read codes 
(n=258) for substance misuse as the study published in 2004.  Between 1993 
and 1998, 15.1% (936,128) of individuals had a code for psychiatric illness, 
0.37% (22,904) had a code for substance misuse and 3969 individuals had 
codes for both.  They estimated that individuals who were coded with substance 
misuse first were 1.54 times more likely to develop a psychiatric illness, whilst 
those with a psychiatric illness were 2.09 times more likely to have a code for 
substance misuse.  The authors concluded that the study did not support the 
hypothesis that an increase in comorbidity was mostly due to an increase in 
substance misuse (Frischer et al., 2005).   
 
A later study by Frischer et al. (2009) examined recorded prevalence and new 
cases of drug misuse in primary care in individuals aged 16-59 years, between 
January 1998 and December 2005 in the UK (Frischer et al., 2009).  In contrast 
to their previous studies, the authors defined drug misuse differently, they still 
included codes for misuse and dependence and further added codes for referral 
and/or prescriptions for treatment, but did not include codes for licit drug 
dependence (Frischer et al., 2000, 2001, 2004, 2005, 2009).  They identified 
241 possible diagnostic codes and 12 prescription codes and suggested that 
individuals who had a diagnostic and/or prescription code had a serious enough 
problem to warrant a recording.  Both the prevalence and incidence rates 
decreased for the 16-24 age-group, whilst in the older age-groups, both 
prevalence and incidence increased or remained relatively stable.  The authors 
suggested a decline in recording which could be due to a decrease in overall 
drug use especially in the 16-24 year age-group as a result of the 1998 drug 
policy (see section 1.3.8 for details) (Frischer et al., 2009).   
 
The authors acknowledged that there were several advantages to using GPRD.  
Firstly, the database contained recorded information on drug misusers 
(regardless of the drug that was being used), time trends of drug misuse, 
associated co-morbidities and prescribing patterns (Frischer et al., 2000, 2001, 
2004, 2005, 2009).  Secondly, from 1997, GPs no longer had to legally notify 
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problem drug users to the home office addicts’ index and Regional Drug Misuse 
Database unless they were receiving opioid substitution treatment (see section 
1.3.8 for details).  Therefore the GPRD was more likely to capture drug users 
than the RDMD (Frischer et al., 2000).  However, they also acknowledged that it 
was difficult to identify the specific drug used (Frischer et al., 2005).  
Furthermore the authors argued that the information from primary care is not as 
prone to bias as population surveys as surveys require self-reporting and do not 
include certain groups (e.g. homeless individuals) (Frischer et al., 2004).  The 
GPRD population had a similarly age and gender distribution to the UK and 
patient level socio-economic status has become available since studies 
conducted in 2001 and the percentage of the population that GPRD represents 
has also increased over time (Frischer et al., 2000, 2001, 2004, 2009).  The 
authors emphasized that GPs were often the first point of contact for drug 
misusers (Frischer et al., 2004).  However, the first three studies (Frischer et al. 
2000, 2001, 2004) were conducted before the 1998 drug policy was 
implemented (see section 1.3.8 for details).  This policy encouraged a transition 
of problematic drug treatment from primary care into community drug clinics and 
therefore cohort studies conducted before this may have identified more 
problem drug users than future studies.   
 
The authors also identified several limitations to using GPRD.  Firstly, they 
acknowledged that the GPRD would only capture individuals who were 
permanently registered with a general practice, who also accessed primary care 
and disclosed their drug misuse to the GP.  Additionally, GPs needed to record 
the drug misuse in the electronic health records using either OXMIS or Read 
codes (Frischer et al., 2004).  The authors however did not acknowledge the 
fact that GPs may record drug misuse using free-text or not record it at all.  
Lastly, Frischer et al. 2009 did question the appropriate use of primary care 
data for examining epidemiology trends in drug misuse as the authors 
recognized that defining a true incident case using primary care databases is 
challenging as the individual may have been recorded previously when 
registered with a different general practice.  The decline of drug misusers 
identified in GPRD in the last study (Frischer et al., 2009) may have been due to 
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more individuals receiving drug misuse treatment from community drug clinics 
rather than general practice and some general practices opted out of treating 
individuals with problematic drug use (Frischer et al., 2009) 
 
Cornish et al. utilised the GPRD to examine individuals who had been 
diagnosed with substance misuse and prescribed opiate substitution treatment 
between 1990 and 2005 in the UK (Cornish et al., 2010).  The main outcome of 
the study was mortality rates related to the timing of prescriptions.  Individuals 
were included if they had at least one prescription of methadone or 
buprenorphine plus a diagnosis for substance misuse (Cornish et al., 2010).  
They were also included if they were prescribed dihydrocodeine together with 
either methadone or buprenorphine, but excluded if they were prescribed 
injectable methadone or buprenorphine (Cornish et al., 2010).  However, the 
authors did not specify which Read or OXMIS codes were used to confirm the 
diagnosis of substance misuse.  After exclusion, 5577 patients were identified 
and the study highlighted that the risk of mortality was increased at the start of 
opioid substitution treatment (14-28 days) and the month after treatment has 
discontinued (Cornish et al., 2010).   
 
The authors acknowledged that the main strengths of using GPRD was that it 
represented approximately 5% of the UK population and provided a 
representative sample of individuals who were prescribed opioid substitution 
treatment in general practice (Cornish et al., 2010).  They also argued that 
mortality rates could be detected more effectively in large observational studies 
using GPRD, compared with examining one general practice, drug clinic or a 
randomised controlled trial.  
 
Cornish et al. also identified several limitations to using GPRD; information 
regarding prescription doses, duration and quantity was sometimes missing for 
some patients, individuals who changed general practice during the study were 
lost to follow-up, covariates were limited due to the nature of recording in 
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electronic health records and the outcome measured was all-cause mortality as 
the records did not always specify the cause of death (Cornish et al., 2010).  
Finally, individuals who were prescribed only dihydrocodeine or other opioid 
substitution treatments were not included in the study.   
 
Based on the studies described above, my first study sought to assess more 
recent changes that may have occurred in GP recording of drug use, include 
individuals recorded with both problematic and recreational drug use and 
include all individuals who were prescribed an opioid substitution treatment.  I 
will then externally compare the results from THIN to annual reports produced 
by The Crime Survey for England and Wales, The National Treatment Drug 
Monitoring System and The Welsh National Database for Substance Misuse.to 
ascertain if electronic primary health records are a suitable tool for surveillance 
of drug use and opioid substitution treatment for the general population. 
 
4.3 Aim of Study 1 
To describe and examine GP recording of drug use and opioid substitution 
treatment in the general population using electronic health records 
 
4.4 Specific Objectives of Study 1 
Using data from England and Wales and the period between 1994 and 2012, I 
sought to: 
1. Explore the level of entry of different codes available for GPs to record 
drug use and opioid substitution treatment 
2. Identify new records (first recording) of drug use and opioid substitution 
treatment in primary care 
3. Examine recording rate ratios for new records of drug use and opioid 
substitution treatment 
4. Estimate the period prevalence (2010/11 to 2012/13) of recorded drug 
use and opioid substitution treatment 
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5. Compare GP recording of drug use and opioid substitution treatment with 
national surveys 
4.5 Hypotheses for Study 1 
Hypothesis 1: Recording Read codes for drug use occurs more in: 
a) males than females,  
b) youngest age-groups (16-24 years) compared to the oldest age-
groups (45-59 years) 
c) those living in the most deprived areas (fifth quintile of Townsend 
scores) compared to those from the least deprived areas (first quintile 
of Townsend scores). 
 
Hypothesis 2: Prescriptions for opioid substitution treatment were more likely to 
be given to: 
a) males, than females 
b) youngest age-groups (16-24 years) compared to the oldest age-
groups (45-59 years) 
c) those living in the most deprived areas (fifth quintile of Townsend 
scores) compared to those from the least deprived areas (first quintile 
of Townsend scores). 
 
Hypothesis 3: Recording of Read codes for opioid substitution treatment 
occurred more in: 
a) males, than females 
b) youngest age-groups (16-24 years) compared to the oldest age-
groups (45-59 years) 
d) those living in the most deprived areas (fifth quintile of Townsend 
scores) compared to those from the least deprived areas (first quintile 
of Townsend scores). 
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4.6 Ethics 
The National Health Service South-East Multicentre Research Ethics 
Committee granted approval for the THIN scheme to obtain and provide 
anonymous patient data for research in 2003.  The Scientific Review Committee 
(set up in 2009 in the UK) approved this study in 2013 (Approval number: 13–
026).  Cegedim Strategic Data Medical Research UK administers SRC 
application process. 
 
4.7 Methods 
4.7.1 Read code and prescription lists  
For each patient a GP can enter a Read code for a symptom or diagnosis and a 
code for a prescription in their computer system (see 1.3.5 and 3.4.2 for 
details).  I developed a list of Read codes and codes for prescriptions according 
to the methods described by Davé and Petersen  to identify individuals who use 
drugs or are prescribed opioid substitution treatment (Davé and Petersen, 
2009).  I used specific illegal and controlled drugs and derivatives of these 
drugs as search terms for drug use Read codes and specific opioid substitution 
treatments as search terms for relevant prescriptions (Drugscope, 2015d; Ford, 
2013, Frischer et al., 2009; Joint Formulary Committee, 2013, NICE, 2010a, 
NICE, 2007a, Office for National Statistics, 2013a; United Nations Office on 
Drugs and Crime, 2014) (Table 4.1).  Many drug users receive opioid 
substitution treatment in the community rather than from their GP (Public Health 
England, 2015).  However, the GP may be aware that they receive treatment 
and thus use these latter Read codes on their computer system.  I therefore 
used specific search terms to develop Read code lists for opioid substitution 
treatment (Table 4.1) (National Treatment Agency for Substance Misuse, 
2012a; Royal College of General Practitioners, 2011a). 
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Table 4.1: Search terms for developing Read and prescription code lists for drug use 
and opioid substitution treatment (OST) 
Read codes for drug use  Prescriptions for OST Read codes for OST 
Amphetamine 
Benzodiazepines 
Cannabis 
Cocaine 
Crack Cocaine 
Crystal Meth 
Dependence 
Heroin 
Inhalant 
Ketamine 
Khat 
Lysergic acid diethylamide 
(LSD) 
Magic Mushrooms 
Mandrax 
Mephedrone 
Methadrone 
Methamphetamine 
Methylone 
Naphyrone 
Nitrites 
Phencyclidine 
Polydrug 
Sedative 
Solvent 
Methadone 
Buprenorphine 
Naltrexone 
Lofexidine 
Dihydrocodeine 
Diamorphine 
 
Methadone 
Buprenorphine 
Opioid substitution treatment 
Opioid replacement therapy 
Drug addiction therapy 
Drug addiction treatment 
Drug dependence therapy 
Drug misuse treatment 
 
 
Once I had developed the code lists, a GP, (Professor Irwin Nazareth) and I 
manually examined the lists and took out any duplicates or any codes that had 
an ambiguous meaning (e.g. “drug tolerance”).  I categorised codes into generic 
and specific codes and examined those codes GPs most frequently used.  For 
each prescription, I examined the dose for each drug and included those which 
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followed the recommended doses by the National Institute for Health and Care 
Excellence (NICE), Royal College of General Practitioners (RCGP) and British 
National Formularies (BNF) for detoxification programmes (Ford et al., 2013; 
Joint Formulary Committee, 2013, National Institute for Clinical Excellence, 
2010a). 
 
For some individuals, it was not entirely obvious if dihydrocodeine was 
prescribed for an indication other than to treat substance misuse.  In those 
situations, I examined time between prescriptions and individuals were only 
considered to receive dihydrocodeine for drug misuse if it were prescribed at 
intervals less than 14 days and a dose greater than 450mg (Ford, 2013).  I 
initially included diamorphine in my opioid substitution treatment prescription 
list, as diamorphine is still prescribed for a small number of opioid dependent 
individuals in the UK, due to 5-10% of these individuals not responding to 
recommended treatments (Strang et al., 2010).  GPs require a home office 
license to prescribe diamorphine (Metrebian et al., 2006).  However, after 
explorative investigations of the data, I decided to exclude diamorphine 
prescriptions as I was uncertain if they were being prescribed for substance 
misuse treatment or for other purposes.   
 
4.7.2  Study population  
I obtained information from all individuals who were aged between 16-59 years 
and permanently registered with a general practice in England and Wales which 
provided data to THIN between January 1994 and December 2012.  Patients 
are registered with a general practice for different lengths of time and I therefore 
used patient years as the denominator.  I stratified analysis by age and year 
and accounted for change over time.  An example to illustrate this was if an 
individual was 18 years in 2000 and contributed 10 years of data, the individual 
would then contribute to the 16-24 age-band until 2006 and subsequently 
contribute to the 35-34 year age band.   
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4.7.2.1 Individuals recorded as either using drugs and/or receiving opioid 
substitution treatment  
I identified a group of people based on the first recording (between 1994 and 
2012) of either a: 
1) Read code for individuals who use drugs and/or  
2) Prescription for opioid substitution treatment and/or 
3) Read code for opioid substitution treatment  
 
I selected the first record for all individuals and examined the association 
between individuals who use drugs and opioid substitution treatment and the 
following covariates: gender, age, deprivation and time-period. 
 
4.7.3 Statistical analysis  
I summarised the socio-demographic profiles of individuals who had a recording 
of drug use or opioid substitution treatment.  I estimated recording rates and 
95% confidence intervals of a new recording entry for calendar years between 
1994 and 2012, taking into account the length of time that each individual was 
registered with the general practice.   
 
I conducted Poisson regressions to calculate the unadjusted and adjusted 
recording rate ratios (RR) with 95% confidence intervals of GP recording of 
people who use drugs and/or opioid substitution treatment.  I decided a priori on 
the basis of the existing literature to include age, gender, deprivation and region 
in the analysis as they may be potential confounders (European Monitoring 
Centre for Drugs and Drug Addiction, 2014a; Frischer et al., 2009; Office for 
National Statistics, 2013b).  I examined if there was effect modification and 
stratified the covariate if effect modification existed (Kirkwood and Sterne, 
2003).  I divided age into four age-bands and calendar years into 1994-2000, 
2001-2006 and 2007-2012 time-periods.  In order to select the model that best 
fits the data, I carried out hypothesis testing using likelihood tests ( 
Table 4.2) (Kirkwood and Sterne, 2003).  
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Table 4.2: Selection of appropriate model 
Model Covariates in model No of parameters 
2 Gender 2 
3 Age 4 
4 Deprivation 5 
5 Time-period 3 
6 Region 11 
7 Gender & age 6 
8 Gender, age & deprivation  11 
9 Gender, age, deprivation & time-period 14 
10 Gender, age, deprivation, time-period & region 25 
 
The prevalence of recording is sensitive to how long a patient has been 
registered in a general practice, I therefore only calculated the prevalence 
between the financial years, 2010/11 to 2012/13.  I then aimed to compare the 
results from THIN with national survey reports, which use financial years for 
reporting.  
 
4.7.4 External comparison  
As previously mentioned in section 1.3.8, the Crime Survey for England and 
Wales is a nationally represented sample of adults between the ages of 16-59 
which measures general population prevalence.  I compared the findings in 
THIN with those of the Crime Survey for England and Wales, National 
Treatment Agency and Welsh substance misuse database, and estimated the 
proportion captured in THIN. 
All data was analysed using STATA (version 13) statistical software (Stata Corp 
LP, College Station, Texas). 
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4.7.5 Sensitivity analysis 
4.7.5.1 Recording of drug use and/or opioid substitution treatment in 
relation to registration  
Primary care databases are used to determine incidence rates of certain acute 
and chronic conditions.  Only new cases should be included when calculating 
incidence rates.  Prevalent cases can, however be misclassified as incident 
cases due to the following two reasons: 
1) When a new patient registers at a general practice, they may be 
asked to fill out a health questionnaire.  Information from the 
questionnaire is then entered into their electronic medical records 
(Lewis et al., 2005).  Their records from their previous general 
practice should be transferred to the new practice and important 
aspects of their patient history should be entered electronically 
(Lewis et al., 2005).  The information is usually highlighted by a 
GP and should be entered as a retrospective diagnosis by the 
GP or administrative staff.  If the information is not entered as a 
retrospective entry, the information may seem as though it is a 
new symptom or condition as the date of the diagnosis will be the 
same as the date of entry (Lewis et al., 2005). 
2) The patient may have registered with a new general practice as a 
result of the condition.  The condition is therefore not a true new 
case. 
Therefore incidence rates could be overestimated during the first year of patient 
registration.  Lewis et al conducted a study using GPRD (section 1.3.6) to 
examine how many months a researcher should exclude after patient 
registration to obtain accurate incidence rates (Lewis et al., 2005).  The study 
also examined if different diseases had a different time lag from patient 
registration.  Lewis et al. found that the incidence rates were consistently 
overestimated for many conditions during the time shortly after patient 
registration (Lewis et al., 2005).  The period of overestimation was different for 
different diseases; overestimation occurred for the first 3, 6 and 12 months for 
acute diseases, neoplastic disease and chronic or relapsing diseases 
respectively.  They therefore recommended that researchers using GPRD 
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exclude a specific time period (dependent on the disease) after patient 
registration, in order to include actual incidence cases.   
 
Lewis et al. developed the ‘Lewis’ plot which is a graph where time since 
registration (x axis) is plotted against the annual incidence rate per 1000 person 
years at risk (y axis).  A researcher can replicate this plot with the particular 
disease or condition that they are examining and determine how long after 
patient registration they should include in order to avoid bias and overestimation 
of incidence rates (Lewis et al., 2005).   
 
For this study I was investigating the recording rate of drug use and opioid 
substitution treatment rather than the incident cases.  The reasons I could not 
determine the incidence of drug use were the following: 
1) The GP may not enter the patient information retrospectively 
2) The patient may have been using drugs previously, but only disclosed 
their drug use for the first time in the first consultation with the new GP or 
in the health questionnaire 
3) The patient may have been using drugs previously, but registered with a 
general practice due to signs and symptoms resulting from drug use. 
I still wanted to investigate when most of the recording of drug use and opioid 
substitution treatment was occurring in primary care in relation to patient 
registration.  I therefore produced a graph for recording of Read codes for drug 
use and prescriptions and Read codes for opioid substitution treatment in 
relation to registration (Lewis et al., 2005).   
 
4.7.5.2 Free-text comments 
As previously mentioned, a GP can enter information about the consultation as 
Read codes or free-text.  In addition to examining Read codes, I developed a 
free-text list by using the following search terms in the THIN comments data 
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file:“addiction”, “amphetamine”, “buprenorphine”, “cannabis”, “cocaine”, 
“dependence”, “drug”, “heroin”, “inhalant”, “ketamine”, “LSD”, “marijuana”, 
“methadone”, “mephedrone”, “sedative”, “solvent”, “overdose”, “withdrawal".  Of 
the possible unique and frequently used comments, I excluded duplicates and 
then went through each of these comments manually to ascertain if they were 
relevant or not.  After excluding duplicates, I merged the remaining comments 
with the medical records and any additional health data records to see how 
many of the individuals who had the comments, also had a Read code for drug 
use and/or a prescription for opioid substitution treatment. 
 
4.8 Results 
4.8.1 Analysis of Read and prescription codes identified and used 
by GPs  
Overall, there were 517 different Read codes for drug use, 154 prescription 
codes for opioid substitution treatment and 54 Read codes for opioid 
substitution treatment available for GPs to use (Table 4.3) (See Appendix 5 for 
comprehensive codes lists).   
 
Table 4.3: Number of Read codes and prescriptions after exclusion of duplicates, 
ambiguous or unrelated codes 
Possible codes Possible codes Number of codes 
included in 
analysis 
Read codes for drug use 765 517 
Prescription codes for opioid substitution 
treatment 
268 154 
Read codes for opioid substitution 
treatment 
488 43 
 
There was a wide range of codes that GPs could use to record drug use, 
however, GPs only used half (51%, 267/517) of the available Read codes for 
drug use in THIN.  The twenty most frequently used codes accounts for only 
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3.7% of the total available codes and only 2.5% (n=6) of these are specific to a 
particular drug Table 4.4 and Table 4.5.   
Table 4.4: Read codes available for GPs to use for recording drug use 
Categories of Read 
codes used 
All drug use Read 
codes 
Specific to drug use 
(e.g. cannabis use) 
Generic drug use 
(e.g. drug user) 
 N/denom %  N/denom % N/denom % 
Drug use Read codes 
available 
517  246/517 
 
46.4 284/517 53.6 
Drug use Read codes 
used by GPs 
267/517 50.3 118/246 47.6 149/284 52.4 
20 most frequent drug 
use Read codes used 
20/517 3.7 6/246 2.5 14/284 4.9 
denom=denominator 
 
Table 4.5: The ten most frequently used Read codes for drug use in THIN 
Description Specific or 
generic 
Frequency % 
(denom=33,508) 
Benzodiazepine dependence 
Cannabis type drug dependence 
Drug addiction 
Drug addiction therapy 
Drug dependence 
Drug user 
Drug withdrawal syndrome 
H/O cannabis misuse 
H/O: drug abuse 
H/O: drug dependency 
Specific 
Specific 
Generic 
Generic 
Generic 
Generic 
Generic 
Specific 
Generic 
Generic 
4,408 
3,169 
2,396 
2,148 
1,760 
1,686 
1,597 
1,557 
1,190 
1,189 
10.9 
7.9 
5.9 
5.4 
4.4 
4.2 
3.9 
3.9 
2.9 
2.9 
denom=denominator 
 
GPs prescribed only 18% (n=27) of the available prescriptions for opioid 
substitution treatment in primary care, furthermore, the twenty most frequently 
prescribed drugs account for only 12.9% of the total available prescription 
codes (Table 4.6 and Table 4.7).  Buprenorphine HCL, sublingual tablets 200µg 
and methadone oral solution (1mg/ml) were the most frequently prescribed 
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drugs for opioid substitution treatment (See Appendix 6 for comprehensive 
codes lists).   
Table 4.6: Prescription codes available for GPs to record opioid substitution treatment 
 N/denom % (denom=154) 
Total prescription codes available 154  
Prescription codes used by GPs 27/154 17.5 
20 most frequent prescription codes used 20/154 12.9 
denom=denominator 
 
Table 4.7: The ten most common prescriptions for opioid substitution treatment in THIN 
Drug prescribed Frequency % 
(denom=
10,869) 
Buprenorphine HCL sublingual tab 200µg 
Methadone oral soln 1mg/ml 
Methadone sf oral soln 1mg/ml 
Buprenorphine HCL sublingual tab 2mg 
Buprenorphine HCL sublingual tab 400 µg 
Buprenorphine HCL sublingual tab 8mg 
Naltrexone HCL tabs 50mg 
Lofexidine tabs 0.2mg 
Methadone linc 2mg/5ml 
Methadone tabs 5mg 
4,270 
2,731 
948 
682 
608 
429 
398 
277 
165 
155 
39.3 
25.1 
8.7 
6.3 
5.6 
3.9 
3.7 
2.6 
1.5 
1.4 
denom=denominator 
 
A larger percentage (72%, n=31/43) of possible Read codes for opioid 
substitution treatment were used by GPs in contrast to Read codes for drug use 
and prescription codes, almost half (46.5%) of these Read codes were included 
in the ten most frequently used (Table 4.8 and Table 4.9) (See Appendix 7 for 
comprehensive codes lists).   
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Table 4.8: Read codes available for GPs to record opioid substitution treatment (OST) 
 All OST Read codes Specific (e.g. methadone 
therapy) 
Generic (e.g. 
drug addiction 
therapy) 
 N/denom % N/denom % N/denom % 
Total OST Read codes 
available 
43  27/43 62.7 16/43 37.3 
OST Read codes used 
in THIN 
31/43 72 16/27 59.2 15/16 93.8 
10 most frequent codes 
used in THIN 
20/43 46.5 9/27 33.3 11/16 68.7 
denom=denominator, OST=Opioid Substitution treatment 
 
Table 4.9: The 10 most common Read codes for opioid substitution treatment in THIN 
denom=denominator 
 
Description Specific  
or generic 
Frequency % 
(denom= 
7,655) 
Drug addiction therapy 
Drug addiction therapy-methadone 
Methadone dependence 
Drug addiction maintenance therapy - methadone 
Drug addiction detoxification therapy - methadone 
Drug dependence therapy 
H/O methadone misuse 
Drug addiction maintenance therapy - buprenorphine 
Buprenorphine maintenance therapy 
Methadone maintenance 
Generic 
Specific 
Specific 
Specific 
Specific 
Generic 
Specific 
Specific 
Specific 
Specific 
4,203 
1,993 
432 
345 
236 
129 
47 
36 
32 
30 
54.9 
26.0 
5.6 
4.5 
3.1 
1.7 
0.6 
0.5 
0.4 
0.4 
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In summary, there are many codes available for GPs to use in contrast to other 
disease areas, however GPs only use a small percentage of these available 
codes.  
 
4.8.2 Rates for first recording of Read codes and/or prescriptions  
In total, there were 33,508 individuals with a record of drug use, 10,869 
individuals with prescriptions for opioid substitution treatment, and 7,655 
individuals with Read codes for opioid substitution treatment.  Patients had 
different combinations of Read and prescription codes in their electronic health 
records (Figure 4:1), but relatively few individuals had entries of all three.  
Hence, there were 28,179 (63.7%) individuals recorded as using drugs, but not 
receiving any opioid substitution treatment in primary care. 
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Figure 4:1: Venn diagram illustrating the number of individuals who had a recording for drug use and/or opioid substitution treatment (OST) 
(Reproduced with permission of the rights holder, Plos One)
Drug use Read codes
28,179 (63.7%) 
OST                                  
Read  code 
2,395 (5.4%)
OST prescription
7,147 (16.2%)
 
1234 (2.8%) 
1278 (2.9%) 
1146 (2.6%) 
2822 (6.4%) 
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Overall there were more males than females with a recording of drug use and/or 
opioid substitution treatment.  Of those with a recording for drug use, most were 
between the ages of 16-24 years, from the North East of England and the most 
deprived quintile ( 
Table 4.10).  Fewer individuals had Read or prescription codes for opioid substitution 
treatment, but the regional and socio-demographic patterns were similar, although 
they were slightly older and most of the individuals with a Read code for treatment 
were from the North West of England.   
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Table 4.10: Demographics, first recording rate (95% CI) for drug use Read codes and opioid substitution treatment (OST) prescription and 
Read codes by gender, age-band, region and Townsend deprivation score.  (Rate=first recording rate/1000 person years at risk) 
 Drug use Read codes OST prescriptions OST Read codes 
Demographics  N (%)             
N=33,508 
Rate (95% CI)    
per 1000/PYAR 
N (%)             
N=10,869 
Rate (95% CI)    
per 1000/PYAR 
N (%)          
N=7,655 
Rate (95% CI)   
per 1000/PYAR 
Gender 
Males 22,622 (67.5) 1.49 (1.40-1.60) 6721 (61.8) 0.45 (0.39-0.51) 5241 (68.4) 0.33 (0.28-0.370 
Females  10,886 (32.5) 0.74 (0.67-0.82) 4748 (38.2) 0.35 (0.29-0.38) 2414 (31.6) 0.50 (0.42-0.56) 
Age-band 
16-24 10,650 (31.8) 2.47 (2.23-2.72) 1,542 (14.2) 0.43 (0.33-0.55) 1,482 (19.4) 0.34 (0.27-0.44) 
25-34 10,994 (32.8) 1.76 (1.60-1.93) 3,122 (28.7) 0.53 (0.44-0.63) 3,377 (44.1) 0.50 (0.43-0.59) 
35-44   6,704 (20.0) 0.88 (0.77-0.99) 2,624 (24.1) 0.37 (0.30-0.46) 1,970 (25.7) 0.24 (0.20-0.30) 
45-59   5,160 (15.4) 0.41 (0.33-0.50) 3,581 (32.9) 0.33 (0.27-0.39) 826 (10.8) 0.06 (0.04-0.08) 
Region 
London 4,051 (12.1) 0.06 (0.05-0.07)   788 (7.25) 0.24 (0.16-0.34)   606 (7.92) 0.16 (0.11-0.24) 
East Midlands 1,514 (4.52) 0.06 (0.04-0.07)   608 (5.59) 0.46 (0.30-0.69)   433 (5.66) 0.27 (0.17-0.43) 
East of England 2,768 (8.26) 0.12 (0.11-0.13)   750 (6.90) 0.34 (0.22-0.49)   453 (5.92) 0.16 (0.10-0.26) 
West Midlands 3,051 (9.11) 0.06 (0.05-0.06) 1,243 (11.4) 0.37 (0.28-0.50)   851 (11.1) 0.22 (0.16-0.31) 
North East 1,258 (3.75) 0.15 (0.09-0.17)   559 (5.14) 0.64 (0.41-0.96)   314 (4.10) 0.29 (0.18-0.48) 
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 Drug use Read codes OST prescriptions OST Read codes 
Demographics  N (%)             
N=33,508 
Rate (95% CI)    
per 1000/PYAR 
N (%)             
N=10,869 
Rate (95% CI)    
per 1000/PYAR 
N (%)          
N=7,655 
Rate (95% CI)   
per 1000/PYAR 
North West 5,513 (16.5) 0.10 (0.09-0.11) 1,721 (15.8) 0.54 (0.42-0.68) 1,669 (21.8) 0.46 (0.37-0.57) 
South Central 3,990 (11.9) 0.12 (0.10-0.15)   417 (3.84) 0.33 (0.25-0.44)   240 (3.14) 0.20 (0.15-0.27) 
South East Coast 3,865 (11.5) 0.13 (0.12-0.15) 1,459 (13.4) 0.34 (0.24-0.48) 1,063 (13.9) 0.16 (0.11-0.26) 
South West 3,112 (9.29) 0.05 (0.05-0.06) 1,127 (10.3) 0.46 (0.34-0.61)   539 (7.04) 0.24 (0.17-0.34) 
Yorkshire & Humberside  1,211 (3.61) 0.05 (0.04-0.07) 1,362 (12.5) 0.35 (0.21-0.56)   782 (10.2) 0.18 (0.10-0.32) 
Wales 3,175 (9.48) 0.09 (0.08-0.10)   835 (7.68) 0.38 (0.26-0.54)   705 (9.21) 0.27 (0.19-0.40) 
Townsend deprivation 
1(least deprived) 3,825 (12.0) 0.45 (0.38-0.53) 1,475 (14.3) 0.19 (0.15-0.25)   526 (7.21) 0.06 (0.04-0.09) 
2 4,200 (13.1) 0.65 (0.56-0.76) 1,552 (15.0) 0.26 (0.20-0.34)   696 (9.62) 0.17 (0.11-0.25) 
3 6,321 (19.8) 1.06 (0.93-1.20) 2,092 (20.2) 0.37 (0.29-0.47) 1,275 (17.5) 0.38 (0.27-0.52) 
4 8,571 (26.8) 1.68 (1.50-1.88) 2,691 (26.0) 0.58 (0.47-0.71) 2,166 (29.8) 0.77 (0.59-1.02) 
5(most deprived) 9,076 (28.4) 2.89 (2.59-3.21) 2,526 (24.4) 0.89 (0.72-1.09) 2,604 (35.8) 1.55 (1.24-1.96) 
Time-period 
1994-2000 5493 (16.4) 1.18 (1.07-1.25) 2011 (15.5) 0.47 (0.41-0.53) 1066 (13.9) 0.18 (0.15-0.21) 
2001-2006  13,307 (39.7) 1.14 (1.11-1.19) 4197 (38.6) 0.36 (0.33-0.39) 3444 (45.0) 0.30 (0.27-0.33) 
2007-2012 14,708 (43.9) 1.11 (1.07-1.16) 4661 (42.9) 0.34 (0.32-0.37) 3145 (41.1) 0.24 (0.22-0.26) 
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4.8.3 Statistical model 
I observed an effect modification for gender and therefore stratified the results of 
age, deprivation and region by gender.  Following my hypothesis testing to select 
the most appropriate model, I included age and deprivation.  As there was no 
evidence that region improved the fit of the model (p=0.08 for males and p=0.07 for 
females), I excluded this variable from my final model. 
 
4.8.4 Recording rate ratios for drug use Read codes  
Men were almost twice as likely to have a Read code in their electronic health 
records for drug use when compared to women (RR 1.71, 95% CI: 1.68-1.75).  For 
men, compared to the oldest age group, the youngest age group was five and a 
half times more likely to have a recording for drug use when adjusted for 
deprivation (RR 5.59, 95% CI:5.37-5.83) (Table 4.11).   
 
Table 4.11: Unadjusted and adjusted Rate Ratios (95% CI) for drug use Read codes by 
age-band and deprivation (1994-2012) 
 Males Females 
Demographics Unadjusted RR 
(95% CI) 
*Adjusted RR 
(95% CI) 
Unadjusted RR 
(95% CI) 
*Adjusted RR 
(95% CI) 
Age-group 
16-24 5.89 (5.66-6.14) 5.59 (5.37-5.83) 2.79 (2.66-2.93) 2.54 (2.42-2.68) 
25-34 5.73 (5.51-5.96) 5.09 (4.89-5.31) 2.54 (2.42-2.66) 2.15 (2.05-2.26) 
35-44 2.86 (2.74-2.99) 2.64 (2.52-2.77) 1.63 (1.55-1.72) 1.49 (1.41-1.57) 
45-59 1 1 1 1 
Deprivation 
1 (least 
deprived) 
1 1 1 1 
2 1.42 (1.35-1.49) 1.41 (1.34-1.49) 1.32 (1.24-1.41) 1.36 (1.27-1.46) 
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 Males Females 
Demographics Unadjusted RR 
(95% CI) 
*Adjusted RR 
(95% CI) 
Unadjusted RR 
(95% CI) 
*Adjusted RR 
(95% CI) 
3 2.18 (2.09-2.29) 2.04 (1.94-2.14) 1.92 (1.81-2.03) 1.89 (1.78-2.02) 
4 3.41 (3.27-3.56) 2.97 (2.84-3.11) 2.75 (2.60-2.90) 2.73 (2.57-2.91) 
5 (most 
deprived) 
5.64 (5.40-5.89) 4.83 (4.62-5.06) 4.39 (4.16-4.64) 4.28 (4.03-4.56) 
*Adjusted for age and deprivation 
There were consistently more individuals between the ages 16-24 years who had a 
Read code for drug use than those in the 25-34 year age-group before 2012.  
However, the rates of these two age-groups converge in 2012 (Figure 4:2). 
 
 
Figure 4:2: First recording rates of Read codes for drug use by age-bands (16-24 and 25-
34 years) per 1000 person years at risk (1994-2012) 
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There was also a trend with regards to social deprivation; men from the highest 
quintile of deprivation were almost five times more likely to have Read code for 
drug use compared to those from the lowest quintile of deprivation when adjusted 
for age (RR 4.83 95% CI: 4.62-5.06) (Figure 4:3 and Table 4.11).  
 
 
Figure 4:3: First recording rate of drug use (Read code) by deprivation for men 
 
For women, the pattern was similar to men, although the contrasts were less stark 
(Table 4.11). 
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a) males than female  (Recording Risk Ratio (RRR): 1.71, 95% CI: 1.68-
1.75)  
b) aged between 16-24 years compared with adults aged 45-59 (RRR: 
5.59, 95% CI: 5.37-5.83)  
c) from the most deprived areas compared to the least deprived areas  
(RRR: 4.83, 95% CI: 4.62-5.06) 
 
4.8.5 Recording rate ratios for opioid substitution treatment 
prescription codes 
There were more individuals with a record for drug use than those receiving a 
prescription for opioid substitution treatment.  More men than women received 
opioid substitution treatment (RR 1.22, 95% CI: 1.18–1.28), and also the most 
deprived group were more likely to have an opioid substitution treatment entry in 
their records (Table 4.12)  
 
Table 4.12: Unadjusted and adjusted Rate Ratios (95% CI) for opioid substitution 
treatment prescriptions by age-band and deprivation (1994-2012) 
 Males Females 
Demographics Unadjusted RR 
(95% CI) 
*Adjusted RR 
(95% CI) 
Unadjusted RR 
(95% CI) 
*Adjusted RR 
(95% CI) 
Age-groups 
16-24 1.38 (1.27-1.49) 1.25 (1.15-1.36) 0.89 (0.81-0.97) 0.81 (0.74-0.89) 
25-34 2.72 (2.55-2.91) 2.33 (2.18-2.50) 1.39 (1.29-1.50) 1.19 (1.12-1.29) 
35-44 1.82 (1.70-1.95) 1.64 (1.53-1.76) 1.16 (1.08-1.25) 1.08 (1.00-1.67) 
45-59 1 1 1 1 
Deprivation 
1 (least 
deprived) 
1 1 1 1 
2 1.40 (1.26-1.54) 1.37 (1.23-1.52) 1.34 (1.21-1.48) 1.33 (1.21-1.47) 
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 Males Females 
Demographics Unadjusted RR 
(95% CI) 
*Adjusted RR 
(95% CI) 
Unadjusted RR 
(95% CI) 
*Adjusted RR 
(95% CI) 
3 2.07 (1.89-2.27) 1.98 (1.80-2.17) 1.66 (1.51-1.83) 1.64 (1.49-1.81) 
4 3.10 (2.84-3.38) 2.87 (2.62-3.12) 2.29 (2.08-2.51) 2.24 (2.05-2.47) 
5(most 
deprived) 
4.86 (4.45-5.30) 4.44 (4.06-4.84) 3.01 (2.74-3.32) 2.95 (2.68-3.25) 
*Adjusted for age and deprivation 
Men were slightly older (25-34 years) when they had their first entry for opioid 
substitution treatment compared to when they had their first record for drug use 
entered in their electronic health records (Table 4.11 and Table 4.12).  Younger 
women compared to the 45-64 year age-band were less likely to have a 
prescription for opioid substitution treatment (Figure 4:4). 
 
 
Figure 4:4: Read (drug use) and prescription codes (opioid substitution treatment) by age-
band (in years) and gender per 1000 person years at risk (1994-2012) 
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There were more individuals with prescriptions for opioid substitution treatment 
between 1997 and 2002, however the age-groups cross each other around 2002, 
and then more individuals in the 25-34 age-band received treatment compared to 
the younger age group (Figure 4:5). 
 
Figure 4:5: First recording rate of opioid substitution treatment by age-bands (16-24 and 
25-34 years) per 1000 person years at risk (1994-2012) 
 
Similar to the Read codes for drug use, there was also a trend with regards to 
social deprivation, men from the highest quintile of deprivation were over four times 
more likely to have a prescription for opioid substitution treatment compared to 
those from lowest quintile of deprivation (RR 4.44, 95% CI:4.06-4.84) (Figure 4:6 
and Table 4.12).   
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Figure 4:6: First recording rate of opioid substitution treatment prescription by deprivation 
for men 
 
4.8.5.1 Accept or reject hypothesis 2 
I accepted parts a and c of the second hypothesis, as individuals who had a 
prescription for opioid substitution treatment were more likely to be: 
a) male than female (RRR: 1.22, 95% CI: 1.18–1.28) 
b) from the most deprived areas compared to the least deprived areas  
(RRR: 4.86, 95% CI: 4.45-5.30) 
I rejected part b of the second hypothesis, as individuals from the older age group 
(25-34 years) compared with the oldest age-group (45-59 years) were more likely 
to have a prescription of opioid substitution treatment. (RRR: 2.72, 95% CI: 2.55-
2.91) 
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4.8.6 Rate ratios for Read codes for opioid substitution treatment 
Similar patterns were found for Read codes for opioid substitution treatment to 
those of the prescription codes (higher RR for males, 25-34 age-band and from the 
most deprived quintile (Table 4.13). 
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Table 4.13: Unadjusted and adjusted Rate Ratios (95% CI) for opioid substitution 
treatment Read codes by age-band and deprivation (1994-2012) 
 Males Females 
Demographics Unadjusted RR 
(95% CI) 
Adjusted RR 
(95% CI) 
Unadjusted RR 
(95% CI) 
Adjusted RR 
(95% CI) 
Age-group 
16-24 4.46 (4.01-4.96) 4.27 (3.83-4.76) 5.94 (5.14-6.86) 5.28 (4.55-6.12) 
25-34 10.3 (9.40-11.31) 9.00 (8.18-9.19) 9.24(8.09-10.55) 7.37 (6.43-8.45) 
35-44 5.39 (4.89-5.95) 4.94 (4.46-5.47) 4.05 (3.50-4.68) 3.56 (3.07-4.13) 
45-59 1 1 1 1 
Deprivation 
1 (least 
deprived) 
1 1 1 1 
2 1.74 (1.52-1.99) 1.69 (1.46-1.92) 1.64 (1.34-2.01) 1.57 (1.28-1.93) 
3 3.03 (2.67-3.42) 2.72 (2.40-3.08) 3.42 (2.86-4.08) 3.00 (2.51-3.59) 
4 5.89 (5.25-6.61) 4.96 (4.42-5.57) 6.11 (5.16-7.24) 4.98 (4.20-5.89) 
5(most 
deprived) 
11.2 (10.0-12.6) 9.21 (8.22-10.31) 10.9(9.19-12.8) 8.38 (7.09-9.91) 
*Adjusted for age and deprivation 
4.8.6.1 Accept or reject hypothesis 3 
I accepted parts a and c of the third hypothesis, as individuals who had a recording 
for a Read code for opioid substitution treatment were more likely to be: 
c) male than female (RRR: 1.62, 95% CI: 1.28–1.78) 
d) from the most deprived areas compared to the least deprived areas  
(RRR: 9.21, 95% CI: 8.22-10.31) 
I rejected part b of the second hypothesis, as individuals from the older age group 
(25-34 years) were more likely to have a prescription of opioid substitution 
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treatment compared with the oldest age-group (45-59 years). (RRR: 9.00, 95% CI: 
8.18-9.19) 
 
4.8.7 Prevalence of Read codes for drug use and prescriptions and 
Read codes for opioid substitution treatment  
Between the financial years of 2010/11 and 2012/13, the prevalence rates 
remained relatively stable for Read codes for drug use (2.3 per 1000), prescriptions 
for opioid substitution treatment (0.8 per 1000) and Read codes for opioids 
substitution treatment (0.3 per 1000).  
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4.8.8 External comparison of findings with national surveys. 
4.8.8.1 The Crime Survey for England and Wales  
The prevalence rates from the Crime Survey for England and Wales and THIN are 
shown in Table 4.14.  Assuming that the Crime Survey for England and Wales is 
representative of the population of England and Wales, 25% (2.2/8.7) of those 
estimated as using drugs in the population were captured in THIN.   
Table 4.14: Comparison of prevalence rates between the Crime Survey for England and 
Wales and THIN 
Year 
 
Estimated number of 
people using drugs in 
England and Wales* 
(million) 
Estimated number of 
people who use drugs 
in England and Wales 
(per 1000) 
Prevalence of people 
with a recording of drug 
use in THIN (per 1000) 
% recorded in 
THIN 
2010/11 2.8 8.6 2.2 25 
2011/12 2.9 8.8 2.1 23 
2012/13 2.9 8.7 2.2 25 
Mean 2.9 8.7 2.2 25 
*(Office of National Statistics 2010-2013) 
4.8.8.2 National Drug Treatment Monitoring System (NDTMS) and the Welsh 
Substance Misuse Database  
Before November 2012, the NDTMS did not categorize where an individual 
received their treatment (Public Health England, 2013a).  I could therefore only 
compare the estimated number of individuals who would have received treatment 
from general practice in 2012/13.  According to the NDTMS, a fifth (22%) of 
individuals received a new prescription for treatment of drug use from their GP in 
2012/13 (Public Health England, 2013a).  About half of the total individuals 
recorded in the NDTMS are in treatment for opioid use alone and may therefore be 
treated with opioid substitution treatment (Public Health England, 2013a).  From 
these figures, I estimated that 548 individuals (6% of population) should be 
receiving their treatment from general practice.  The amount of individuals that I 
identified receiving a new prescription for opioid substitution treatment was very 
close to the number recorded by NDTMS (98.7% 541/548), (Table 4.15). 
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Table 4.15: Comparison of individuals recorded in National Drug Treatment Monitoring 
System and THIN 
NTMDS report 2012/13 England  
Number of people in drug treatment in England during 2012/13 194,110 
0.37 per 1000  
 
% receiving first-time psychosocial or pharmaceutical 
interventions 
 
72.4% 
(140,629/194,110) 
 
% receiving first-time pharmaceutical interventions 
 
61.4%  
(86,392/140,629) 
 
% receiving pharmaceutical treatment from general practice 
 
22%  
(19,014/86,392) 
 
% of opiate users in drug treatment (therefore requiring OST) 
 
48%  
(93,434/194,110) 
 
Estimated number receiving opioid substitution treatment from 
general practice 
 
9127 
(0.48x19,014) 
 
Estimated number receiving opioid substitution treatment in THIN 
 
547  
(0.06 x 9127) 
 
No of individuals with a new recording for opioid substitution 
treatment capture in THIN  
 
528 
(Public Health England, 2013a) OST=Opioid Substitution Treatment 
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I was unable to estimate the number from the Welsh substance misuse database, 
as they did not categorise where individuals received their opioid substitution 
treatment from (Welsh Government, 2013). 
 
4.8.9 Sensitivity analysis 
4.8.9.1 Recording of drug use and opioid substitution treatment in relation to 
registration 
Recording for drug use drops steeply after in the first two months after registration 
(Figure 4:7).  The pattern is similar for prescriptions and Read codes for opioid 
substitution treatment  
 
 
Figure 4:7: Recording rates of drug use Read codes in the first 2-3 months after patient 
registration 
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As previously mentioned, I decided not to exclude individuals with their first code 
recorded shortly after registration as I was not looking for incidence cases and did 
not want to underestimate the recording. 
 
4.8.9.2 Free-text comments 
From the 313,240 anonymised free-text comments, I identified 198 unique free-text 
comments from the THIN comments data file that related to drug use and opioid 
substitution treatment (Figure 4:8).   
 
Figure 4:8: Development of relevant free-text comments 
 
Of these, 185 were unique and 13 were used more than once (Table 4.16). 
 
Table 4.16: Frequently used free-text comments relating to drug use and/or opioid 
substitution treatment 
Free-text comment 
Advised to stop Diazepam and derivatives Heroin overdose 
Amphetamine Dihydrocodeine Methadone 
Cannabis Drug induced Overdose 
Codeine and derivatives Heroin Valium dependence 
Counselled   
 
There were 520 individuals who had a free-text comment relevant to drug use 
and/or opioid substitution treatment (Figure 4:9).  Therefore, when I examine free-
text comments, an extra 520 individuals were identified as using drugs.  Almost 
three quarters (73.5%, n=32,356) of individuals who had a Read and/or drug code 
313,240 anonymised 
free text comments in 
THIN
1,113 free text 
comments possibly 
relating to drug use and/
or opioid substitution 
treatment 
218 free text comments 
definitely relating to drug 
use and/or opioid 
substitution treatment 
1,043 non-duplicates 198 non-duplicates
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for drug use or opioid substitution treatment also had an anonymised free-text 
comment.  However, only 4.2% (n=1,356) of these free-text comments were 
relevant to drug use or treatment (Figure 4:9). 
 
8,273,004
(16-64 male and 
females)
99.7%
(8,250,606/
8,273,004) 
without a Read or 
drug code 
0.03%
(520/1,613,016)
had a relevant free 
text comment
0.5%
(44,218/
8,273,004)
with a Read or 
drug code 
4.2%
(1,356/32,356)
had a relevant free 
text comment
 
Figure 4:9: Relevant free-text comments for individuals with and without Read and/or 
prescription codes for drug use or opioid substitution treatment.  
 
4.9 Discussion 
4.9.1 Summary of main findings 
The main findings of this study illustrate that there were individuals who were 
recognised and have a recording for drug use in their primary care records, 
however, only a quarter of those estimated as using drugs in the population were 
captured in THIN.  Furthermore, a large proportion of these individuals did not 
receive treatment in primary care.  However, 96% of individuals receiving 
prescriptions for opioid substitution treatment from general practice were identified 
in THIN.   
 
Overall, there were more males than females with recordings for drug use and of 
those with a record, most were between the ages of 16-24 years, in the highest 
quintile of deprivation, residing in the North East of England and during the period 
1994 and 2000.  Most of the men in the older age-group (25-34 years), from same 
quintile of deprivation and region had a prescription for opioid substitution 
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treatment, whilst more men from the North West of England and Read code for 
opioid substitution treatment.  Annual prevalence rates remained relatively stable 
between 2010/11 and 2012/13.   
 
4.9.2 Comparison with existing literature 
 
4.9.3 Gender 
Findings from this first study show that women were two thirds less likely to have a 
recording for drug use and/or opioid substitution treatment compare with men in 
THIN.  As previously mentioned, this is consistent with the Crime Survey for 
England and Wales, the National Drug Treatment Monitoring System and the 
Welsh drug misuse database (National Treatment Agency for Substance Misuse, 
2012a; Office for National Statistics, 2013a; Welsh Government, 2012).  Since 
1996 there have been 50-60% more male drug users in England and Wales and 
73% of people in treatment were male (National Treatment Agency for Substance 
Misuse, 2012a; Welsh Government, 2012).  However, the gender difference in my 
study may be slightly underestimated for two reasons; firstly, women between the 
ages of 16-60 years consult their GP more than men and secondly, younger males 
from more deprived areas are slightly under-represented in THIN (Blak et al., 2011; 
Wang et al., 2013).   
 
4.9.4 Age-group 
The results regarding age-group from this study showed similar patterns to the 
Crime Survey for England and Wales, whereby individuals from the younger age-
group (16-24 years) were more likely to have a recording for drug use compared 
with individuals from the older age-groups (Office for National Statistics, 2013b).  
 
In my study, more individuals from the younger age-group (16-24 years old) were 
receiving a prescription for opioid substitution treatment group up until 2002.  
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However, after 1999, more individuals from the 25-34 year age-group received 
prescriptions (National Treatment Agency for Substance Misuse, 2012a).  These 
findings echo annual reports from the National Drug Treatment Monitoring System 
whereby opiate use has decreased significantly in the 16-24 year age-group.  
Additionally the percentage of heroin and methadone users in the population has 
remained unchanged for the last few years and this could explain that individuals 
who require opioid substitution treatment are shifting into the older age-groups 
(National Treatment Agency for Substance Misuse, 2012a).   
 
4.9.5 Social deprivation 
Findings from my study illustrate that the larger recording rates of drug use are 
associated with higher social deprivation.  Similarly, The Crime Survey for England 
and Wales also found an inverse association between frequent drug use and 
income and reported that frequent drug use is higher in more deprived urban areas 
(Office for National Statistics, 2013b).  Likewise, more prescriptions for opioid 
substitution treatment were given to individuals from the highest quintile of 
deprivation in THIN.  These findings echo the annual reports from The National 
Treatment Agency where individuals in treatment for drug use are more socially 
deprived (National Treatment Agency for Substance Misuse, 2012a).  
 
4.10 Conclusion 
It was evident from this study that primary care databases could be used to monitor 
trends but not rates of drug use in the general population.  In contrast, even though 
little opioid substitution treatment occurs in general practice, it is well recorded in 
electronic health records and therefore it can be used to monitor both trends and 
rates in the general population. 
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4.11 How Does This Chapter Support My Thesis? 
Results from the first study suggested that THIN is similar to national surveys with 
regards to trends in the general population and could potentially be used to 
understand and examine drug use and opioid substitution treatment in and around 
pregnancy.  The next chapter will focus on females from the first study who were 
also pregnant. 
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 STUDY 2: GP RECORDING IN AND 
AROUND PREGNANCY 
 
5.1 Content and Structure of Chapter 5 
My first study (Chapter 4) focused on GP recording of individuals who use drugs 
and are treated with opioid substitution treatment in the general population.  In this 
chapter, I focus on recording of women in and around pregnancy.  I use the 
females obtained in my first study and narrow it down to women who were also 
pregnant in order to examine the number of women who have one or more 
recordings for drug use and/or opioid substitution treatment during the time-period 
36 months either side of and during pregnancy.  This chapter contains the 
introduction, aim, specific objectives, methods, results and discussion for the 
second study. 
 
The study addresses objective two of the thesis (section 2.4) and will also 
contribute to answering the second part of my main research questions (section 
2.3):  
1. Can a large primary care database (The Health Improvement 
Network (THIN)) be used as a surveillance tool for understanding 
drug use and opioid substitution treatment in the general population 
and specifically during pregnancy (in England and Wales)? 
2. Can a large primary care database (THIN) be used as a tool to 
research drug use and opioid substitution treatment in general 
practice in the general population and specifically during pregnancy 
(in England and Wales)? 
 
5.2 Introduction 
In England and Wales, there have been few large epidemiological studies that 
have examined the prevalence of drug use and opioid substitution treatment in and 
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around pregnancy.  (Advisory Council on the Misuse of Drugs, 2011; Farkas et al., 
1995; Fergusson et al., 2002; Sherwood et al., 1999).  Drug use during pregnancy 
is complex due to the increased risk to the unborn child (Advisory Council on the 
Misuse of Drugs, 2011).  Additionally, a woman’s circumstances may be 
exacerbated by concurrent adverse social and lifestyle factors for example; 
poverty; physical and emotional abuse or neglect, separation, inadequate 
accommodation and exposure to criminal activity (Advisory Council on the Misuse 
of Drugs, 2011). 
 
Estimates of drug use during pregnancy may be inaccurate due to a large amount 
of underreporting.  The reasons for underreporting or non-disclosure include the 
following (Centre for Maternal and Child Enquiries, 2011): 
 the stigma of drug use during pregnancy; 
 unawareness of pregnancy due to amenorrhoea; 
 no or late attendance to the GP and/or antenatal clinic; and 
 the fear of the newborn being taking away 
 
However, it may more likely that a GP would record a woman as a drug user if she 
is pregnant because a child would be involved (Advisory Council on the Misuse of 
Drugs, 2011).  In contrast to drug use, if opioid substitution treatment is prescribed 
in general practice, it should be accurately documented in the electronic health 
records (Public Health England, 2015).  However, if a woman receives 
prescriptions from either the community drug clinic or specialist midwife service, 
the information may not be captured in the woman’s primary electronic health 
record. 
 
As mentioned in section 1.3.13, there have been four significant studies conducted 
in the England, but none in Wales that have examined drug use in pregnancy up to 
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April, 2013.  The studies by Farkas et al. and Sherwood et al. used biological 
measures (urine analysis) to determine drug use during pregnancy (Farkas et al., 
1995; Sherwood et al., 1999).  Whilst the studies by Ferguson et al. and the 
Advisory Council on the Misuse of Drugs utilised questionnaires (Advisory Council 
on the Misuse of Drugs, 2011; Fergusson et al., 2002).   
 
The first study conducted by Farkas et al. found that 10% (106/1,000) of women 
attending a 12 week antenatal check in East London, tested positive (urine 
analysis) for drug use, with cannabis being the most common (8.5%, 85/1,000) 
drug used (Farkas et al., 1995).  Sherwood et al. also used anonymous urine 
samples sent by GPs for analysis during the first trimester in South London 
(Sherwood et al., 1999).  Their sample size was slightly smaller (807 vs 1,000), 
however, almost 6% more women tested positive for drug use (15.6%, 126/807) 
(Sherwood et al., 1999).  As with Farkas et al., cannabis was the most common 
(14.5%, 117 of 807) drug used by women in the first trimester (Sherwood et al., 
1999).   
 
The main strength of these two studies was that they relied on biological methods 
rather than self-reporting (Farkas et al., 1995; Sherwood, et al., 1999).  
Additionally, the studies did not require signed consent as the identity of the 
women was completely anonymised (Professor R Sherwood, 2015: personal 
communication (email) 11th August).  The main limitations of both studies were that 
they used a relatively small sample size and included women from only one area of 
London which meant that results were not generalisable to the rest of the UK 
population.   
 
The third study involved analysis of the Avon Longitudinal Study of Parents and 
Children Study (ALSPAC) (Fergusson et al., 2002).  Pregnant women (n=12, 000) 
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enrolled on the study (expecting to give birth between 1 April 1991-31 December 
1992) were given self-reported questionnaires on cannabis use between 18-20 
weeks gestation.  Only one other question about other drug use was included 
(“Use of hard drugs during pregnancy” yes/no).  The following adverse foetal 
outcomes were also examined; late foetal and neonatal death, neonatal special 
care admissions, birth weight, length and head circumference. The authors 
reported that 5% of women in their study smoked cannabis during pregnancy, 
whilst 6.8% reported using other hard drugs.  Women who used cannabis were 
more likely to be younger, more educated, have lower parity, smoke, drink more 
alcohol, coffee and tea and use other hard drugs.  They also reported that 
cannabis did not lead to any of the measured adverse birth outcomes, however the 
babies born from mothers who used cannabis were smaller (90 grams lighter) 
(Fergusson et al., 2002).   
 
The final study was conducted by The Advisory Council on the Misuse of Drugs 
prevention working group in June 2011, which subsequently produced the Hidden 
Harm report in response to the need of children of problem drug users (Advisory 
Council on the Misuse of Drugs, 2011).  The findings estimated that between 
200,000-300,000 children (2-3% of under 16 year olds) in England and Wales, 
have at least one parent who uses drugs (Advisory Council on the Misuse of 
Drugs, 2011).  The study sent a questionnaire to 423 maternity units in Sheffield 
and Glasgow and ninety percent (92%, 238/259) of the responding units reported 
frequently asking pregnant women about drug and alcohol use.  A mean of 1% 
(24/2,407, range 0-172) of women who gave birth in the maternity units disclosed 
their drug use during pregnancy (Advisory Council on the Misuse of Drugs, 2011).   
 
The findings of both the later studies showed that less women used drugs during 
pregnancy compared with the studies that used biological measures (Advisory 
Council on the Misuse of Drugs, 2011; Ferguson et al., 2002).  Ferguson et al. 
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acknowledged that drug use may be under-reported in the ALSPAC study as the 
self-reported questionnaire is subject to response bias (Fergusson et al., 2002).  
Furthermore, the study conducted by the Advisory Council on the Misuse of Drugs 
had a response rate of 61% and therefore a risk of selection bias due to non-
responders was introduced (Pannucci and Wilkins, 2010).  Additionally, using a 
questionnaire could increase the risk of recall bias by the staff in the maternity units 
(Choi and Pak, 2004).  Reporting of drug use to health professionals could lead to 
adverse consequences, and women may therefore chose not to disclose.   
 
These four studies are the largest regarding recreational drug use during 
pregnancy in England and Wales to date.  However, results are conflicting and 
there are no studies that identify women who use drugs during pregnancy in a 
general practice setting.  For 77% of newly pregnant women, GPs are the first 
healthcare practitioners they see (Redshaw and Heikkila, 2010).  My second study 
therefore aims to give an estimate of recording of women who use drugs in and 
around pregnancy in primary care.  Additionally by using a primary care database, 
the risk of response and recall bias may be reduced.  In my first study (Chapter 4), 
where I examined the recording of drug use and opioid substitution treatment in the 
general population, I found that a third of individuals who had a recording for drug 
use and/or opioid substitution treatment were female and the majority of these 
females were of child bearing age.  A large primary care database study may 
therefore be beneficial to examine GP recording of drug use and opioid substitution 
treatment in and around pregnancy and to also assist in answering the two 
research questions (section 2.3) 
 
5.3 Aim of Study 2 
To describe GP recording of drug use and/or opioid substitution treatment in and 
around pregnancy. 
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5.4 Specific Objectives of Study 2 
Using data for women residing in England and Wales in the time-periods 36 
months either side of and during pregnancy, I sought to:  
1. Examine the parity and demographics for women with and without 
recordings for drug use and/or prescriptions for opioid substitution treatment  
2. Examine the timing of recordings for drug use and/or prescriptions for opioid 
substitution treatment  
3. Explore the frequency of Read and/or prescription codes entered for each 
woman during specific time periods  
5.5 Hypotheses for Study 2 
Hypothesis 1: There was no difference in the recording of drug use (Read codes) 
in the time periods before and after pregnancy compared with during pregnancy 
 
Hypothesis 2: There was no difference in prescribing opioid substitution treatment 
in the time periods before and after pregnancy compared with during pregnancy 
 
Hypothesis 3: There was no difference in recording of opioid substitution treatment 
(Read codes) in the time periods before and after pregnancy compared with during 
pregnancy 
 
5.6 Methods 
5.6.1 Women who have Read codes for drug use and or 
prescriptions/Read codes for opioid substitution treatment in and 
around pregnancy  
In order to examine the parity and demographics for women with and without a 
recording for drug use and/or prescriptions for opioid substitution treatment, I firstly 
describe how I developed the time definitive pregnancy cohort from the pregnancy 
cohort in THIN.  Secondly I examined the number of women who had at least one 
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Read and/or drug code and finally, I examined the parity and demographics of 
women in the time definitive cohort.  
 
5.6.1.1 Pregnancy cohort in THIN  
The pregnancy cohort in THIN was created by my supervisor, Dr Irene Petersen in 
2012.  This cohort includes all women who have had a complete pregnancy (based 
on the delivery date of the baby) or women who have a recording for a pregnancy 
(based on the estimated due date of the baby).  In order to be sure that true 
pregnancies were included in the cohort, some restrictions were applied when 
obtaining records of individual women in THIN.  Each pregnancy needed to adhere 
to at least two situations in order to be included (Table 5.1).  If a woman only had 
evidence from the last menstrual period and antenatal records, she also needed 
evidence from conditions 6 (“Last antenatal record must be at least 105 days after 
estimated pregnancy start date”) and 7 (“A woman must not have another 
pregnancy record with a delivery date within 280 days either before or after the 
delivery date for the current pregnancy record”) (Table 5.1).  Condition 7 could 
indicate that a miscarriage record has been mixed up with another pregnancy 
record.  If a woman had more than one record for a pregnancy with the same start 
date, the record with the latest delivery date was used, as records tended to be 
more complete and if a record was problematic and/or ambiguous, it was not 
included in the cohort.   
 
Table 5.1: Evidence to determine a true pregnancy in THIN 
Different indications of a true pregnancy 
1. Last menstrual period date* 
2. Antenatal record* 
3. Delivery record 
4. Postnatal care record 
5. Child whose GP record could be matched to the current pregnancy 
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*If an individual only had evidence from 1 and 2, they also needed evidence from the following two 
conditions 
6. Last antenatal record must be at least 105 days after estimated pregnancy start date 
7. A woman must not have another pregnancy record with a delivery date within 280 days 
either before or after the delivery date for the current pregnancy record. 
 
The start of the pregnancy was calculated from various methods including the date 
of last menstrual period, delivery date and postnatal check dates.  A pregnancy 
could not be validated by the birth of a child and therefore some of the recorded 
pregnancies could be false.  Some of the pregnancies with an estimated due date 
may not have gone to term due to a miscarriage which may not have been 
recorded.  The final pregnancy cohort comprised of 420,234 women and 586,312 
pregnancies. 
 
5.6.1.2 Time definitive cohort (Preg_81_cohort)  
In order to develop the cohort of pregnant women who were registered 
permanently for 36 months either side of and during pregnancy, I first defined and 
generated the different time-periods.  I initially examined different time-points 
between the start of pregnancy and delivery.  After exploration, I decided to 
examine time-period of pregnancy as one time-point as there was very little 
difference in recording during the first 6 weeks, first, second and third trimester. 
Definition and generation of time-periods in pregnancy cohort (Figure 5:1) 
a. Before pregnancy: 
I divided the 36 months prior to the start of a woman’s pregnancy into 9 month 
time-periods (-36 to -28, -27 to -19, -18 to -10, -9 to -1).   
b. During pregnancy 
This includes the time between the start of pregnancy and the delivery of the baby.  
The time period was approximately 9 months, but this depended on the length of 
gestation for each pregnancy. 
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c. After pregnancy 
I divided the 36 months after the delivery of the baby into 9 month time-periods 
(Birth to +9, +10 to+18, +19 to +27, +28 to +36).   
 
Figure 5:1: Time definitions in and around pregnancy 
 
Women who fitted the following three criteria were defined as preg_81_cohort 
(Figure 5:2): 
1. Included in the original pregnancy cohort in THIN, and 
2. Resided in England or Wales, and 
3. Were continuously registered with the same practice for 36 
months before, during and 36 months after pregnancy 
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Figure 5:2: The development of preg_81_cohort 
 
5.6.1.3 Women who had Read codes for drug use and/or prescriptions or 
Read codes for opioid substitution treatment in THIN  
I included all women with a recording for drug use and/or opioid substitution 
treatment, aged between 16-55 years, from my first study (see section 4.7.2).  I 
also decided to identify all recordings of drug use and/or opioid substitution 
treatment and not just the first recording.  The reason being that a woman may 
have had her first recording outside the defined study time periods in and around 
pregnancy.  I therefore created three new sub-groups of females with:  
1) One or more Read codes for drug use 
2) One or more prescriptions for opioid substitution treatment 
3) One or more Read codes for opioid substitution treatment  
The three sub-groups together included all women who had at least one recording 
for drug use and/or opioid substitution treatment.  
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I then merged the women who had at least one recording for drug use and/or 
opioid substitution treatment with the preg_81_cohort using the unique identities of 
the women.  The total number of women in preg_81_cohort was the denominator 
when conducting analysis (Figure 5:3). 
 
Figure 5:3: Preg_81_cohort merged with women with at least one recording for drug use 
and/or opioid substitution treatment (OST) 
 
5.6.2 Parity and demographics for all women in preg_81_cohort  
5.6.2.1 Selecting a random sample from preg_81_cohort 
Some women have more than one pregnancy, so I decided to use similar methods 
to Petersen et al., and Man et al., and selected a random pregnancy for each 
woman (Man et al., 2012; Petersen et al., 2011).  This was to avoid clustering of 
data and ensure that the pregnancies in the sample were independent of each 
other (Kirkwood and Sterne, 2003).  All women from preg_81_cohort would then be 
included but only one of their pregnancies would be used in the analysis.   
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5.6.2.2 Parity of women 
In order to examine the parity of women in the particular general practice, I 
summed their total number of pregnancies.  I examined if the distribution of parity 
was similar for women with and without a recording for drug use and/or opioid 
substitution treatment  
 
5.6.2.3 Age of woman at pregnancy  
In order to examine the age of all women at the start of their randomly selected 
pregnancy, I subtracted the date at the start of pregnancy from the mother’s date of 
birth. I then divided the ages into six categories: <19, 20-24, 25-29, 30-34, 35-39 
and >=40 years old. 
 
5.6.2.4 Deprivation and region 
In order to examine the deprivation status and the region the women resided in, I 
examined the Townsend deprivation scores and region (strategic health authority 
(SHA)) for all women (section 3.4.2) 
 
5.6.3 Timing of recording for drug use and/or opioid substitution 
treatment in preg_81_cohort  
In order examine the timing of recordings for drug use and/or prescriptions for 
opioid substitution treatment, I examined if a woman had at least one recording for 
drug use and/or opioid substitution treatment for each nine month time-period, as 
defined in Figure 5:1.   
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5.6.4 Frequency of Read codes for drug use and prescription/Read 
codes for opioid substitution treatment at different time intervals 
during pregnancy  
In order to explore the frequency of Read and/or prescription codes entered for 
each woman during specific time periods, I explored the most frequently used 
Read codes for drug use and prescriptions and Read codes for opioid substitution 
treatment that were used at different time-periods in and around pregnancy, and 
examined if their frequencies differed during these time intervals. 
 
5.6.5 Statistical analysis 
I conducted the following statistical analysis: 
1. Summarised the following in terms of frequencies and percentages: 
i) Recording for Read codes for drug use and/or prescriptions and Read 
codes for opioid substitution treatment (first recording and all recordings) 
for all females from the first study  
ii) Number of women in preg_81_cohort who had one or more recordings 
for drug use and/or opioid substitution treatment 
2. Conducted a t-test for age at the start of pregnancy to ascertain if there was 
a difference between women with and without a code for drug use and/or 
opioid substitution treatment 
3. Conducted logistic regressions to explain the effects of age, deprivation and 
region on recording of drug use (binary outcome).  I decided a priori on the 
basis of the existing literature to include age, deprivation and region in the 
analysis as they may be potential confounders (European Monitoring Centre 
for Drugs and Drug Addiction, 2014; Frischer et al., 2009; Office for National 
Statistics, 2013a).  I examined if there was effect modification by age, 
deprivation and region (Kirkwood and Sterne, 2003).  If effect modification 
existed, I stratified the covariate.  In order to select which model fitted the 
data the best, I carried out hypothesis testing using likelihood ratio tests 
(Table 5.2) (Kirkwood and Sterne, 2003).  
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Table 5.2: Selection of appropriate model 
Model Covariates in model No of parameters 
2 Age 6 
3 Deprivation 5 
4 Region 11 
5 Parity 2 
6 Age & deprivation 10 
7 Age, deprivation & region 20 
8 Age, deprivation, region & parity 21 
 
4. Calculated the timing of recording of drug use and/or opioid substitution 
treatment prescriptions for women in preg_81_cohort: 
i) using all women in preg_81_cohort as the denominator 
ii) I calculated prevalence ratios and 95% confidence intervals.  The 
reference group was the time-period during pregnancy for 
preg_81_cohort. 
5. Summarised the most frequently used codes for drug use and opioid 
substitution treatment for all records for each woman in preg_81_cohort 
All data was analysed using STATA (version 13) statistical software (Stata Corp 
LP, College Station, Texas). 
 
5.6.6 Sensitivity analysis 
In order to ascertain if a more transient population with regards to registration gave 
different results, I obtained a different time-definitive cohort which included women 
who were registered permanently for nine months before, during and nine months 
after pregnancy. I conducted the same statistical analysis as in section 5.6.5. 
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5.7 Results 
5.7.1 Parity and demographics for women with and without a recording 
for drug use and/or prescriptions for opioid substitution 
treatment 
 
5.7.1.1 Number of women with a code for drug use and/or opioid substitution 
treatment  
A third (32.5% 18,048/52,632) of individuals with a first recording for drug use 
and/or opioid substitution treatment from my first study (Chapter 4) were female.  I 
identified a total of 872,798 recordings for drug use and/or opioid substitution 
treatment from the electronic health records (Table 5.3). 
Table 5.3: Number of Read codes for drug use, prescriptions and Read codes for Opioid 
substitution treatment (OST) 
 Read code 
for drug use 
Prescription 
for OST 
Read code 
for OST 
Total  
All females, first 
record 
10,886 4,748 2,414 18,048 
All females, all records 236,926 576,788 59,084 872,798 
*OST=opioid substitution treatment 
 
5.7.1.2 Number of women in preg_81_cohort 
There were originally 420,234 women in the pregnancy cohort, of those women, a 
fifth (20.5%, n=86,002) were registered permanently for 36 months either side of 
and during pregnancy in a practice located in either England or Wales.  Of the 
women in preg_81_cohort, 0.98% (835/86,002) had a recording for drug use 
and/or opioid substitution treatment (Figure 5:4).   
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Figure 5:4: Results for the preg_81_cohort (OST=Opioid Substitution Treatment) 
 
5.7.1 Statistical model  
Following the hypothesis testing to select the most appropriate model, I included 
age, deprivation and region.  There was no evidence that parity improved the fit of 
the model (p=0.08) and I therefore excluded this variable from my final model.  I 
observed no effect modification by any of the covariates   
 
5.7.1.1 Parity 
The parity between the women who did and did not have a recording for drug use 
and/or opioid substitution treatment was similar.  Almost 90% (86.8%, 
74,661/85,167 and 87.5%, 731/835) of the women in preg_81_cohort had one 
pregnancy and 11% (9,552/85,167and 92/835) had two pregnancies (Table 5.4).   
 
1.1.1.1 Maternal age at the start of the pregnancy 
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The mean age of women with a recording for drug use and/or opioid substitution 
treatment (27.3 years, sd ± 6.1) differed significantly by 2 years compared to 
women without a recording (29.3 years, sd ± 6.3) (p<0.0001).  Women who were 
younger than 24 years were twice as likely to have a recording for drug use and/or 
opioid substitution treatment compared with women over 40 years (Table 5.4).   
 
5.7.1.2 Maternal level of deprivation  
The rate of recording was highest for women in the most deprived group (2.08 per 
100 pregnancies).  Additionally, women from the most deprived group were five 
times more likely to have a recording compared with women in the least deprived 
group (5.05 (3.96-6.44).   
 
5.7.1.3 Maternal region 
Women residing in the North East of England had the highest recording rate (1.79 
per 100 pregnancies).  Furthermore, women living in the North East (OR: 3.4, 95% 
CI: 2.2-5.2) and East Midlands (OR: 3.03, 95% CI: 1.9-4.6) regions of England 
were approximately three times more likely to have a recording for drug use and or 
opioid substitution treatment, compared with women living in London (Table 5.4).  
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Table 5.4: Summary of the preg_81_cohort (N=86,002): Parity, age, deprivation and region 
 No recording 
N=85,167(99.02%) 
Rate per 100 
pregnancies 
Recording       
N=835 (0.98%) 
Rate per 100 
pregnancies 
Unadjusted           
OR (95% CI) 
Adjusted*            
OR (95% CI) 
Parity N (%)  N (%)  OR (95% CI) OR (95% CI) 
1 
2 
74,661 (86.8) 
  9,552 (11.2) 
99.03 
99.05 
731 (87.5) 
  92 (11.0) 
0.97 
0.09 
1.07 (0.90-1.27)  
Age (years) N (%)  N (%)  OR (95% CI) OR (95% CI) 
<19 
20-24 
25-29 
30-34 
35-39 
>=40 
  6,510 (7.60) 
12,601 (14.7) 
21,386 (24.9) 
26,546 (30.9) 
15,215 (17.7) 
  2,909 (3.40) 
98.47 
98.48 
98.99 
99.26 
99.31 
99.39 
101 (12.1) 
194 (23.2) 
218 (26.1) 
199 (23.8) 
105 (12.6) 
  18 (2.20) 
1.53 
1.52 
1.01 
0.74 
0.68 
0.62 
2.51 (1.52-4.15) 
2.49 (1.53-4.03) 
1.65 (1.01-2.67) 
1.21 (0.74-1.96) 
1.11 (0.67-1.84) 
1 
2.26 (1.36-3.74) 
2.25 (1.38-3.66) 
1.53 (0.95-2.49) 
1.15 (0.71-1.87) 
1.09 (0.66-1.80) 
1 
Deprivation N (%)  N (%)  OR (95% CI) OR (95% CI) 
1 least deprived 
2 
3 
4 
5 most deprived 
21,624 (25.1) 
16,685 (19.4) 
17,474 (20.3) 
16,086 (18.7) 
11,098 (12.9) 
99.58 
99.37 
99.17 
98.57 
97.92 
    91 (10.9) 
  105 (12.6) 
  147 (17.6) 
  233 (27.9) 
  236 (28.3) 
0.42 
0.63 
0.83 
1.43 
2.08 
1 
1.48 (1.12-1.96) 
1.99 (1.54-2.59) 
3.44 (2.69-4.38) 
5.05 (3.96-6.44) 
1 
1.47 (1.11-1.95) 
1.99 (1.53-2.60) 
3.29 (2.57-4.22) 
4.62 (3.58-5.96) 
Region N (%)  N (%)  OR (95% CI) OR (95% CI) 
 149 
 
 No recording 
N=85,167(99.02%) 
Rate per 100 
pregnancies 
Recording       
N=835 (0.98%) 
Rate per 100 
pregnancies 
Unadjusted           
OR (95% CI) 
Adjusted*            
OR (95% CI) 
London 
East Midlands 
East of England 
West Midlands 
North East 
North West 
Y&H* 
South Central 
South East Coast 
South West 
Wales 
   7,195 (8.40) 
   4,647 (5.40) 
   6,538 (7.60) 
10,567  (12.3) 
   3,357 (3.90) 
13,495  (15.7) 
    3,797 (4.40) 
11,794  (13.7) 
    7,383 (8.60) 
    9,931 (11.6) 
    6,463 (7.60) 
99.52 
98.75 
99.02 
98.94 
98.22 
98.73 
99.32 
99.08 
99.46 
99.21 
98.85 
    35 (4.20) 
    59 (7.10) 
    65 (7.80) 
 113  (13.5) 
    61 (7.30) 
 173  (20.7) 
    26 (3.10) 
109  (13.1) 
    40 (4.80) 
    79 (9.50) 
    75 (9.00) 
0.48 
1.25 
0.98 
1.06 
1.79 
1.27 
0.68 
0.92 
0.54 
0.79 
1.15 
1 
2.61 (1.72-3.97)** 
2.04 (1.35-3.09) 
2.19 (1.50-3.21) 
3.73 (2.46-5.76) 
2.64 (1.83-3.79) 
1.41 (0.85-2.34) 
1.90 (1.29-2.78) 
1.11 (0.71-1.75) 
1.64 (1.09-2.43) 
2.39 (1.59-3.57) 
1 
3.03 (1.98-4.63) 
2.76 (1.82-4.19) 
2.64 (1.80-3.88) 
3.40 (2.23-5.18) 
2.85 (1.97-4.12) 
1.62 (0.97-2.72) 
2.73 (1.85-4.02) 
1.55 (0.98-2.46) 
2.00 (1.34-3.00) 
2.69 (1.78-4.03) 
OR=Odds Ratio CI= Confidence Interval  
*Adjusted for maternal age, deprivation and region 
Y&H=Yorkshire and Humberside
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5.7.2 Timing of recordings for drug use and/or prescriptions for opioid 
substitution treatment 
 
5.7.2.1 Timing for all women in preg_81_cohort (denominator: all women in 
cohort, n=86,002) 
Read codes for drug use 
Compared to 36 months before pregnancy, recording of Read codes for drug use 
increased in the time-period 9 months before pregnancy, where 0.2% (175/86,002) 
of women in preg_81_cohort had a recording.  Recording of Read codes for drug 
use reduced (0.14% (123/86,002) during pregnancy.  After pregnancy, recording of 
drug use gradually increased until it remained relatively stable.  Approximately 
0.17% (143/86,002) of women in preg_81_cohort had a recording after the 27 
month time-period (Figure 5:5). 
 
Prescriptions for opioid substitution treatment 
Conversely, a lower percentage (0.09%, 75/86,002) of women in preg_81_cohort 
had at least one prescription for opioid substitution treatment in the time-periods 
before pregnancy.  Prescriptions reduced slightly during pregnancy, but increased 
in the time-periods after pregnancy, where approximately 0.12% (106/86,002) of 
women in preg_81_cohort received a prescription (Figure 5:5). 
 
Read codes for opioid substitution treatment 
The percentage of women with at least one Read code for opioid substitution 
treatment remained lower (± 0.003%, 26/86,002) but relatively stable compared to 
prescriptions and Read codes for drug use (Figure 5:5). 
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Figure 5:5: Timing of recording of at least one recording (Read code for drug use, 
prescription and Read code for Opioid Substitution Treatment (OST)) with the time-
periods; 36 months either side of and during pregnancy. (Denominator: total number of 
women, N=86,002) Time-periods defined in methods section 5.6.1.2 
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5.7.2.2 Prevalence rate ratios for recording codes and prescriptions in 
preg_81_drug_cohort and accept or reject hypotheses 1-3 
Read codes for drug use  
I rejected the first hypothesis as recording occurred 42% more 9 months before 
pregnancy compared with the time period during pregnancy (Prevalence Ratio 
(PR): 1.42: 95% CI: 1.23-1.81) (Table 5.5).  
 
Table 5.5: Prevalence ratios (PR) of recordings of Read codes for drug use (Reference 
time=during pregnancy) Time period defined in methods section 5.6.1.2. 
Time periods  Prevalence 
ratios (95% CI) 
 
  
 
-36 to -28 
 
-27 to -19 
 
-18 to -10 
 
-9 to -1 
 
During 
Pregnancy 
 
0 to 9 
 
10 to 18 
 
19 to 27 
 
28 to 36 
1.09 (0.85-1.41) 
 
1.25 (0.98-1.60) 
 
1.15 (0.89-1.47) 
 
1.42 (1.23-1.81) 
 
 
1 
 
0.93 (0.71-1.21) 
 
1.09 (0.85-1.40) 
 
1.15 (0.90-1.48) 
 
1.18 (0.92-1.51) 
 
 
  
-36
-27
-18
-9
0
9
18
27
36
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.8 1 1.2 1.4 1.6 1.8
prevalence ratio
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Prescriptions for opioid substitution treatment (Hypothesis 2) 
I rejected the second hypothesis as prescriptions for opioid substitution treatment 
were given 30-40% more 9 months (PR: 1.34, 95% CI: 1.01-1.83), 18 months (PR: 
1.31, 95% CI: 1.01-1.79), 27 months (PR: 1.40, 95% CI: 1.03-1.91), and 36 months 
(PR: 1.43, 95% CI: 1.05-1.95), after pregnancy compared with during pregnancy  
(Table 5.6). 
 
Table 5.6: Prevalence ratios (PR) of recordings of prescriptions for opioid substitution 
treatment use (reference time=during pregnancy) Time period defined in methods section 
5.6.1.2. 
Time periods  Prevalence 
ratios (95% CI) 
 
  
 
-36 to -28 
 
-27 to -19 
 
-18 to -10 
 
-9 to -1 
 
During 
Pregnancy 
 
0 to 9 
 
10 to 18 
 
19 to 27 
 
28 to 36 
0.93 (0.66-1.31) 
 
1.10 (0.79-1.54) 
 
1.08 (0.77-1.50) 
 
1.10 (0.79-1.54) 
 
1 
 
 
1.34 (1.01-1.83) 
 
1.31 (1.01-1.79) 
 
1.40 (1.03-1.91) 
 
1.43 (1.05-1.95) 
 
 
  
-36
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-18
-9
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Read codes for opioid substitution treatment (Hypothesis 3) 
I accepted the third hypothesis as there as was no significant difference in 
recording of Read codes for opioid substitution treatment in the time periods before 
and after pregnancy compared with during pregnancy. (Table 5.7). 
 
Table 5.7: Prevalence ratios (PR) of recordings of Read codes for opioid substitution 
treatment use (reference time=during pregnancy) Time period defined in methods section 
5.6.1.2. 
Time periods  Prevalence 
ratios (95% CI) 
 
  
 
-36 to -28 
 
-27 to -19 
 
-18 to -10 
 
-9 to -1 
 
During 
Pregnancy 
 
0 to 9 
 
10 to 18 
 
19 to 27 
 
28 to 36 
0.66 (0.37-1.14) 
 
0.57 (0.31-1.02) 
 
0.82 (0.48-1.39) 
 
0.77 (0.45-1.31) 
 
1 
 
 
0.74 (0.43-1.27) 
 
0.60 (0.33-1.06) 
 
0.83 (0.48-1.39) 
 
0.66 (0.37-1.14) 
 
 
5.7.3  Frequency of Read and/or prescription codes entered for each 
woman during specific time periods 
Read codes for drug use 
The most frequently used generic Read codes for drug use in and around 
pregnancy in preg_81_cohort were “drug dependence”, “drug withdrawal 
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syndrome”, “misuse of drugs NOS” and “opioid type drug dependence” (Figure 
5:6). 
 
 
Figure 5:6: Four most frequently used generic Read codes for drug use 36 months in and 
around pregnancy (preg_81_cohort) (-36=36 months before pregnancy, 0=during 
pregnancy, 36=36 months after pregnancy) Time-periods defined in methods section 
5.6.1.2 
 
Whereas the most frequently used specific Read codes in and around pregnancy 
were “heroin dependence” and “benzodiazepine dependence” (Figure 5:7). 
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Figure 5:7: Most frequently used specific Read codes for drug use (-36=36 months before 
pregnancy, 0=during pregnancy, 36=36 months after pregnancy) Time-periods defined in 
methods section 5.6.1.2 
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Prescriptions for opioid substitution treatment 
Approximately 40% of the prescriptions for opioid substitution treatment were for 
methadone in and around pregnancy.  Whilst 20% of the prescriptions were for 
buprenorphine (Figure 5:8). 
 
 
Figure 5:8: Five most frequently prescribed opioid substitution treatments used 36 months 
in and around pregnancy (-36=36 months before pregnancy, 0=during pregnancy, 36=36 
months after pregnancy) Time-periods defined in methods section 5.6.1.2 
 
  
0
10
20
30
40
p
e
rc
e
n
t 
o
f 
re
c
o
rd
in
g
B
up
re
no
rp
in
e
D
ih
yd
ro
co
de
in
e
Lo
fe
xi
di
ne
M
et
ha
do
ne
N
al
tre
xo
ne
-36 0 36 -36 0 36 -36 0 36 -36 0 36 -36 0 36
 158 
 
Read codes for opioid substitution treatment 
The most frequently used Read codes for opioid substitution treatment around and 
during pregnancy were “drug addiction therapy”, “drug addiction therapy-
methadone” and “methadone dependence” (Figure 5:9). 
 
 
Figure 5:9: Most frequent Read codes for opioid substitution treatment used 36 months in 
and around pregnancy (-36=36 months before pregnancy, 0=during pregnancy, 36=36 
months after pregnancy) Time-periods defined in methods section 5.6.1.2 
 
5.7.4 Sensitivity analysis 
Results from the cohort of women permanently registered nine months before, 
during and after pregnancy were similar to the results from the women in 
preg_81_cohort.  I therefore did not include these results. 
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5.8  Discussion 
5.8.1 Summary of results 
A fifth of women in the THIN pregnancy cohort were permanently registered for 36 
either side of and during pregnancy.  One percent of these women had at least one 
recording for drug use and/or opioid substitution treatment.  Both women with and 
without a recording for drug use and/or opioid substitution treatment had similar 
parity.  However, women with a recording for drug use and/or opioid substitution 
treatment were 2 years younger compared to the women without a recording.  
Women less than 24 years, from the most deprived areas and residing in the North 
East or East Midlands regions of England were more likely to have a recording for 
drug use and/or opioid substitution treatment compared with women aged over 40 
years, from the least deprived areas and residing in London.   
 
Compared with the time-period during pregnancy, recording of drug use occurred 
12% and 13% less during the time periods of 36 months before and 9 months after 
pregnancy respectively.  Approximately 24% more prescriptions for opioid 
substitution treatment were given 18 to 36 months after pregnancy, compared with 
during pregnancy.   
 
GPs used both specific and generic Read codes to record drug use in and around 
pregnancy.  The generic Read code, “drug dependence” and the specific Read 
codes, “heroin dependence” and “benzodiazepine dependence” were used most 
frequently. GPs prescribed methadone mostly in and around pregnancy for opioid 
substitution treatment.  Finally, GPs used the Read codes “drug addiction therapy” 
and “drug addiction therapy-methadone” most frequently for recording opioid 
substitution treatment in and around pregnancy. 
  
 160 
 
5.8.2 Comparison to previous literature 
 
5.8.2.1 Pregnant women who have a recording for drug use and/or opioid 
substitution treatment 
One percent of the pregnant women in my study had a recording for drug use 
and/or opioid substitution treatment.  My findings were similar to the study in the 
hidden harm report, where a mean of 1% (24 of 2,407, range 1-172) of women in 
midwifery units disclosed that they used drugs during pregnancy(Advisory Council 
on the Misuse of Drugs, 2011).  However, my findings were lower than findings 
(range 6.8%-15.6%) from studies that used biological measures of drug use and 
self-reported questionnaires to measure drug use (Farkas et al., 1995; Fergusson 
et al., 2002; Sherwood et al., 1999).  As previously mentioned, the reasons for the 
differences in these findings could be that disclosure of drug use could be more 
forthcoming when their identities are anonymous.  Additionally the amount of 
women receiving opioid substitution treatment in my study seems relatively low, as 
the National Treatment Agency estimated that nearly half of women who were 
seen by drug treatment services had at least one child and 6% (914 of 16,277) of 
women who started treatment in 2011/12 were pregnant (National Treatment 
Agency for Substance Misuse, 2012b).  This could indicate that opioid substitution 
treatment moves from general practice during pregnancy, however transfer of 
treatment seems to move back to general practice once the baby is born (see 
section 5.8.2.3 for details).  
 
5.8.2.2 Parity and demographics of pregnant women with a recording for 
drug use and/or opioid substitution treatment 
The parity of women in my study was similar to the total fertility rate of 1.85 
pregnancies per woman in England and Wales (Office for National Statistics, 
2014).  Most (30.9%, 26,546 of 85,167) of the pregnant women in my study without 
a recording for drug use and/or opioid substitution treatment had their first 
pregnancy when they were between 25-30 years.  This corresponds to the average 
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age for a mother at first birth (27.3 years ± 0.46) in England and Wales between 
1994-2012 (Office for National Statistics, 2010).  Pregnant women who had a 
recording for drug use and/or opioid substitution treatment were on average two 
years younger (26 years, ± 6.1) than women without a recording (28 years ±6.3).  
Similarly, Farkas et al. and Ferguson et al. all found that women in England who 
used recreational drugs during pregnancy were younger than those who did not 
(27 years compared to 28 years (no significance reported, 25.5 years compared to 
27.8 years (p<0.0001) respectively) (Farkas et al., 1995; Fergusson et al., 2002). 
 
Women residing in the North East and East Midlands regions of England were 
more likely to have a recording for drug use and/or opioid substitution treatment in 
my study.  Similarly, the highest reported prevalence rates of opioid use by women 
were in the North East region(9.51 per 1000 women) compared with the South 
East (5.27) and East of England (5.44) (Hay et al., 2013).  Additionally, the North 
East of England has the highest number of emergency admissions (38 per 100 
000) with a primary diagnosis of poisoning by illicit drugs among female adults 
aged between 16-59 years (Hay et al., 2013).  
 
5.8.2.3 Timing of recording of drug use and/or opioid substitution treatment 
in and around pregnancy 
The role of a GP in antenatal care has changed over the years in the UK (Smith, et 
al., 2010).  Before the 1920s GPs played an integral role in perinatal care and the 
majority of deliveries were conducted at the mother’s home (Smith, et al., 2010).  
The high rate of maternal deaths and stillbirths led to the Confidential Enquiry into 
Maternal and Child Health in 1952 (Smith, et al., 2010).  Following this enquiry, 
recommendations were made which led to an improvement in perinatal care and 
subsequently both maternal deaths and stillbirths decreased significantly (Smith, et 
al., 2010).  Subsequently maternity units were set up in community hospitals in the 
early 1950s, where GPs worked closely with midwives to provide antenatal care 
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(Smith, et al., 2010).  GPs started being less involved in intrapartum care, and by 
1970, most of the GP maternity units either closed or became midwife-led units 
(Smith, et al., 2010).  Presently there are approximately 243 obstetric units and 116 
midwife-led units in the UK (Smith, et al., 2010).  NICE recommends that all 
women are referred to antenatal services and women with further difficulties 
require additional care (National Institute for Clinical Excellence, 2010b).  One of 
these categories that requires additional care are women with “complex and social 
factors” which includes women who use drugs during pregnancy (National 
Collaborating Centre for Women’s and Children’s Health (UK), 2010).  Therefore 
GPs should refer women who use drugs during pregnancy either to the midwife 
service or directly to the midwife team (National Collaborating Centre for Women’s 
and Children’s Health (UK), 2010).  Women who are referred to the midwife team 
are subsequently triaged to the specialist midwife team.   
 
It was evident in my study that there was a higher proportion of recording of drug 
use and/or opioid substitution treatment nine months before the start of pregnancy.  
In other words, GPs may have been enquiring about drug use before pregnancy 
and/or women may have disclosed information about drug use more before 
conception.  Even though GPs may not provide care during pregnancy, the Royal 
College of General Practitioners recommended that GPs should provide pre-
pregnancy counselling and support for women of child bearing age, especially if 
the woman has existing medical or mental health issues (Royal College of 
Obstetricians and Gynaecologists, 2010).   
 
In contrast, recording for both drug use and prescriptions for opioid substitution 
treatment decreased during pregnancy.  This decrease in recording could be due 
to four factors.  Firstly, some of the care of women regarding her pregnancy moves 
from general practice into the midwifery services during pregnancy (National 
Institute for Clinical Excellence, 2010b).  A referral letter should be sent by the GP 
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to the service and a discharge letter should be sent back to the GP at the end of 
the pregnancy (Perinatal Institute, 2015).  Although the information is in letter form 
and may be scanned into the patient’s electronic health records, however, the GP 
may not always record the information from the discharge letter using Read codes.  
Secondly, a specialist midwifery team usually takes over the management of the 
individual and prescribes appropriate opioid substitution treatment, which would not 
be coded in the patient’s electronic records during pregnancy (National Institute for 
Clinical Excellence, 2010c).  Thirdly, a woman may underreport or chose not to 
disclose drug use, as there is a fear that the baby would be taken away by social 
services (National Collaborating Centre for Women’s and Children’s Health (UK), 
2010).  Lastly, evidence suggests that women may reduce their drug intake during 
pregnancy as it is a critical time where women may be more motivated to modify 
their behaviour in order to decrease adverse effects on her unborn child (Australian 
Institute of Health and Welfare, 2015; Crozier et al., 2009; Ebrahim and Gfroerer, 
2003; Moore et al., 2010).  Behaviour change during pregnancy was highlighted by 
the Southampton Women’s study (self-reported questionnaire, n=1490) where 
women decreased adverse health behaviours, such as smoking, drinking alcohol 
and drinking caffeinated drinks.  However, women in the study, who were younger 
and less educated were less likely to change these negative behaviours (Crozier et 
al., 2009).  Moore et al. (n=171, self-reported questionnaire) found that pregnant 
women in London were more likely to decrease alcohol and ecstasy use during 
pregnancy, however, they did not reduce smoking or cannabis use (Moore et al., 
2010).  Furthermore, Ebrahim and Gfroerer analysed the National Household 
Survey in the USA between 1996-1998 and found that 28% of women who 
previously used drugs, stopped during pregnancy and this increased to 
approximately 93% in the third trimester (Ebrahim and Gfroerer, 2003).  Women in 
my study who had a recording for drug use were also younger.  Although there is 
some evidence that women change their drug behaviour during pregnancy, the 
cessation of drug use can be difficult, especially if the woman has become a 
problem drug user (see section 1.3.2.4). 
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Finally, prescriptions for opioid substitution treatment increased after pregnancy.  
This may indicate that the care and treatment of the women moves back into 
general practice after the baby is delivered (National Collaborating Centre for 
Women’s and Children’s Health (UK), 2010). 
 
5.8.2.4 Codes used most frequently by GPs to record drug use and/or opioid 
substitution treatment in and around pregnancy  
Read codes for drug use 
GPs used generic Read codes more for recording drug use; however, the specific 
codes for heroin and benzodiazepine dependence were also frequently used in 
and around pregnancy. This is different to other studies who all found that most of 
the pregnant women who tested positive for drug use, used cannabis (Farkas et 
al., 1995; Fergusson et al., 2002; Sherwood et al., 1999).  Sherwood et al., also 
found that 0.5% (4/807) of women tested positive for benzodiazepine use, and 
Farkas et al. showed that 1.4% (14/1000) of the women tested positive for opiate 
use (Farkas et al., 1995; Sherwood et al., 1999).  However, as mentioned before, 
both these studies were in a clinical rather than a primary care setting and signed 
consent was not required.  Two specific Read codes for drug addiction therapy and 
opioid drug dependence were only used after pregnancy, which could indicate that 
the GP coded this information from the discharge letter.  The reason that GPs may 
be using generic codes is that poly-drug use is common in people who use drugs 
(Drugscope, 2015c; National Treatment Agency for Substance Misuse, 2010).  
However, both heroin and benzodiazepine dependence have serious and 
conclusive consequences for the baby including neonatal abstinence syndrome 
(Hudak et al., 2012).  
 
Prescriptions for opioid substitution treatment 
Methadone was the most common opioid substitution treatment prescribed.  
Buprenorphine and dihydrocodeine were also prescribed, but at a lower frequency.  
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Methadone is the recommended opioid substitution treatment for pregnancy, as 
buprenorphine is not yet licensed for use during pregnancy in the UK (Whelan and 
Remski, 2012).  However, there is increasing evidence that buprenorphine is safe 
to use during pregnancy (Jones et al., 2010; Unger et al., 2011).  Therefore the 
recommendation in the UK for women who are stable on buprenorphine before 
pregnancy is that they should remain on buprenorphine during pregnancy 
(Johnson et al., 2003).  My study suggests that this occurs for some of the women 
receiving opioid substitution treatment.  Results from my study also show that 
some GPs are prescribing dihydrocodeine in and around pregnancy.  
Dihydrocodeine is not licensed for opioid substitution treatment in the UK, however, 
it has been used to wean the patient off opioids (Mawhinney et al., 2006; 
Robertson et al., 2006; Swadi et al., 1990).   
 
5.8.3 Conclusion 
The findings illustrate the tip of the iceberg with regards to drug use and opioid 
substitution treatment in and around pregnancy.  Although many women may not 
have contact with their GP during pregnancy, the majority have contact at the 
beginning of and after their pregnancy.  These may be critical time-points when 
GPs could ask about drug use.  If GPs chose to record in the electronic health 
records, the records could contribute to the continuation of care and support to 
both mother and child.  
 
5.9 How Does This Chapter Support My Thesis? 
Drug use and/or opioid substitution treatment during pregnancy is a multifaceted 
public health problem which can not only impact seriously on the health of the 
mother, but also for her foetus and developing child.  An indirect way of measuring 
drug use during pregnancy is to observe the outcomes of a newborn baby.  
Neonatal Abstinence Syndrome (NAS) has been found to be a definitive indicator 
of drug use and/or opioid substitution treatment during pregnancy.  Infants born 
from women who take opioids, benzodiazepine and barbiturates are at risk of 
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having NAS.  In the second study Read codes for heroin dependence 
benzodiazepine dependence were frequently used and methadone and 
buprenorphine were the most common opioid substitution treatments prescribed.  I 
will therefore examine the recording rate of NAS in THIN in the next chapter to 
ascertain an indirect measure of drug use during pregnancy.  
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 STUDY 3: GP RECORDING OF NEONATAL 
ABSTINENCE SYNDROME 
 
6.1 Content and Structure of Chapter 6 
In this chapter, I describe and discuss my third study, which focuses on recording 
of Neonatal Abstinence Syndrome (NAS).  I include infants that are permanently 
registered with a practice within the first 6 months of their life and link them to the 
pregnant women in the second study (Chapter 5) to ascertain if any of these 
women with a recording for drug use and/or opioid substitution treatment also have 
an infant with a recording for NAS.  I also compare the rates of recording of NAS in 
both primary and secondary care and assess how much information regarding 
NAS is being transferred to primary care in electronic health records. This chapter 
contains the introduction, aim, specific objectives, methods, results and discussion 
for the third study. 
 
This study addresses the third objective of my PhD (see section 2.4 for details) and 
will also contribute to answering the second part of my main research questions as 
NAS could be an alternative method for examining drug or opioid use during 
pregnancy (section 2.3):  
1. Can a large primary care database (The Health Improvement 
Network (THIN)) be used as a surveillance tool for understanding 
drug use and opioid substitution treatment in the general population 
and specifically during pregnancy (in England and Wales)? 
2. Can a large primary care database (THIN) be used as a tool to 
research drug use and opioid substitution treatment in general 
practice in the general population and specifically during pregnancy 
(in England and Wales)? 
Part of this chapter has been published in the Archives of Disease in Childhood-
BMJ, 2015 (Journal article is included in Appendix 11) 
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6.2 Introduction 
Misuse of addictive drugs, particularly opioids during pregnancy is a multifaceted 
public health problem (Madgula et al., 2011; O’Donnell et al., 2009).  Opioid use 
during pregnancy can have serious adverse effects on both the mother and her 
foetus, including NAS which affects an estimated 60-80% of babies born to opioid 
users (Doberczak et al., 1991).  Causes of NAS include prescribed opioid 
replacement therapy (namely methadone or buprenorphine) and/or heroin and 
other opioids (Hudak et al., 2012).  Foetal exposure to benzodiazepine, 
barbiturates, selective serotonin reuptake inhibitors (SSRIs) also contributes to a 
small proportion of NAS. (Hudak et al., 2012; Klinger and Merlob, 2008).   
 
Babies affected by NAS present with symptoms within hours of birth such as 
feeding difficulties, irritability, seizures and respiratory distress, due to the effect of 
drug withdrawal on multiple organs (Lloyd and Mysercough, 2006; O’Donnell et al., 
2009; O’Grady et al., 2009).  Neonatal treatment of NAS can require intensive care 
and prolonged hospitalisation  (Johnson et al., 2003; O’Donnell et al., 2009; Uebel 
et al., 2015a).  Opioid misuse during pregnancy is associated with preterm birth 
and poor foetal growth, but it is not clear whether these effects are caused by 
opioid misuse, other drug misuse or maternal mental health problems and/or an 
adverse environment (Abdel-Latief et al., 2013; Hudak et al., 2012).  Compared 
with the general population, children born with NAS are at increased risk of neglect 
and other forms of child maltreatment during their childhood and their mother is 
more likely to die during their childhood (Kahila et al., 2010; O’Donnell et al., 2009; 
Uebel et al., 2015a).  There is also a risk of the infant being taken away from the 
mother however, if the child remains with the mother and the mother is identified by 
the GP, the GP has a unique advantage of identifying the child too and could 
provide continuous support to both mother and child (Advisory Council on the 
Misuse of Drugs, 2011). 
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Information on the burden of NAS is important for maternity, neonatal, child health 
and welfare services, primary care and policy on drug prevention and treatment 
(O’Donnell et al., 2009).  The prevalence of NAS has been examined in Scotland, 
Western Australia and the USA in secondary care (National Statistics Scotland, 
2012; O’Donnell et al., 2009; Patrick et al., 2012).  There was however, no 
population-based information on the prevalence of NAS in primary and secondary 
care in England and Wales.  To achieve this, the infant needs to be diagnosed and 
recorded for NAS in secondary care initially.  This information should be on the 
discharge records, and the GP should receive a summary of these discharge 
records.  NAS is a definitive outcome and therefore an indirect measure of drug or 
opioid use during pregnancy.  As a result, I wanted to explore if recording of NAS 
in electronic health records could be an approach to estimating the incidence of 
opioid drug use during pregnancy.  In order to calculate recording rates of NAS, I 
used Read codes in primary care and International Classification of Disease-10 
codes in secondary care to compare trends over time.  I also examined 
demographic and other factors associated with a recording of NAS and examined 
how many mothers with a recording for drug use also had a baby with a recording 
for NAS.  
 
6.3 Aims of Study 3 
To explore recording of NAS, a symptom of drug use during pregnancy in primary 
and secondary care. 
 
6.4 Specific Objectives of Study 3 
1. Develop a list of Read codes for NAS in primary care 
2. Identify infants who have a Read code indicated for NAS and examine 
the demographics of infants with and without a recording  for NAS in 
primary care 
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3. Calculate the recording rate of NAS per 1,000 live births in primary care 
4. Calculate the recording rate of NAS per 1,000 live births in secondary 
care and compare how much of this information is entered in primary 
care electronic health records 
6.5 Hypotheses for Study 3 
Hypothesis 1: Recording rates of NAS are the same in THIN and HES between 
1997-2011 
Hypothesis 2: The time-trends for recording of NAS are similar compared with HES 
 
6.6 Methods 
I only had access to births in England from Hospital Episode Statistics (HES) and 
therefore restricted my analysis in THIN to infants born in England. 
 
6.6.1 Methods for THIN 
6.6.1.1 Read code list for Neonatal Abstinence Syndrome (NAS) 
I developed a Read code list according to the methods described by Davé and 
Petersen, 2009, in order to identify infants who had a recording for NAS.  I used 
search terms from the literature to develop my Read code list (O’Donnell et al., 
2009; Patrick et al., 2012) (Table 6.1). 
 
Table 6.1: Search terms for developing a Read code list for Neonatal Abstinence 
Syndrome 
Search terms used for Read codes for Neonatal Abstinence Syndrome 
neonatal abstinence syndrome 
neonatal withdrawal syndrome 
NAS 
abstinence syndrome 
withdrawal syndrome 
maternal drug use 
drug use during pregnancy 
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Once I had developed the Read code list for NAS, with clinical guidance from a 
GP, I manually examined the list and took out any duplicates or any Read codes 
that had an ambiguous meaning. 
 
Defining the denominator (Infants aged between 0-6 months) in THIN 
I obtained records for infants aged between 0-6 months and permanently 
registered in the same general practice in England.  I will refer to this group of 
infants as the THIN_birth_cohort.  I retained the electronic health records for all 
infants who were born between the financial years of 1997 and 2011 (31 March 
1997-1 April 2012).  This time period is slightly different to the time-period used for 
the first two studies (1994-2012 see section 4.4 and 5.4).  The reason for the 
difference is that birth records in HES were only available between the financial 
years of 1997 and 2011 and I therefore decided to examine infants for the same 
time period in THIN.  I used the live births for each calendar year as the 
denominator when calculating the recording rate of NAS per 1,000 live births in 
THIN. 
 
6.6.1.2 Defining the numerator (Infants with a Read code for Neonatal 
Abstinence Syndrome) in THIN 
I merged the THIN_birth_cohort with the Read code list for NAS to obtain the 
number of infants with and without a recording for NAS.  I used the number of 
infants recorded with NAS for each calendar year as the numerator when 
calculating the recording rate of NAS per 1,000 live births in THIN. 
 
6.6.1.3 Demographics for infants with and without a Read code for Neonatal 
Abstinence Syndrome. 
6.6.1.3.1 Demographics 
I examined the gender, deprivation and strategic health authority (region) for 
infants with and without a recording for NAS.   
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6.6.1.3.2 Infants with and without NAS linked to a mother 
Mothers and infants can be linked in THIN, if both records have the same family 
identifier codes, delivery month (mother) and birth month (infant).  In order to 
identify how many infants with and without a recording for NAS had a mother with a 
recording for drug use and/or opioid substitution treatment, I merged the 
THIN_birth_cohort with the preg_81_cohort (from my second study, section 
5.6.1.2).  I examined the women who were identified as a mother of an infant in the 
THIN_birth_cohort to see if they had a recording for drug use and or opioid 
substitution treatment.  
 
6.6.2 Methods using Hospital Episode Statistics (HES) 
6.6.2.1 Defining the denominator (Infants 0-6 months) extracted from HES 
I used pseudonymised data from HES(see section 3.5.1) for all infant admissions 
(up to the age of 6 months) to the NHS in England in financial years of 1997 to 
2011 (Health and Social Care Information Centre, 2012).   
 
The denominator population was all singleton live birth admissions to the NHS in 
England (comprising 96% of all births) (Birthplace in England Collaborative Group 
et al., 2011; Health and Social Care Information Centre, 2012).  I excluded all 
births identified as stillborn based on method of discharge or birth status (Health 
and Social Care Information Centre, 2012).  To minimise the risk of double 
counting cases, I restricted analyses to single births and in addition, excluded 
duplicate records by searching for the same HES identifier (HES ID) or for identical 
clusters of characteristics (e.g. birth weight, date of episode start, age, birth order) 
with different HES IDs (Health and Social Care Information Centre, 2012; Murray et 
al., 2013).  I used the live births for each calendar year as the denominator when 
calculating the recording rate of NAS per 1,000 live births in HES 
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6.6.2.2 Defining the numerator (Infants with a recording for NAS) 
I searched the ICD-10 code dictionary (see section 3.5.1) and literature for codes 
that indicated NAS (O’Donnell et al., 2009; Patrick et al., 2012; World Health 
Organisation, 2010).  Together with a neonatologist (Dr Kathryn Johnson) and 
clinical paediatric epidemiologist (Professor Ruth Gilbert), we examined and kept 
the following relevant codes: P96.1 (“Neonatal withdrawal symptoms from maternal 
use of drugs of addiction”, or P04.4 (“Foetus and newborn affected by maternal 
use of drugs of addiction”).  These codes detect any neonatal abstinence 
syndrome and have previously been shown to be specific for NAS managed by 
clinicians in studies of clinical records (O’Donnell et al., 2009; Patrick et al., 2012). 
For the numerator, I identified singleton babies with records for NAS based on the 
ICD-10 diagnostic codes up to 6 months of age (Health and Social Care 
Information Centre, 2012; World Health Organisation, 2010).  I used the number of 
infants with a recording of NAS for each calendar year as the numerator when 
calculating the recording rate of NAS per 1,000 live births in HES.   
 
6.6.3 Statistical Analysis 
All data was analysed using STATA (version 13) statistical software (Stata Corp 
LP, College Station, Texas). 
 
6.6.3.1 Statistical analysis for THIN 
I calculated the following for infants (0-6 months) in THIN_birth_cohort: 
1. Most frequently used Read codes used for recording NAS  
2. Number of infants with and without a recording for NAS   
3. Distribution and unadjusted and adjusted odds ratios with 95% confidence 
intervals for gender, deprivation, region for infants with and without a 
recording for NAS.  I examined if there was effect modification by gender, 
deprivation and region (Kirkwood and Sterne, 2003).  If there was evidence 
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of effect modification, I stratified the covariate.  In order to select which 
model fitted the data the best, I carried out hypothesis testing using 
likelihood tests (Kirkwood and Sterne, 2003).  
4. Recording rate per financial year (1997-2011) for NAS per 1,000 live births 
 
6.6.3.2 Statistical analysis for HES 
1.  I calculated the annual recording rates for NAS per 1,000 live births in 
England (1997-2011) infants in HES.   
2. I compared recording rates of NAS in THIN and HES by comparing 
intercepts and 95% confidence levels and beta coefficients using the suest 
command in stata   
 
6.7 Results 
6.7.1 Results for THIN 
6.7.1.1 Possible Read codes for neonatal abstinence syndrome (NAS) in 
primary care 
There were four Read codes available for GPs to record NAS in primary care.  The 
most commonly (0.04%, 254/637,707) used Read codes that GPs used to record 
NAS was “Neonatal abstinence syndrome” (Table 6.2). 
 
Table 6.2: Frequency of Read codes used to record Neonatal Abstinence Syndrome 
(NAS) 
Read code Description Frequency (%)      
N=637,707 
14I6.00 H/O: neonatal abstinence syndrome 3 (0.0004) 
Q485000 Neonatal withdrawal symptom from maternal use of drugs 109 (0.02) 
Q485200 Neonatal abstinence syndrome 254 (0.04) 
Q485.00 Newborn drug withdrawal syndrome 120 (0.02) 
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 Total 486 (0.08) 
N=number of infants in cohort 
 
6.7.1.2 Infants who have a Read code indicated for NAS and demographics 
of infants with and without a recording for NAS in primary care 
There were 809,227 infants who were born and registered with the same practice 
in the UK for the first six months of their lives.  Of these infants, 637,707 (79.3%, 
637,707 /809,227) were from England and born between 1 April 1997 and 31 
March 2012.  I will now refer to this group of infants as the THIN_birth_cohort.  
Within the THIN_birth_cohort, 486 (0.08%, 486/637,707) infants had a recording 
for NAS (Table 6.3). 
 
6.7.1.3 Statistical model  
I observed no effect modification by any of the covariates.  There were slightly 
more males than females, but this was not statistically significant.  Infants from the 
most deprived areas were two times (Unadjusted OR=2.18, 95% CI: 1.59-2.98) 
more likely to have a recording for NAS compared with infants in the least deprived 
areas.  Additionally, infants from the North East region of England were 3.5 times 
(Adjusted OR=3.59, 95% CI: 2.28-5.66) more likely to have a recording of NAS 
compared to infants in London.   
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Table 6.3: Demographics of infants with and without a recording for Neonatal Abstinence Syndrome (NAS) 
Infants born between 1 April 1997 and 31 March 2012 in England (N=637,707) 
 No NAS recording 
N=637,221(99.92%) 
Rate per 1000   
live births 
NAS Recording 
N=486 (0.08%) 
Rate per 1000 
live births 
Unadjusted OR 
(95% CI) 
*Adjusted OR 
(95% CI) 
Gender N (%)  N (%)  OR (95% CI)  
Male 
Female 
326,190 (51.2) 
311,027 (48.8) 
999.19 
999.29 
265 (54.5) 
221 (45.5) 
0.81 
0.71 
1 
0.87 (0.73-1.04) 
 
Deprivation N (%)  N (%)  OR (95% CI) OR (95% CI) 
1 least deprived 
2 
3 
4 
5 most deprived 
Missing 
135,292 (21.2) 
111,108 (17.4) 
126,941 (19.9) 
129,203 (20.3) 
  97,892 (15.4) 
  36,785 (5.8) 
999.50 
999.32 
999.21 
999.10 
998.95 
999.40 
  68 (13.8) 
  76 (15.5) 
100 (20.4) 
117 (23.8) 
103 (22.0) 
  22 (  4.5) 
0.50 
0.68 
0.79 
0.90 
1.05 
0.60 
1 
1.36 (0.98-1.88) 
1.56 (1.15-2.13)* 
1.80 (1.34-2.43)* 
2.09 (1.54-2.84)** 
 
1 
1.36 (0.98-1.89) 
1.64 (1.21-2.24)* 
1.89 (1.39-2.55)* 
2.18 (1.59-2.98)** 
Region N (%)  N (%)  OR (95% CI) OR (95% CI) 
London 
East Midlands 
East of England 
West Midlands 
North East 
North West 
94,604 (14.8) 
25,043 (  3.9) 
72,388 (11.3) 
73,440 (11.5) 
25,804 (  4.0) 
71,880 (11.3) 
999.60 
998.80 
999.13 
999.27 
998.57 
999.00 
38 (  7.8) 
30 (  6.2) 
63 (11.9) 
54 (11.3) 
37 (  7.6) 
72 (13.4) 
0.40 
1.20 
0.87 
0.73 
1.43 
1.00 
1 
2.99 (1.85-4.84)** 
2.17 (1.45-3.25)** 
1.87 (1.24-2.83)** 
3.59 (2.28-5.64)** 
2.52 (1.70-3.73)** 
1 
3.29 (2.03-5.33)** 
2.54 (1.69-3.83)** 
2.05 (1.35-3.11)** 
3.59 (2.28-5.66)** 
2.69 (1.81-3.99)** 
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Infants born between 1 April 1997 and 31 March 2012 in England (N=637,707) 
 No NAS recording 
N=637,221(99.92%) 
Rate per 1000   
live births 
NAS Recording 
N=486 (0.08%) 
Rate per 1000 
live births 
Unadjusted OR 
(95% CI) 
*Adjusted OR 
(95% CI) 
Y&H 
South Central 
South East Coast 
South West 
27,585 (  4.7) 
97,555 (15.2) 
75,268 (11.8) 
73,654 (11.5) 
998.91 
999.35 
999.40 
999.27 
30 (  6.8) 
63 (13.1) 
45 (  9.2) 
54 (10.9) 
1.09 
0.65 
0.60 
0.73 
2.76 (1.73-4.39)** 
1.61 (1.08-2.41)** 
1.49 (0.96-2.29) 
1.83 (1.20-2.78)** 
2.99 (1.84-4.84)** 
1.94 (1.28-2.92)** 
1.74 (1.12-2.71)** 
2.10 (1.38-3.19)** 
*Adjusted for deprivation and region **significant, OR=Odds Ratio, Y&H=Yorkshire and Humberside 
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6.7.1.4 Infants with and without NAS linked to a mother 
Of the infants in the THIN_birth_cohort, 17.6% (112,283 of 637,707) were linked to 
a mother in the preg_81_cohort.  Within the group of infants linked with a mother, 
0.03% (29 of 112,283) had a recording for NAS.  Additionally only half (55%, 16 of 
29) of the mothers who were linked with an infant with NAS had a recording for 
drug use and/or opioid substitution treatment (Figure 6:1).
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Figure 6:1: Infants linked with mothers in THIN with a recording or no recording for NAS (OST=Opioid substitution treatment) 
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6.7.1.5 Recording rate of NAS per 1,000 live births in primary care 
Of the 637,707 infants born between the financial years of 1997-2011 in England, 
0.08 (486 of 637,707) had a recording of NAS.  A mean of 30.4 (sd = ± 13.2) 
babies had a recording for NAS per year.  The mean recording rate of NAS was 
0.78 (sd = ± 0.33) per 1000 live births for the entire period and 1.03 for the most 
recent year, 2011.  The recording rate increased six fold between 1997 and 2005.  
The rate then fluctuates until it reaches a five-fold increase (compared with 1997) 
in 2011 (Figure 6:2). 
 
 
Figure 6:2: Recording rates of NAS per 1000 live births in THIN (1997-2011) 
 
6.7.2 Results for HES 
6.7.2.1 Recording rate of NAS per 1,000 live births in secondary care 
There were 8,956,382 live births deliveries in hospital between 1997 and 2011, of 
which 22,681 neonates had records indicating NAS (a mean of 1,515 (sd = ± 254) 
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babies per year).  The mean prevalence rate of NAS was 2.6 per 1,000 live births 
for the entire period and 2.7 for the most recent year, 2011.  Figure 6:3 shows a 
2.5 fold increase in the prevalence of recorded NAS between 1998 and 2004.  The 
rate then approximately remained stable until 2011.   
 
 
Figure 6:3: Recording rate of NAS per 1000 live births in HES (1997-2011) 
 
6.7.2.2 External validation of the proportion of recording of NAS in both HES 
and THIN and accept or reject hypotheses 1 and 2 
The total number of infants with NAS divided by the total births (between 1997 and 
2011) was a third (0.32, 0.77/2.41) lower in THIN than in HES.  I rejected the first 
hypothesis as the intercepts of the two models are significantly different as the 
confidence intervals do not overlap (HES: 1.89 per 1000 living birth 95% CI: 1.54-
2.25) and THIN: 0.35 per 1000 living birth, 95% CI: 0.12-0.62) suggesting that 
recording rates were significantly lower in THIN compared with HES. 
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The Beta coefficients (the slope of the two models) were not significantly different 
(X2=0.01, p=0.9415), therefore I accepted the second hypothesis as time-trends for 
the recording of NAS in THIN and HES are similar.(Figure 6:4). 
 
 
Figure 6:4: Recording rate of NAS per 1000 live births in THIN and HES (1997-2011) 
 
6.8 Discussion 
6.8.1 Summary of results 
There were 637,707 infants registered permanently with a practice in England 
participating in THIN between the financial years of 1997-2011.  Of these 0.08% 
had a recording for NAS.  Infants in the most deprived areas and in the North East 
region of England were more likely (2 and 3.5 times respectively) to have a 
recording for NAS.  Only 0.03% infants with a recording for NAS were linked to a 
mother and of those, only half were linked to a mother who had a recording for 
 183 
 
drug use and/opioid substitution treatment.  The mean recording rate of NAS in 
primary care was 0.78 (±0.33) per 1,000 live births and the most recent recording 
rate was 1.04 per 1,000 live births in 2011.  In contrast the mean recording rate for 
NAS in secondary care was almost three (2.9, 2.3/0.78) times that of secondary 
care.  Approximately a third of the recording of NAS in the hospital setting is 
recorded in primary care.  There were four possible Read codes for NAS that were 
available for GPs to use in primary care and the most frequently used was 
“Neonatal Abstinence Syndrome”.   
 
6.8.2 Comparison to previous literature 
6.8.2.1 Annual recording rates of NAS 
The increase in recording of NAS seen in both primary and secondary care may 
reflect increased recognition or recording of drug use during pregnancy and/or 
recognition or recording of NAS.  The increase in detection of NAS seen in both 
primary and secondary care in the late 1990s coincided with a Department of 
Health recommendation that obstetric departments establish good links with 
addiction centres, GPs and social services (Department of Health, 1999).  The 
small decline in NAS in both primary (after 2005) and secondary care (after 2006) 
may reflect the declining number of women entering treatment for opiate addiction, 
which may relate to decreased use, or decreased contact with drug treatment 
centres and hence notification of obstetric and neonatal services (House of 
Commons Home Affairs Committee, 2013; National Treatment Agency for 
Substance Misuse, 2010).  Furthermore, addiction services were vulnerable to 
funding cuts which may partly account for the variation in recent years (National 
Treatment Agency for Substance Misuse, 2012a).   
 
The increase in recording of NAS in both primary and secondary care could also 
be attributed to increased analgesic opioid use.  There has been a significant rise 
in recording of NAS in Scotland and the USA which is thought to reflect partly the 
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growing use of opiate analgesics (National Statistics Scotland, 2012; Patrick et al., 
2012).  Since 2000, prescription opioids have replaced heroin addiction as the 
main reason for starting methadone in Toronto.(Kuehn BM, 2007; Manchikanti et 
al., 2012).  A national survey of drug use in the USA reported that sources of opioid 
analgesics included prescriptions for the women themselves, analgesics obtained 
from family members, and direct purchase of opioid analgesics over-the web or, in 
some US states (Kuehn BM, 2007; Manchikanti et al., 2012; National Institute of 
Drug Abuse, 2014).  The increase of recording of NAS in Western Australia in the 
1990s was attributed to increasing heroin and methadone use, which has since 
stabilised (O’Donnell et al., 2009).  However, there is increasing evidence that a 
similar problem with regards to the misuse of prescription opioids is developing in 
Australia (Dobbin, 2014).  Evidence is still lacking about whether maternal use of 
opioid analgesics is increasing in the UK (House of Commons Home Affairs 
Committee, 2013; Stannard, 2013).  There is however evidence in my second 
study (section 5.7.3) which suggests that GPs are aware and record opioid use in 
and around pregnancy.  One of the most frequently used Read codes for drug use 
in and around pregnancy was “opioid type drug dependence”; it is likely this Read 
code could be used for recording opioid type drugs other than heroin.   
 
This is the first external validation study to illustrate how much of the recording of 
NAS from secondary care entered into the primary care electronic health records.  
My results indicated that a third of the information from secondary care is being 
entered into the electronic health records as Read codes in primary care.  
However, the fact that the infant had NAS may still be in the electronic health 
records but in the scanned discharge letter and not as a Read code. 
 
6.8.2.2 Babies with NAS linked with mothers 
Few infants with a recording for NAS could be linked to a mother through electronic 
health records in primary care.  To date there are no other studies which link the 
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records of mothers who use drugs and or opioid substitution treatment and their 
infants in primary care in the UK.  In Hospital Episode statistics mother and baby 
records are also not linked (Health and Social Care Information Centre, 2012).  
Primary and secondary health care systems in other countries vary and it is 
therefore difficult to make a direct comparison.  An example of this is in Australia, 
where the infants can be linked to the mother’s records using hospital 
administrative data (O’Donnell et al., 2009).  O’Donnell et al linked 802 infants 
recorded with NAS with mothers who used drugs.  With regards to primary care, 
the management of drug users by GPs is a complex and controversial issue 
(Advisory Council on the Misuse of Drugs, 2011).  Nevertheless, my first two 
studies indicated that treatment of drug use is occurring in primary care.  Likewise, 
the Hidden Harm report suggests that although there are primary care teams 
providing management for drug use, there seems to be less focus on the children 
(Advisory Council on the Misuse of Drugs, 2011).  A reason for why my results 
indicated such a low number of linked infants with a recording for NAS and women 
who use drugs is that if the woman reveals information about drug use they run the 
risk of being separated from their baby (Advisory Council on the Misuse of Drugs, 
2011).  Their baby may then be taken into care, assigned a new NHS number, 
registered with a different general practice and their records would therefore not be 
linked.   
 
6.8.2.3 Demographics and NAS 
6.8.2.3.1 Gender  
There was no difference with regards to gender and a recording of NAS in my 
study.  This was the same in other countries which have looked at the gender of 
the infant and recording of NAS (O’Donnell et al., 2009; Patrick et al., 2012) 
 
6.8.2.3.2 Deprivation  
My study found that children in more deprived areas were more likely to have a 
recording for NAS.  There are currently no other studies in the UK looking at the 
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deprivation of infants with a recording for NAS.  However there are numerous 
studies in other countries highlighting that mothers who give birth to an infant with 
NAS are more likely to come from disadvantaged groups (O’Donnell et al., 2009; 
Patrick et al., 2012).  Additionally, the Hidden Harm report suggests that the 
majority of children of drug users are from the most deprived areas (Advisory 
Council on the Misuse of Drugs, 2011).   
 
6.8.2.3.3 Region  
My results showed that infants in the North East were more likely to have a 
recording for NAS.  Additionally the highest reported prevalence rates of opioid use 
by women were in the North East and North West (9.5 per 1,000 population) 
regions of England in 2011/12, compared with the lowest rate in South East and 
East of England (5.3 per 1,000 population) (Health and Social Care Information 
Centre, 2013). The North East of England also has the highest number of 
emergency admissions (38 per 100,000) with a primary diagnosis of poisoning by 
illicit drugs among female adults aged between 16-59 years (Health and Social 
Care Information Centre, 2013) 
 
6.8.2.4 Read codes 
To date there have been no previous studies looking at the specificity and 
sensitivity of Read codes used to record NAS in primary care.  Nevertheless, the 
Read codes that I identified in THIN were clinically scrutinized by a GP and myself 
and any codes with ambiguous meaning were removed.  Furthermore, if NAS is 
diagnosed and recorded in secondary care it should also be recorded in the 
discharge summary records of the infant which is later sent to the GP (British 
Medical Association, 2014).  The discharge summary transfers the care of the 
individual from the hospital to the GP (British Medical Association, 2014).  There 
are several objective scoring systems used to diagnose NAS (O’Grady et al., 
2009).  In a national survey of practice in the UK and Ireland, O’Grady et al, 2009, 
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reported the use of different protocols and screening tools in neonatal units and 
some units had no protocol in place (O’Grady et al., 2009).  Where screening tools 
are used to detect NAS, inter-rater reliability coefficients of scoring methods ranged 
from 0.77-0.98 and small sampled studies have shown both specificity and 
sensitivity close to 100% (Bagley SM et al., 2014; O’Grady et al., 2009).  Under-
recording may however occur in secondary care if the mother is not identified as 
using drugs during pregnancy and the neonate is discharged soon after delivery 
(Osborn et al., 2010).  Additionally a small percentage of mothers may avoid 
contact with health professionals in and around pregnancy in order to reduce the 
risk of her child being taken away and therefore these mothers are not identified as 
a drug user (Advisory Council on the Misuse of Drugs, 2011).  Therefore there is a 
low risk of false positive diagnosis and recording for NAS in secondary care, which 
may later be recorded in primary care.   
 
6.9 Conclusion 
My findings illustrate the minimum estimate with regards to NAS in primary and 
secondary care.  However, most infants are registered with a GP after birth and the 
electronic health records could contribute to the continuation of care.  Both mothers 
and infants recorded with NAS could be monitored and supported. 
 
6.10 How Does This Chapter Support My Thesis? 
The results from my third study regarding recording of NAS link with my second 
study as the two most frequently used specific Read codes for drug use in and 
around pregnancy were for “heroin and benzodiazepine dependence”; 
“methadone” was the most frequently prescribed opioid substitution treatment; and 
finally the most frequently used specific Read code for opioid substitution treatment 
was for “methadone”.  Together with my first two studies, the third study will help 
establish if THIN can be used as a surveillance and/or research tool for drug use 
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and/or opioid substitution treatment during pregnancy.  I will discuss this more in 
Chapter 8. 
 
Additionally, as found in my first two studies, it is still unclear as to why and when 
GPs decide to use Read codes to record NAS.  As previously mentioned in 
sections 3.4.4, the main strength of using a large primary care dataset is that it 
provides a large amount of data from real life primary care.  However, meaning and 
understanding need to be incorporated into large datasets (Pope et al., 2014).  
This can be done by using qualitative methods to help understand the methods, 
classification and the circumstance for recording (Pope et al., 2014).  My fourth 
study (Chapter 7) will therefore be a qualitative study to understand how and why 
GPs record drug use in the general population, in and around pregnancy and NAS 
in primary care. 
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 STUDY 4: FACTORS AFFECTING 
RECORDING OF DRUG USE – A QUALITATIVE STUDY 
7.1 Content and Structure of Chapter 7 
In this chapter, I present my qualitative research which encompasses the fourth 
and final study of the thesis.  I used analysis from semi-structured qualitative 
interviews to assist in understanding GP recording of drug use and opioid 
substitution treatment and to aid in answering questions that arose from the 
previous three quantitative studies.  This chapter contains the introduction, aim, 
specific objectives, qualitative data collection methods, analysis, results and 
discussion for the fourth study. 
 
This study addresses the fourth objective of the thesis (see section 2.4 for details) 
and also contributes to answering the main research question by combining with 
data from the other studies to understand the reason for the gap in recording rates 
in a primary care database compared with national surveys, a hospital database 
and other studies (section 2.3):  
1. Can a large primary care database (The Health Improvement 
Network (THIN)) be used as a surveillance tool for understanding 
drug use and opioid substitution treatment in the general population 
and specifically during pregnancy (in England and Wales)? 
2. Can a large primary care database (THIN) be used as a tool to 
research drug use and opioid substitution treatment in general 
practice in the general population and specifically during pregnancy 
(in England and Wales)? 
 
7.2 Introduction 
Electronic health records can contribute to a longitudinal view about the individual 
and document continuous care, even if the individual is not always seeing the 
same GP (Freeman and Hughes, 2010).  As previously mentioned in section 1.3.4, 
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the benefits of good record-keeping in general practice are summarised by the 
Department of Health’s good practice guidelines for electronic patient records 
(Royal College of General Practitioners, 2011b).  The primary purpose of the 
electronic record is to support the care of the patient and health professionals can 
also use the records to structure their thoughts and make suitable decisions in 
order to ensure patient-centred care (Freeman and Hughes, 2010).  The electronic 
health record can also be shared amongst other health professionals who are 
involved in the same patient’s care and include other documentations such as 
discharge letters from the midwifery services (Freeman and Hughes, 2010).  Other 
uses for electronic health records include; clinical audit, research, education, 
service planning and contract delivery are also important (Royal College of General 
Practitioners, 2011b).   
 
There are currently few qualitative studies exploring GP recording in primary care 
and no studies looking at how GPs record drug use and opioid substitution 
treatment in electronic health records.  However, two qualitative studies have 
previously explored GP recording of other sensitive issues which may be difficult to 
disclose in primary care:, alcohol misuse and child maltreatment (Department of 
Health, 2005; Woodman et al., 2013) (previously mentioned in section 1.3.12).  
The first study, “The Alcohol Needs Assessment Research Project” used both 
qualitative and quantitative methods to explore GP recording of alcohol misuse in 
electronic health care records in England (Department of Health, 2005).  The 
project included eight separate studies conducted for six months between 2004 
and 2005 in the England.  In order to try and establish the number of individuals 
with a record for alcohol misuse, they examined the General Practice Research 
Database (GPRD) and also telephoned 424 GPs to find out the number of patients 
who were recorded as misusing alcohol (Department of Health, 2005).  Five times 
more GPs were aware of individuals who misused alcohol compared to the number 
that were recorded in GPRD (Department of Health, 2005).  These results 
suggested that GPs were aware of alcohol misuse but did not always record it in 
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the electronic health records.  The project also conducted six focus groups with 
Drug Action Team professionals (Department of Health, 2005).  The findings 
indicated that GPs were reluctant to record alcohol misuse in health records and 
refer patients due to limited access of overstretched services and the lack of 
patient engagement with services (Department of Health, 2005).  The second study 
was conducted by Woodman et al. who also used mixed methods to examine 
recording and responses to child maltreatment in primary care (Woodman et al., 
2013, 2012).  Using the THIN database, they found that child maltreatment was 
recorded in 1% of children’s electronic health records in the UK.  They 
acknowledged that the result was an underestimate compared with other data 
sources (Woodman et al., 2012) (section 1.3.12).  GPs seemed to be cautious 
when recording child maltreatment in electronic health records and they 
subsequently conducted in-depth qualitative interviews with GPs (n=14), practice 
nurses (n=2) and health visitors (n=2) in England (Woodman et al., 2013).  Their 
findings suggested that GPs used previously learnt skills for long term 
management of families who prompted concerns about child maltreatment 
(Woodman et al., 2013).  Woodman et al. did not explicitly explore GP recording of 
child maltreatment however, they went a step further towards ascertaining and 
understanding the responses and actions of the health professionals regarding a 
very sensitive issue (Woodman et al., 2013).  Although both studies looked at 
recording of other issues than drug use, there is a strong argument that the issues 
discussed above may be similar to drug use as they are also examples of sensitive 
and sometimes stigmatised issues that may have repercussions if recording in 
electronic heath records (Alcohol and Drugs Misuse Subgroup of the Changing 
Minds Campaign, 2003). 
 
Even though there are no specific studies exploring GP recording of drug use, 
there two studies by McKewon et al. and McGillen et al. which explore GP attitudes 
to people who uses drugs which could impact on the recording of drug use 
(McGillion et al., 2000; McKeown et al., 2003).  McKeown et al. conducted 48 
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semi-structured interviews to understand the attitude of GPs to drug misusers and 
drug misuse services in Scotland (McKeown et al., 2003).  Their focus was on GPs 
who saw and treated problem drug users, mainly those treated with methadone 
(McKeown et al., 2003).  The study highlighted that some GPs viewed drug use as 
more of a societal rather than a medical issue.  Whilst most of the GPs were willing 
to treat drug users, the behaviour of the patient and the GP’s confidence in 
managing addiction affected their decision of whether or not to provide treatment 
(McKeown et al., 2003).  Shared care with other health professionals and specialist 
services was therefore considered the best way to treat drug users (McKeown et 
al., 2003).  McGillion et al. sent a questionnaire to 206 GPs in the inner London 
area to examine their attitudes and knowledge towards management of problem 
drug users (McGillion et al., 2000).  Most of the GPs who responded to the survey 
felt that general practice was an ideal place for drug use to be detected, however 
less than half felt that they had adequate and appropriate knowledge to treat drug 
use (McGillion et al., 2000).  Both studies by McKeown et al. and McGillion et al. 
were conducted in the time-period when heroin was used more frequently and 
individuals who used heroin were often quite chaotic and needed long term 
treatment for their heroin addiction.  GP attitudes may have changed with the 
variation in drug trends used over time.  Both these qualitative studies contribute to 
the understanding of GPs’ views of treating drug use.  However they focus on 
problem drug users and do not include recreational drug users and drug use during 
pregnancy.  The studies also do not give an indication of how, when and why GPs 
record drug use.   
 
It was evident from my quantitative studies that GPs are recording drug use and 
opioid substitution treatment in the general population and during pregnancy.  It is 
however, still unclear why recording is lower compared with national surveys, 
hospital data and other studies as well as to why, when, how and for whom they 
record.  The main strength of using a large primary care dataset is that it provides 
a large amount of data from real life primary care (Pope et al., 2014).  However, 
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meaning and deeper understanding need to be combined with large datasets 
(Pope et al., 2014).  This can be done by using qualitative methods to help 
understand the methods, classification and the circumstance for recording (Pope et 
al., 2014).  Methodological triangulation would strengthen the evidence of my 
quantitative work.  This qualitative study therefore complements my existing 
studies by exploring the factors which determine recording by GPs of drug use and 
or opioid substitution treatment in primary care.  It also aims to contribute to the 
landscape of literature regarding recording in primary care. 
 
7.3 Aims of Study 4 
To understand GP recording of drug use and opioid substitution treatment and to 
use existing literature to contextualise the findings. 
 
7.4 Specific Objectives of Study 4 
The qualitative study was based on interviews with a purposive and theoretical 
sample of GPs to determine how these GPs record drug use in primary care.  My 
aim was therefore not to describe standard practice across the whole of the 
England and Wales.  The specific objectives were: 
1. To explore and generate an understanding of the factors determining 
GP recording of people who use drugs and/or receive opioid 
substitution treatment in primary care. 
2. To examine if GPs use any specific protocols or codes for recording 
drug use and/or opioid substitution treatment 
3. To examine and generate an understanding of the similarities and 
differences of recording drug use and/or opioid substitution treatment 
between the general population and pregnant women 
4. To examine if GPs use any specific protocols or codes for referring 
individuals for treatment of drug use and/or opioid substitution 
treatment 
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7.5 Methods 
7.5.1 Ethics 
Ethical approval for the interviews was granted by UCL Ethics committee in June 
2014 (Ethics approval number 5664/001) (See Appendix 8.1).  Following the initial 
ethical approval, an amendment was applied for and granted (See Appendix 8.2): 
1) Request to increase payment to participants from £20 to £30 (granted on the 
18 June 2014) 
 
The study was registered with UCL records office and is covered by the UCL Data 
Protection Registration, reference No Z6364106/2014/05/34, section 19, Research: 
Health Research. 
 
7.5.2 Sampling of participants 
Purposive sampling is a technique that involves selecting participants from a 
particular group who are likely to generate useful and appropriate data (Coyne, 
1997).  A researcher can select participants according to factors such as age, 
gender, status, profession, experience or location (Coyne, 1997).  I decided to use 
purposive sampling for my qualitative study as I intended to interview GPs who had 
a special interest in patients who use drugs.  The clinical director of Substance 
Misuse Management in General Practice agreed to contact GPs who had 
completed the RCGP Certificate in the Management of Drug Misuse (Royal 
College of General Practitioners, 2015a).  However, after initial interviews, analysis 
and discussion during my data clinic (see section 3.6.4 for details), I decided to 
also use theoretical sampling (section 3.6.2) and include GPs who did not have a 
special interest in drug use, but who still treated patients for other clinical problems. 
I will now discuss my sampling process in more detail. 
Inclusion criteria 1: 
Participants (GPs) were selected if they fitted the following inclusion criteria: 
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 Currently work in a general practice in the England and Wales 
 Has a special interest in treating patients who use drugs 
 Had completed at least one module of the RCGP training in substance 
misuse 
 Range of years of GP experience (from GP trainee to very experienced) 
 Both males and females 
Inclusion criteria 2 
Following my data clinic (see section 7.5.5), I included the following criteria: 
 GPs who did not have a special interest in drug use i.e. they saw individuals 
who use drugs, but did not treat them for drug use. 
 
I recruited 11 GPs from different practices across the England and Wales.  In order 
to select a purposeful sample the clinical director of Substance Misuse 
Management in General Practice (SMMGP) circulated a short summary of my 
study and contact details (Appendix 9) to GPs who had completed the course: she 
also broadcast the study more widely via the SMMGP twitter account.  If a GP was 
interested in participating in the study, they could email myself directly.  Once I 
received their email, I asked a few more questions about their location and type of 
work they did in order to ascertain if they fitted the inclusion criteria for my study.  I 
also answered any queries they had regarding the study.  There were a few GPs 
who did not fit the specific criteria (e.g. GPs who worked only in drug treatment 
clinics and not in general practice).  If this occurred, I met with my supervisor to 
discuss if the GP could be included or not.  Once I had confirmed that they were 
eligible for the study, I arranged a suitable time and place for the interview.  I also 
sent the information and consent forms via email and informed the GP that I would 
bring two hard copies for both of us to sign and keep. 
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Pilot interview: 
I initially conducted a pilot interview with one of the GPs working in the Department 
of Primary Care and Population Health, UCL.  I sent an email to this particular GP, 
who was willing to participate.  The GP was employed for four sessions per week 
at a practice in South West London and worked as an academic GP for the rest of 
the week.  He did not have a special interest in drug use or a SMMGP certificate in 
the management of drug misuse, however the practice was located in a deprived 
area and he saw many patients who used drugs and presented to the practice for 
other reasons.  After completion of my interviews, I decided with my qualitative 
supervisor to include the pilot interview in the analysis and obtained consent from 
the participant. 
 
Following the pilot interview, I had three stages of sampling which allowed me to 
interview and analyse the data concurrently.  I also intended to revise the topic 
guide iteratively in order to include new questions which emerged during the 
analysis.   
 
Stage 1 sampling 
The clinical director of the Substance Misuse Management in General Practice 
(SMMGP) sent the initial email to approximately 30 GPs who had completed the 
RCGP modules.  I received responses from five GPs, however, two did not fit my 
inclusion criteria as they were GPs in drug treatment clinics rather than GPs 
working in general practice.  One of the GPs worked as a prison GP, but had also 
recently worked in a general practice that registered homeless individuals.  After a 
discussion with my supervisor, we decided to invite this GP to participate in my 
study.  The three GPs from this first sampling stage were all from inner city 
practices. 
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Stage 2 sampling 
A colleague who had recently conducted a qualitative study with GPs had several 
contacts from the RCGP.  She offered to send an email to those GPs she was 
aware of who had completed the SMMGP modules.  Two GPs responded to this 
email and both were eligible for the study.  They were also from inner city 
practices. 
 
Once I had completed five interviews, I held a data-clinic (see section 7.5.5).  As 
previously mentioned, I decided to include GPs who saw patients who used drugs 
in their practice, but did not necessarily have a special interest in drug misuse. 
 
Stage 3 sampling 
I asked both the clinical director of SMMGP and two other colleagues to send 
additional emails, to include GPs who had not completed the SMMGP modules.  
Seven GPs responded but only five fitted the inclusion criteria.  Two of the GPs 
were from inner city practices and had a special interest in drug use. A further 
three GPs did not have a specific interest in treating people who used drugs: two 
worked in outer city practices and one in an inner city practice (Table 7.1) 
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Table 7.1: Demographics of GPs interviewed 
Gender Years’ of 
experience 
Location Sampling stage No of GPs in practice 
(male :female) 
GPs with a special interest in drug use and a SMMGP certificate 
#1-M* >15 Inner city 1 8 (3:4) 
#2-M* >15 Inner city 1 4 (1:3) 
#3-F* >15 Outer city 
neighborhood 
1 5 (2:3) 
4-F* 5-10 Inner city 2 6 (2:4) 
5-M* 5-10 Inner city 2 6 (1:5) 
6-M* >15 Inner city 3 4 (2:2) 
#7-F* >15 Inner city 3 7 (1:6) 
#8-F* >15 Inner city 3 7 (3:4) 
GPs without a special interest in drug use 
9-M 5-10 Outer city 
neighborhood  
3 8 (3:5) 
10-F 5-10 Outer city 
neighborhood 
3 7 (3:4) 
11-F GP trainee Inner city 4 9 (3:6) 
12-M >15 Inner city Pilot 8 (3:5) 
*Completed at least one module of RCGP training 
#Recruited through the clinical director for SMMGP  
 
 
GPs were from a geographical spread of general practices across England. 
Unfortunately, I was unable to recruit any GPs working in practices in Wales 
(Figure 7:1). 
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Figure 7:1: Location of general practices where participants worked in England 
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7.5.3 Interviews 
After careful consideration and discussion amongst my supervisors and collegues, 
I decided to use face-to-face semi-structured interviews for my qualitative study 
(section 3.6.1).  The main reason that I chose this method was that semi-structured 
interviews suited the type of data I wished to generate which reflected a specific, 
relatively self-contained action.  I aimed to gain a deeper understanding of their 
perceptions, context and process of their recording practice of drug use.  I also 
chose semi-structured interviews as there were some specific questions I needed 
to ask at the beginning of the interview, followed by more open-ended questions.   
 
I asked each GP for permission to record the interview and all participants agreed.  
I also emphasised that the identity of both GP and patients would remain 
anonymous and that the general practice would only be identified at a borough or 
closest town level.  I also asked all participants if they had any further questions 
about the study and then asked them to read and sign two copies of the consent 
form.  Once this was done, I filled in the fact sheet that I had developed in order to 
record the time, date, location, special conditions and participant’s demographics 
(see Appendix 10).  Prior to the interview, I had developed the interview guide 
which contained key topics and open-ended questions (see Appendix 10).  The 
interview questions initially covered the following areas for both the general 
population and pregnant women: 
 if and why GPs record drug use; 
 which methods GPs use for recording drug use;  
 GP’s actions if a patient asks for the information not to be recorded and 
 GP’s actions if they suspect a patient uses drugs but does not disclose the 
information.   
 
I used an iterative approach and revised my topic guide after each interview.  
Versions of the first and last interview schedules can be seen in Appendix 10. 
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After each interview, I wrote my field notes, which included my thoughts and 
interpretations about the interview.  I tried to do this as soon as possible after the 
interview, in order to reduce incorrect recall.  I also typed these field notes up at a 
later date. 
 
7.5.4 Transcription 
I transcribed the first interview myself and sent the rest of the interviews to a 
professional transcriber who had previously transcribed interviews for other 
members of the department.  I sent the audio file via Hightail software 
(https://www.hightail.com/), which is secure software for sending and sharing large 
files.  Once the transcriptions were complete, I familiarised myself with the data by 
going through each interview with both the transcript and audio file to ensure that 
they had been transcribed accurately.  If words had been left out, I revised the 
transcripts accordingly and analysed these final transcripts. 
 
7.5.5 Improving reliability 
In order to improve the reliability and rigour of my interpretation, I set up a data-
clinic during the interviewing and analysis stages (Thomas and Magilvy, 2011).  
The clinic focused on discussing themes and codes that I had identified during my 
analysis (Bergman and Coxon, 2005; Green and Thorogood, 2004).  Different 
researchers may not identify the same themes, due to their different backgrounds, 
experiences, interests, knowledge and theoretical approaches (Green and 
Thorogood, 2004).  I therefore invited qualitative, mixed methods and quantitative 
researchers from a variety of disciplines from the department of Primary Care and 
Population Health.  Six researchers with disciplinary backgrounds in sociology, 
psychology and epidemiology attended the data clinic in October 2014.  One of my 
supervisors chaired the data-clinic, which meant I could focus on actively listening 
and taking notes during the discussion.  However, on reflection and after attending 
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a different data-clinic - where the researcher recorded the conversation - I would 
record the session, so that I could review the dialogue in more detail. 
 
Before the data-clinic, I sent each researcher a copy of a transcript from the third 
interview (Participant 3) and a summary of my PhD thesis.  During the data-clinic, I 
began by outlining my PhD and describing how I intended to use the qualitative 
results to help understand the three quantitative studies.  I also justified why I had 
chosen the particular transcript to discuss; the main reason was that I felt more 
confident with my interview technique by the time I conducted my third interview, 
furthermore, participant 3 was a female GP who was a similar age to me, and I felt 
more comfortable and at ease when interviewing her.  Conversely, the previous 
two interviewees were older male GPs and I felt slightly intimidated during the 
interviews.  In addition, participant 3 was an example of a GP who was not always 
following a specific protocol with regards to recording.  She worked part-time as a 
GP and in a drug treatment clinic and consequently her experience working in the 
drug treatment clinic seemed to influence her way of recording and treating 
patients who use drugs. 
 
I decided to focus on particular sections of the transcript to see if my interpretations 
were the same or different to the other researchers.  We had an in-depth 
discussion about each specific section and after the data-clinic, I categorised the 
discussion into 4 sections; 
 
 Questions that I could include in the next interviews 
 Similar themes that came up 
 Other themes that came up 
 Actions to be taken 
 
 203 
 
I found the data-clinic extremely useful for reinforcing the themes that I had 
identified, identifying new themes and introducing new questions into my topic 
guide.  As mentioned previously, it also became clear that I needed to not only 
interview GPs who treated people who use drugs and who had a special interest in 
these patients, but to also include GPs who did not necessarily have a special 
interest in drug use and treated these individuals for other symptoms and co-
morbidities.  I therefore used both theoretical and purposive sampling in my 
sampling methods (section 3.6.2). 
 
7.5.6 Reflexivity 
Reflexivity is a central part to qualitative research (Cutcliffe and McKenna, 2002; 
Kingdon, 2005).  It is a process whereby the researcher reflects on how their own 
perceptions, values and practice can influence the data collection and data 
analysis (Green and Thorogood, 2004).  As mentioned in section 3.6.4.5, the 
researcher acts as the research instrument in qualitative research and therefore 
needs to monitor and critique their opinions, attitudes and interview techniques 
(Green and Thorogood, 2004).  After I had completed my first quantitative study 
using THIN, it became apparent that recording of drug use was more complex than 
recording of other conditions such as diabetes.  After discussion with my 
supervisors, we decided that I should include a qualitative study to explore the 
factors that influenced the GP recording of drug use. Before starting my 
quantitative study, I conducted a thorough literature review on drug use in the UK 
and recording in primary care.  I also read English policy documents, training 
guides and Royal College of General Practitioners guidelines.  I spoke to various 
GPs informally about their experiences of seeing people who used drugs in primary 
care.  During this stage of my PhD, I had developed a set of beliefs and 
presumptions about drug use and the role of the GP with regards to recording.  As 
part of the reflexive process, I wrote down the following assumptions in my field 
notes, before starting my interviews with GPs.  I have included my initial 
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assumptions and how these assumptions (In italics) changed through the interview 
process. 
1. Drug use is stigmatised in society and it may be difficult for a patient to be 
honest about their drug use 
 Drug use may be stigmatised in society, but the general practices 
offered a non-judgmental place for the patient to discuss their drug 
use.  Some GPs had developed a good rapport with patients and 
these patients may have felt more willing to disclose and discuss their 
drug use. 
 
2. Drug use was often combined with other social and medical issues 
 This assumption remained the same and was supported by the 
evidence as most of the GPs described how individuals who used 
drugs came to see them about both medical and social problems 
other than their drug use, these included the following; depression, 
anxiety, job loss, homelessness 
 
3. Drug use during pregnancy often leads to children being taken away from a 
mother 
 This was not always the case, but it did happen in some cases.  
Social workers were usually involved when a woman took drugs 
during and after pregnancy.  
 
4. People who use drugs can sometimes be difficult patients 
 This was not always the case, although there were some patients 
who were more chaotic than others and who did not engage with 
services.  Some patients were however more engaging and the GP 
and patient had developed a good rapport. 
 
5. Some practices chose to not treat individuals who use drugs 
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 This assumption did not change, however the general practices 
choosing not to treat drug misuse, usually treated other medical 
conditions. 
 
6. GPs could be in an appropriate position to identify and treat people who use 
drugs 
 This assumption did not change, and if the individual attended a 
consultation, GPs could be in a suitable position to identify individuals 
who use drugs.  However barriers such as time and expertise may 
inhibit GPs from identifying individuals. 
 
7. GPs would usually record important information from a consultation and this 
should include drug use 
 This assumption changed throughout the interview process as data 
emerged highlighting that GPs did not always record all information 
from consultations.  Recording drug use was a particularly complex 
issue and was therefore not always recorded. 
 
8. GPs should be using guidelines and protocols for recording drug use in 
electronic health records 
 This assumption changed as not all general practices had or were 
using specific protocols for recording drug use in electronic health 
records. 
 
9. Recording is important not only for research purposes but also for the 
continuous care of the individual. 
 This assumption changed, as some of the GPs viewed trust and truth 
from the individual as more important for treatment of the individual 
rather than recording drug use. 
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Looking back on my assumptions, I feel that I was slightly naïve in my thinking and 
beliefs.  I felt that THIN was an effective tool for surveillance and research and that 
GPs would be at the forefront of accurate recording of their consultations.  
Reassessing the situation, I should have discussed these assumptions with my 
qualitative supervisor before the interviews, as after the first few interviews I gained 
a somewhat different perspective and understanding of GP recording of drug use.  
I tried to set my beliefs aside during the interview although I did find it difficult in the 
beginning to sit and listen rather than to interact with the conversation.  After 
listening to the first few interviews, I realised that I was saying “ok” a lot in order to 
show understanding of what the participant had said.  I tried to change this to a 
non-verbal nodding of my head and asking questions such as “could you tell me 
more about x”.  I also tried to summarise and repeat important points back to the 
participants to ensure that I had heard them correctly.  I found that I was exhausted 
after each interview as I was trying to actively listen to each word carefully.  I felt 
nervous during my first few interviews as they were both male GPs with over 15 
years’ experience.  My third interview was with a female GP who was around the 
same age as me and this interview helped me gain more confidence and improve 
my interviewing technique.  Frequent meetings with my qualitative supervisor and 
the data-clinic also helped me with both my confidence and including other 
questions in order to gain insight into other issues such as how changing computer 
software helped or hindered. 
 
I made it very clear in my emails, the information sheet and at the beginning of the 
interview that I was a PhD student and that this was part of my PhD.  I clarified that 
their identity and the identity of the general practice would be anonymous and I 
think that this put them at ease at the beginning of the interview.  I noticed that 
most of the GPs described their experience rather than using guidelines for 
recording or not recording drug use in the patient notes.  I found most of the GPs 
very easy to speak to.  Although on one occasion, I had a migraine the night before 
one of my interviews.  I woke up feeling very cloudy and thought about postponing 
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the interview.  I decided against this as it had been quite difficult securing the 
interview time and the GP had agreed to be interviewed in-between his morning 
and afternoon sessions.  The interview did not flow as previous interviews had and 
I think it was a combination of me feeling poorly and therefore not gaining rapport 
within the interview. 
 
I wrote the following in my field notes: 
“I had a migraine the night before and was feeling extremely foggy and exhausted on the 
morning of the interview. I almost cancelled the interview, but decided not to. I did feel that 
the interview was a bit flat, and I’m not sure if it was the interaction between the two of us, 
or because I was not expressing myself as clearly as I could have. On reflection and 
listening to the interview, it was ok, a bit slow to start though.  I think that he had a slower 
way of talking and a very quizzical expression when I asked him a question which unnerved 
me slightly. He was also eating his lunch during the interview, so it was difficult for him to 
speak at times.” 
 
I was aware of my role as a researcher and how this could potentially influence my 
interviews.  During the first interview, the participant asked me a specific question 
about neonatal abstinence syndrome.  By this stage, I had completed a thorough 
literature review and had written the introduction part of my chapter on neonatal 
abstinence syndrome.  When he asked, it took me by surprise and my immediate 
reaction as a researcher was to give him the information from my literature review.  
I started to tell him and then felt that it would interfere with the interview and 
therefore stopped and said that I would email the relevant articles after the 
interview.  When I was writing up my field notes, I reflected on the situation and 
decided that if a similar situation arose, I would tell the GP that I would be happy to 
discuss the matter after the interview, but not during it.  As it happened, in the very 
next interview the GP asked about prescribing guidelines specifically during 
pregnancy, I therefore told her that I was happy to discuss the guidelines after the 
interview, and subsequently emailed her the most recent guidelines.   
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Most of my interviews took place in the GP’s consulting room in the general 
practice.  It was interesting for me to take note of the surrounding environment, not 
only inside the general practice but also the location.  Some of the practices were 
located in very socially deprived areas, whilst others were located in relatively 
affluent areas.  I did conduct two interviews in coffee shops as the GPs had 
suggested this and I found it a bit distracting during the interview.  I did a sound 
check before each interview to ensure that I could hear the GP clearly. 
 
I was aware of how busy all of the GPs were and was very conscious of the timing 
of the interviews.  My information sheet had stipulated that the interview wouldn’t 
take more than 40 minutes.  Most of the GPs agreed to be interviewed on days 
when they were not seeing patients and two of the GPs actually came into the 
practice especially to see me.  Most of the interviews ended naturally around 30-40 
minutes but one or two continued for over an hour.  I did interrupt the interview in 
order to check that it was ok for the GP to carry on with the interview. 
 
In summary, there were many different aspects that contributed to my interview 
journey.  My set of beliefs changed during the interview process and I felt that I 
became less judgemental of GPs who were sometimes putting patient care before 
accurate recording.   
 
7.5.7 Analysis 
I used inductive thematic analysis in order to analyse my data.  Firstly, I coded the 
first few transcripts and developed a coding structure and together with my 
supervisor, we appraised the developing coding structure.  I then used these codes 
to code the next transcripts and if any new codes emerged, I went back to the 
previous transcripts to ascertain if they contained any of the newly emerged codes.  
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I then organised the codes into emerging themes.  Following this process, I met 
with my supervisor to discuss the emerging themes and how I would contextualize 
the themes.  I also sorted the organising themes into two main global themes and 
arranged sub-themes into the organising themes.   
 
Many themes emerged from the data and I had to be vigilant about including 
themes that were answering my research question about recording, namely: 
 How does the GP record or not? 
 How are decisions made in relation to the use of Read codes or free-text? 
 How and why are they using templates or protocols? 
 In what way is this different if a patient is pregnant? 
 
In order to really ascertain if the themes emerging from the data were answering 
my research question, I went through each one carefully and decided whether it 
fitted with the four questions about recording.  If it did not, then I decided to take it 
out of my findings as I wanted to focus on those themes.   
 
It was evident from my quantitative studies, that GPs are recording drug use in the 
general population and in and around pregnancy.  However, as previously 
mentioned in sections 4.9.2, 5.8.2 and 6.8.2, the annual rates of recording drug 
use in my studies were lower than national surveys and this suggests that either 
people who use drugs are not going to see their GP and/or if they are seeing their 
GP, their drug use is not being recorded.  It is unclear why, when, how and which 
circumstances GPs record drug use and why they use particular Read codes.  
Particular processes need to take place before a GP can record information into an 
individual’s electronic health record.  From the data, there were two clear 
processes that emerged so I decided to organise these two processes as global 
themes.  The first global theme was “acquiring information about drug use” and the 
second was “management and treatment of drug use”.  There seemed to be 
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several factors that influenced these proceedings which can vary for different GPs, 
individuals and situations.  I decided that these factors would be the organising 
themes.  Three possible organising themes contributed to my first global theme 
and two organising themes contributed to the second global theme Figure 7:2.  My 
first three studies were examining the end product of the two global processes; 
recording the information from the consultation.   
 
Figure 7:2: Global, organisational and sub-themes of recording 
 
I will now discuss the findings of my qualitative work.  I will do this in sequential 
order and discuss the global themes, organising themes and sub-themes.   
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7.6 Findings 
To aid navigation of this section, I inserted a version of Figure 7:2 at the start of 
each section with the highlighted organising and sub-themes discussed in that 
section.  I then introduce the findings, with quotes from the data to support the 
findings.  I conclude each section with a summary of the key findings. 
 
7.6.1 Global theme 1: Acquiring information about drug use 
As drug use is legislatively an illegal action which can lead to adverse 
consequences, questioning about it is a sensitive topic.  Additionally, negative 
attitudes and societal disapproval regarding drug use have created a stigma 
associated with it.  The GP accounts from my qualitative study illustrated that 
asking patients about drug use is a complex and sometimes difficult issue.  
Consequently the first global theme that was identified and developed from my 
data was the topic of acquiring information.  Two sub-themes (“the context of 
acquiring information” and “the interaction between GP and patient”) transpired 
initially, which helped me to set the scene before I considered the third sub-theme 
of “the process of acquiring information about drug use”. 
 
7.6.1.1 The context of acquiring information 
There were two distinct sub-themes incorporated in the “context of acquiring 
information”.  The first was the “organisational context” which focused on the 
environment and regulations of the general practice.  The second sub-theme was 
the “individual context” which focused on the perceptions and experiences of the 
GP.  Both the organisational and individual contexts influenced the reason and 
methods used for acquiring information from patients about drug use Figure 7:3.   
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Figure 7:3: Context of acquiring information; first organising theme of Global theme 1 
 
7.6.1.1.1 Organisational context 
I will discuss three areas/topics which I identified from the data and grouped within 
the theme of “organisational context” of the general practice.  These included the 
location and the size of the general practice, whether or not the general practice 
receives financial incentives for treating drug use and finally the time that GPs are 
allocated to see and treat patients. 
 
Location and size of the general practice 
The location of the general practice was significant to the convention of acquiring 
information.  Practices located in areas where drug use was more prevalent, were 
more likely to have patients registered with the practice, who use drugs.  The GPs 
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from these practices perceived that this made primary care more accessible for 
individuals who used drugs.  Accounts from GPs from areas where drug use is 
relatively high (inner city) depicted that they had numerous patients registered with 
their practice whom they knew used drugs.   
“Well, in [borough], we’ve traditionally been very keen, you know we’ve been very involved, 
quite a lot of GPs I think are involved, in terms of substitution prescribing, particularly for 
maintenance, but also for reducing and stopping. So I think we provide a very good place 
for managing the less chaotic people.” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
“Our practice manager has set up the practice in such a way that it is quite attractive to 
people who want to join, particularly those who are having problems with access to their 
GPs, because we (sic) our practice is open for longer than average.”  
(GP, male, 5-10 years’ experience, outer city, did not have a special interest in drug 
use) 
 
Consequently, these practices were accustomed to seeing patients for problems 
both directly and indirectly relating to drug use.  The fact that patients who use 
drugs were regularly attending consultations in the practices seemed to desensitise 
the perception of drug use.  
“But it’s the same as smoking or alcohol or obesity, you know, it’s a choice unfortunately 
that people can make, even though we can advise them.  So I would bring it up, but I would 
basically say, you know, “Do you think that’s something that you would be concerned 
about?  Do you understand what it might do?  Do you understand the risks you run?”  
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
In comparison, one of the general practices located in an outer city area where 
drug use was less prevalent seemed to have fewer patients registered with the 
practice that they knew used drugs.  The GP commented that as far as she was 
aware, not many of the patients registered with the practice used drugs. 
“I imagine a GP practice that has loads of drug users or if they’re doing clinics for 
homelessness and drug centres or whatever, I’d imagine they’d have systems set up.  But I 
think possibly we don’t, just because we don’t see that many [people who use drugs].”   
(GP, female, 5-10 years’ experience, outer city, special interest in drug use) 
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Not only does the location influence the organisational context, but the size of the 
general practice and the number of GPs in the practice appeared to influence the 
organisational context and continuity of care.  I was unable to compare smaller and 
larger general practices as all of the GPs I interviewed worked in relatively large 
general practices which had at least 6 full-time GPs.  A few GPs reported that a 
problem for recording drug use was that patients seen in larger practices did not 
always see the same GP at each visit.   
“…because a lot of the time this isn’t their regular doctor and they sort of say, “Well, if you 
were my own doctor I might tell you a bit more detail.” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
However, some of these larger practices had a sufficient number of GPs to have 
the facility to appoint a lead GP for substance misuse.  Patients who use drugs 
were therefore referred to and seen continuously by the same lead GP.  This 
continuity of care was seen as especially important if the patient needed treatment 
for their drug use.   
“So, we found that we had patients within the practice who had drug problems, nobody had 
any great expertise.  There were different GPs working at that point in the practice, but 
different people were doing different things, so there wasn’t a kind of co-ordinated 
response, and they weren’t being seen by any dedicated person, or having any sort of input 
from secondary care.  So it was because we felt we weren’t looking after the patients well, 
that we decided, as a practice, we needed to develop more of an expertise.  It then just fell 
on one of the partners to decide to do the course, so that was me” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
“So in general practice, people who are specifically presenting with concerns [about drug 
use] will get channelled into me.” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
The data indicated that the location of the general practice influenced the need for 
a lead GP in substance misuse.  General practices located in areas where 
awareness of drug use was relatively high seemed to have more registered 
individuals who they knew used drugs.  The data also suggests that although there 
is less continuity of care for most patients registered in larger general practices, 
patients who are identified as using drugs received continuous care from the lead 
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GP in substance misuse.  Two of the inner city practices had an allocated weekly 
drug clinic, where the patient could see the same GP or drug worker each week. 
“We’ve been running a specifically dedicated drug clinic, a substance abuse clinic, which is 
run in liaison with [local drug treatment clinic] who are the voluntary organisation that offer 
drugs workers support, and since 2006, that’s how we’ve dealt with patients.  So if a patient 
comes to us who isn’t in that system, has a drug issue and wants advice or support, then 
the other GPs will refer that person to see me, depending on what drugs are involved, if it’s 
something that needs substitution prescribing, so if we’re talking heroin, or opiates, then we 
would refer to [local drug treatment clinic] for an assessment; they would be assessed for 
suitability for shared care and then we would be seeing them through my clinic.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
As well as the location and size of the practice, financial incentives for recording 
and treating drug use seemed to influence the organisational context.   
Financial incentives for GP practice 
As mentioned previously in section 1.3.8, treating drug use is not in the GMS 
contract, however practices in certain areas where the need has been identified 
have a local enhanced service for treating drug use and are financially incentivised 
for treating individuals who use drugs.  The GP lead in substance misuse from an 
inner city practice described how patients from other practices in the area who do 
not have a GP lead refer their patients to her practice.  All the practices in the area 
are financially incentivised by a local enhanced service for treating drug use and 
she described how recording of drug use and treatment was mandatory.  
Consequently, recording of drug use was not only financially beneficial for all the 
practices in the area, but also facilitated continuity of care for the patient.   
 “…and locally the way our enhanced services have gone is that it isn’t just for your own 
practice, it’s actually for the whole of Southwark, as GPs; we all have to sort of reach that 
target for the whole group to be paid.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
Conversely, one of the GPs from a practice that was not financially incentivised for 
drug use treatment, described how there were no Quality Outcome Framework 
(QOF) indicators for drug use.  His view was that some GPs may not feel that it is 
necessary to record drug use unless there were financial incentives.   
“Yeah, it will be great if it [recording drug use] did [get financially incentivised], but it’s 
always been resisted because drug treatment isn’t part of the current GMS contract.   
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
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“My experience is that unless you’ve got some little incentive for making people ask, they 
don’t” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
A general practice can choose not to treat patients who use drugs, however they 
are obliged to treat patients for other healthcare issues.    
“They [GPs] have to provide medical care to people with drug problems, but they don’t have 
to do drug treatment, and as long as that stays the situation, it won’t go into QOF, I don’t 
think, because it will be seen as an extra thing.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
It was interesting to see from the data that GPs perceive that recording of drug use 
is limited due to the GMS contract not including drug use and treatment, 
furthermore there are no QOF indicators for recording drug use.   
 
Allocated time for GPs to see and treat patients 
The final topic that I identified within the organisational context of general practice 
is the amount of time allocated for GPs to see and treat patients.  GP time can 
influence whether or not a GP asks about drug use.  The data indicated that the 
majority of the GPs perceived that they did not have enough time within their 
consultation time to enquire and if necessary treat a patient who uses drugs.  GPs 
who were not leads in substance misuse expressed that time was a barrier for 
enquiring about drug use. 
 
“From the moment you’ve finished seeing your last patient, you’ve tidied up and you want to 
see the next patient, you’ve got about 7½ minutes, and the first thing you’ll do when you 
click on the file for your next patient is to just have a quick read of what’s been going on 
before.  It’s nice if it’s written in concise text so you can scan it in 15 seconds, rather than 
spend a minute trying to read through and work out, OK, what is actually the relevance of 
that!” 
(GP, male, 5-10 years’ experience, outer city, did not have a special interest in 
drug use) 
 
“But I don’t routinely ask.  I mean to be honest, we just don’t have time to do that.”   
(GP, female, GP trainee, inner city, did not have a special interest in drug use) 
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In most general practices, it seems that an inadequate amount of time is allocated 
for seeing and treating the patient and writing up the consultation.  This lack of time 
could impact on whether or not GPs ask and record drug use in the electronic 
health records.  I will now discuss the organising theme, “individual context.” 
 
7.6.1.1.2 Individual context 
The second organising theme of “context of acquiring information” is the “individual 
context” of the GP who is seeing the patient.  Two sub-themes that I identified from 
the data were the “experience and training of a GP” and the “perception of the role 
of a GP”. 
 
GP experience and training 
The first topic that emerged with regards to the individual context was the 
experience and training of GPs.  GPs with more experience who were the clinical 
lead for substance misuse and who had completed 1 or 2 modules of the RCGP 
training on substance misuse felt more confident asking individuals about drug use.  
One of the GPs in an inner city practice explained that she did the RCGP training 
when she was appointed as the clinical lead for substance misuse in her practice.  
She described how the practice needed to improve the service for drug use in their 
practice.   
“Well, I did it specifically to set up a shared care service…so it was because we felt we 
weren’t looking after the patients well, that we decided, as a practice, we needed to develop 
more of an expertise” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
Another of the GPs, who was also a clinical lead, described how the RCGP training 
gave him more confidence to work with people who use drugs. 
“I’ve done the certificate in Substance Misuse, Part 1 and Part 2… probably just in terms of 
more of confidence.” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
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It was evident from the interviews that most of the GPs who were clinical leads for 
substance misuse had completed one or both modules of the RCGP training in 
substance misuse.  In contrast, a GP trainee felt that she was not as confident now 
but with experience she would gain more confidence which would enable her to 
ask about drug use more. 
“I mean, in general, I’m not as confident as I imagine I will be in ten years’ time when you’ve 
seen a lot more of this, and maybe as you get older you have more confidence to push an 
issue…” 
(GP, female, trainee, inner city, did not have a special interest in drug use) 
 
It is possible for GPs to divide their work time between the general practice and 
working in a drug treatment clinic.  GPs who worked in the drug treatment clinic 
seemed to be more aware of the signs and symptoms of people who use drugs.  
 
“It [working in the drug treatment clinic] helps me suspect things earlier and address them I 
think, because a lot of people are nervous to ask.” 
(GP, female 5-10 years’ experience, outer city, special interest in drug use) 
 
A GP’s working week is divided into sessions and each of these sessions is 
approximately four hours.  The narrative from a GP in an outer city practice with a 
special interest in drug use suggested that working in both a drug treatment clinic 
and general practice helps her to be more aware and to question about drug use 
earlier. This suggests that combining experience from working across both general 
practice and drug treatment clinics contributes to improved awareness of people 
who use drugs and will therefore influence if the GP asks about and records drug 
use in the electronic health records. 
 
Do GPs have a role in recording drug use? 
Some GPs who treated individuals who use drugs used words that had a slightly 
negative connotation with regards to drug use.  One of the more experienced male 
GPs perceived that there are other GPs who may have an antiquated and negative 
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perception of people who use drugs.  This was however a preconception rather 
than from direct experience. 
“There is still some doctors I think out there, if they saw a long list of past medical history 
saying, you know, cannabis use, heroin use, whatever and then they automatically are 
thinking about how this is a druggie type patient, you know, and therefore will explain 
everything in terms of their past medical history..” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
A narrative from a female GP from inner city practice who is a lead in substance 
misuse, used words such as “cagey”, “admit” “other “and “most” that suggested 
that she perceived drugs use as an illicit or forbidden behaviour. 
“…but other people are a bit more cagey and most people wouldn’t admit to it if they didn’t 
want you to know it,…” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
Although the words used in the narratives may have slightly negative connotations, 
most of the GPs I interviewed perceived that their role for treating individuals who 
used drugs was essential.  They also described how they had become more 
accepting and desensitised to the stigma associated with drug use. 
 “I think we’ve got to get involved, it’s a very satisfying area to get involved in.  So it’s an 
assessment in signposting them to the right service if you don’t think you can deal with it 
here.  A lot of the time it is getting them involved with others; there’s voluntary sector 
agencies we work with for either drugs or alcohol, and trying to get them into treatment.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
It was interesting to hear that a GP trainee with little experience of seeing 
individuals who used drugs also viewed her role with regards to identifying 
individuals who drug use as important. 
“yeah, I think that GPs definitely have a role.  I think one of the first things is actually 
uncovering that there’s a problem” 
(GP, female, trainee, inner city, did not have a special interest in drug use) 
 
GPs who were interviewed perceived primary care as one of the first points of 
contact for some individuals who use drugs. The views and perceptions seemed to 
be moulded by their experience and how they viewed their role in the treatment of 
drug use.  Overall, it seemed that GPs perceived that they had an important role 
with regards to managing patients who use drugs.  The role encompassed 
identifying the problem and working together with other health professionals and 
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services in order to manage and support individuals who use drugs.  Perceiving 
their role as important could influence whether or not a GP asks and records drug 
use in the electronic health records. 
 
7.6.2 Key points from the organisational theme “context of acquiring 
information” 
Most of the points from this section were expected, however the fact that overall 
GPs thought that including drug use in QOF would be beneficial for enquiring, 
management, treatment and recording of drug use was surprising.  General 
practices located in areas where awareness of drug use is higher seemed to be 
more likely to have funding from local enhanced services to manage and treat drug 
use in primary care.  All the GPs I interviewed worked in larger practices which 
seemed to be better equipped to have a clinical lead in substance misuse.  Many 
of the clinical leads in substance misuse had completed the RCGP training in 
substance misuse and perceived the training to be valuable for enquiring about, 
managing and treating individuals who use drugs.  Time constraints and expertise 
were identified as barriers to questioning individuals about drug use.  Most of the 
GPs felt that their role was important with regards to drug use, this included 
identifying patients and shared care with other health professionals and drug 
treatment services.  It was evident that all of these contextual issues influenced 
recording of drug use in electronic health records through acquiring information 
form the individual.  I will now move on to the findings from the organising theme; 
“interaction between GP and patient”. 
 
7.6.2.1  Interaction between GP and patient 
Within the global theme of “acquiring information” the organising theme of 
“interaction between the GP and patient” developed from the data.  I considered 
the following sub-themes were integral to this theme; “building a relationship” and 
“clash of agendas within the consultation” (Figure 7:4).   
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Figure 7:4: Interaction between GP and patient;second organising theme of global theme 1 
 
7.6.2.1.1 Building a relationship between the GP and the patient 
The first organising theme of “interaction between GP and patient” is the notion 
that a “relationship should be established and maintained between the GP and 
patient”.  Two sub-themes emerged from the data; “respect and patient choice” and 
“the clash of GP and patient agendas” 
 
Establish and maintain a respectful and empathetic relationship 
The continuity of the individual seeing the same GP at each visit can facilitate in 
the development of a relationship between the GP and patient and can also assist 
in the continuity of care for the patient.  A GP who had a special interest in drug 
use described how it was beneficial for both her and the patient to establish a 
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respectful relationship and used words such as “rapport” “and “what is actually 
going on” to indicate this.   
“We do actually encourage a bit of continuity, so they’d stick with one person because then 
you build up a rapport and you’re more likely to have an idea of what is actually going on at 
home and with their drug abuse” (emphasis added) 
(GP, female, 5-10 years’ experience, outer city, special interest in drug use) 
 
It also seemed as though she was aiming to gain a deeper understanding of the 
patient’s situation outside of the general practice.  A different GP who did not have 
a special interest in drug illustrated how he had empathy with regards to the 
patient’s social situation and was not there to judge the patient, but rather to help 
and support.  
“But it’s never our job to preach and I’m very careful not to, because people have got tough 
lives, and for some of them, it’s just their way of coping really.” 
(GP, male, 5-10 years’ experience, outer city, did not have a special interest in drug 
use) 
 
The narratives illustrate that GPs perceived that their relationship with patients is 
important and the relationship can be strengthened when the GP is empathetic.  
Furthermore, most GPs perceived that barriers to building and establishing 
relationships with patients were time constraints and continuity of care.  However, 
as described in the sub-theme of organizational context where a general practice 
has a clinical lead for substance misuse, the patient may receive more continuous 
care and therefore allow time for rapport to be established. 
 
At times GPs need to balance between clinically appropriate actions and the 
established relationship.  This decision can impact the continuity of care as seen in 
the following narrative where a GP refused to give the patient additional medication 
on top of their opioid substitution treatment, and the patient then chose to see 
another GP. 
“If I don’t give them what they want, they’ll try, some of them will try to just test another 
doctor out and see how far they’ll go and whether or not they will be prepared to modify the 
prescription.  “ 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
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The GP seems to be balancing between the needs, wants and requests of the 
individual and the appropriate clinical decision.  The development of rapport can 
influence asking about and recording of drug use in electronic health records.  This 
section leads me into the next sub-theme of trust from both GP and patient 
perspective. 
 
Trust between GP and patient  
The relationship that is established between the GP and patient requires trust from 
both parties in order for it to remain intact.  An example of this is that the GP 
should trust that the patient is being honest whilst the patient should trust that the 
GP is going to use the information carefully and keep consultations confidential.  
The word “trust” was used frequently to illustrate that GPs viewed that in order to 
build a relationship, it is essential for them to accept what the patient is reporting as 
true and for the patient to have confidence about both their clinical and 
interpersonal skills. 
“…once people establish a relationship, then it’s easier for them to, you know, for trust to 
build up one way and another, and for things to work.” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
The trust can be compromised if the GP needs to record information regarding 
drug use.  Some of the GPs expressed that it was more important that the patient 
felt comfortable discussing issues in order to treat the patient appropriately, rather 
than to record the drug use. 
 “Because if they felt that to come and talk to you about something and that would require it 
being recorded would stop them coming to see you, then that would be detrimental to their 
care, so you’ve always got to be quite pragmatic.” 
(GP, female, >15 years’ experience, outer city, special interest in drug use) 
 
Additionally, one of the GPs viewed that patients may perceive the trust to be 
damaged if the GP did not keep the information about drug use confidential and/or 
the GP chose to record the information about drug use, without their consent.  A 
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GP with a special interest in drug use viewed that shared decision making 
regarding what was recorded was imperative. 
“And you just have to reassure people about the confidentiality.  If they don’t want 
information shared on the NHS form, if they don’t want that to go on, then they can decide 
not to.  You have to tell people and let them know what their rights are, yeah.” 
(GP, female, >15 years’ experience, outer city, special interest in drug use) 
 
However, GPs were aware that they did not always believe patients when they told 
them about the amount and types of drugs used. One GP described he is not 
always confident that the patients’ accounts fully report drug use.  This seemed to 
be parallel with patients’ accounts of alcohol use. 
“Erm, I think, generally, if people are willing to talk about it, then I’ve noticed people will, sort 
of, talk it down, and say something like “Oh, well, I just sort of, you know, occasionally might 
use.” 
(GP, male, 5-10 years’ experience, inner city, special interest in drug use) 
 
The data from this section suggests that trust between patient and GP was 
essential for establishing relationships and improving the continuity of care.   
 
GPs’ views about patient’s choice 
The interaction between the GP and patient also includes how the GP views a 
patient’s choice under certain circumstances.  Some of the GPs respected the 
patient’s choice by accepting the patient’s request of drug use not to be recorded.  
These GPs described how they would not record if the patient had asked them 
specifically not to. 
“…but if someone asked me specifically not to, then I wouldn’t.” 
(GP, male 10-15 years’ experience, inner city, special interest in drug use) 
Conversely, one GP, whilst respecting the patient’s choice, still perceived that 
convincing the patient that they need to record the information was a priority. 
“but I do think I would have the discussion with the person and make a judgement, and if it 
was really important, I’d try to persuade them that it actually is important to put on their 
medical notes.” 
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(GP, female >15 years’ experience, inner city, special interest in drug use) 
 
However the GPs’ actions depended on the circumstances and GPs seemed more 
uncompromising about recording drug use if a woman was pregnant or if there was 
someone else involved (e.g. a child) and/or other agencies needed to be brought 
in.  In these circumstances, most of the GPs were willing to discuss with the patient 
why the drug use needed to be recorded.  
“there are some situations where I would record, regardless of the use; if there was,  if it 
was relevant to the consultation or if there were children involved, or the person was 
pregnant, or situations where it would be relevant anyway, regardless of the extent of the 
use.” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
The narratives illustrated that most of the GPs respected the patient’s choice, and 
if they did not want the drug use recorded, they would question this and in some 
cases highlight the importance of recording.  Although overall GPs seemed 
unanimous in their actions with regards to recording when a woman was pregnant 
and a child was involved.   
 
7.6.2.1.2 Clash of agendas 
The final topic that was incorporated within the “interaction between a GP and 
patient” was the “clash of agendas” within a consultation.  The GP may be aware of 
the patient using drugs or certain signs and symptoms may trigger their 
awareness, whereas the patient may be coming to see the GP for a problem other 
than their drug use. 
 
Awareness and triggers of awareness 
Firstly, the experience of a GP may help to enhance their awareness of a patient 
who uses drugs.  GPs who worked in both general practice and drug treatment 
services perceived that they were probably more aware of the signs and symptoms 
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of an individual who uses drugs.  The word ‘suspect’ was frequently used and may 
suggest that GPs are doing detective like work to establish if the patient uses 
drugs.  
 “It helps me suspect things earlier and address them I think, because a lot of people are 
nervous to ask” 
(GP, male 5-10 years’ experience, inner city, special interest in drug use) 
“I can think of a particular case where I suspected it for a long time, and I was right, but it 
took them a long time to actually sort of seek help, or admit to it” 
(GP, male >15 years’ experience, inner city, special interest in drug use) 
 
GPs with less experience of seeing patients who use drugs may be less likely to 
recognise relevant signs or symptoms.  There were however some common signs, 
symptoms and co-morbidities that seemed to trigger the GP’s awareness of drug 
use and prompt the GP to ask about drug use.  Examples of these signs, 
symptoms and/or comorbidities included depression, anxiety, insomnia, stomach 
pain and chronic obstructive pulmonary disease.   
“It’s (drug use) potentially relevant to their you know to their stress or insomnia, I mean 
these are the main sorts of things they present with. Also social problems, work problems” 
(GP, male 5-10 years’ experience, inner city, special interest in drug use) 
 
“so they generally come along with emotional difficulties: symptoms of depression and 
anxiety, and have just been unhappy with the way they are really.” 
(GP, male 5-10 years’ experience, inner city, special interest in drug use) 
 
Overall the GPs described similar signs and symptoms that triggered their 
awareness of drug use.  The next section explains how this trigger of awareness 
could potentially be problematic for the relationship between the GP and patient. 
 
Patient seeking help for a specific problem and disclosure of patient 
There may be a “clash of agendas” when the patient consults the GP about a 
problem, unrelated to drug use, but the GP still questions about drug use.  GPs 
described how a patient would come for one problem and the fact that he/she uses 
drugs might emerge during the consultation.  The consultation may be sent in a 
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different direction and there could be a concern that the agenda of the patient is 
not properly met and an increased risk that the consultation may break down.  The 
following narratives illustrate how the fact that the patient used drugs emerged 
during a consultation about a different problem and this may affect recording. 
 “…mostly in general practice, it’s more kind of mostly an incidental thing that will come up 
as part of questioning during a consultation” 
(GP, male >15 years’ experience, inner city, special interest in drug use) 
 
“I think if someone was to come with a completely unrelated problem, say, a young person, 
a student or someone had come about something else, and admitted to maybe occasionally 
smoking cannabis, then I wouldn’t [record] it would depend how relevant I thought it was.” 
(GP, male 10-15 years’ experience, inner city, special interest in drug use) 
 
However, some patients may consult the GP in order to disclose their drug use as 
they are seeking help.  This was illustrated by a male GP who had a special 
interest in drug use.  He described a case where he had seen an individual 
frequently.  He noticed that the individual had signs and symptoms of steroid use 
and ask about steroid use on several occasions.  The patient always refuted the 
use of steroids. However when he disclosed a more serious problem of heroin use, 
he also disclosed his use of anabolic steroid.   
“But later actually when he came for his heroin problem, he actually did say that he’d used 
anabolic steroids as well.  “ 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
The data suggests that there may be an agenda clash when a GP focuses on a 
problem that the patient has not actually come to seek help about.  This problem 
could then trigger a GP’s awareness of drug use, and the GP may choose to focus 
on the drug use rather than the original problem, which could affect recording in the 
electronic health records. 
 
7.6.3 Key points from the organisational theme “interaction between 
GP and patient” 
It is imperative that GPs and patients establish and maintain a respectful 
relationship in order to have open communication during the consultation.  
Continuity of care and empathy seem to assist with the establishment and 
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maintenance of the relationship.  The trust should be two-way, whereby the GPs 
should assume that the patient is disclosing the truth, whilst the patient needs to be 
confident that disclosure is kept confidential.  Overall GPs agreed that they 
respected the patient’s choice and found that shared decision making with regards 
to recording was good practice.  Their decision to record drug use was different 
when a woman was pregnant or a child was involved.  However recording may 
occur in the referral letter rather than as Read codes in the electronic health 
records.  GPs who had a special interest in drug use seemed to be more aware of 
signs and symptoms that could indicate drug use, however other GPs were aware 
that certain signs and symptoms could trigger their awareness of drug use.  GPs 
were not always aware that they prioritised their agenda over the patient’s agenda 
and that could have a negative impact on the consultation.  It was evident that the 
interaction between GPs and patients can impact GP recording drug use in 
electronic health records.  I will now discuss my findings from the organising 
theme; “process of acquiring information.” 
 
7.6.3.1 Process of acquiring information 
In the previous section, I have described the interaction between GP and patient, I 
am now going to describe and discuss the findings from the third organisational 
theme of “acquiring information”; “the process of acquiring information” (Figure 
7:5).   
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Figure 7:5: Process of acquiring information; third organising theme of Global theme 1 
 
GPs ask about drug use? 
The first organisational theme of the “process of acquiring information” is 
describing if, who, how and in which situations to the GP asks about drug use.  The 
four sub-themes that emerged from the data were: “why does the GP ask about 
drug use?”; “who does the GP ask?”; “how does the GP ask?”; and “in which 
situations does the GP ask” 
Why do GPs ask about drug use? 
GPs did not appear to routinely ask individuals about drug use during 
consultations.  The experience of both the number of years that a GP has 
practiced, and regularly seeing patients who use drugs, seemed to influence 
whether or not a GP asked a patient about drug use.  GPs with more experience 
seemed more likely to question patients about drug use.  Additionally, those GPs 
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who frequently saw patients who used drugs were more confident to ask about 
drug use.  One of the GPs who also works in a drug treatment clinic, perceived that 
the question about drug use usually arises during the consultation about a different 
problem.  She also suggested that GPs are quite nervous to ask about drug use, 
whereas they are more comfortable asking about alcohol as drinking alcohol is a 
societal norm. 
“it’s more kind of mostly an incidental thing that will come up as part of questioning during a 
consultation I mean, people ask all the time about alcohol and are quite confident and 
comfortable talking about that, but a lot of people I think are quite nervous to actually 
suggest to someone, especially not your typical you know, they might ask a guy in their 
twenties, but they probably wouldn’t ask a pregnant woman in her thirties.” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
Conversely to GPs with a lot of experience, GPs with less experience seemed 
more hesitant and less confident to ask about drug use. This was previously 
mentioned in the section on GP experience and training.  Additionally, GPs may 
not choose to ask about drug use for reasons other than their experience of 
working with patients who use drugs.  It was interesting to hear the views of a GP 
with 25 years of experience of working in the same inner city practice.  She 
perceived that GPs who were and were not leads in substance misuse differed with 
regards to asking patients about drug use.  She alluded to the fact that it was like 
“opening a can of worms” and that the GP might not have time to help with the 
complex issues that emerged together with drug use at that point in time.   
“Otherwise a lot of people [GPs] are just thinking they’re going to open a can of worms and 
it’s going to make a consultation twice as long if you start talking about it and they have a 
problem” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
Despite concerns about managing disclosure about drug use this GP did suggest 
that the patients are actually relieved to be asked as they can then get the 
appropriate help. 
 “I think often people are relieved [to be asked or offered help] and actually quite pleased to 
sort of feel like there is some help, because a lot of people just don’t realise there actually is 
help and maybe they have a problem.”   
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
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It seems that GPs who had a special interest in drug use perceived that GPs not 
regularly seeing patients who use drugs, did not routinely ask about drug use.  
Additionally, if they did ask, they may have felt uncomfortable about asking.  This 
could have been due to the fact that they may not have felt they had the expertise 
to deal with drug use, but also because it might reveal a myriad of other problems 
that the GP may not be able to deal with within the consultation time.  One of the 
GPs suggested that GPs were more comfortable asking about alcohol rather than 
drug use.  GPs are well positioned to query about drug use, however barriers such 
as time, experience and the complexity of the issue seem to have an impact on the 
number of patients GPs ask and therefore record in electronic health records.   
 
Who do GPs ask? Stereotypical vs atypical 
GPs are more likely to ask certain individuals about drug use in primary care.  Most 
of the GPs recounted that they did not ask about drug use routinely and justified 
that the reason they only asked certain individuals was due to the fact that they 
lacked time to ask everyone.   
 
Some of the GPs described how during their GP experience there were certain 
presenting characteristics of individuals who used drugs and they therefore 
directed their queries regarding drug use to those particular individuals.  This was 
illustrated by a GP who does not have a special interest in drug use, but from her 
experience has found that men who have depression often use both alcohol and 
drugs.  She therefore always asks about alcohol and drug use if a man presents 
with depression. 
“There’s one group that I do always ask and that’s men who come to me with depression” 
(GP, female, 5-10 years’ experience, outer city, did not have a special interest in drug 
use) 
 
 232 
 
This was similar for GPs who had a special interest in drug use who also asked 
individuals with certain presenting characteristics such as depression or mental 
health issues. 
“And anybody who comes in with depression or mental health issues we’d ask, regardless 
of age, in the same way as you’d ask about alcohol.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
GPs with a special interest in drug use perceived that the many individuals who 
used drugs also had mental health issues.  GPs also appeared to consistently ask 
certain groups of people about drug use.  These included young professionals, 
students, homeless people or people with insecure housing. 
“I mean a lot of the time young professional people or students” 
(GP, male, 5-10 years’ experience, inner city, special interest in drug use) 
“They were homeless patients or they would be vulnerably housed, so in unstable housing” 
(GP, male, >15 years’ experience, outer city, special interest in drug use) 
 
“I think if I look back, I’d probably say it would be young professionals, if they come in with 
sort of anxiety or depression problems, or problems with alcohol, so that would be a trigger 
most often for me to ask the questions.  
(GP, female, GP trainee, inner city, did not have a special interest in drug use) 
 
“the majority of people in this situation have got mental health problems, and a significant 
proportion have got personality disorder” 
(GP, male, 5-10 years’ experience, inner city, special interest in drug use) 
 
It appeared that certain types of people were triggers for GPs asking about drug 
use.  However, a GP who also worked in a drug clinic argued that there was a risk 
that individuals may be missed if GPs only asked certain types of people.  In her 
experience she had found some unexpected individuals used drugs 
“They [GPs] might ask a guy in their twenties, but they probably wouldn’t ask a pregnant 
woman in her thirties.  Whereas there’s no reason to think that she hasn’t or isn’t using 
recreational drugs; it may be less likely but it’s not impossible and so I think that can 
probably get missed quite a lot.” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
Other GPs with and without a special interest in drug use described some patients 
that they asked about drug use even though they did not fit the typical stereotype 
of a drug user. 
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“He also was um different in that he was a professional and was in a job, and found it very 
difficult to keep going” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
“I can clearly recall one patient who was quite well-to-do, in quite a senior management job, 
and in that case was taking cannabis, and not someone I’d have expected or anticipated” 
(GP, male, 10-15 years’ experience, outer city, did not have a special interest in drug 
use) 
 
It was interesting to see that both of the GP accounts above described how they 
asked certain individuals, not fitting their perception of stereotypes who use drugs, 
but presented with similar characteristics (insomnia, depression, anxiety) during a 
consultation.  Barriers such as time inhibit GPs from asking everyone about drug 
use, however, the data highlighted that there may be individuals who do not 
necessarily fit GPs’ perceptions of someone who uses drugs.  It may therefore be 
necessary for a GP to ask about drug use, if an “atypical” person presents with 
certain symptoms.  A GP who has a special interest in drug use perceived that 
some of individuals who use drugs and are in certain professions may not present 
to GPs.   
“I think some of the party drugs male patients are not presenting, not being honest about it, 
and maybe that’s because they’re in sort of more professional roles such as solicitors and 
barristers, than our typical drug user in the past” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
GPs therefore do not always have the opportunity to ask and therefore record 
certain individuals.  GPs did not report routinely initiating discussion about drug 
use, but if they did, they tended to ask certain people about drug use or people 
with particular signs and symptoms.  A key difference that emerged between GPs 
who saw and did not see patients regularly who used drugs, was that the former 
viewed that there was a risk that individuals may be missed if the GP only focused 
on asking particular groups of patients.  
 
7.6.3.1.1 How do GPs approach asking about drug use? 
Direct versus indirect styles questioning style  
GPs have developed different styles of questioning in order to ask about drug use.  
GPs seemed to have reflected on their experience and found a style of questioning 
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that worked and fulfilled the purpose of acquiring information about drug use.  
Some GPs used a gentler indirect approach to try and explore the issue more and 
elicit information from the patient.  A male GP from an outer city practice who did 
not have a specific interest in drug use discussed how he had read and reflected 
on a journal article about questioning styles and decided to change the way he 
asked about sensitive topics such as drug use. 
“I don’t ask people directly whether they are taking or misusing substances.  I ask them 
permission to ask it first, and so they have a ‘get out’ clause, before saying, you know, “Are 
you taking any recreational drugs?”  
(GP, male, 5-10 years’ experience, outer city, did not have a special interest in drug use) 
 
Conversely a female GP from a different outer city practice used a more factual, 
direct and closed question approach to asking about drug use.   
I think you have to ask your question to the point, because otherwise you might not get the 
answer and people might not understand your questions either.  So, normally I’d say, you 
know, “Have you been using any illicits while you’re in prison?”  You know, “Are you taking 
your medications as they’re prescribed?”  So, I’m not quite sure how you could ask those 
questions otherwise.  
(GP, male, >15 years’ experience, outer city, special interest in drug use) 
 
It was interesting to hear about the different questioning styles from various GPs.  
Their experience and reflection seemed to have shaped their questioning style and 
it seemed to fulfil the purpose of acquiring about drug use. Some found it easier to 
be more direct, whilst others find they obtain more information if they use a gentler 
indirect style of questioning.  Questioning style may influence if individuals tell 
about their drug use and subsequently if GPs record it in the electronic health 
records. 
 
When are the critical time-points for asking?  
There were distinctive and significant time points where GPs reported questioning 
about drug use.  These include during registration of a patient, asking together with 
another sensitive issue and life changing events such as pregnancy or when a 
child is involved. 
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Health check on registration 
Patients usually have a health check and answer a health questionnaire when they 
register with a new general practice.  Most of these questionnaires ask about 
alcohol use and smoking, but some also ask about drug use.  A lead GP in 
Lambeth described how the information from the questionnaire would be coded 
(using Read codes) in the patients’ electronic health records.  However he 
perceived that patients were not always honest with the amount of alcohol they 
consumed and even less honest with regards to drug use. 
“This is our new Patient Health Questionnaire, and on it, it has a section, ‘Do you misuse 
any of the following drugs or substances? Alcohol is slightly easier than substance misuse, 
and, you know, in a questionnaire, I probably don’t get the whole details of alcohol and less 
of drugs”  
(GP, male, >15 years ‘experience, inner city, special interest in drug use) 
 
It seems that although the patient questionnaire may be an opportunity for the GP 
to indirectly ask about drug use, there was some scepticism about the validity of 
the results.  Although registration of a new patient may be a critical time for asking 
about drug use, it may not be the right time for an individual to disclose and 
therefore affects recording of drug use in electronic health records. 
 
Asking together with another sensitive issue 
Asking about drug use together with another sensitive topic may also be helpful.  A 
GP trainee without a special interest in drug use described how she does not 
routinely ask about drug use on its own, but found it easier to ask about drug use 
together with sexual health issues. 
“I guess the other situation that’s come into it in the other time when I would have asked 
those questions would have been thinking back, sort of, sexual encounters or people who’d 
come in for the Morning After Pill, and you’re kind of asking the protective questions about, 
you know, “Was this a sexual encounter that you wanted?”  I may ask, “Was drugs or 
alcohol involved?” you know, those sorts of questions.” 
(GP, female, GP trainee, inner city, did not have a special interest in drug use) 
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Consultations regarding other sensitive but maybe slightly less stigmatised issues 
may present and opportune time for asking about drug use. 
 
Perinatal period 
When a woman finds out that she is pregnant, she usually sees her GP who will 
refer her to the midwife services.  If the woman sees her GP, it is an opportune 
time for a GP to ask about certain health behaviours such as smoking, alcohol and 
drug use.  If she answers positively regarding drug use, GPs unanimously agreed 
that they would record this information as the drug use not only impacts the 
mother, but the foetus too.   
 
“I think my recording for somebody who is pregnant is much more thorough; just historically 
it’s always more thorough because you want as much information as possible. 
(GP, female, >5-10 years’ experience, inner city, special interest in drug use) 
 
And I guess the other area would be in pregnancy, so for example if I’m concerned that 
either someone might be smoking or could potentially be using, or in their notes it says that 
they’ve had some usage in the past, then again that’s another trigger to ask, is that a 
problem now, or is that a new problem.   
(GP, female, >trainee, inner city, did not have a special interest in drug use) 
 
GPs rarely see pregnant women during the gestation period.  Evidence from my 
second study (Chapter 5) supports this.  However, once the woman is discharged 
from the midwifery service, GPs receive a detailed discharge letter.  A GP trainee 
who did not have a special interest in drug use mentioned that she would record 
drug use in the woman’s electronic record if it was mentioned in the discharge 
letter. 
“I would certainly record if I got that [drug use in the discharge letter] letter back,” 
(GP, female, >trainee, inner city, did not have a special interest in drug use) 
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Pregnancy is a critical and opportunistic time for the GP to ask a woman about 
drug use.  GPs ask many other questions, some of them quite sensitive and 
therefore drug use could be included.   
 
7.6.4 Key points from the organisational theme “process of acquiring 
information” 
Most GPs did not routinely ask individuals about drug use.  Time, expertise and 
opportunity costs seemed to be the main barriers for not asking.  GPs targeted 
particular individuals when asking about drug use.  However keeping an open-mind 
was perceived to be important.  GPs have developed different questioning styles 
when asking about a sensitive topic such as drug use.  There are critical time-
points when GPs may be more likely to ask about drug use, these include 
registration of a patient, when the patient presents with another sensitive issue and 
during the perinatal period.  It is evident that asking about drug use is a 
multifaceted issue and can influence recording in electronic health records.  I will 
now move onto discuss recording of drug use in electronic health records. 
 
7.6.5 Recording of drug use 
From the previous section, my data clearly indicates that “acquiring information 
about drug use” is influenced by many factors.  As “acquiring information about 
drug use” precedes recording, it follows that GP recording is indirectly impacted by 
these factors.  Recording of drug use is therefore a complex process (Figure 7:6).  
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Figure 7:6: Factors from Global theme 1 influencing recording of drug use 
 
7.6.5.1.1 When and who do GPs record 
GPs may ask certain individuals about drug use, but whether or not they record 
drug use for these same individuals seems be dependent on the situation.  
Similarly recording also depends on the context and how relevant it is at that time. 
 
Permission from patient to record and requests not to 
GP opinions’ differed with regards to when and how to record drug use in a 
patient’s electronic health record.  Some GPs did not feel that it was necessary to 
ask a patient for their permission to record and a GP trainee described how she 
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records on the computer once the consultation is finished and doesn’t discuss this 
decision with the patient.   
“No, it’s whenever the patient has left; I always record notes after they’ve left….Erm … no, I 
probably wouldn’t routinely ask someone [if I can put it in their notes] because I guess you 
would everything that’s told in the medical consultation, you know, is sort of confidential 
between you and them, really. So I wouldn’t necessarily, no.  No, I’ve never asked 
someone whether I could put it in their notes.” 
(GP, female, GP trainee, inner city, did not have a special interest in drug use) 
 
Similarly a GP whose practice was to record information whilst the patient was still 
in the consulting room, reported not asking for the patient’s permission to record.  
She assumed that the patient was consenting to her recording by being in the 
consulting room. 
“I suppose, yeah, I always have to write something when somebody comes in.  So if 
somebody comes in about a drug issue, they would see me writing during the consultation.  
So I guess that’s implied consent.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
In contrast, some GPs seemed to respect the patient’s choice and reported asking 
or making the patient aware that about recording the drug use.  A GP indicated that 
recording drug use on the electronic health record was a serious matter as it would 
be on the patient’s record eternally. 
“I don’t know, I think that’s something we’d have to discuss with the patient because the 
problem is that once it’s on their record, it’s on their record forever.”   
(GP, female, > 15 years’ experience, inner city, special interest in drug use) 
 
“I think I’m always aware that what goes into people’s medical records follows them.  I think 
you can expand it from substance misuse to mental health, because people worry about 
mental health problems being recorded in their notes, sort of, and that’s from across the 
spectrum of care provision, so in mainstream general practice as well. 
(GP, female, 10-15 years’ experience, outer city, did not have a special interest in 
drug use) 
 
Two of the GPs who both had special interests in drug use viewed that it was more 
important to obtain accurate information regarding drug use rather than recording it 
and he would explain this to his patients. 
“I’ve asked somebody about their drug use and said to them that they, it’s not, you know, 
I’m not looking to record this, I think it’d just be useful to  know cos it’s potentially relevant 
to their stress or insomnia” 
(GP, male, 5-10 years’ experience, inner city, special interest in drug use) 
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If a patient asked for the drug use not to be recorded, some GPs asked why and 
then decided depending on the answer whether or not to record.  A female GP 
from an outer city practice expressed how recording in the electronic records was 
permanent and compared drug use to being recorded with mental health problems.   
 
In contrast, a different GP described how he would try and explain to the patient 
why it was essential for them to record the information, especially with regards 
using the electronic health record to help with continuous care of the individual. 
”So I usually say to them, “Look, if you’re seeing somebody and they don’t know something 
about you that’s going to influence how they treat you, then it’s in your interest to have it on the 
record.”  
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
There was an interesting argument with regards to not recording drug use in the 
records because of the impact to future insurance applications.  A GP from an 
outer city practice who did not have a special interest in drug use described how he 
felt torn between his role as a GP and role as providing information. 
“I mean, it always does concern me, any type of recording of anything, you know, that 
influences people’s ability to apply for insurance or things like that subsequently.  And I think 
that’s where there’s this interface between acting as a care-giver and also acting as a provider 
of information sometimes, which, you know, I have concerns about.” 
(GP, male, 5-10 years’ experience, did not have a special interest in drug use) 
 
This reflection illustrates how GPs also act as bureaucratic gatekeepers in primary 
care.  In contrast to his argument, a female GP from an inner city practice with a 
special interest in drug use perceived that it was important to record for insurance 
purposes, as if she chose not to record, the records would not be legally valid. 
“Well, I would explain to them that actually … well, I suppose why they wanted that, I 
suppose I would want to find out why.  Was it for insurance or what exactly, and I’ll try and 
get people to actually let us record it because it’s very important information.  And even if 
you don’t do it, I would be liable if say it’s an insurance report, it’s still if you know the 
information then it would make their insurance thing null and void if it was a fact that it was 
known that they had a problem, you know, that they’ve been injecting drug users, say, and 
they hadn’t been checked for blood borne viruses, and I knew it and I hadn’t put it into 
there, it would make their health insurance void.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
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However her account did not distinguish between individuals who used drugs 
occasionally for recreation purposes compared with those who used drugs 
persistently.  It seemed that the decision to record was a balancing act with 
regards to patient care.  There were however critical times where GPs 
unanimously said that they would record the fact that the person uses drugs.  One 
of these times was during pregnancy as the drug use not only impacted on the 
mother, but on the foetus as well.  GPs may not record the information as a Read 
code, but rather in the referral letter to the midwifery service.  Additionally GPs 
perceived that they write a lot more detail in the referral letter compared to a 
patient who was not pregnant on the patient’s electronic health record. 
“I don’t know if we take a robust approach or if we’re more harder [sic] on people (who are 
pregnant), but we wouldn’t give people much leeway.  I mean, we would say, “If I know 
about it, then I have to pass that information on.” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
“Usually when I’m doing a consultation with someone who is pregnant or if I was doing a 
consultation where I thought that it would be a social work concern, I’d be more structured 
and detailed I think than just my usual rambling free-text” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
The other critical time that GPs would record drug use was when a child was 
involved.  All the GPs were unanimous about recording in detail if a child was 
affected by drug use of the mother and/or the father.  GPs viewed it as their duty 
and responsibility to record any adverse situations if it affected a child.  If the 
problem was severe they described how they would usually refer the case onto 
social services.  A GP described how the communication between different 
agencies such as social services was extremely important and that recording 
helped with this. 
 
However this was not the case with Neonatal Abstinence Syndrome (NAS).  NAS 
was not always recorded in the child’s electronic health record.  The GP accounts 
were divided with regards to the long term implications of NAS.  Some GPs 
perceived NAS to be a medical problem which was dealt with in the hospital 
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setting.  These GPs were more reluctant to Read code the fact that the child had 
NAS.   
“It would be recorded.  Well, I mean, it isn’t that relevant for us because the baby will be 
over it.”  
(GP, female, 15 years’ experience, inner city, special interest in drug use) 
 
Conversely other GPs viewed it more as a continuous social problem that could 
have effects on the child later in life.   
“I think it is and the chances are, this baby will be on the ‘at risk’ register, so I think almost 
undoubtedly, this baby would be well known to Social Services, and it’s important that all 
professionals are aware that this baby is potentially at risk, so that we can look for signs of 
whatever, relapse on the mum’s part or neglect or whatever it may be.” 
(GP, female, 5-10 years’ experience, outer city, did not have a special interest in drug 
use) 
 
A GP trainee described how when she was doing her training in obstetrics, they 
would always include the fact that the baby had neonatal withdrawal syndrome in 
the discharge letter.  She said that she would always therefore use a Read code to 
record NAS in the baby’s primary care electronic health record. 
“Oh, all of the letters that we wrote in paediatric, it will all have that in there, yeah. “Certainly 
if I got that letter back, one of the jobs as a GP if you get a letter through that you code it, or 
if you don’t code it, then you send it to the admin to code it.  And I would certainly code as 
much as I could in terms of that, and I’d put it on the baby’s and the mother’s records.  
That’s what you should do.” 
(GP, female, GP trainee, inner city, did not have a special interest in drug use) 
 
It was interesting to hear the account of a GP who described a case where he did 
not know that the woman was using drugs until he saw the discharge letter and 
saw that the child had NAS.  
“I had one many years ago: went through the pregnancy (she’s still a patient of ours) and 
the first time I knew that this person was using drugs was when the child was admitted to 
the special care baby unit with a drug withdrawal.” 
(GP, male, > 15 years’ experience, inner city, special interest in drug use) 
 
In summary GPs views’ differed with regards to recording drug use.  Some GPs 
viewed that it was more important for the patient to be honest about drug use 
rather than recording it.  Most of GPs were sensitive to the fact that recording drug 
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use on an individual’s electronic record may have a future impact and were 
therefore sometimes reluctant to record as Read code.  There were critical time 
points when all the GPs agreed that they would record the drug use, this included 
the perinatal period and when a child was involved.  Neonatal abstinence 
syndrome however was not always recorded as it was sometimes perceived as a 
medical rather than a social problem and treated in the hospital setting rather than 
in primary care. 
 
7.6.5.1.2 How do GPs record information about drug use? 
Finding specific Read codes to use for recording drug use can be time consuming 
and it is sometimes easier and quicker for a GP to use free-text rather than Read 
codes.  Some GPs who did and did not have a special interest in drug use, 
expressed that there were too many Read codes to use and it was often easier and 
quicker for them to record the information using free-text or generic codes.   
“So, yes, I think that’s very true of EMIS that it probably needs to be cleaned, but I guess 
there’s often one to find, but whether you can find the exact thing you’re looking for and you 
just don’t have the time to search.  So you’ll use a couple of key words and then if they’re 
not bringing up what you need, then I’ll just put it in the notes in another way, which is 
probably a problem because then if you were specifically looking for it, it won’t come up the 
same way or as easily for someone like you doing a random search.” 
(GP, female, GP trainee, inner city, did not have a special interest in drug use) 
 
And sometimes that’s I mean it’s not because I shouldn’t be (slight laugh) but I do it just 
because mostly I would just be freetexting everything, rather than specifically looking for 
Read codes for it. 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
A GP trainee described how the whole Read code system needed to be sorted and 
inapplicable codes needed to be removed. 
“Erm, I think that everyone will get into a pattern of finding a new thing, the ones that they 
know are there.  I think there are a lot of silly ones, and I think it really needs to go through 
a kind of, er … a sort of … Well, just I think a clean-up, yeah.” 
(GP, female, GP trainee, inner city, did not have a special interest in drug use) 
 
Both GPs with and without a special interest in drug use described how they would 
Read code the primary problem that the patient had come about rather than record 
drug use. 
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“Otherwise it’s you know they be [sic] coded as we normally include the main thing that we 
see them for so you know like other bits and pieces” 
(GP, male, 5-10 years’ experience, inner city, special interest in drug use) 
 
“In general practice it would just be what you thought the main problem was or something, 
so either the one that has been coded before” 
(GP, male, 5-10 years’ experience, outer city, no special interest in drug use) 
 
GPs described how information in the discharge letter was scanned into the 
woman’s electronic health records once a woman was discharged from the midwife 
services.  A GP trainee recounted how she usually highlighted the important 
symptoms or diagnoses from the letter and then enters these as Read codes.  It 
was interesting to hear that she knew of more experienced GPs, who due to time 
constraints, had the practice administrator choose and enter the Read codes.  
There was no indication from my data that practice administrators received any 
training on how to choose particular Read codes. 
“Well, to be honest, I don’t do that, because it’s not my habit to do it, but I know certainly 
some of the older GPs in the practice I think who have the greater work burden, they 
highlight what the issues are and then send it back to say, these are it.  But I think in my 
practice certainly and in what I do, I would open up the mum’s records, I would open up the 
kid’s records, and pick a Read code and put it in.” 
(GP, female, GP trainee, inner city, did not have a special interest in drug use) 
 
Some general practices have developed templates or protocols to use specific 
Read codes to record drug use.  GPs who worked in these practices perceived that 
using these templates was easier and more time efficient as they did not need to 
spend time scrolling through the many Read codes.  The template also offered 
more opportunity for auditing the information regarding drug use in their general 
practice, as the same Read codes would be used.  Larger practices seemed more 
likely to have developed a template or protocol. 
“this lady I saw yesterday.  I would have used our template to record her illicit drug use” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
“Yeah, well, they have to because as long as they use the template they’re using those. So 
the only way you’re going to get people to use similar Read codes is to make them use a 
template.” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
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I will go into more detail with regards to templates in the next section.  To 
summarise there are many different views with regards to using Read codes to 
record drug use.  Some of the GPs found using Read codes time-consuming as 
they had to scroll through to find the most appropriate Read code to use.  There 
was an overall perception that free-text was a quicker and easier way to record.  
There seemed to be a view that there were too many Read codes and this could 
be revamped to get rid of unnecessary codes.  GPs described how discharge 
letters are usually scanned, but some important information is regularly recorded 
as Read codes in the electronic health records.  GPs may sometimes rely on the 
practice administrator to choose and enter the Read codes.  Some practices have 
templates for recording drug use which seems to make the recording more 
organised and systematic.   
 
7.6.6 Key points from accounts of recording drug use 
GPs reported that they do not always record drug use if the patient discloses the 
information during a consultation.  They will normally look at the context and make 
a decision on whether or not to record.  GPs usually recorded the primary problem 
(e.g. insomnia, depression) as a Read code rather than drug use.  The timing of 
recording in consultations differed with GPs and they did not always explicitly tell 
the patient that they are recording drug use in the electronic health records.  GPs 
unanimously record more when a woman is pregnant or when a child is involved, 
but the recording may be in the free-text and not necessarily a Read code.  
However, there was a difference of opinions with regards to the importance of 
recording NAS.  There are numerous Read codes to choose from and 
consequently GPs find it easier to free-text rather than Read code.  Practice 
administrators are sometimes also choosing and entering Read codes highlighted 
by the GP.  Some practices have developed templates for recording drug use 
which means that they are consistently using the same Read codes to record drug 
use. 
 
 246 
 
I will now discuss the findings for the second global theme that emerged from the 
data. 
7.6.7 Global theme 2: Management and treatment of drug use 
The second global theme I identified and developed from the data was 
“management and treatment of drug use”.  In order for recording regarding 
treatment to take place, an individual needs to be managed and treated in the 
general practice or in a drug treatment service.  Consequently, two organising 
themes emerged; “management and treatment in general practice” and “other drug 
treatment services”   
 
7.6.7.1 Management and treatment of drug use in general practice 
Within the organisational theme of “management and treatment in general 
practice”, I identified two sub-themes, these were the “context and the process of 
the management” and “treatment within the different practices”.   
7.6.7.1.1 Context of management and treatment 
The context within the general practice emerged as an imperative aspect with 
regards to recording as not all general practices treat drug use and subsequently 
have the opportunity to record in the electronic health records (Figure 7:7). 
 247 
 
 
Figure 7:7: Context of management and treatment in general practice, first organising 
theme of Global theme 2 
 
Does a general practice treat or not? 
Treatment of drug use is not part of the General Medical Service (GMS) (section 
1.3.8) contract and therefore general practices are not obligated to treat individuals 
who use drugs.  However, if a general practice does not treat drug use, the 
practice should still be responsible for the medical care of individuals who use 
drugs.  General practices that do treat drug use have usually been commissioned 
by and are funded by local enhanced services (section 1.3.8.2).  A GP working in 
an inner city general practice perceived that they had a relatively high percentage 
of individuals who used drugs because they treated drug use in the practice. 
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“And our practice has had, if you like, probably a disproportionately high number of patients, 
because we take part in the Level 2 Enhanced Service, so that’s one thing” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
As previously mentioned in the section “financial incentives for general practices”, 
the data also indicated that some areas have one specific general practice that 
served the area, rather than treatment taking place in all the general practices.  A 
female GP from an inner city practice described how patients from other general 
practices were referred to and treated for drug use in her general practice. 
“We do quite a lot of drug work.  We look after our own patients, 30 something, 33, 35 or 
maybe 36, patients who are on methadone or buprenorphine.  We also look after another 
30-40 who are registered at other practices where their own GP won’t prescribe; we do the 
prescribing of the opiates and drug clinics.” 
(GP, female, > 15 years’ experience, inner city, special interest in drug use) 
 
It is evident that there are a few options available for general practices with regards 
to treating drug use.  General practices are not obligated to treat drug use and it 
may be more beneficial that individuals are treated in either practices that have the 
expertise and confidence to treat individuals or treated in specialised drug 
treatment service.  It is also evident that GPs should have a clear understanding of 
where to sign-post or refer individuals in order that they receive the most 
appropriate treatment.  However whether or not the general practice treats 
individuals for drug use will have an impact on recording of drug use and treatment 
in the electronic health records. 
 
GPs may not see or treat individuals during pregnancy 
GPs may not have much contact with a woman during her pregnancy which 
impacts recording in the electronic health records.  GPs refer pregnant women via 
a referral letter to either normal or specialist maternity services.  Additionally, the 
specialist maternity services usually take over treatment if a woman requires 
treatment for drug use.  One of the GPs described that she would always put a 
greater amount of detail into these referral letters to the midwifery services than if 
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the referral was to a different service.  These referral letters are sometimes 
scanned onto the patient’s electronic health records, but Read codes are not 
always used.  The same GP also explained that she would always indicate if the 
woman smoked, used alcohol or drugs as she perceived that this information was 
imperative in order for the pregnant women to obtain the correct treatment.   
“But in general practice, I can think of one woman recently who was a cannabis user, but 
she wasn’t using any opiates, so I put that in her letter because that had been picked up 
during her pregnancy and a social worker had been involved in the pregnancy” 
(GP, female, 5-10 years’ experience, outer city, did not have a special interest in drug 
use) 
 
In one region, the specialist antenatal service is incorporated into the local area 
addiction unit.  Therefore GPs refer straight to the addiction service and pregnant 
women will be seen within the unit. 
“They would have been transferred to the local … within [place] there is the [place] 
Addiction Unit, and the [place] Addiction Unit at that time were, and still are, commissioned 
to provide the antenatal specialist prescribing.  So we would have had to have referred into 
them.” 
(GP, female, >15 years’ experience, outer city, special interest in drug use) 
 
The treatment of drug use during pregnancy seems to be unanimously transferred 
to the midwifery services.  The referral is either directly to the specialist midwife 
service or to the generic midwife services, which may then be triaged to the 
specialist service.  As mentioned in section 5.8.2.3, once a woman is discharged 
from the maternity service, GPs should receive a discharge letter.  Information from 
these letters is usually scanned into an individual's electronic health record.  
Important information from these letters can be recorded as a Read code, but this 
does not always occur in the electronic health records.   
 
Is there shared care? 
Some general practices who offer treatment for drug use have a designated drug 
worker and/or drug nurse working with the GP lead.  This model of shared care 
seemed to work effectively and GPs viewed the working relationship with either the 
drug worker and/or drug nurse as very beneficial.  An effective working relationship 
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allowed good communication between GP and drug worker, however meetings can 
be relatively informal and not always recorded in the electronic health records.   
 
“I think that we have to get better at recognising the need for good communication, and for 
multidisciplinary care and continuation of care as well, and that’s about developing services 
So it takes time and I think it starts with people coming in and taking ownership of that, that 
group.  And bringing expertise in and bringing experience in and sharing experience, and 
then looking at how we can do things.” 
(GP, female, > 15 years’ experience, outer city, special interest in drug use) 
 
“She’s a practice nurse, but she sort of was a specialist nurse before she became a 
practice nurse in substance misuse, and she does all my alcohol detoxes as well, we 
usually communicate face to face and might not record all the information” 
(GP, male, > 15 years’ experience, inner city, special interest in drug use) 
 
There was however a setback when either the drug worker or practice nurse left 
the practice and was not replaced. 
“We had a very good substance misuse worker working with us when we first started doing 
it, so I learnt a lot from her. She’s unfortunately not here now” 
(GP, female, > 15 years’ experience, inner city, special interest in drug use) 
 
In two of the inner city practices, they offer a weekly clinic for patients requiring 
treatment for drug use.  The patient will see either the lead GP or drug worker on 
alternate weeks.  The consultations are recorded using a standardised template 
(discussed more in section 7.6.10.1).   
 “Yes, we do, yes.  We do based on … for a small group of patients.  We have about 20-ish 
patients who attend the clinic; they come and they go but it’s about 20.  They’re either seen 
weekly, fortnightly or monthly, depending on their stability.  We use a template to record 
each week” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
In contrast some practices did not have been a designated drug worker and/or 
practice nurse.  In these instances some of the GPs had formed a good 
communication relationship with other health professionals involved in treatment of 
drug use outside the general practice.  However, the data shows that one of the 
GPs who has a special interest in drug use conducts most of her communicating 
with health visitors over the phone as the health visitors are located away from the 
general practice.  Not all of the conversation is recorded. 
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“The health visitors are really good actually, the health visitors in our practice, so they keep 
quite a close eye on people in their postnatal period, and we have quite good links and 
communications with them, if they had any concerns. They’re based slightly, they’re not 
based in the exact same part of the practice as we are, so I do a lot of my communication 
with them just over the phone, which isn’t ideal either, because we’re both obviously having 
to make a summary of our discussion.” 
(GP, female, 5-10 years’ experience, inner city, special interest in drug use) 
 
Shared care is beneficial, however, much of the communication occurs on the 
phone or in meetings and it is not always documented and entered into the 
electronic health records.  Recording of management and treatment seems to work 
in the inner city practice that has developed a protocol together with drug workers.  
It was not always seen as time efficient, but that could be because GPs have so 
much other information to record.  I provide more detail about this recording 
template in section 7.6.10.1. 
 
7.6.8 Key points from the organisational theme “management and 
treatment in general practice” 
Not all general practices chose to manage and treat drug use.  General practices 
choosing not to treat, are still responsible for the patient’s medical care and for 
referring to and signposting patients for the most appropriate treatment which they 
may record using either Read codes or free-text.  GPs may not see women during 
their pregnancy, but referral and discharge letters from midwifery services are 
usually scanned, however Read codes are not always used to record important 
information in the electronic health records.  Some general practices that manage 
and treat drug use have a shared care model of practice which can be beneficial in 
delivering patient centred care, however communication between health 
professionals regarding the patient is often informal and not recorded.   
 
7.6.8.1.1 Process of management and treatment 
Who can GPs refer to? 
If a general practice does not offer treatment for drug use, a GP has a few different 
referral options.  GPs described how they can refer a patient to the drug treatment 
clinic or in some cases, another GP practice where treatment takes place.  They 
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may use Read codes or free-text to record the referrals.  Two GPs described how 
they suggest to the patients that they refer themselves to the drug treatment clinic.  
The first quote indicates that he perceived that patients were more likely to attend 
the drug treatment clinic if they referred themselves rather than being referred by 
the GP. 
“I tend to get people to self-refer for most things that they can self-refer for, because I think 
they’re more likely to actually attend if they self-refer themselves.  I usually record this as 
free-text” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
“they can self-present, so that’s why I think it’s rare and a lot of people don’t want their GPs 
necessarily at first to know they’ve got drug addictions so they go to the services 
separately” 
(GP, male, 5-10 years’ experience, inner city, special interest in drug use) 
 
The second quote illustrates that if a patient self-refers without the GPs knowledge, 
the GP cannot record this information in the electronic health records.  There are 
some cases when a GP chooses not to treat the patient in the general practice, 
even though treatment for drug use is offered.  One of the GPs explained that she 
referred more chaotic patients, to the drug treatment services.  She perceived that 
patients who did not adhere to their clinic appointments may get more support and 
be managed more appropriately in the drug treatment services and she would 
either use a Read code or free-text to record the referral.   
“And the ones we might refer on, they get too chaotic, they’re drinking too much, they’re just 
not able to manage their own shared care in terms of totally unable to turn up for 
appointments, injecting their neck or some really dangerous practices, where we think they 
might benefit, we’ve got a local injecting clinic so we might send them to that.  So where 
they’re just not able to engage with our service, we refer on and I may use a Read code or 
just free-text.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
In summary the data highlighted that there are various options for GPs to refer to 
or sign post the patients to for self-referral.  GPs who saw patients more frequently 
who used drugs and who were involved in shared care seemed to be more aware 
of the referral processes and options for referrals.  If GPs made the referral, they 
reported using either Read codes or free-text.  
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7.6.9 Other Drug treatment services 
There are various drug treatment services that GPs can refer individuals to.  There 
seems to be either segregation or integration of care between general practices 
and services (Figure 7:8).   
 
Figure 7:8: Other drug treatment services; organising theme of Global theme 2 
 
7.6.9.1.1 Segregation or integration of care 
Communication between the services and the GPs 
In some circumstances there seems to be more segregation rather than integration 
of care.  Once the patient goes to the drug treatment service or maternity service 
there may not be much communication between the GP and the service regarding 
the patient.  A GP explained how the lack of communication could be detrimental; 
as a patient could be receiving opioid substitution treatment from the drug 
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treatment services without the GP knowing and the patient may then try to obtain 
additional medication from the GP. 
“But that’s generally a problem with our secondary care service anyway, the drugs service, 
they don’t communicate they don’t write letters.  They’re not very good at sort of 
communicating back to us.”  
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
GPs are therefore not able to record information regarding treatment in the 
patient’s electronic health record because of the communication gap between 
services.  There are also areas where good communication and integration of care 
between the drug treatment service and the general practice occurs.  The data 
showed evidence of good practice of integration of care in a region where drug use 
is highly prevalent.  The regional addiction service use the same software system 
(system One) as the general practices in the area.  If a patient gives consent, the 
GP can access a patient’s electronic records from the drug treatment service and 
see the quantity of medication being prescribed.  This then decreases the risk of 
over-prescribing. 
“The nice thing is we’re on the same computer system, so we can see when they’ve been 
seen there and we can see what’s been going on as well” 
(GP, male, 5-10 years; experience, outer city, did not have a special interest in drug 
use) 
 
It is evident that there are examples of both integration and segregation of care 
with regards to communication between other services and general practice.  It 
seems that different services are using different recording systems which are not 
usually linked to the general practice.  The GP will only hear about the information 
if they get a discharge letter, communicate directly with the other services or if the 
patient tells them the information.  As mentioned in the previous section, some of 
the GP practices recording systems are set up, so that the GP can link into the 
records of the patient at the treatment centre.  The general practices that are using 
the same electronic systems as the drug treatment services seem to be benefitting 
from this ongoing communication.  As long as the patient consents to their records 
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being shared, the GP has a more accurate picture of the patient’s care in other 
services.   
 
7.6.10 Key points from segregation or integration of care 
There seems to be more segregation rather than integration of care when the 
patient’s care is transferred to other services and communication regarding the 
patient is not always adequately fed back to the GP.  Finally, there are regions in 
the UK who have set up the same electronic systems and therefore information 
regarding the patient is shared between the drug treatment service and the general 
practice.  These aspects all impact GP recording of drug use in the electronic 
health records. 
 
7.6.10.1 Recording drug use and treatment using templates 
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Figure 7:9: Recording of drug use 2 
 
Some general practices have developed templates for recording drug management 
and treatment.  A lead GP in an inner city practice described how over the years 
there was a need for her to develop a template for recording drug use, especially to 
ensure that they were receiving the correct payment for treatment.   
“So our template for substance misuse is that one, and so because we get a payment for 
drug addiction treatment, so to use this template, you have to use the drug addiction, one of 
these three codes” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
The template was linked to various Read codes in the patient’s electronic health 
record, but the drug workers and GPs also had the opportunity to free-text 
additional information. 
“Then there’s a thing underneath it where you can free-text the amount of illicit use that 
there has been.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
She had worked together with other GPs, drug workers and an IT specialist to 
develop the template.  She also described how the template was annually updated 
to ensure that appropriate information was being recorded.   
“I had an opportunity to work with the IT guy to improve the template .So I did quite a bit of 
work with them [drug workers] to make sure that what was on the template would be useful 
for them as well, for their templates.  So it works quite well because we did actually consult 
quite a lot of people, the people who were frontline in making sure that we had what they 
wanted in the template.  I worked it out so that the drug workers would be able to record 
stuff onto the computer and we’d be able to search for it.  So when it comes to recording 
illicit use, this is the thing.” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
I interviewed another GP who was using this particular template, and she 
perceived the template as extremely useful with regards to recording and the 
continuity of care of the patient.  She did however express how she had found it bit 
time-consuming to complete. 
“It’s a template developed by them (the other GP practice) which we use, usually in each 
consultation, but actually it’s quite repetitive.”   
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
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This particular template is only used in this particular London borough and has not 
been rolled out to other general practices.  After viewing the template and 
observing how quickly a vast amount of relative information could be entered and 
then linked to Read codes, I asked the GP if she had thought about rolling it out to 
other general practices.  She unfortunately has not had the time, initiatives are at a 
local level and reliant on individuals for roll out. 
“I’ve done an awful lot locally, but I’ve never really got hugely involved in the RCGP or stuff 
nationally, because, well, I had kids and I haven’t time, and I was more interested in 
working locally” 
(GP, female, >15 years’ experience, inner city, special interest in drug use) 
 
A different inner city GP had developed a template for recording.  During the 
transfer of computer systems his template disappeared.  He described how 
frustrating it had been and he was trying to find the time to develop a new template 
but he felt that he did not have the IT expertise and did not have any IT support. 
“I have got a template, but it’s all a bit of a mess, because for 20 years, I’ve been using 
Emis and we had our templates, but they were mainly templates that I built myself and used 
all the time.  And now we’ve transferred to System One and all that data is actually lost. 
Um, I’m really at sea at the moment, because I’m so used to coding my information, at the 
moment I feel I cannot make any proper notes!  ” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
 “It was actually one of the reasons why we were very cautious about not switching to Emis 
Web because Emis Web said it couldn’t be done.  SystemOne, under false pretences, said 
that it could be done and they could adapt all my codes, and I could build the templates 
again with the old codes.  But, no, so we’re not quite sure how to solve it.” 
(GP, male, >15 years’ experience, inner city, special interest in drug use) 
 
Templates seem to be very useful and efficient with regards to recording 
management and treatment of drug use in general practice.  They do however take 
individual commitment to develop, but there are no process to help roll out.   
7.7 Discussion 
7.7.1 Summary of findings 
I have included the key summaries after each organising theme in the findings 
section.  Many factors appear to influence recording of drug use is general 
practice.  I have produced an algorithm to illustrate the various ways that recording 
of drug use can be captured in electronic health records in THIN (Figure 7:10).
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Figure 7:10: Algorithm illustrating how drug use is recorded in THIN 
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In order for recording to take place, the patient has to see a GP and the GP needs 
to either ask or the patient needs to disclose that they use drugs.  Decisions are 
made at all points (figure 7.10) as to whether or not to record drug use and if so 
whether or not to use Read codes or free-text.  As mentioned previously, it is more 
useful and practical to extract and examine Read codes than free-text when using 
THIN as a surveillance or research tool.  It is difficult to capture information using 
free-text as to date, only a third (35%) of free-text comments have been 
anonymised in THIN (CSD health research, 2015).   
 
7.7.2 Comparison with previous literature 
In this section, I have analysed all the data together with regards to pregnancy, 
NAS and GPs who did and did not have a special interest in drug use.  The 
analysis identified and explored different levels that influence recording of drug use 
in electronic health records which fitted into the following conceptual framework; 
the first level was the individual GPs, the second being the general practice, the 
third, the CCG and finally how government policies can impact recording (Figure 
7:11). 
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Figure 7:11: Interpretation of findings 
 
General Practitioner level: 
Primary care may be the first point of contact for some individuals who use drugs.  
When a GP sees an individual who uses drugs, many factors (mentioned in 
previous section) seem to influence if and how they record in the individual’s 
electronic health record.  Most of the GPs interviewed in this study with and without 
a special interest in drug use perceived that their role for managing and treating 
individuals who use drugs was essential and important.  Some of them also 
described how they had become more accepting and desensitised to the stigma 
associated with drug use.  These perceptions echo the Royal College of General 
Practitioners (RCGP) recommendation that GPs should try to maintain a non-
judgemental attitude towards patients (Royal College of General Practitioners, 
2010).  The GPs’ views and perceptions seemed to be moulded by their 
experience and how they viewed their role in the treatment of drug use.  Their role 
encompassed identifying the problem and working together with other health 
professionals and services in order to manage and support individuals who use 
Policy 
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Group level
General Practice level
Individual GP level
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drugs.  It can be clearly seen that recording of drug use is potentially affected by 
how the GPs view their role with managing and treating individuals who use drugs. 
 
GPs’ experience and training also seemed to influence how they recorded drug 
use in electronic health records.  A GP’s working week is divided into sessions 
which are approximately four hours each.  Data from this study supported the fact 
that GPs who worked in both general practice and drug treatment felt that they 
were more aware and therefore asked individuals about drug use more frequently, 
which then influenced if the GP recorded or not.  The RCGP offers standardised 
training in substance misuse in the form of two modules (Royal College of General 
Practitioners, 2015a).  Once the two modules are complete, the GP is awarded a 
certificate in the Management of Drug Misuse (Royal College of General 
Practitioners, 2015a).  It was evident from the data that most of the GPs who were 
clinical leads for substance misuse had completed one or both modules of the 
RCGP training.  This highlights adherence to RCGP guidelines which recommends 
that “practitioners with special interests” should undergo specific training and 
accreditation (Department of Health (England), 2007; Ford et al., 2013).  Currently 
there are no guidelines regarding recording in the modules (Dr C Ford, 2014: 
personal communication (email) 8 Dec).  I will discuss this in more detail in the 
clinical implications (section 9.8) 
 
Development of good rapport can influence the information the individuals tells the 
GP during a conversation.  The narratives from this study illustrated that most of 
the GPs perceived that developing rapport with a patient was important and the 
relationship can be strengthened when the GP is empathetic.  These opinions 
resonate with Goold and Lipkin’s argument that the doctor-patient relationship is an 
imperative aspect of patient care and is possibly as important as therapeutic 
treatment (Goold and Lipkin, 1999).  If a GP incorporates empathy into the 
relationship, it allows the patient to feel heard and they may then open up more to 
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the GP and develop a relationship which could impact on their decision to stay with 
the same GP (Goold and Lipkin, 1999).  However, Gott et al. found that GPs felt 
that there was insufficient time to build rapport with the patient when they asked 
about another perceived sensitive topic; sexual health, which the GPs perceived as 
a sensitive issue (Gott et al., 2004).  The GP accounts from my study also suggest 
that GPs aim to create a balance between the needs, wants and requests of the 
individual.  Unfortunately relationships between GPs and patients can decline, 
which could be exacerbated if a patient is requesting something that the GP cannot 
concede to.  Furthermore, most of the GPs in my study perceived that the main 
barriers to building and establishing relationships with patients were time 
constraints and continuity of care.  According to the GP service report, patients 
value a long term and continuous relationship with their GP (Monitor, 2015).  If the 
general practice has a clinical lead for substance misuse, the patient should be 
seeing the same GP and therefore receiving more continuous care.  This continuity 
of care should therefore allow time for rapport and interpersonal continuity of care 
to be established between the GP and patient.  Continuity of the individual seeing 
the same GP could influence what the individual tells the GP and therefore 
influence if the GP records the drug use in the electronic health records or not. 
 
Building rapport can also aid in developing trust between the GP and an individual.  
The narratives in this study illustrated the value GPs placed on the trust of the 
patient.  The opinions regarding trust echo with Croker et al, who rationalized that 
the trust patients have in their GP is essential for effective and efficient 
consultations (Croker et al., 2013).  This is especially evident when the patient is 
disclosing sensitive information and may feel a sense of vulnerability (Croker et al., 
2013).  Goold et al. reasoned that a patient who does not trust or like their GP will 
not disclose all the information efficiently during a consultation (Goold and Lipkin, 
1999).  Furthermore, it was also interesting to hear that most of the GPs did not 
always seem to think that the patient was openly communicating and disclosing the 
whole story and therefore GP’s could start to distrust the information they receive 
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from the individual.  It is evident that the development of trust between the GP and 
patient can impact on the patient disclosing drug use and whether or not the GP 
records drug use.  
 
Together with gaining the patient’s trust, respect for each other is also imperative 
to the consultation.  The narratives in this study illustrated how most of the GPs 
respected the patient’s autonomy by not recording the drug use in the electronic 
health records if the patient asked them not to.  However in some cases GPs tried 
to highlight the importance of recording to the individual.  Shared decision making 
and a sense of partnership can help to maintain the patient’s trust in a GP (Croker 
et al., 2013; Little et al., 2001).  Although overall when a woman was pregnancy or 
a child was involved, GPs in this study seemed unanimous in their actions with 
regards to always recording drug use.  Woodman et al. found that the role of health 
professionals identifying children who have been maltreated or neglected was 
increasing in primary care (Woodman et al., 2013).  Furthermore, perinatal 
exposure of illicit drugs during pregnancy has recently been included in the 
definition of child neglect (HM Government, 2013).  Therefore GPs may be inclined 
to record drug use more in electronic health records when a woman is pregnant or 
a child is involved.  In summary GPs used their judgement on whether or not to 
record drug use in the electronic health records.   
 
Individuals presenting with certain signs and symptoms may trigger a GP’s 
awareness of drug use.  This trigger of awareness could potentially be problematic 
for the relationship between the GP and patient as the patient may be seeking help 
for a problem other than their drug use.  Overall GPs with and without a special 
interest in drug use described similar signs and symptoms that triggered their 
awareness of drug use, which sometimes resulted in the GP asking about drug 
use.  Medical practitioners play an important role as a first point of contact for 
people who are seeking help (Royal College of General Practitioners, 2010).  
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Hamilton and Britton argued that the agenda (problems) that the patient present to 
the GP may clash with the GP’s prioritisation (Hamilton and Britten, 2006).  Prior to 
consulting a GP, patients have usually judged the seriousness of the issue 
(Hamilton and Sharp, 2004).  If this problem then triggers a GP’s awareness of 
drug use, and the GP focuses on the drug use rather than the original problem, the 
patient could become frustrated and not feel heard.  Goold et al. described how 
three factors determined how the consultation would be successful to both GP and 
patient (Goold and Lipkin, 1999).  The three factors were the following; the GP’s 
agenda, the patient’s agenda and the outcome and plan of the consultation (Goold 
and Lipkin, 1999).  They theorised that if the three factors overlapped considerably, 
the consultation could be deemed productive by both GP and patient, however if 
there was little overlap, one or both of the parties could deem the consultation as 
unsuccessful (Goold and Lipkin, 1999).  This conflict of interests could contribute to 
of the demise of the GP-patient relationship and therefore influence if the GP 
decides to record drug use in the electronic health records or not. 
 
In order to record drug use, GPs usually need to first ask the individual.  Asking 
about drug use seemed to differ between GPs who did and did not have a special 
interest in drug use. GPs who did not have a special interest in drug use in this 
study seemed to see patients who use drugs infrequently and therefore did not ask 
about drug use routinely.  Additionally, if they did ask, they seemed to feel 
uncomfortable about asking.  This seemed to be because they may not have felt 
they had the expertise to deal with drug use, but also because asking about drug 
use may reveal a myriad of other problems that the GP may not be able to deal 
with within the consultation time.  McGillion et al. and McKeown et al. found similar 
issues with regards to expertise and time when they interviewed GPs and practice 
nurses regarding managing individuals who used drugs (McGillion et al., 2000; 
McKeown et al., 2003).  Similarly, Gott et al., found a similar issue when they 
interviewed GPs and practice nurses regarding barriers to talking about sexual 
health (Gott et al., 2004).  The same phrase “can of worms” as well as “pandora’s 
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box” was used in both my study and the study by Gott et al. to illustrate how a 
sensitive and complex issue was difficult to discuss within the time and resource 
limitations present (Gott et al., 2004).  It could be considered an opportunity cost if 
the GP decides not to ask about drug use.  Furthermore, if a GP decides to ask 
they risk learning about the patient’s various complex issues and would then be 
required to help and support the patient.   
 
Some GPs in this study suggested that GPs were more comfortable asking about 
alcohol rather than drug use, however, Lock et al. argued that GPs are not 
routinely asking patients about alcohol in primary care, and most only ask in 
response to certain physical signs and symptoms (Lock et al., 2009).  Even though 
alcohol may be seen as a slightly less sensitive and more acceptable to ask about, 
it seems that GPs are still not always asking about alcohol use and even less 
about drug use.  GPs are well positioned to query about drug use, however 
barriers such as time, experience and the complexity of the issue seem to have an 
impact on the number of patients GPs ask and therefore the number they record in 
electronic health records.   
 
GPs in this study reported not routinely initiating questioning about drug use, but if 
they did ask, they tended to ask certain people about drug use or people with 
particular signs and symptoms.  My findings echo the survey conducted by Lock et 
al. who found that 64% of GPs who answered their survey acknowledge they 
would ask about alcohol use if the patient presented with certain physical, 
psychological or social symptoms (Lock et al., 2009).  A key difference that 
emerged in my findings between GPs who had a special interest in drug use and 
those who did not was that the former viewed that there was a risk that individuals 
may be missed if GPs only focused on asking particular groups of patients.  The 
fact that some patients who used drugs could be missed would consequently affect 
recording of drug use in electronic health records.  GPs could possibly be made 
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aware of this to ensure that they are not missing opportunities to ask certain people 
about drug use. 
 
My findings showed that GPs seemed to develop their own style of questioning 
about drug use.  Some found it easier to be more direct, whilst others find they 
obtain more information if they use an indirect style of questioning.  The RCGP 
recommend that two of the core competencies of a GP consultation should be to 
“Adapt communication skills to meet the needs of the patient” and to “Demonstrate 
focused questioning and examination to obtain sufficient relevant information to 
diagnose, manage and refer appropriately” (Royal College of General Practitioners, 
2015b).  Both of these competencies were demonstrated by all GPs in my study 
when asking about drug use.  Some GPs found it easier to question together with 
another sensitive topic, such as sexual health.  This echoes Mitcheson et al.’s 
findings that suggest individuals engaging in risky sexual behaviours, should also 
be asked about drug and alcohol use (Mitcheson et al., 2008).  Questioning style 
and context could have an indirect effect on recording of drug use, depending on 
how the patient reacts to the questions. 
 
GPs views differed with regards to whether or not it is important to record drug use.  
Health professionals sometimes view coding as a complex sociotechnical issue (de 
Lusignan et al., 2003).  Some GPs in this study felt that it was more important for 
the patient to be honest about drug use rather than recording it.  My data echoes 
the findings of the Department of Health study exploring recording of alcohol 
misuse where some GPs expressed that they would rather build a trustful 
relationship than be intent on recording the alcohol misuse (Department of Health, 
2005).  Most of the GPs with and without an interest in drug use were sensitive to 
the fact that recording drug use on an individual’s electronic record may have a 
future impact and were therefore sometimes reluctant to record drug use as Read 
code.  Similarly, Woodman et al. also described how GPs would think twice before 
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and were very careful before coding a child with a maltreatment code as the code 
was effectively there for life (Woodman et al., 2012). As mentioned previously, 
there were critical time points when all the GPs in this study agreed that they would 
record the drug use, this included the perinatal period and when a child was 
involved.  Pregnancy is a critical and opportunistic time for the GP to ask a woman 
about drug use.  GPs ask many other questions, some of them quite sensitive and 
therefore drug use could be included.  Although GPs seem to not have much 
contact with a woman during her pregnancy, if the fact that she is using drugs is 
flagged up and recorded, the GPs could then monitor and support her once she is 
discharged from the midwifery unit.  Once a woman is discharged from the 
midwifery service, GPs receive a detailed discharge letter.  These discharge letters 
are usually scanned into the electronic health records, but only some of the 
information is Read coded. Neonatal abstinence syndrome (NAS) however was not 
always recorded in the child’s electronic health records as some GPs perceived 
NAS as a medical rather than a social problem.  Most of the GPs were not aware 
of any long term complications of NAS and they felt that treatment was completed 
in hospital and it was therefore not necessary to record in primary care records.   
 
There were many different views with regards to using Read codes to record drug 
use.  Some of the GPs in this study found that using Read codes was time-
consuming as they had to scroll through to find the most appropriate Read code to 
use.  Some GPs also felt that there were too many Read codes to choose from and 
it would be helpful if the list of Read codes could be revised and unnecessary 
codes could be excluded.  GPs with and without a special interest in drug use felt 
that free-text was a quicker and easier way to record.  Discharge letters are usually 
scanned into the electronic health records, and only important information from the 
letters is recorded as a Read code.  Some GPs however may rely on the practice 
administrator to record these Read codes and therefore practice administrators are 
deciding which Read codes to use.  Some GPs have templates for recording drug 
use which seems to make the recording more organised and systematic.  Similarly, 
 268 
 
Maisey et al. and Dixon et al. found that if a disease is included in QOF and the 
disease or outcome would be recorded more systematically (Dixon et al., 2010; 
Maisey et al., 2008).  
 
In summary, in deciding whether or not to ask the patient about drug use - and 
subsequently if and how this information should be recorded - GPs must weigh up 
many factors and competing priorities.  GPs act at an individual level, but GPs are 
also required work within the general practice level. 
 
General Practice level 
The organisational and contextual aspects of different general practices can 
indirectly influence GP recording of drug use in electronic health records.  The data 
in this study indicated that the location of the general practice could influence the 
need for a lead GP in substance misuse.  A lead GP is a GP with a special interest 
in a certain area of medicine and patients with the specific medical condition are 
usually channelled to the lead GP (Royal College of General Practitioners, 2015c).  
The recognized needs of the local population usually inform which specific services 
in a general practice need to have an allocated practitioner with a special interest 
to help implement and deliver these services (Royal College of General 
Practitioners, 2008).  The data in this study also suggested that although there was 
less continuity of care for most patients registered in larger general practices, 
patients who were identified as using drugs received continuous care from the lead 
GP in substance misuse.  This may influence recording of drug use at a practice 
level as one GP would make the decision whether or not to record drug use in the 
patient’s electronic health record. 
 
Time was identified as a barrier for building rapport and asking individuals about 
drug use in the previous section on GPs. In most general practices, ten minutes 
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are allocated for seeing and treating a patient and writing up the consultation 
(Hamilton and Britten, 2006).  GPs are expected to work within these time 
constraints and some general practices encourage patients to make more than one 
appointment if they have several problems that they need to see a GP about 
(Hamilton and Britten, 2006).  Time limitations seemed to be critical for GPs who 
were not leads in substance misuse as they felt they had limited time to explore 
issues other than the primary reason for the patient attending the consultation.  
Patients who use drugs often have more complex problems and the normal 
consultation time may not be enough for acquiring information about drug use.  In 
contrast, GPs who were leads in substance misuse did not suggest that time was a 
barrier.  In previous studies, time has been found to be a barrier for involvement of 
GPs with patients with other complex issues such as alcohol (Lock et al., 2009), 
sexual health (Gott et al., 2004) and other risky lifestyle behaviours (Pocetta et al., 
2015).  However, GPs have to work within time constraints and therefore it may 
save time if a patient who uses drugs and has complex problems sees the same 
GP.  This may then influence whether or not the GP records the drug use in the 
electronic health records. 
 
New patient registration forms could be an opportunity for general practices to 
indirectly ask about drug use. However, it appears that patients are not always 
willing to disclose drug use in the form and if they do disclose, they may not have 
an opportunity to disclose the whole story.  There does not seem to be any clear 
guidelines on what to include in new patient registration forms.  Forms seem to 
have been developed and evolved in different practices.  The forms are generally 
short and ask for generic information.  The high turnover of patients and increased 
administration time warrant the forms to be succinct and consequently questions 
regarding drug use are not always included in the form (Dr G Rait and Dr S 
Singh,2015, personal communication (face to face conversation) 30 November).  
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It was evident from the data that there are a various options available for general 
practices with regards to treating drug use.  General practices are not obligated to 
treat drug use and it may be more beneficial that individuals are treated in either 
practices that have the expertise and confidence to treat individuals or treated in 
specialised drug treatment services (McKeown et al., 2003).  Drug treatment 
services are commissioned by CCG (discussed in more detail in the next section 
on CCGs).  The model of shared care has been implemented in these areas, 
where the general practice works together with statutory NHS and voluntary sector 
drug treatment services (National Treatment Agency for Substance Misuse, 2006).  
The individual can therefore either receive treatment at a specific general practice, 
be referred or they can self-refer to the drug treatment services (National 
Treatment Agency for Substance Misuse, 2006).  It is essential though that GPs 
have a clear understanding of where to sign-post or refer individuals in order that 
they receive the most appropriate treatment.  GPs who saw patients more 
frequently who used drugs and who were involved in shared care seemed to be 
more aware of the referral processes and options for referrals.  In some cases 
there could be improved communication between drug treatment clinics and GPs 
which could then allow GPs to decide the best option for the individual and also 
make a decision about recording the drug use or not. 
 
There are examples of both integration and segregation of care with regards to 
communication between other services and general practices.  The RCGP 
recommends that integration of care in general practice should be; “Patient-
centred, primary care led, delivered by multi-professional teams, where each 
profession retains their professional autonomy but works across professional and 
organisational boundaries to deliver the best possible health outcomes.” (Royal 
College of General Practitioners, 2012).  Integration of care can therefore be 
advantageous, not only for the patient, but also for GPs as patient care can be 
planned and co-ordinated with patients who have complex needs (Royal College of 
General Practitioners, 2012).  The RCGP also recommends that services can also 
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be designed to incorporate both services in the community and professionals in 
general practice to make up a multidisciplinary team (Royal College of General 
Practitioners, 2012).  It is beneficial to have shared care, whether it is within the 
practice or provided by a designated drug worker from the drug treatment services.  
The data showed evidence of an effective working relationship between the GP 
and drug worker, which seemed to benefit patient-centred care (Royal College of 
General Practitioners, 2014).  However, a problem could arise if the drug worker or 
drug nurse leaves, as it takes time for a new relationship to develop between a GP 
and drug worker and the post could also become redundant.  Shared care is 
beneficial, however a considerable amount of the communication occurs on the 
phone or in meetings and it is not always documented and entered into the 
electronic health records.  Recording of management and treatment seems to work 
in the inner city practice that has developed a protocol together with drug workers.  
It was not always seen as time efficient, but that could be because GPs have so 
much other information to record.  I provide more detail about this recording 
template in section 9.8. 
 
Templates seem to be very useful and efficient with regards to recording 
management and treatment of drug use in general practice.  Maisey et al. 
reasoned that templates can also help ensure quality assurance with regards to 
recording in General practice (Maisey et al., 2008).  Templates do however take 
time to develop and can require IT support, especially if the Read codes are 
embedded in the template.  A report by the RCGP raised the question of whether 
or not templates (Read codes embedded in these templates) could be used as 
evidence that intervention with regards to recovery from drug use is taking place 
(Harris L and Halliday K, 2013).  Using templates could make recording drug use in 
electronic health records easier and more uniform.  
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In summary the general practice level indirectly influences how and why GPs 
record drug use in electronic health records.  General practices and other services 
are commissioned by a higher level, the clinical commissioning groups (CCG) 
 
Clinical commissioning group level 
CCGs became responsible for commissioning hospital and community services in 
their area in April 2013 (NHS Clinical Commissioners, 2015).  CCGs decide which 
services are required in the area and are also responsible for providing these 
services including drugs and alcohol services (NHS Clinical Commissioners, 2015).  
General practices are incorporated into the applicable CCG (NHS Clinical 
Commissioners, 2015).  Therefore decisions and services provided by the CCG 
can indirectly influence GP recording of drug use in electronic health records.  
 
CCGs located in areas where there was an awareness of high drug use seemed to 
have more registered individuals in general practices who they knew used drugs.  
As previously mentioned in section 1.3.8.2, The Localism Act (2011) influenced a 
shift of responsibility from central to locally based Public Health bodies (Harris L 
and Halliday K, 2013).  As mentioned previously in section 1.3.8.2, treating drug 
use is not in the General Medical Services (GMS) contract, however general 
practices in certain areas where the needs of the local population have been 
identified have a Local Enhanced Service for treating drug use and are financially 
incentivised for treating individuals who use drugs (Department of Health, 2003; 
Royal College of General Practitioners, 2008).  It was interesting to see from the 
data in this study that GPs perceived that recording of drug use is limited because 
the GMS contract does not include drug use and treatment.  Drug treatment 
services in the community are also commissioned by the CCG and local authorities 
(NHS Commissioning Board, 2012).  As mentioned previously, the data highlighted 
that there are various options and services for GPs to treat or refer to or sign-post 
the patients to for self-referral.   
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Midwifery services are provided by the CCG.  As mentioned previously in section 
5.8.2.3, GPs rarely see pregnant women during the gestation period and empirical 
evidence from my second study (section 5.7.2.1) supports this.  The treatment of 
drug use during pregnancy seems to be unanimously transferred to the midwifery 
services rather than continuing at general practice level.  Treatment of drug use is 
more complicated during pregnancy and could be the reason that treatment takes 
place outside the general practice (Ford et al., 2013).  The referral is either directly 
to the specialist midwife service or to the generic midwife services, which may then 
be triaged to the specialist service.  GPs seem to be detailing medical and health 
conditions more when referring women to the midwifery services, however as 
previously mentioned, these details my not be Read coded in the electronic health 
records.  It is however a concern that once a woman has been referred to the 
midwifery services, the GPs generally do not see her until after the baby is born.  
The RCGP have made the following recommendations; “the management of 
pregnancy in all drug users should be multidisciplinary at all times (Ford et al., 
2013). Good communication between the professionals involved is particularly 
important”.  From the data, I would argue that these recommendations are not 
always being followed in primary care and therefore GPs would be less likely to 
record in the electronic health records. 
 
It seems that different services are using different recording systems which are not 
usually linked to the general practice.  GPs will only hear about the information if 
they get a discharge letter, communicate directly with the other services or if the 
patient tells them the information.  As mentioned in the previous section, some of 
the GP practices recording systems are set up, so that the GP can link into the 
records of the patient at the treatment centre.  The general practices that are using 
the same electronic systems as the drug treatment services seem to be benefitting 
from this ongoing communication.  As long as the patient consents to their records 
being shared, the GP has a more accurate picture of the patient’s care in other 
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services.  This link of electronic health records could be an effective way of sharing 
information and to improve the patient centred care.  They can then see how much 
and when the patient was prescribed opioid substitution treatment.  This electronic 
linkage is evidence of a method that works to integrate the care of the patient and 
facilitate recording in electronic health records.  I will discuss later (in section 9.8) 
how this system could potentially be rolled out to other areas in the country.  
 
CCGs indirectly influence GP recording of drug use in electronic health records.  
CCGs are however affected by policies. 
 
Policy level 
QOF is a framework that was implemented together with the new GMS contract in 
2004 to for performance management and payment of general practices (Dixon et 
al., 2010).  There are currently no QOF indicators for recording drug use in primary 
care electronic health records.  There is also no QOF for the treatment of alcohol 
misuse in primary care, Lock et al. (2009) argued that the inclusion of alcohol 
misuse treatment should be in both the GMS contract and QOF (Lock et al., 2009).  
The same could be argued for drug use and drug treatment.  The Payment-by-
Results pilot study (see details in section 1.3.8.1) is currently evaluating incentives 
for delivery of recovery for drugs and alcohol in primary care (Department of 
Health, 2012).  The final results of the pilot study have not been published yet, 
however both Maisey et al. and Dixon et al. found that diseases or outcomes 
incentives by QOF were in fact better recorded (Dixon et al., 2010; Maisey et al., 
2008).  Dixon et al. also argued the QOF can be a barrier to CCGs commissioning 
services that are meeting the needs of the local population and this is especially 
evident in areas which serve populations with complex needs, such as the 
repercussions of drug use.  It therefore follows that if QOF indicators for recording 
drug use were included, recording of drug use in individuals’ electronic health 
records may improve.  
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In summary GPs directly influence GP recording of drug use in primary care 
electronic health records, whilst three other hierarchical levels indirectly impact 
recording.  It is evident that recording of drug use in primary care is a complex 
issue and affected on many factorial levels. 
 
7.8  Conclusion 
My qualitative study presents an understanding of how and why GPs record drug 
use in general practice.  My findings illustrate the complexity of recording.  A 
confluence of factors affect both how GPs acquire information about drug use and 
the management and treatment of drug use which influence various pathways that 
can lead to GPs recording drug use.  The fact that drug use is still a stigmatized 
and sensitive issue could influence whether or not GPs follow RCGP guidelines, 
practice protocols or templates.  Additionally the analysis identified and explored 
four distinct levels which influence GP recording of drug use; GPs directly influence 
recording while the general practice, CCGs and government policy indirectly 
influences recording of drug use in an individual’s electronic health records.  
Recording of drug us is complex and varies amongst GPs and, GPs face complex 
choices when deciding whether or not to record drug use.  
 
7.9 How Does This Chapter Support My Thesis? 
I have described and discussed my fourth study which used qualitative methods to 
explore GP recording of drug use and looked at the impact of contextual, 
organisational, institutional and policy issues.  I used qualitative work to increase 
knowledge and my understanding of the empirical data in THIN.  I found that 
recording of drug use is a complex issue.  The two global themes that lead to 
recording were how GPs acquired information about drug use and the 
management and treatment of drug use. 
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My findings have made it clearer as to why, when, how and who GPs decide to 
record and if they use Read codes or not.  As previously mentioned, the main 
strength of using a large primary care dataset is that it provides a large amount of 
data from real life primary care.  However, meaning and understanding need to be 
incorporated into work with large datasets (Pope et al., 2014).  This has been done 
by using qualitative methods to help understand the methods, classification and the 
circumstance for recording (Pope et al., 2014).   
 
Together with my first three studies, the fourth study helped to reflect on the 
advantages and limitations of using THIN as a surveillance and/or research tool for 
drug use and/or opioid substitution treatment during pregnancy.  I will synthesize 
results from all four studies and discuss this more in Chapter 8. 
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 Integration and synthesis of results 
8.1 Content and Structure of Chapter 8 
In this chapter, I describe the integration and synthesis of results of the qualitative 
and quantitative studies.  
 
To help navigate this section, I have divided it into four parts.   
1. GP recording of drug use in the general population 
2. GP recording of opioid substitution treatment in the general population 
3. GP recording of drug use and opioid substitution treatment in and around 
pregnancy 
4. GP recording of Neonatal Abstinence Syndrome 
 
8.2 Integrating and Synthesising the Results of the Qualitative 
and Quantitative Studies  
As previously mentioned, I chose to take a pragmatic approach and used both 
quantitative and qualitative methods, as one methodological approach could not 
optimally answer all my research questions.  Hammersley reasoned that 
triangulation of two methods helps achieve more of a comprehensive 
understanding of an issue (Hammersley, 2005).  Mixed methods research is 
increasingly popular in health care research, particularly in primary care (Woodman 
et al., 20012, 2013).  I used the qualitative findings to help explain the results of the 
quantitative analysis.  A strength of the thesis as a whole was that I was able to 
continue working on my quantitative analysis whilst I undertook my qualitative 
work.  I could therefore iteratively shape the topic guide to answer some of the 
questions I had regarding recording and the qualitative study therefore helped to 
add insight and complemented the three epidemiological studies.  I will now 
discuss how the qualitative findings helped me to gain a clearer understanding of 
GP recording.   
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8.2.1 Gaining a clearer understanding of GP recording of drug use in 
electronic health records. 
Results from the first study, where I explored GP recording of drug use and opioid 
substitution treatment in the general population, raised the question of why there 
are apparent gaps in recording rates (Chapter 4).  As previously mentioned in 
section 7.7, it is important to clarify that THIN only includes recorded information 
about individuals at the top section of the adapted access to healthcare pyramid of 
healthcare (Huxley and Goldberg, 1993). Figure 8:1. 
 
Figure 8:1: Adapted access to healthcare pyramid as describe previously in section 3.4.4. 
 
Individuals who are recorded as using drugs need to be permanently registered 
with a general practice, consult their GP, disclose their drug use and the GP needs 
to record the drug use in the electronic health record.  The qualitative findings 
suggest that GPs do not always record information regarding drug use in the 
electronic health records of all individuals who they know use drugs.  GPs seem to 
record drug use when the drug use is the primary problem and contributing to 
adverse consequences such as difficulties with relationships, financial and legal 
problems and imbalance with physical and mental health.  It seems therefore that 
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individuals being captured in THIN are those with more problematic drug use.  The 
shape of the access healthcare model for drug use is similar to the study by 
Woodman et al. where they suggested that the number of children with a 
maltreatment code in THIN was underestimated compared to the amount of child 
maltreatment occurring in the community (Woodman et al., 2012).  Individuals may 
also perceive that potential consequences to their disclosure and/or recording of 
drug use could occur, whereas in a survey, such as The Crime Survey for England 
and Wales, individuals self-complete the questionnaire and their identity is 
pseudonomised.  Therefore, although the Crime Survey results may be 
underestimated, it is more likely to capture a larger number of drug users which 
may resemble a community prevalence of drug use more compared with data from 
THIN (depicted as the bottom section of the pyramid in Figure 8:1).  In contrast to 
other diseases/conditions such as diabetes and cardiovascular disease, there are 
currently no national guidelines or QOF indicators for recording drug use in 
electronic health records and therefore it is up to general practices (policy affecting 
organisational decision) and GPs (individual decision) to decide whether or not 
they should record drug use or not.  The presence of QOF for other chronic 
disease, may aid in the difference between recording in general practice and 
community prevalence sections of the healthcare pyramid being less profound. 
 
My qualitative findings brought to light the many different factors that seem to 
influence whether or not GPs (individual decision) choose to record drug use in the 
patient’s electronic health record.  The findings indicated that influences are 
complex and that individual GPs’ perceptions and past patient experience seemed 
to affect recording, as well as the organisational levels of general practices, Clinical 
Commissioning Groups and government policies.  It was also evident that GPs 
make the decision to record drug use on a case-by-case basis.  Consequently 
figures relating to drug use in THIN are likely to be underestimated but in contrast, 
demographic and time-trends in THIN mirror those in the Crime Survey for England 
and Wales.  The qualitative findings suggested that GPs did not always have time 
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to ask every individual about drug use, and directed their questions to individuals 
presenting with similar characteristics.  These characteristics reflected the 
demographics of individuals who were most likely to have a recording of drug use 
in my first study and the Crime Survey for England and Wales, namely; younger 
males from more deprived areas.  The findings also suggested that some patient-
groups (e.g. older women from less deprived areas) may be missed because GPs 
are not asking them about drug use, and this could also contribute to the under-
recording in electronic primary care health records. 
 
The timing of recording in the first study showed that a large amount of first 
recording for drug use occurs within the first two months after the patient registers 
with a general practice.  Previous studies using THIN to evaluate incidence of a 
condition/disease usually exclude recording during this time-period after 
registration as these may represent prevalent cases (explained in section 4.8.9), 
but I decided not to as my qualitative findings suggested that the registration period 
was an opportune time for enquiring about and/or recording drug use.  A small 
number of GPs described how they have included a question about drug use in the 
patient registration questionnaire and this inclusion could explain why there is this 
surge of recording during this time.  Again, this disclosure is subject to 
consequences and therefore individuals may not disclose at all. 
 
Results from the first study also revealed that over 500 Read codes are available 
for GPs to record drug use however GPs were only using half of theses codes.  
This could partially be explained by the findings from the qualitative interviews (see 
section 7.6.5.1.2 for details).  The GP accounts also highlighted that GPs 
perceived that individuals who used drugs were more likely to be poly-drug users 
and therefore a generic code would describe the drug use better than using a 
specific code.  GPs also explained that instead of using a Read code for drug use, 
they used a Read code for the primary problem that the patient presented with 
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(insomnia, depression) and if they also recorded drug use, it would usually be as 
free-text.  However, in some cases, GPs described that they would use a Read 
code for drug use if this was the primary problem.  Again, this implies that GPs are 
possibly using Read codes more for problematic drug use (see section 1.3.2.4 for 
details) rather than for recreational drug use in patient’s electronic health records.  
These results concur with the small validation study conducted by Frischer et al., 
where 92% of individuals with a recording for drug use were being treated for 
problematic drug use (Frischer et al., 2004) 
 
8.2.2 Gaining a clearer understanding of GP recording of opioid 
substitution treatment in electronic health records  
Results from the first study, where I examined prescriptions of opioid substitution 
treatment, indicated that the number of people who were given a prescription for 
opioid substitution treatment in general practice were similar to those reported by 
the National Treatment Agency (Chapter 4).  Choosing to treat drug use with opioid 
substitution treatment is an organisational decision within the general practice.  
The general practices that chose to treat were usually financially incentivised by a 
local enhanced service set up by the Clinical Commissioning Group.  Recording of 
drug use and treatment, including prescriptions were therefore expected in these 
organisations.  However the lack of incentives seemed to affect recording in 
general practices that did not treat problem drug use.  The findings from my 
qualitative study suggested that regions that were more aware of drug use had 
more local enhanced services for drug use and often had a practice lead for 
substance misuse.  GPs who had a special interest in drug use seemed to have 
developed their own templates in order to record drug use and treatment.  The 
practicality of templates seemed to help make recording of drug use and treatment 
more practical and systematic.  One of these templates was linked to Read and 
prescription codes in the software which made it easier to audit, as recording was 
essential in order to receive payment from the local enhanced services.  GPs who 
treat drug use also should provide the figures to the National Treatment Agency on 
a monthly basis.  A few of the GPs viewed that more recording of drug use might 
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take place if there was a QOF indicator for drug use.  The question is whether this 
should be the case and if so would it affect the relationship between GP and 
patient (as discussed in section 7.6.2.1).  I will discuss whether or not QOF 
indications for drug use would be an appropriate method for incentivising and 
recording drug use in section 9.8. 
 
The number of Read codes for opioid substitution treatment was less than 
prescriptions in the first study.  Two reasons for this lower rate could be that firstly 
GPs described how they seldom use a Read code for a drug prescribed as well as 
a prescription code, and with almost half (44%) of referrals to drug treatment 
centres being self-referrals, GPs may not always be aware of individuals who self-
refer and are receiving treatment from somewhere else (Public Health England, 
2014).,    The qualitative interviews suggest that that there seems to be more 
segregation of care once an individual is seen by another service and GPs 
perceived that the information is poorly fed back to the GP.  There does not appear 
to be an electronic system in place for communication between most general 
practices and other services.  This could be also an explanation for the low number 
of Read codes for opioid substitution treatment found in THIN. 
 
8.2.3 Gaining a clearer understanding of GPs recording of drug use 
and opioid substitution treatment in and around pregnancy in 
electronic health records 
The decrease in recording of drug use and/or opioid substitution treatment in and 
around pregnancy can be partly explained by findings from the qualitative study 
(Chapter 5).  GPs described how they referred newly pregnant women to the 
midwifery services and how they may write a large amount of detail in the referral 
letter.  The detail in the referral letter may include information about adverse life-
style factors such as smoking and drug use if a woman discloses this information.  
However GPs did not always record this information as a Read code in the 
electronic health records.   
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Additionally, pregnant woman did not appear to consult GPs through most of their 
pregnancy.  This was particularly the case if a woman was using drugs as GPs 
described how they would usually refer her to a specialist midwifery service which 
usually takes care of a woman’s antenatal and other medical care.  During 
pregnancy, the midwifery services provide pregnant women with hand-held 
antenatal notes which the women retain throughout their pregnancy (Perinatal 
Institute, 2015).  Information about drug use may be in the hand-held notes and/or 
the maternity computer system rather than in a centralised recording system and 
consequently the discharge summary may not include some information from these 
notes.  Once the baby has been delivered, the hand-held notes, antenatal 
summaries (usually completed by the midwife between 8-10 weeks of the 
pregnancy) and intrapartum notes, are retained and stored in the hospital archives 
(Perinatal Institute, 2015).  The GP receives two summaries; a birth summary after 
hospital discharge and a discharge summary upon transfer of the mother and baby 
to the primary care team (Perinatal Institute, 2015).  The writing of these 
summaries is overseen by the community midwife and should be sent to the GP 
when they see a woman six weeks after her baby is delivered (Perinatal Institute, 
2015).  GPs described how these summaries were usually scanned in the 
electronic health records, however if there were problems occurring during the 
perinatal period, GPs sometimes used either Read codes or free-text to record 
these issues in the electronic health records.  
 
Another key finding from the second study was that there was a decrease in opioid 
substitution treatment prescriptions during pregnancy and then a subsequent 
significant increase after pregnancy.  A possible explanation for this was described 
by GP accounts where they would usually refer women who were receiving opioid 
substitution treatment to either the midwifery services or directly to the specialist 
midwifery services, which would take over their treatment.  GPs reiterated that 
communication between the specialist midwifery services and themselves was 
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lacking during the antenatal period, consequently the quantitative study, using 
THIN, showed little recording of Read codes for opioid substitution treatment 
during pregnancy.  However, with regards to the increase in prescriptions for opioid 
substitution treatment, women may have disclosed their drug use to the midwives 
during pregnancy.  Once the baby is delivered, care is usually transferred back to 
the GP and the discharge summary may notify GPs to start prescribing opioid 
substitution treatment.  Prescriptions would then be recorded in a woman’s 
electronic health records and contribute to the data in THIN.   
 
8.2.4 Gaining a clearer understanding of GP recording of neonatal 
abstinence syndrome 
In the third study where I examined an indirect measure of drug use (opioids, 
benzodiazepine, barbiturates), approximately a third of the recording of NAS in the 
hospital setting was recorded in electronic health records in primary care (Chapter 
6).  The qualitative accounts described how they would record drug use in the 
electronic health records if a child was involved.  However, this did not seem to be 
the case with NAS and can potentially be explained by the two opposing opinions 
from GP accounts regarding recording of NAS in electronic health records.  The 
first view was that NAS was a medical issue which was treated in the hospital and 
as there were no known long term affects GPs decided not to record it as a Read 
code.  The contrasting view was that NAS was both a medical and a social issue 
and it was important for identifying children who were potentially at risk for both 
medical and social problems.  There are currently no guidelines for recording NAS 
in the electronic health records, GPs appeared to make individual decisions based 
on their view about the long term outcomes of NAS.  Additionally NAS is an indirect 
measure of only a few specific drugs.  I will expand on the clinical implications of 
recording NAS in the electronic health records in section 9.8.   
 
I have now integrated my quantitative and qualitative results which demonstrate 
that methodological triangulation helped to strengthen the evidence of my 
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quantitative work and helped to uncover the missing pieces of the jigsaw puzzle by 
creating a clearer picture and comprehension of recording drug use in electronic 
health records.  I will now discuss the interpretation in context with other studies. 
 
8.3 How Does This Chapter Support My Thesis? 
Together with my first three studies, the fourth study helped to reflect on the 
advantages and limitations of using THIN as a surveillance and/or research tool for 
drug use and/or opioid substitution treatment during pregnancy.  I have described 
how the qualitative study has incorporate meaning and understanding into the 
studies using THIN.  I will now discuss the contribution my thesis has made to 
knowledge and improved method, overarching strengths and limitations, 
justification for using the CSEW, what I support the argument of the thesis, clinical 
and research implications and the overall conclusion of the thesis in Chapter 9. 
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 Discussion 
 
9.1 Content and Structure of Chapter 9 
In this final chapter, I will firstly present an overview of the thesis and summary of 
the findings.  I will then present the following: 
1) Illustrate how the thesis brings new knowledge and/or improves 
method. 
2) Discuss the value of the Offending Crime and Justice Survey as a 
measure of drug use in the population. 
3) Describe the overarching strengths and limitations of the thesis 
4) Discuss what I have learnt during the thesis and what I might 
have done differently 
5) Discuss if THIN is sufficient to address the hypothesis concerning 
drug use during pregnancy or the consequences of NAS? 
6) Consider both the clinical and research implications of the thesis 
7) Present the conclusions of the thesis 
 
9.2 Overview of the PhD thesis  
There are few studies in England and Wales to date, that estimate the burden of 
drug use and opioid substitution treatment during pregnancy.  Pregnancy usually 
triggers women to visit their general practitioner (GP) which may provide an 
opportunity for drug use to be raised and recorded.  A 2010 survey found GPs are 
the first healthcare professionals that 77% of women see when they first find out 
they are pregnant and 45% of antenatal appointments occur in general practice 
(Redshaw and Heikkila, 2010).  I therefore hypothesized that examining electronic 
health records may be an appropriate method to gain an understanding of the 
burden of drug use and opioid substitution treatment during pregnancy. 
 
Misuse of drugs is a public health problem which can lead to poor health outcomes 
and drug use during pregnancy could also potentially harm the unborn baby.  Drug 
use is more common in men, however misuse of drugs has increased in women 
over the past 30 years (HM Government, 2013).  Two thirds of women who enter 
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treatment for drug use are mothers with only approximately half having custody of 
their children (National Treatment Agency for Substance Misuse, 2010).  
Furthermore, it is estimated that between 2-5% of children in England and Wales 
are living with a parent with drug and/or alcohol problems (HM Government, 2013).  
One of the main reasons for the lack of studies conducted during pregnancy may 
be the complexity of accurately obtaining information about drug use due to the 
stigma which may be intensified during pregnancy.  However, women who use 
drugs may be more willing to seek help from health professionals during pregnancy 
for a number of reasons (for example: they may be concerned that the drugs may 
have an adverse impact on their unborn child). 
 
In the UK, all women have an opportunity to be registered with a GP and receive 
free antenatal care (National Institute for Clinical Excellence, 2010b).  Women are 
recommended to visit either their GP or midwife once they know they are pregnant 
(National Institute for Clinical Excellence, 2010b).  The antenatal care is usually 
transferred to the midwifery service, and transferred back to the GP when a woman 
visits her GP six weeks after the birth of her baby (National Institute for Clinical 
Excellence, 2010b).  Depending on the situation, women may still consult their GP 
for other medical care during their pregnancy (National Institute for Clinical 
Excellence, 2010b).  If a woman chooses to consult her GP at the beginning of her 
pregnancy and/or after giving birth, these timely appointments lend themselves as 
opportunity for a GP to enquire about drug use together with other health related 
behaviours.  If a woman discloses that she uses drugs, the GP is in a better 
position to offer long term support for both mother and child.  GPs may also record 
information regarding drug use during and after pregnancy as a Read code in a 
woman’s electronic health record.  Therefore, data from electronic health records 
could be viewed as an approach to monitoring women who use drugs and/or are 
prescribed opioid substitution treatment.   
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I decided to conduct a database cohort study in order to evaluate if primary care 
data could be utilised as a source of surveillance and research in relation to drug 
use and opioid substitution treatment, specifically during and 36 months either side 
of pregnancy.  However, in order to understand recording of drug use and/or opioid 
substitution treatment in women who were pregnant, I first had to examine the 
recording of drug use and/or opioid substitution treatment in the general population 
registered in general practice.  Previous studies had used the GPRD database to 
explore trends of problematic drug use and opioid substitution treatment up until 
2005, however there were no recent studies from primary care in England and 
Wales and no studies included recreational drug use (Cornish et al., 2010; Frischer 
et al., 2000, 2001, 2004, 2005, 2009).  Annual reports are produced from the 
following national surveys: The Crime Survey for England and Wales, The National 
Treatment Drug Monitoring System and The Welsh National Database for 
Substance Misuse (Office for National Statistics, 2015a; Public Health England, 
2015; Welsh Government, 2015).  These reports make it possible to externally 
compare drug use and opioid substitution treatment recorded in primary care data.   
 
In summary, GP recording trends for the general population were in keeping with 
national surveys, but with lower rates.  Recording was relatively low in and around 
pregnancy.  GP recording of NAS was similar to hospital data, however rates were 
lower.  Finally, qualitative interview analysis identified that influences on recording 
drug use were complex and related to pressures at the individual as well as 
organisational (general practices, Clinical Commissioning Groups) and 
governmental levels in the shape of government policies.   
 
In the next section I explain how my work builds on previous studies of drug use 
and demonstrate how the different studies introduce new knowledge and improve 
methods. 
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9.3 How the thesis brings new knowledge and/or improves 
method. 
Study 1: GP recording of drug use and opioid substitution treatment in the general 
population 
The thesis contributes to the field of knowledge by providing both empirical and 
qualitative evidence to an area where there are is limited evidence.  The studies by 
Frischer et al and Cornish et al examined problematic drug use and opioid 
substitution treatment respectively using GPRD up until 2005 (Cornish et al., 2010; 
Frischer et al., 2001, 2000, Frisher et al., 2009, 2004) .  My first study was 
exploratory and contributed new knowledge by including further analysis of data 
between 1994 and 2012 and therefore time-trends for the later years could be used 
to compare with other data sources.  Furthermore, future longitudinal studies 
examining individuals with a record in primary care for drug use, will have a longer 
follow-up period.  Additionally, Read code lists for problematic drug use and opioid 
substitution treatment had been previously developed by Frischer et al and Cornish 
et al in GPRD.  For this PhD, I updated these lists and also sought to include 
recreational drug use when examining recording.  The reason I decided to include 
recreational drug use was that the previous studies examining drug use during 
pregnancy included recreational drugs and I intended to compare my results from 
THIN with these studies (Farkas et al., 1995; Fergusson et al., 2002; R A 
Sherwood et al., 1999).  However, I later learned from my quantitative and 
qualitative studies that recreational drug use was poorly recorded in primary care 
and confirmed that primary care electronic health records are more appropriate for 
investigations of problematic drug use.  Additionally, I decided to include 
dependence for prescription drugs as this seems to be an emerging problem in 
high-income countries (Giraudon et al., 2013; Mehdi, 2012; Stannard, 2013).  I felt 
it was important to include ‘dependence for prescription drugs’ when examining 
problematic drug use in electronic health records.  Indeed, I found that 
benzodiazepine dependence was one of the most frequently used Read code 
(10.9%) for drug use in the electronic health records.  Furthermore, I explored 
whether GPs may be recording drug use as free-text and I found an extra 0.03% 
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(n=520) individuals had a free-text comment relating to drug-use, but no relevant 
Read and/or prescription code.  GPs may also be recording the primary problem 
(e.g. depression) rather than drug use and/or they may not be recording it at all.  
Furthermore, my qualitative study also suggested that many of GPs are using free-
text rather than Read codes for recording drug use.  Future studies could 
potentially examine free-text in more detail.     
 
While previous work has been unable to examine regional differences in detail, I 
was able to examine both England and Wales and analysed the data according to 
the English Strategic Health Authorities.  The findings confirmed that most of the 
recordings for both drug use and opioid substitution treatment occurred in the 
North East of England and Read codes for opioid substitution treatment occurred 
most frequently in the North West of England.  These regional results concur with 
results from more problematic drug use data, namely; mortality rates related to 
drug misuse from England and Wales, where the highest rates were found in the 
North East and North West of England (69.3 and 61.9 per 1 million population 
respectively), and the prevalence of opioid and crack use was highest in the North 
East (9.89 per 1,000 person years) and North West (9.99 per 1000 person years) 
of England (Hay et al., 2013; Office for National Statistics, 2015b) 
 
I contributed to new knowledge regarding how much of the recording of opioid 
substitution treatment is being reported to the National Treatment Agency (NTA) by 
including all possible prescriptions for opioid substitution treatment according to 
guidelines and comparing these with figures with reports from the NTA.  The 
results were similar and although it is not mandatory for GPs to report prescribing 
to the NTA, my findings suggest that they are in fact doing it consistently.   
 
 291 
 
Cornish et al. examined individuals who had been prescribed opioid substitution 
treatment in GPRD between 1990 to 2005 (Cornish et al., 2010).  They however, 
did not include all possible treatment available for GPs to prescribe.  I therefore 
decided to include all possible treatments available for GPs to prescribe from the 
NICE and RCGP guidelines (Ford et al., 2013; National Institute for Clinical 
Excellence, 2010a).  I also examined the dose for each drug to ensure that they 
were being prescribed as part of a detoxification programme.  I therefore 
contributed to improved methods by including these other prescribed drugs in the 
drug code list I developed.  
 
Additionally, the Read and drug code lists I have developed have contributed to 
improved methods as drug use is a potential confounding factor in various 
epidemiological studies.  A study examining the association between smoking and 
schizophrenia using THIN, is currently being conducted at UCL.  The authors have 
asked to use the Read and drug code lists to include as a confounder (R Jones 
2016, personal communication (email), 9th September).  Future studies can also 
use my Read and drug code lists to identify individuals with a recording for drug 
use and include this in their analysis. 
 
Study 2: GP recording of drug use and opioid substitution treatment in and around 
pregnancy 
The second study is the first to examine recording of drug use and/or opioid 
substitution treatment in and around pregnancy in electronic health records.  The 
results from the second study echo the pattern of findings of the 2010 national 
survey of women’s experience of maternity care, where more (77%) women 
consulted their GP when they were first pregnant, but less (45%) went to their GP 
for subsequent antenatal appointments (Redshaw and Heikkila , 2010).  The 
survey was sent to 10,000 randomly selected women who were 16 years and older 
and had given birth in England between October and November 2009.  Non-
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response bias may have influenced the results as the response rate was relatively 
low (51.2%).  Women with the following characteristics were more likely to 
respond: older, married, living in the least deprived area, born in the United 
Kingdom and therefore findings within these demographic factors may be 
overestimated.  This survey was repeated in 2014, and the response rate had 
decreased to 48% with women with the same characteristics being more likely to 
respond.  The proportion of women seeing their GP for antenatal appointments, 
had decreased to 15% (Redshaw and Henderson, 2014).  The authors attributed 
the lower response rate to increasing number of surveys being sent out and 
increasing time pressures, especially with a new baby.   
 
The findings from my second study were comparable to those from the pilot 
questionnaire study in Glasgow and Sheffield maternity units where 1% of women 
had used drugs during pregnancy (Advisory Council on the Misuse of Drugs, 
2011).  The majority (92%) of maternity units reported that pregnant women were 
routinely assessed for both alcohol and drug use during pregnancy.  However, 
different health professionals and different methods were used to routinely assess 
including biological testing, information gathered by clinical observation and self-
disclosure or information from a third party.  Additionally, both Sheffield and 
Glasgow are in the top 10% of most deprived areas in England and Scotland 
respectively (UK online centres, 2014).  Alcohol, smoking and drug use are usually 
higher in deprived areas and therefore health professionals in these areas may be 
more aware than in maternity units located in less deprived areas.  A strength of 
my study was that I included English Strategic Health Authorities and Wales in the 
analysis and found that as with the general population, the recording rates for drug 
use and opioid substitution treatment was highest for the North East and North 
West of England.  As previously mentioned this concurs with results regarding 
regional problem drug use and contributes to knowledge about regional service 
requirements.  
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Results from my study and the pilot questionnaire study suggest that there was 
under-recording of drug use in primary care.  This is strengthened by the fact that 
the results of drug use in the two biological, cross-sectional London studies were 
higher in pregnant women (Farkas et al., 1995; Sherwood et al., 1999).  The first 
biological study was conducted in a hospital located in East London in 1994 
(Farkas et al., 1995).  Testing of 1,000 urine samples of women attending their 12 
week antenatal appointments found that 10% tested positive for drug use, 8.5% 
positive for cannabis, 1.4% positive for opiates and 1.1% positive for cocaine 
(Farkas et al., 1995).  The second study was conducted in South London (1994-
1995) and found that urine of 15.6% (126/807) women tested positive for drug use 
during pregnancy (Sherwood et al., 1999).  Since my initial literature review, 
another study examining drug use in pregnancy was published in 2014 (David et 
al., 2014).  The results from this study agreed strongly with the studies by Farkas 
et al. and Sherwood et al., although they conducted their studies in three sites 
(London, Bristol and Birmingham) rather than restricting to London (Farkas et al., 
1995; Sherwood et al., 1999).  David et al. analysed hair samples of pregnant 
women and their findings suggested that 14.9% (77/517) of women used drugs 
during pregnancy (David et al., 2014).  In these three studies, the identity of 
women was anonymous and therefore positive findings of drug use would not have 
potential adverse consequences from the mother’s perspective as would disclosure 
to health professionals.  Additionally, biological measures are more accurate than 
self-reporting (David et al., 2014; Farkas et al., 1995; Sherwood et al., 1999).  The 
biological studies were able to test for recreational drug use, however my findings 
suggest that recreational drug use is not being captured in electronic health 
records which could also explain the comparatively lower results.  Furthermore, 
Ferguson et al. analysed data from the ASLPAC study (Fergusson et al., 2002).  
The self-reported questionnaire included questions on cannabis and other illicit 
drugs (Fergusson et al., 2002).  Consent was required and identities of women 
were not anonymised which could explain why their findings were lower compared 
to the three biological studies.  In contrast, the findings from Ferguson et al. were 
higher than the pilot study by the Advisory Council on the Misuse of drugs and my 
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study (6.5% compared with 1%).  This could be due to the fact that disclosure of 
drug use remained confidential and therefore would not have adverse 
consequences (e.g. the baby being taken away from the mother).   
 
All five of these studies had relatively small sample sizes and covered three or less 
areas of the UK.  In contrast my study had a larger sample size and included the 
following maternal characteristics: age, deprivation and regional variation.  
Although the findings suggested that little recording occurs during pregnancy, drug 
use recorded before pregnancy and opioid substitution treatment recorded after 
pregnancy can be used as a proxy for drug use and opioid substitution treatment in 
pregnancy in future studies based on primary care data.  I have included a study 
protocol in section 9.7.2. in order to examine if an independent association exists 
between drug use during pregnancy and adverse birth outcomes.  As with the 
general population, drug use and opioid substitution during pregnancy could be a 
potential confounder in future studies.  Studies by Petersen et al used the Read 
and drug code lists I had developed, to control for drug use in and around 
pregnancy (Petersen et al., 2016a, 2014) and doctoral work included drug use 
(from the Read code lists I developed) as a confounder for parental depression 
during pregnancy and the first year postpartum (Wijlaars, 2014).  Future studies 
can also use my findings to include these variables as potential confounders in 
their analysis.   
 
Study 3: GP recording of neonatal abstinence syndrome 
The third study contributes to both new knowledge and improved methods as it is 
the first study to examine recording of NAS in primary care and also provides a 
birth prevalence for NAS in England using HES.  The HES study was based on 
and used similar methods to the studies conducted by O’Donnell et al and Patrick 
et al.(O’Donnell et al., 2009; Patrick et al., 2012)  Since my initial literature review, 
a study by Jones et al. was published which examined recording trends of NAS in 
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Welsh births (Jones et al., 2013).  They found that rates of recorded NAS 
increased from 0.28 to 1.6 live births between 1999 and 2011 (Jones et al., 2013).  
Additionally, Turner et al., published a study in 2015 which showed a 15-fold 
increase of recorded NAS between 1999 and 2011 in Ontario, Canada (0.28 to 
4.29 per 1000 live births) (Turner et al., 2015).  Recorded NAS rates in England 
have remained relatively stable in recent years compared with Wales, Scotland, 
the USA and Ontario, Canada (Jones et al., 2013; National Statistics Scotland, 
2012; O’Donnell et al., 2009; Patrick et al., 2012; Turner et al., 2015).  As with all 
the studies, the findings are reliant on identification, recording and correct coding of 
NAS in the hospital data.  Furthermore, work is being conducted at the institute for 
child health to link the babies recorded with NAS that I identified in HES with family 
courts data (Professor R Gilbert and Dr L Wijlaars, 2016, personal communication 
(face to face conversation), 9th November).    
 
NAS is less well recorded in primary care than in hospital settings. This may 
suggest that NAS is a transient issue, but it may potentially be a marker for 
maternal drug use.  Future studies could examine the risk of having a recording for 
both NAS and child maltreatment and compare the birth prevalence of NAS in 
England and other countries.  Again, NAS could also be a potential confounder and 
therefore my findings could help future research include NAS in analysis.   
 
Study 4: Factors affecting recording of drug use – a qualitative study 
My qualitative study is the first to provide new knowledge and a deeper 
understanding of the factors that influence GP recording of drug use. My work can 
help future researchers when designing studies using primary care data, especially 
if it includes sensitive and stigmatised issues similar to drug use. 
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Finally, as well as developing Read and drug code lists for future research, I have 
also developed different cohorts using THIN and HES which could be used for 
future research examining problem drug use, drug use during and around 
pregnancy and infants who have been recorded with NAS:  
1) Individuals who are recorded as using drugs or prescribed with opioid 
substitution treatment (registered with a general practice in England and 
Wales). 
2) Women who are pregnant and have a code for drug use and/or prescription 
for opioid substitution treatment (registered with a general practice in 
England and Wales). 
3) Infants with a recording for NAS in both THIN (registered with a general 
practice in England) and HES (in England).  
 
I will now discuss the Crime Survey for England and Wales (CSEW) and the 
offending Crime and Justice Survey and justify why I used the CSEW to compare 
my results to.  
 
9.4 The value of the Offending Crime and Justice Survey as a 
measure of drug use in the population. 
In Chapter 4, I compared the results from THIN with the Crime Survey for England 
and Wales (CSEW).  The main reasons for using the CSEW were that it has been 
used both nationally and internationally to compare recreational drug use, it has a 
relatively large sample size (n=46,031), appropriate stratification, relatively high 
response rate (75%) and the survey includes weightings in the analysis to adjust 
for non-responders (Lynn and Elliot, 2000; Office for National Statistics, 2015a).  
However, the CSEW also has several limitations which include underestimation of 
drug use as it provide trends of drug use rather than an absolute count, potential 
sampling bias, sampling error and underrepresents individuals from younger age-
groups (16-24) (Lynn and Elliot, 2000; Tipping et al., 2010).  The survey has tried 
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to compensate for this by randomly selecting and interviewing more than one 
person aged 16-24 per household and thereby also increasing the sample size of 
this age-group, however the response rate for the age-group is still relatively lower 
(68%) (Tipping et al., 2010) 
 
The Offending Crime and Justice Survey (OCJS) is an alternative survey which 
could be used together with the CSEW as it was developed and implemented with 
the aim of obtaining a more accurate prevalence of both offending and drug use in 
England and Wales, specifically amongst younger age-groups (10-25 years).  The 
OCJS was a panel study that was commissioned by the Home Office and 
conducted by the British Market Research Bureau Social Research and the 
National Centre for Social Research (NatCen) between 2003 and 2006 (Home 
office, 2008).  The rotating panel design allows some of the previous year’s sample 
to be re-interviewed as well as adding new people in the next wave (Home office, 
2008).  Approximately 10,000 interviews were conducted each year, with half the 
sample being in the 10-25 age-group (Home office, 2008).  The response rate was 
relatively high; 82% from the original panel sample and 69% for the fresh sample 
(Matthews et al., 2006).  The survey also allows a more detailed analysis of 
criminal behaviour (including drug use) than the CSEW, as it focuses on the 
relevant contextual data (Hales et al., 2009).  Similar to the CSEW, the OCJS has 
a separate self-completion section for sensitive topics (which include drug use) to 
help improve privacy and confidentiality and uses Computer Assisted Self-
Interviewing (CASI) to complete these questions (Office for National Statistics, 
2015a).  CASI is also very useful for individuals with literacy problems, which may 
be more in the case of the OCJS due to inclusion of younger age-groups (Hales et 
al., 2009).  The OCJS includes questions about the use of specific drugs and if 
they have been used in the last month, last year or in their lifetime (Office for 
National Statistics, 2015a).  The types of drugs and timing of drug use is similar in 
both surveys.  However, the OCJS also includes the following additional questions: 
“if the individual used alcohol and drugs together”, “if they used more than one 
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drug at a time”, “if they had missed usual commitments such as school or work 
because of drug use”, “if they had committed a crime in order to obtain money for 
drugs”, “if anyone had found out about their drug use”, “if they had been in contact 
with the Crime and Justice System due to drug use”, “whether or not they had 
looked for help regarding their drug use” and “the age the person started and last 
age they used drugs”  Questions from both the CSEW and OCJS can be found in 
the respective user guides (Home Office, 2006; Office for National Statistics, 
2015c) 
 
As with the CSEW, the OCJS also has several limitations.  Firstly, the OCJS omits 
serious offences such as homicide and sexual offences which the authors 
suggested would not have too much impact on drug use estimates (Hales et al., 
2009).  I agree with the authors that these crimes are unlikely to have a major 
impact on drug use estimates, although many crimes are often related to drug use 
(Social Unit, 2002; Stewart, 2008).  Secondly, both surveys have been criticised for 
having sampling bias by excluding certain groups of people, including those in 
hostels, the homeless, prisoners, students living in university halls of residents, 
individuals living in very remote locations (Lynn and Elliot, 2000).  These groups 
have zero probability of selection and the estimates of drug use are therefore likely 
to be underestimated.  However, access to individuals from some of these groups 
may be unfeasible for any survey as the individual may have a relatively more 
chaotic lifestyle or no fixed address.  Thirdly, non-response bias exists in both 
surveys, as with the CSEW, younger people and individuals who have more 
chaotic lives may be more difficult to interview and/or refuse to participate in the 
OCJS (Hales et al., 2009). 
 
Fourthly, as with most surveys, response bias frequently occurs.  However, a self-
completion section for answering sensitive questions (including illicit drug use) has 
been included to help reduce response bias.  Particularly in the OCJS, younger 
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participants may not understand the questions and some participants may not 
disclose this drug use even though they are assured of anonymity and 
confidentiality (PRCI, 2007; Wilson et al., 2006).  The context of the surveys may 
also impact on how honestly the participants report.  In the CSEW, interview 
questions on being a victim of crime precede the self-completion questions on drug 
use whilst questions on criminal behaviour precede the drug use questions in the 
OCJS.  Qualitative interviews were conducted on the accuracy of answering 
questions in the CSEW (n=35) (White and Lewis, 1998).  Most people reported that 
they were honest when questions about crime were asked, however in the self-
completed questionnaire, they often underestimated drug use (White and Lewis, 
1998).  Factors that encouraged more accurate reporting were good sense of 
rapport with the interview and how confidential they perceived the information to be 
(White and Lewis, 1998).  
 
The two main reasons most surveys underestimate drug use is that firstly 
individuals with problematic drug use may not be living in private households and if 
they are, they may be more reluctant to participate.  Secondly, the accuracy of the 
information depends on the understanding of questions, recalling events accurately 
and willingness to provide accurate and honest answers.  There are no absolute 
accurate estimates to compare drug use to.  However, if the underestimation 
remains constant, the trend of the data may be informative even if the actual 
prevalence may be underestimated.   
 
Although both surveys have their limitations, there is no gold standard for 
measuring drug use as neither surveys can obtain the actual prevalence.  However 
these surveys offer the best information that is available on drug use and Hickman 
et al suggested that findings from both the OCJS and CSEW are comparable 
(Hickman et al., 2007).  I decided to use the CSEW as it has previously been used 
both nationally and internationally (European Monitoring Centre for Drugs and Drug 
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Addiction, 2013; Frisher et al., 2009).  In addition, the OCJS was only conducted 
between 2003 and 2006 and my analysis covered the years between 1994 and 
2012.  On further reflection however, the two surveys could be used concurrently 
as the OCJS could strengthen the weaknesses of the CSEW namely, that it 
focuses on the younger age-groups and asks more detailed questions about drug 
use.  
 
9.5 Overarching Strengths and Limitations 
The strengths and limitations of the thesis rely on the strengths and limitations of 
using the different databases and qualitative methods; THIN, HES and qualitative 
interview methods.   
 
9.5.1 Strengths and limitations of using THIN 
The main strength of using THIN is that it includes a large amount of data from real 
life patient-GP consultations in primary care and results can be generalisable to the 
UK population (see section 3.4.2 for details).  Individuals who are permanently 
registered with a general practice can be analysed longitudinally as they are 
assigned a unique identity number (ID) within the general practice.  Frischer et al. 
noted that the main advantages of using a primary care database (GPRD) for 
monitoring drug use was that it contained recorded Read codes for drug use, time 
trends of drug misuse, associated co-morbidities and prescribing (Frischer et al., 
2001, 2000; Frischer et al., 2009).  It is also mandatory for GPs to record all 
prescriptions in electronic health records, subsequently if an individual was 
receiving a prescription for opioid substitution treatment from their GP, it would be 
captured in THIN.  It can be difficult to differentiate between individuals who were 
being treated for drug dependence with opioid substitution treatment and for 
chronic pain medication.  However, I applied strict inclusion criteria when 
examining the dosage of drug being prescribed and time between prescriptions 
(BMJ group, 2013; Cornish et al., 2010; Royal College of General Practitioners, 
2011; Strang et al., 2010).   
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The findings from both the quantitative and qualitative studies suggest that 
individuals who are on the more severe spectrum of dependency and/or addiction 
are more likely to be recorded in primary care records.  The advantage of this is 
that primary care records have higher specificity with regards to individuals who 
use drugs and therefore those who are recorded as using drugs are likely to be 
true positives.   
 
Another strength of using THIN is that in order to receive free antenatal care, 
women in the UK are encouraged to register with a GP and therefore consultations 
may be recorded in their electronic health records  (Maternity Action, 2011; NHS 
Choices, 2014).  The study by Dhalwani et al. suggests that recording of smoking 
(a different harmful health behaviour) in general practice was comparable to 
national surveys in the general population and also in early pregnancy; however 
there seems to be a large amount of under-recording in the later stages and after 
pregnancy (Dhalwani et al., 2014).  I could therefore use THIN to examine 
recording in and around pregnancy as the database provides access to information 
about women during their pregnancy, which is often a challenging period to 
conduct other research.  Read codes that are used to identify infants with NAS are 
specific and there is little risk of false positive recording of NAS.  Additionally, I 
could identify babies who were linked to mothers if they were registered with the 
same general practice.  Furthermore, THIN has previously been used to study 
relatively rare exposures effectively and I could therefore justify using THIN to 
explore recording of drug use and/or opioid substitution treatment, especially 
during pregnancy.   
 
There were several limitations to using THIN.  Firstly, THIN only includes 
information about individuals who are permanently registered with a general 
practice and have been in contact with their GP.  This may be an issue with 
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regards to problematic drug users who may have a more chaotic lifestyle and may 
be more transient.   
 
Secondly, disclosure of drug use may have more to do with the consequences and 
therefore a self-selected group may be disclosing drug use to their GP.  Fewer 
individuals become problem drug users compared with those taking drugs 
recreationally (Public Health England, 2015) and my findings suggest that GPs 
seem to record problematic drug use more in electronic health records.  Recording 
may be picking up the effects of drug use rather than the actual drug use, unless 
the individual is wanting to stop using drugs and then this may either be recorded 
as a Read code or in the free- text.  The disadvantage is that we are only seeing 
the tip of the iceberg with regards to drug use and the full effect of drug use is not 
being captured in primary care electronic records.  Individuals that have a record of 
drug use or indications that they receive opioid substitution treatment could be 
included as a confounding factor in longitudinal analysis, but it should be 
emphasised that the adjustment may only account for the more severe 
dependency.  My findings also agree with de Lusignan et al. whereby GPs may 
also be aware that the patient-doctor relationship could be compromised if the 
patient is coded as a drug user and therefore decide not to record the drug use (de 
Lusignan et al., 2003).  Therefore, examination of THIN reveals the minimum 
estimate of people who use drugs and not a community estimate or prevalence of 
drug use in society.  The closest community prevalence (bottom section of pyramid 
in Figure 8:1) of drug use is estimated by the annual Crime Survey for England and 
Wales which is conducted in approximately 375,000 households (Office for 
National Statistics, 2015a).  The confidential survey includes a self-complete 
section on drug use and therefore individuals may be more inclined to disclose 
both their problematic and recreational drug use than if they were seeing their GP.   
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Thirdly, there are to date no large validation studies for recording drug use if the 
person is not receiving treatment in secondary care and no validation studies for 
recreational drug use.  This was also acknowledged in earlier studies by Frischer 
et al. who examined drug misuse recorded in GPRD (Frischer et al., 2001, 2000).  
Frischer et al. did however conduct a small validation study for recording problem 
drug use in primary care databases in a later study (Frischer et al., 2004).  They 
looked at a random sample and found that 92% of this sample of patients being 
treated for substance misuse in secondary care also had a diagnosis of substance 
misuse by their GP (Frischer et al., 2004).  In contrast, a systematic review by 
Kahn et al. presents the various validation studies that have been conducted for 
recorded diagnoses primary care databases (Khan et al., 2010).  Diagnoses with a 
high positive predictive values and high sensitivity include those for psychosis, 
COPD and current smoking (Lewis and Brensinger, 2004; Nazareth et al., 1993; 
Soriano et al., 2001).  Within the scope of the PhD there was insufficient time to 
conduct further validation study.  
 
Fourthly, the majority of Read codes that are available for GPs to use were generic 
and not specific for a particular drug.  Frischer et al. acknowledged the numbers of 
individuals with Read codes for specific drugs were too low to analyse (Frischer et 
al., 2005).  This could be because poly-drug use is common amongst drug users 
(Leri et al., 2003).  Symptoms are more obvious with opiate drug users whilst 
symptoms of other drugs are not as obvious and could be missed.  
 
Fifthly, my results reflect that recording rates were higher for more socially 
deprived groups.  This may be because there are more people using drugs 
amongst the socially deprived groups, but it could also be masking the fact that 
drug users with less social deprivation could be seeking help elsewhere (e.g. 
private health care) or denying the problem and avoiding the stigma associated 
with drug use (United Kingdom Drug Policy Commission, 2010).  THIN does not 
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capture individuals who use private health care, unless a discharge letter has been 
sent to GPs, but again, the information may not be captured as a Read code.  I 
therefore could not examine individuals using private care when I used THIN.  
Electronic primary care records may also not include individuals from groups where 
drug prevalence is known to be relatively high, which include prisoners, the 
homeless and students (see section 3.4.4 for details). 
 
Sixthly, GPs may not be aware that an individual is receiving a prescription 
elsewhere and not record it as a Read code in the individual’s electronic health 
record.  The National Treatment Agency only clarified where an individual received 
treatment from and the type of treatment they received (psychological vs 
pharmaceutical) from April 2012.  It was not possible to compare the number of 
those with prescriptions in THIN to the total number from the National Treatment 
Agency Monitoring System (Public Health England, 2013a).  I could therefore only 
compare the previous years’ prescriptions with those in 2012.  Furthermore, the 
Welsh Substance Misuse Database does not categorise the settings and I could 
therefore not compare the results for opioid substitution treatment capture in THIN 
in Welsh general practices.  Additionally due to the strict inclusion criteria that I 
applied with regards to opioid substitution treatment, I would have excluded 
individuals who were being treated with diamorphine (Strang et al., 2010) 
 
The final limitation of using THIN to examine recording of drug use during 
pregnancy is that even though women are encouraged to register with a GP when 
they are pregnant, some women who use drugs may choose to self-refer to either 
the midwifery or drug treatment services and therefore they will not be captured in 
THIN.  (National Institute for Clinical Excellence, 2010b; National Treatment 
Agency for Substance Misuse, 2010).  Pregnancy may be a critical point for 
seeking help and in this case disclosure and recording in electronic health records 
may increase.  However, due to the increased stigma and fear of the child being 
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taken away, disclosure may decrease and there is little chance for recording 
occurring (Advisory Council on the Misuse of Drugs, 2011; United Kingdom Drug 
Policy Commission, 2010).  As with the study by Dhalwani et al., they suggested 
that women who are pregnant may not disclose their smoking status due to the 
social stigma attached to the behaviour (Dhalwani et al., 2014).   
 
Following referral to the midwifery service, information regarding drug use and/or 
opioid substitution treatment is not recorded in a centralised recording system, and 
unless this information is included in the discharge summary, the GP may not 
know.  Additionally if the information regarding drug use is in the discharge 
summary, the GP may scan the summary and not include the information about 
drug use as a Read code.  The information about drug use during pregnancy would 
not be captured in THIN. 
 
In contrast if prescriptions for opioid substitution treatment need to be given, these 
would be recorded in the electronic health records and captured in THIN, however 
this would be for the period after pregnancy.  As with the study by Dhalwani et al., 
it was also challenging to determine the timing of recording of drug use in the THIN 
database.  GPs may have used a Read code to record drug use before the woman 
was pregnant and may not have re-recorded this with a Read code at the 
beginning of pregnancy, additionally GPs may have only recorded drug use after 
pregnancy when they became aware of the drug use.  Therefore, in order to try 
and include these women, I examined all recordings for drug use and/or opioid 
substitution treatment 36 months either side of and during pregnancy and not just 
the first recording.   
 
It was evident that using THIN in a cohort study design for examining drug use 
and/opioid substitution treatment encompasses both strengths and limitations.  An 
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alternative to using THIN could be an anonymous and confidential questionnaire 
conducted in various general practices each attender at a general practice could 
be asked about drug use.  (This is depicted in the third section in the health care 
pyramid Figure 8:1).  This study design may give less of an under-estimate of drug 
use as no consequences would result from disclosure and the questionnaire may 
capture both recreational and problem drug users.  However recruitment and 
collection of data would be time-consuming and costly, the study would have a 
smaller sample size and may be less representative of the general UK population 
compared with using THIN.   
 
Despite its limitations, THIN is possibly the most suitable database to use to 
examine GP recording of problematic drug use and opioid substitution treatment at 
present.  However, because women are not regularly in contact with their GP 
during pregnancy, it may be more appropriate for researchers to use drug use one 
year before pregnancy and/or 6 months after and infants recorded with NAS as 
proxies for drug use during pregnancy.  I will discuss how other studies have used 
this approach when controlling for drug use in their studies in section 9.6 (Petersen 
et al., 2016a) 
 
9.5.2 Strengths and limitations of using the Hospital Episode Statistics 
database 
The main strengths of using HES is that it has developed into a key resource for 
monitoring health outcomes and assisting in epidemiological research (mentioned 
in detail in section 3.5.3) (Morleo et al., 2011; Murray et al., 2013; Royal College of 
Obstetricians and Gynaecologists, 2014).  The database is an extensive electronic 
resource which is cost-effective, and can compare outcomes between hospitals 
and trusts (Health and Social Care Information Centre, 2012; Morleo et al., 2011).  
The unique HESID, allows longitudinal analysis of each individual patient. HES 
includes approximately 96% of births in England and it was therefore ideal for 
examining the recording of NAS to obtain an estimated prevalence of NAS in 
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England (Birthplace in England Collaborative Group et al., 2011). Individuals are 
also given specific ICD-10 diagnostic codes for syndromes like NAS and I could 
therefore identify babies who had been diagnosed with NAS. 
 
As with THIN, the main limitation of using HES was that it was not intended for 
research purposes, but rather designed primarily for costing in secondary care 
(Health and Social Care Information Centre, 2012).  The variation in recording is 
likely to reflect partly whether trusts have specialist services or protocols for 
dealing with drug misuse in pregnancy which in turn impinges on recognition, 
diagnosis, recording, and coding (O’Grady et al., 2009).  Variation is also likely to 
be related to geographical area and to local protocols (O’Grady et al., 2009).  
Hospital staff do not routinely check and test for NAS, unless they are aware that 
the mother has used drugs and/or has been treated with opioid substitution 
treatment during pregnancy (Dr K Johnson 2013, personal communication (face to 
face conversation), 19th November).  There may then be infants with NAS that are 
undiagnosed or discharged too early and not recorded for NAS in secondary care 
and therefore will definitely not be recorded in primary care.  There are no national 
standards for coding and therefore the quality of data coded and sent to HES is of 
varying quality (Knight et al., 2013b).  Consequently, the quality of baby data is still 
relatively poor, especially with regards to missing data and the index of multiple 
deprivation (IMD).  I therefore could not look at IMD in the second part of my third 
study as 75% of IMD was missing in the baby records.  Using HES can also lead to 
systematic error, either because of incorrect recognition of NAS or recording by the 
doctor and/or coding by the hospital coder.  The mother and baby identities were 
not linked in HES and I could therefore not obtain information regarding the mother 
(e.g. type of drug used) as it may not be in the baby record.  As with THIN, HES is 
not a flawless database, however, it is the most appropriate database to examine 
the prevalence of NAS in English births at present.  
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9.5.3 Strengths and limitations of qualitative interview methods 
Finally, the main strength of the qualitative study design was that it gave 
perspective about GP recording of drug use using GP accounts describing when 
and why they did not record drug use in electronic health records.  The interviews 
provided an insight into some of the reasons why GPs did not follow RCGP and 
practice guidelines on recording for drug use.   
 
Another strength of my qualitative study was that I was able to recruit and interview 
GPs with and without a special interest in drug use, but also with various 
demographic factors.  I recruited and interviewed GPs from a geographical spread 
which allowed me to gain an understanding of different perspectives and practices 
in different regional areas.  Males and females, who were in various stages of their 
careers-from a GP trainee to GPs with over 15 years’ experience- were recruited.  
Both GPs who were leads in substance misuse and GPs who did not see 
individuals who used drugs regularly in their practice were interviewed.  This 
allowed me to explore if there were similarities and differences in recording 
practices of GPs with more and GPs with less interest in drug use.  All the GPs had 
and described examples of individuals who used drugs, whether they treated them 
for their drug use or not.  There was consistency of themes between the interviews, 
but there were also contrasts of opinions and descriptions of recording action 
between individuals, which allowed me to compare and contrast the data during 
analysis.  My sample size was relatively small, but in order to gain a deeper 
qualitative understanding it was important to keep it small.  With all qualitative 
studies the relatively small sample size makes it difficult to generalize to a wider 
population.  However, I have described my research context and assumptions 
thoroughly to improve transferability and to allow someone to conduct a similar 
study. 
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The qualitative findings of my study offers an insight into GPs accounts of their 
perspectives and what they have done under certain circumstances.  In some 
cases GPs referred back to the electronic records to ascertain exactly how they 
had recorded in the electronic health records, but this was not always the case.  
These are also the views and perspectives of GPs alone, and this study lacks 
opinions from other health professionals, including practice nurses and drug 
workers.  The voice of individuals who use drugs and come to see GPs about their 
drug use is also not included in my study.  I will discuss how future research could 
include recruitment of health professionals and patients in section 9.8.2. 
 
My qualitative interviews were influenced and shaped by myself, as I was working 
on my own most of the time.  I tried to improve this by having regular meetings with 
my supervisors to discuss my interviews, transcripts, coding structure and 
developing themes.  I also organised and executed a data-clinic where other 
qualitative researchers could interpret and comment on one of my transcripts. 
 
Finally, not all of the GPs I interviewed used the same software for patient 
management (Vision) that is used in general practices which contribute data to 
THIN.  Some GPs used EMIS and others used System One.  The different type of 
software might have an impact on how data is recorded, but I did not examine this 
in further detail. 
 
I would argue that interviews were the most appropriate method to use to help 
answer the research questions given/within the time available within my PHD.  
Now that I have discussed the strengths and limitations of using the two databases 
and qualitative interview methods in the thesis I will now discuss how the evidence 
from all four studies has helped to answer the research questions of the thesis. 
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9.6 What I have learnt during the thesis and what I may have 
done differently 
From my first study, I learnt that GPs are recording drug use in the electronic 
health records.  However, my qualitative study suggests that individuals who use 
drugs do not always disclose this to their GP.  Disclosure seems more likely to 
occur when the drug user’s behaviour causes harm and functional impairment and 
consequently more problematic drug use seems to be recorded.  Furthermore, 
recording of drug use will only be captured when a GP ultimately makes a clinical 
decision to record or not when an individual discloses information.  Recording may 
therefore be picking up the effects of drug use rather than the actual drug use, 
unless the individual is wanting to stop using drugs and then this may either be 
recorded as a Read code or in the free- text.  Therefore on reflection, electronic 
primary care records may be best suited for studies that involve problematic drug 
use.   
 
I also learnt from my research that GPs were using a variety of Read codes to 
record drug use, but that most of them were generic.  I therefore could not do sub-
analysis on different recorded drug types.  The qualitative work supports the fact 
that GPs are often using generic codes as an individual may be using more than 
one drug, but GPs do not always spend time looking for specific Read codes and 
often record the type of drug in the free-text rather than as a Read code.  A lot of 
information about the type of drug used is therefore not captured for analysis in 
THIN.  I was however surprised that a tenth of recorded Read codes were 
specifically for individuals who were dependent on the prescription drug 
benzodiazepine and 7% for individuals dependent on cannabis.  This again seems 
to be coding for individuals with a dependency problem relating to drug use and 
therefore is included in the definition of problematic drug use.  Depending on the 
research question for future studies that involve dependence on prescription drugs 
could also be included as my research indicates that this seems to be an emerging 
problem. 
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Before working with THIN, I was unaware that primary care electronic health 
records would not capture those in temporary accommodation (e.g. the homeless, 
ex-prisoners) or those in prison.  This unfortunately is a limitation of using THIN 
and other primary care databases as prevalence of drug use in those groups could 
potentially be high.  I also learnt that the demographics (age, gender and 
deprivation) for individuals recorded with a Read code and/or opioid substitution 
treatment were similar to other national surveys and surveillance databases which 
indicates that individuals with similar demographics are being identified and 
recorded in primary care.  The qualitative study suggested that GPs are focusing 
on asking certain individuals with these characteristics and therefore other 
individuals without these characteristics could in fact be missed and consequently 
recording of these individuals is not captured in primary care.  The studies support 
the fact that drug-use in THIN is underestimated and future research needs to 
acknowledge that THIN is only capturing the tip of the ice-berg with regards to 
drug-use in the community.   
 
I also found that more recording was occurring in regions that are known to have a 
higher prevalence of problematic drug use, namely North East, North West and 
South East regions of England.  These regions may have more local enhanced 
services for drug use which the qualitative findings suggest may initiate the 
development of protocols for recording drug use.  I did not expect to find that 
London had one of the lowest rates, but this could be because individuals may be 
accessing community drug clinics rather than going to their GPs.  Additionally, the 
lower rates could also be an indication of the higher transient population in London 
and therefore individuals may not be captured in THIN as they are not permanently 
registered with a general practice for a certain amount of time.  I would recommend 
that future studies also include both region and deprivation as confounders.   
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Furthermore, I learnt that although it was not mandatory for GPs to report 
individuals who were receiving opioid substitution treatment in general practice to 
the National Drug Treatment Monitoring System (NDTMS), results from my first 
study indicated good comparability between THIN and the NDTMS.  These findings 
suggest that GPs are being compliant with regards to reporting and this was also 
supported by findings in the qualitative study when interviewing GPs who treated 
opioid substitution treatment in general practice.  These GPs may have templates 
set up which aid reporting to the NDTMS because they have a local enhanced 
service which financially incentivises their recording.  
 
As previously mentioned, findings from my second study revealed that very little 
recording of drug use occurred during pregnancy.  However, drug-use was 
recorded significantly more before pregnancy and opioid substitution treatment was 
recorded significantly more after pregnancy.  This is one of the key findings of the 
thesis which is supported by the qualitative study which illustrated that GPs 
routinely referred pregnant women to midwifery services and are often referred 
straight to the specialist service if they were known to use drugs.  The qualitative 
findings also highlighted that although some women may still see their GP for other 
issues during pregnancy, women who were cared for by the specialist midwifery 
services would usually be seen by the assigned GP in the specialist service.  
Women who use drugs were considered high risk pregnancies and managed 
differently.  The increase in opioid substitution treatment after pregnancy indicated 
that some women’s care was transferred back to the GP.  Again it seems that 
THIN is capturing more problematic drug use than recreational drug use in and 
around pregnancy.  This could be another explanation for why the rates were lower 
than previous biological and survey studies.  GPs may have used a Read code to 
record drug use before the woman was pregnant and may not have re-recorded 
this with a Read code at the beginning of pregnancy.  Additionally, GPs may have 
only recorded drug use after pregnancy when they became aware of the drug use.  
Therefore, in order to try and include these women, I examined all recordings for 
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drug use and/or opioid substitution treatment 36 months either side of, and during 
pregnancy and not just the first recording.  I was also able to perform a sensitivity 
analysis in THIN with regards to the stability of the pregnant population and I found 
that women who may be more transient with regards to GP registration had similar 
drug-use results compared with women who were registered for longer period of 
time.  
 
Despite its limitations, THIN is possibly a suitable database to use to examine GP 
recording of problem drug use and opioid substitution treatment at the present time 
and future research could include recording of drug use before and after pregnancy 
as a proxy for drug use during pregnancy.  This has been done recently by 
Petersen et al. who argued that alcohol, illicit drug use and smoking are not 
recorded regularly in electronic health records (Petersen et al., 2016a).  They 
therefore used a sensitive rather than specific approach to capture women who 
used illicit drugs by including women if they had at least one recording of drug use 
and or opioid substitution treatment up to three years before the start of pregnancy 
(Petersen et al., 2016a). 
 
Furthermore, in my third study, I learnt that GPs were recording a third of infants 
diagnosed with NAS in the electronic health records of the infant rather than the 
mother.  It would have been valuable to have linked mother-baby records within 
HES to obtain more information about which drugs the mother used at the time of 
delivery.  Unfortunately, due to time constraints, this was not possible during my 
PhD, however current work is taking place to link mothers and babies in HES 
which could be used in future research studies (Harron et al., 2015).  As mentioned 
previously, it would have also been useful to have linked HES and THIN data, but 
this link had not occurred whilst I was conducting my analysis.  Once the linking 
has been completed future research can use this to ascertain which infants 
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diagnosed with NAS are being recorded in primary care and also longitudinally 
analyse these infants using both their primary care and hospital records.   
 
If I had the chance to repeat my research, I may have done the qualitative work 
before the quantitative studies.  However, I was under the assumption that drug-
use would be well recorded in primary care and it was only after conducting my 
quantitative studies that I realised that I needed to include a qualitative study in 
order to answer the question that arose during conducting the quantitative work.  
There is no pre-defined order within mixed methods research as the order usually 
depends on which questions need to be answered and which is the best method to 
answer them. 
 
9.7 Is THIN sufficient to address the hypothesis concerning drug 
use during pregnancy or the consequences of NAS? 
There are various approaches I could have used to address the hypothesis 
concerning drug use during pregnancy or the consequences of NAS.  Several birth 
cohort studies have been designed and developed to examine pregnant women 
and their children longitudinally.  These include the Avon Longitudinal Study of 
Parents and Children (ALSPAC), the Southampton Women’s Survey, the Born in 
Bradford Cohort Study and the Millennium Cohort Study (Boyd et al., 2012; 
Connelly and Platt, 2014; Fraser et al., 2012; Inskip et al., 2006; Wright et al., 
2012).  All cohort studies recruited women between a specific time period; 
ALSPAC (1991-1992, n=13,761 women and 13,876 pregnancies), Southampton 
(1998-2002, n=12,500), Born in Bradford (2007-2010, n=13,500) and Millennium 
(2000-2001, n=19,000).  All cohorts have a relatively large sample size which is 
essential as the occurrence of both outcomes is relatively low.  Previous studies 
have shown that drug use time-trends vary in the UK and therefore a limitation of 
obtaining information from cohort studies during pregnancy is that the information 
would be obtained during a specific time period and may not be representative of 
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other time periods.  Additionally, the first three of these cohort studies recruited 
women locally and is therefore only representative of that particular area and not of 
the rest of the UK population.  In contrast, the Millennium Cohort Study recruited a 
UK national representative of women and children.  Only the ALSPAC and Born in 
Bradford studies included questions on drug use during pregnancy, however these 
were limited to marijuana and ecstasy.  Furthermore, none of these cohort studies 
ask specific questions about NAS in the birth questionnaires.  A potential way of 
examining drug use during pregnancy is if more detailed questions on drug use 
and NAS are included in the questionnaires.  A limitation of questionnaires in 
cohort studies such as these is that a high risk of recall bias exists, if the questions 
are asked retrospectively.  Alternatively the children of mothers in the original 
cohorts have started or may have children of their own and questions could be 
included in these prospective questionnaires.  In order to add any additional 
questions to my qualitative study, I would have required additional design work, 
development, ethics board submissions, piloting and implementation, all of which 
were not achievable within the funding and time constraints of my PhD. 
 
As it was not feasible to use the existing cohort studies, I explored electronic health 
records.  THIN may not be sufficient to address problematic drug use during 
pregnancy and NAS on its own, however it may provide the best option as it is 
cost-effective, representative of the population in England and Wales over a long 
time period.  Hence my study focused on the extended time-period between 1994 
and 2012.  The findings from both my quantitative (studies 2 and 3) and qualitative 
(study 4) studies support the use of examining drug use and opioid substitution 
treatment before and after pregnancy but not during pregnancy.  As with studies by 
Petersen et al, if information regarding drug-use is captured outside pregnancy (3 
years before and 6 months after), I have made the assumption that the individual 
would also be using drugs during pregnancy (Petersen et al., 2016b, 2016c).  The 
qualitative findings have given further justification for using the recording on either 
side of pregnancy as GPs do not usually see women during pregnancy, but if they 
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know that a women uses drugs, they will refer her to the specialist midwifery 
services and continue her care after delivery.   
 
Additionally, it would have been ideal to link the electronic health records with the 
maternity health records, but unfortunately at present most of the maternity notes 
are kept in hard copy.  University College London Hospital does retain some 
information from maternity notes electronically, however these records have not yet 
been de-identified and therefore permission to access them was not possible 
during my PhD (Professor R Gilbert, 2015: personal communication (face-to-face) 
1st August).  Pilot studies are currently evaluating the transfer of maternity records 
electronically in Shrewsbury and Telford and Bradford (details in section 9.7.1.)  If 
the results from these pilot studies are positive, future studies could link the 
electronic health records from primary care with the maternity records and 
researchers would then have a clearer picture of a woman’s pregnancy journey. 
 
Furthermore, since June 2015, the Information Standards Notice (which mandates 
the national collection of data) requires maternity service providers to collect data 
locally and submit the data centrally (NHS Digital, 2012).  Approximately two thirds 
of the providers are currently providing data (Harron et al., 2016).  A recent report 
conducted by the Family Nurse Partnership (FNP) in 2015 justified that using both 
population-based linkage from the FNP and administrative data from other services 
would provide evidence for monitoring and evaluating maternal and child health 
(Harron et al., 2016).  These services include maternity data and CPRD and 
therefore future studies could use the linkage to obtain a closer community 
estimate of drug use during pregnancy. 
 
Finally, with regards to NAS, the findings from my third quantitative and qualitative 
(study 4) studies support the fact that around a third of diagnosed NAS is being 
recorded in primary care electronic health records.  The linkage of THIN and HES 
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would have benefited the thesis and shed more light onto which particular infants 
were diagnosed and recorded with NAS in the primary care records.  Since 
conducting my analysis, the two databases have been linked as previously 
mentioned on page 313.  Therefore future studies could use the linked data to 
expand the results from the second and third studies (drug use during pregnancy 
and NAS).   
 
I have discussed if THIN sufficient to address the hypothesis concerning drug use 
during pregnancy or the consequences of NAS and I will now discuss the 
implications the findings have on policy, clinical practice and research. 
 
9.8 Implications for Policy, Practice and Research 
9.8.1 Implications for policy and practice 
General practitioners may be reticent to manage drug dependency in primary care 
but still play an integral role in the management of patients’ physical health and 
people who use drugs often have poor physical health (National Institute for 
Clinical Excellence, 2007b).  Presently the General Medical Service contract does 
not have specific QOF indicators for substance misuse.  QOF indicators may not 
be the most suitable method for incentivising recording of drug use in general 
practice.  However the proposed local incentive schemes could include recording 
of drug use and may be more appropriate, especially in areas where a high amount 
of drug use is recognized (NHS England, 2015).  Local incentive indicators could 
be introduced to help GPs identify and refer on to other services or treat this 
vulnerable group of people.  However recording of drug use should still be 
discussed with the individual as the qualitative findings suggest that there is a risk 
that the GP-patient relationship could be compromised if the GP is obliged to 
record drug use in the electronic health records.   
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The RCGP have developed a certified course in the management of drug misuse 
which can go some way towards helping GPs to manage and treat patients with 
drug use problems (Royal College of General Practitioners, 2015a).  The topic of 
recording drug use in electronic health records is not included in the modules, but 
my qualitative findings suggest that the topic of recording could be included in the 
curriculum (Professor C Ford, 2015: personal communication (email) 8th 
December 2015).  The scope to develop clear care pathways for those identified in 
general practice and then treated either in the practice or referred to an appropriate 
community drug clinic needs careful consideration.  It is possible that not all GPs 
would wish to engage with people who use drugs leading to a disparity in the 
provision of care (United Kingdom Drug Policy Commission, 2012).  Nevertheless, 
appropriate identification of people who use drugs by GPs and appropriate 
management or referral can go some way in ensuring clarity in the management of 
this group of people.   
 
Findings from the second study show the minimum estimate of drug use during 
pregnancy in primary care (Chapter 5).  Women who use drugs, often have a 
myriad of other social and medical problems which can lead to complex lives, 
social disadvantages and vulnerability (Advisory Council on the Misuse of Drugs, 
2011).  Drug use may or may not be detected and/or recorded in and around 
pregnancy (Rayns et al., 2013).  However, my qualitative findings suggest that it is 
not recorded because women are referred to maternity services during pregnancy 
and do not always see their GPs during this time.  Additionally, the Saving Mothers’ 
Lives report (2007) highlighted the fact that woman using drugs did not always look 
for early antenatal support and often missed subsequent antenatal appointments 
(Royal College of Obstetricians and Gynaecologists, 2010).  However, pregnancy 
is a critical time to engage and support women who use drugs and GPs may be the 
first point of contact and a gateway to appropriate services (Rayns et al., 2013).  
The first appointment between a woman and GP once she learns that she is 
pregnant may be an opportune time for the GP to ask about drug use, together 
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with asking about other adverse health behaviours such as smoking (Dhalwani et 
al., 2014).    
 
Various recommendations have been made with regards to the care pathway for 
pregnant women who use drugs.  NICE recommends that the first point of 
antenatal contact with a health professional should include guidance on smoking 
cessation, the consequences of recreational drug use and alcohol during 
pregnancy (National Institute for Clinical Excellence, 2010b).  Whilst, the 
Department of Health advises GPs to refer pregnant women who use drugs directly 
to specialist midwife services (Department of Health, 1999).  In addition, the saving 
mother’s report also recommends that when GPs refer pregnant women who use 
drugs to the midwife services, they should include information such as psychiatric 
history and alcohol and drug use in the referral form (Centre for Maternal and Child 
Enquiries, 2011).  If this information is included in the referral form, it could also 
potentially be recorded as a Read code in the electronic health records.  Presently, 
maternity services and general practice are segregated and communication via 
phone calls, emails and faxes may not be recorded electronically.  Referral and 
discharge letters may only be scanned and may miss out some information (Centre 
for Maternal and Child Enquiries, 2011).  Electronically recorded maternity notes 
may help with communication and loss of information and some trusts have 
already started introducing paperless maternity services.  Shrewsbury and Telford 
Hospital NHS Trust have piloted using an electronic system to replace hand-held 
maternity notes for antenatal consultations and are rolling out the programme to 
include postnatal notes (System C Connected Care, 2013).  Similarly, Bradford 
Teaching Hospital NHS Foundation Trust is piloting replacing hand-held maternity 
notes with an electronic recording system from February 2015 (Bradford Teaching 
Hospitals NHS Trust, 2015).  A centralized or improved integration of recording 
systems between maternity services and GPs may be model of healthcare that 
could be implemented (Centre for Maternal and Child Enquiries, 2011).   
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Women who use drugs and alcohol during pregnancy need support as they are 
vulnerable and have a higher risk of suicide, especially if there is a chance that 
their baby will be taken away (Advisory Council on the Misuse of Drugs, 2011).  
This support could be offered by a GP, especially if a trusting and therapeutic 
relationship has developed between the woman and GP.  However, once a woman 
has been referred to the antenatal or specialist midwife service she has very little 
contact with her GP.  A model of shared care, incorporating more GP appointments 
together with midwife appointments has been developed and implemented for all 
low-risk pregnant women in the London borough of Tower Hamlets (Smith et al., 
2010).  This model could potentially be rolled out to ensure that all pregnant 
women, including those who use drugs, receive more continuous care and support 
during and after pregnancy.  Recording of drug use as a Read code in the 
electronic health records at the initial consultation may be helpful to GPs during 
subsequent consultations. 
 
The findings from my third study (Chapter 6) suggest that the rates of NAS in 
secondary care seem to be stable in England, however rising rates in Scotland, 
Wales, the USA and Ontario and the increased use of opioid analgesics highlight 
the need for national NAS surveillance and for monitoring the source of opioids 
used (Jones et al., 2013, National Statistics Scotland, 2012; O’Donnell et al., 2009; 
Patrick et al., 2012; Tolia et al., 2015).  Additionally, children who have been 
recorded with NAS are more likely to suffer from child maltreatment and hospital 
readmission later (O’Donnell et al., 2009; Uebel et al., 2015b).  The identification, 
management and provision of a high standard of care for children whose parents 
use drugs is not always the focus (Advisory Council on the Misuse of Drugs, 2011).  
Given the high cost and serious consequences for mother and baby of opioid use 
in pregnancy, policy makers should consider extending surveillance through 
linkage with administrative data (primary and secondary care) to guide pre- and 
post-natal health and social care provision and improve outcomes for both mother 
and child (Bagley et al., 2014). 
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The qualitative study suggested that many factors influence how GPs ask and 
record drug use in electronic health records (Chapter 7).  There did not seem to be 
a uniform way of asking about drug use, however GPs used their experience to 
develop ways of asking patients about a sensitive issue.  As mentioned previously, 
the RCGP offers a certified course in the management of drug misuse and GPs 
who had completed the course found that it helped them with their confidence in 
enquiring about, managing and treating patients with problematic drug use 
(Roberts, 2005; Royal College of General Practitioners, 2015a).   
 
My findings also suggested that there seem to be redundant Read codes for drug 
use, therefore Read codes for drug use could be revised and only relevant and 
utilised codes kept.  Particular general practices with relatively more registered 
patients who used drugs have developed special templates for recording drug use 
and treatment.  The templates are linked with specific Read codes in the patient’s 
electronic health records.  General practices using these templates found them 
easy to use and helped with systematic recording and auditing recording of drug 
use.  The templates could potentially be rolled out to other CCGs to ensure more 
uniform and systematic recording of drug use in electronic health records.  
Additionally, recording systems between services and general practices are linked 
in a CCG located in Yorkshire and Humberside (Leeds & York Foundation Trust, 
2015).  If a patient gives consent, GPs can monitor and acquire a clearer picture of 
a patient’s management and treatment in other drug treatment services (Leeds & 
York Foundation Trust, 2015).  The linkage of services using Read codes could 
also potentially be rolled out nationally.  
 
Finally, it was evident from my findings that people who use drugs (both problem 
and recreational drug users) are consulting with their GP.  Recording drug use with 
Read codes in electronic health records may be challenging as the recording is 
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permanent and may impact on the trust between GPs and patients.  HIV is an 
example of a sensitive and stigmatised disease, where information regarding 
diagnoses is confidential (Madge et al., 2011).  However in order to understand the 
size of the problem, clinicians and laboratories voluntarily report anonymised 
information to the Health Protection Agency (Public Health England, from April, 
2013) (Madge et al., 2011).  Between 1968-1997, it was mandatory for doctors to 
notify the Home Office of any confirmed and suspect addicts (Corkery, 2002).  
Notified individuals were then recorded in the Home Office Addicts Index (details in 
section 1.3.8).  I would argue that in order to understand the burden of drug use, 
especially during pregnancy, a similar reporting system to Public Health England 
could be introduced.  However, unlike the Home Office Addicts Index, the identity 
of individuals would be pseudonymised to reduce double counting of individuals. 
 
9.8.2 Implications for research 
Various research implications have arisen from the thesis.  Firstly, templates for 
recording drug use could be rolled out nationally and evaluated using qualitative 
research methods.  Additionally, if linked communication between services (using 
Read codes) is rolled out and implemented, evaluation of these linked systems 
would be necessary in order to assess the value and cost-effectiveness of the 
linking services.  GPs are only using half the available Read codes for recording 
drug use in electronic health records.  My qualitative findings suggested that there 
were too many unnecessary Read codes for recording drug use and that it was 
often time-consuming to try and find the most appropriate Read code to use.  A 
qualitative study is therefore needed to understand which Read codes are the most 
useful and need to be kept with regards to drug use. 
 
THIN could potentially be used as a research tool to examine outcomes of 
individuals who are recorded as using drugs. There was little known about how 
recreational drug use (in young people) impacts long term outcomes and potential 
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complications and studies are needed (McCambridge and Strang, 2004).  
Furthermore, following on work conducted by Cornish et al., individuals who have 
been prescribed with opioid substitution treatment in general practice could be 
followed up longitudinally and relative health outcomes and adherence to opioid 
substitution treatment could be explored (Cornish et al., 2010).   
 
This would be particularly relevant during pregnancy, especially if babies were 
linked to mothers in THIN, so that other outcomes could be examined.  It may also 
be appropriate when researching drug use during pregnancy using electronic 
health records to include women who have at least one recording of drug use up to 
3 years before the start of pregnancy (Petersen et al., 2016a).  I have included a 
potential analysis plan at the end of this section to examine drug use during 
pregnancy and adverse birth outcomes. 
 
At the time of doing my analysis, I did not have access to linked HES and THIN 
data.  It would be valuable to examine infants who are recorded with NAS in HES 
and follow them up longitudinally in both THIN and HES to examine long term 
outcomes and also hospital admissions. 
 
Finally, based on the results of my qualitative study, I have only looked at GP 
accounts and therefore an in-depth qualitative study is needed to explore other 
health professionals such as practice nurses’ and drug workers’ narratives as well 
as patients’ perspectives and experiences when accessing general practice for 
drug use.  As mentioned previously, an ethnographic study could also be 
conducted to gain a clearer understanding of recording practices in the context of 
which they occur. 
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Analysis Plan: History of drug use and risk of adverse birth outcomes 
Background: 
There is evidence that certain adverse and poor birth outcomes occur due to drug 
use during pregnancy.  Madgula et al conducted a systematic review on this 
subject and their findings concluded that opioid use during pregnancy caused 
neonatal abstinence syndrome (Madgula et al., 2011a).  However, the causal 
effects of drug use on other birth outcomes was inconclusive as studies 
contributing to the systematic review had small sample sizes, used different 
methods and were conducted in different settings (Summary of studies in Appendix 
13) (Madgula et al., 2011a).  The Health Improvement Network (THIN) contains 
both mother and baby electronic health records that have previously been linked 
and used to examine the associations between prescribed medicines in pregnancy 
on specific adverse birth outcomes (Ban et al., 2014, 2012, Petersen et al., 2016a, 
2016b, 2016c).  THIN can therefore be used to examine whether drug use either 
side of and during pregnancy is associated with specific birth outcomes. 
 
Aims: 
To determine if history of drug use is associated with the following adverse birth 
outcomes; congenital heart anomalies, major congenital malformations, and poor 
birth outcomes (low birthweight, preterm birth and caesarean section).   
 
Hypothesis: 
Women who use drugs or opioid substitution treatment around and during 
pregnancy will be more likely to give birth to infants with adverse and/or poor birth 
outcomes.  
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Data Source: 
Data from the large primary care database, THIN will be used.  THIN provides 
anonymised information from individual’s electronic health records which include 
clinical signs and symptoms and prescriptions.  Longitudinal analysis can be 
conducted on individuals who are permanently registered with a general practice 
and THIN represents approximately 6% of the UK population.   
 
Study population: 
For this study I will use a linked mother-child cohort which includes records for the 
time period between 1st January 1995 and 31st December 2012.  Mother and 
infants have been linked within THIN based on family identifier codes, delivery 
month (mother) and birth month (infant).  I will include mothers who have been 
permanently registered with a general practice for at least 36 months before during 
and 36 months after pregnancy as this represents a relatively stable cohort. I will 
have two cohorts, those women who have a record of drug use in the 36 months 
before or during pregnancy (Cohort A) and those who have no record in this period 
or at any time before (Cohort B). 
 
Exposures: 
Women will be defined as having a history of drug use if they have had at least one 
recording for drug use and/or opioid substitution treatment 36 months before, 
during or 6 months after pregnancy.  Some women have more than one 
pregnancy, for these women I will select a random pregnancy.  This is to  ensure 
that the pregnancies in the sample were independent of each other (Kirkwood and 
Sterne, 2003).   
 
Outcome measures: 
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I will examine the following adverse and poor birth outcomes as these are often 
examined in studies of prescribed medication. 
Adverse birth outcomes (EUROCAT, 2016; Madgula et al., 2011a; World Health 
Organisation, 2010) 
 Congenital heart anomalies 
 Major congenital malformations 
Poor birth outcomes (Madgula et al., 2011a; World Health Organisation, 2010) 
 low birthweight (<2500g) 
 preterm birth (<37 weeks) 
 caesarean section 
All outcome measures will be binary (yes/no). 
 
Potential confounding variables: 
I will include the following variables based on previous studies examining drug use 
during pregnancy and adverse birth outcomes and the information that can be 
obtained from the woman’s electronic health records; calendar year of delivery, 
age of mother at time of delivery, pre-pregnancy BMI (obtained from maternal 
height and weight up to a year before pregnancy), parity, smoking status, history of 
problem alcohol use, pre-existing medical conditions (depression, epilepsy, 
psychosis, hypertension and diabetes), pre-existing prescriptions (antidepressants, 
anxiolytics, hypnotics, anticonvulsant mood stabilisers and lithium) (BMJ group, 
2013; E Day and George, 2005; Fergusson et al., 2002; Madgula et al., 2011b; 
Petersen et al., 2016a, 2016b, 2016c).   
 
Maternal age will be categorized into the following six categories; <19, 20-24, 25-
29, 30-34, 35-39 and >=40 years old.  I will obtain pre-gestation height and weight 
from the additional health records in THIN.  I will then calculate the pre-gestational 
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BMI (kg/m2) and group into four categories; underweight (<18.5), normal weight 
(18.51-24.9), overweight (25-29.9) and obese (>30). 
 
I will use the same Read codes as Petersen et al to obtain smoking status and 
history of alcohol problems from the additional health records in THIN and 
transform into binary variables (yes/no) (Petersen et al., 2016b).  As with drug use, 
smoking and alcohol are not recorded on a regular bases, so I will include any 
recording thirty six months before and during pregnancy (Petersen et al., 2016b).  
In order to examine the parity of women, I will sum their total number of 
pregnancies and use it as a continuous variable.   
 
In order to examine the social deprivation status and the region, I will use 
information about quintiles of  the Townsend deprivation scores and region 
(strategic health authority (SHA)) (Health and Social Care Information Centre, 
2013a; Townsend, 1987) which is available in THIN at individual level.   
 
Analyses: 
1. Tabulate characteristics and of women and birth outcomes in cohorts A 
(women who had a history of drug use ) and cohort B (women who had no 
history of drug use )  
2. Ascertain if there is potential confounding by examining if there is an 
association between the exposure and confounder and an association 
between the confounder and the outcome. (Kirkwood and Sterne, 2003).   
3. I will estimate the absolute risks and 95% confidence intervals as well as the 
risk difference for each of the outcomes.  
4. Perform Poisson regressions to estimate the relative risk ratios and 95% 
confidence intervals using cohort B as the reference cohort.  I will carry out 
hypothesis testing using likelihood test and Akaike information criterion to 
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select the model of best fit (Akaike, 1974; Kirkwood and Sterne, 2003; 
Zucchini, 2000) 
 
All data will be analysed using STATA (version 14) statistical software (Stata Corp 
LP, College Station, Texas). 
 
Limitations: 
Drug use during pregnancy may be underestimated in electronic health records 
and that is why I have chosen to examine the effect associated with a history of 
drug use by including records three years prior to the pregnancy.  It is possible that 
some of the women in this cohort may not be using drugs during pregnancy. If that 
is the case my estimates may be diluted towards the null.  It is possible that the risk 
of adverse pregnancy outcomes may differ between different drugs, but most of the 
Read codes are generic and the numbers of women recorded with specific Read 
codes are too small for stratified analysis.  Some women would have received 
parts of their care outside primary care, including women who are treated for opioid 
substitution treatment in community drug clinics.  Some of these women may not 
have any information about this treatment in their primary care records and 
therefore the number of women prescribed opioid substitution treatment during 
pregnancy may be underestimated.  In terms of the outcomes it is likely that some 
information from the hospital discharge letters may not be entered as a Read code 
in the mother’s or baby’s records.  However if the diagnosis is more complicated 
such as congenital heart anomaly, it is likely to be entered as a Read code in the 
primary care records.  Women who have experienced domestic violence may be 
underestimated as they may be re-housed and transferred to another GP practice 
and therefore not be captured in THIN. 
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9.9 Overall Conclusions 
The thesis has made a considerable contribution to the broader landscape of 
knowledge and improved method, by generating a clearer picture and deeper 
understanding of GP recording of drug use and opioid substitution treatment in 
general practice using a mixed methods approach.  My quantitative studies 
highlighted epidemiological recording trends were similar to national survey reports 
and other studies, but recorded at lower rates.  The qualitative findings 
demonstrate the complexities and challenges GPs face when making decisions on 
whether or not to record in the patient’s electronic health records.  If GPs choose to 
record drug use, they often use free-text rather than Read codes, or they may 
record for the primary problem rather than a Read code for drug use.  In contrast, 
recording of prescriptions for opioid substitution treatment is mandatory.  If an 
individual was however prescribed opioid substitution treatment from a drug 
treatment service, it was not always recorded as a Read code in the electronic 
health records.  General practice is the cornerstone of primary care and possibly 
ideal for identification and management of individuals who are problematic drug 
users.  A confluence of factors affects both how GPs acquire information and how 
they manage and treat problematic drug use which in turn influences GPs decision 
to record drug use. 
 
Primary care databases can assist in monitoring trends of drug use in the general 
population, however those individuals who are recorded in the electronic health 
records are more likely to be problematic drug users.  Primary Care electronic 
health records could potentially be a useful tool to assess the level of burden of 
drug use during pregnancy by looking at recording of drug use either side of 
pregnancy as a proxy.  Recording guidelines should be revised and questions 
about drug use could be asked routinely together with questions about smoking 
and alcohol.  Recording guidelines regarding NAS could also be revised, as this is 
an indirect measure of drug use during pregnancy.  The current antenatal care 
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model lends itself to two opportune times where GPs could ask about drug use: the 
first consultation after the start of pregnancy, and the 6 week appointment after 
delivery.  GPs could then discuss together with the pregnant woman about 
recording drug use in electronic health records.  
 
Information regarding drug use may be in hand-held maternity notes, but this 
information either does not always get reported back to the GP or the GP is aware 
of the information but decides not to enter the information as a Read code in the 
electronic health record.  Improved integration of maternity and primary care 
recording systems could improve communication and pass on relevant medical, 
lifestyle and social information, which may include drug use.   
 
In conclusion, the evidence from my thesis supports the use of THIN as a suitable 
tool for monitoring trends but not rates of problematic drug use in the general 
population.  Additionally, THIN could potentially be used as a tool to monitor the 
impact of drug use during pregnancy.  The thesis also supports the use of THIN as 
a research tool to identify drug use and to monitor those individuals who have been 
recorded with drug use longitudinally in the general population and in and around 
pregnancy.   
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Appendix 1  
 
Table 1: Change of definition from DSM IV to DSM V (American Psychiatric Association, 2013b) 
Change DSM IV DSM V 
1 The section was divided into two sections: 
‘Substance abuse’ 
‘Substance dependence’ 
The two sections have been incorporated 
and re-labelled: 
‘Substance use disorder’ 
2 The statement; ‘Frequent legal problems 
(e.g. arrests, disorderly conduct) for 
substance abuse’ was removed from DSM 
V- 
The statement; ‘Craving, or a strong desire 
or urge to use the substance’ was added to 
DSM V 
3 The threshold for diagnosis of ‘substance 
abuse’ was at least one criteria and the 
threshold for diagnosis ‘substance 
dependence’ was at least three criteria  
The threshold for diagnosis of ‘substance 
use disorder’ is at least 2 criteria  
4  ‘Cannabis withdrawal’ has been added 
5  The severity of substance use disorder is 
based upon the number of criteria 
2-3=mild disorder 
4-5=moderate disorder 
>6=severe disorder 
6  ‘Early remission’ is defined as at least 3 but 
less than 12 months 
7  ‘Sustained remission’ is defined as 
remission for at least 12 months 
8  New specifiers include 
‘in a controlled environment’ 
 and ‘on maintenance therapy’ 
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Appendix 2  
Table 2: Breakdown of cost of opioid substitution treatment in the United Kingdom (Joint Formulary Committee, 2013) 
Opioid substitution treatment Recommended 
dose 
Dose breakdown 
 
Cost per day (Prices based on 
BNF version 66) 
Methadone hydrochloride oral 
solution 
60-120mg liquid 
1mg/ml (can be more concentrated but 
under special circumstances) 
Injectable 
10mg (1ml) ampoules 
35mg (3.5ml) 
50mg (5m, 2ml or 1ml) 
Tablets not licensed for opioid 
substitution treatment but are used 
1mg/mL, net price 
100mL=1.27 
60-120mL needed =£0.76-
£1.52 per day 
Buprenorphine (licensed in 
1999 for opioid dependence) 
Subutex ®(only formula until 
2008)   
12-32mg 0.4mg, 2mg, 8mg sublingual tablets 0.4mg 7 tablets =£1.60 
£6.99-£18.44 
2mg 7 tablets=£2.79 
£2.34-£6.24 
8mg 7 tables=£5.58 
£1.19-£3.16o 
Buprenorphine/naloxone – 
Suboxone ®(licenced in 
2007)  Scottish Medicines 
consortium has advised that 
this should be used in those 
where methadone is 
 2mg/0.5mg, 8mg/2mg sublingual tablets Suboxone: £25.40 per 28 
tablets.  Need 6-16 tablets per 
day 
£5.44-£14.51 per day 
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Opioid substitution treatment Recommended 
dose 
Dose breakdown 
 
Cost per day (Prices based on 
BNF version 66) 
unsuitable 
Lofexidine hydrochloride 
Managing symptoms of opioid 
withdrawal 
7-10 day duration if no opioid 
use (longer may be required 
2.4 (max dose at a 
time is 800µg) 
200mg tablets 12 tablets =£12.38 
Naltrexone hydrochloride 
To prevent relapse in 
previously opioid dependent 
patient (should be opioid free 
for 7-10 days) 
50mg 50mg tablets daily, but can spread out 
through week 
£0.81 per day 
Dihydrocodeine (not licenced 
for opiod dependence but is 
used in General practice) 
480-1800mg 60mg, 90mg, 120mg tablets £0.75-£2.83 
£0.77-£3.09 
£0.79-£2.97 
Diamorphine used in a small 
group who do not respond to 
other treatment.  Needs 
specialist advice and license 
by GP 
Dependent on 
patient 
Injectable  
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Appendix 3 
I used the following terms for the literature search (Chapter 1):  
 Study design-Quantitative: 
 “epidemiological monitoring”, “medical audit”  
 Study design-Qualitative 
 “interviews” “focus groups” 
 Setting: 
 “primary care”, “general practice”, “general practitioner”, “primary medical 
 care”,  “primary care databases” 
 Drug use 
 “substance abuse”, “drug misuse”, “drug dependence”, “drug abuse”, “illicit 
 drug”,  drug dependence”, “problematic drug use”, “methadone”, 
 “buprenorphine” “opioid substitution treatment” 
 Information processing 
 “recording”, ”medical record”,  
 Timing 
 “pregnancy”, “peri-natal”, “ante-natal”, “post-natal” 
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Appendix 4 
Table 3: Structure of Read codes (Chisholm, 1990) 
Structure of Read code Description 
0 Occupations 
1 History and symptoms 
2 Examination and signs 
3 Diagnostic procedures 
4 Laboratory procedures 
5 Radiology and physics in medicine 
6 Preventative procedures 
7 Operations, procedures and sites 
8 Other therapeutic procedures 
9 Administration 
A Infectious and parasitic diseases 
B Neoplasms 
C Endocrine, nutrition, metabolic and 
immunity disorders 
D Diseases of blood and blood forming 
organs 
E Mental disorders 
F Nervous system and sense organ 
diseases 
G Circulatory system diseases 
H Respiratory system diseases 
J Digestive system diseases 
K Genitourinary system diseases 
L Complications of pregnancy, childbirth 
and the puerperium 
M Skin and subcutaneous tissue diseases 
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Structure of Read code Description 
N Musculoskeletal and connective tissue 
diseases 
P Congenital anomalies 
Q Perinatal conditions 
R [D] Symptoms, signs and ill-defined 
conditions 
S Injury and poisoning 
T Causes of injury and poisoning 
U [x] External causes of morbidity and 
mortality 
Z Unspecified conditions 
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Appendix 5 
Read codes for drug use in THIN 
Read code Description 
1P62.00 Abnormal craving for drugs 
13r0.00 Abstinent from drug misuse 
13r1.00 Abstinent from drug misuse in normal environment 
13r2.00 Abstinent from drug misuse in protected environment 
13r3.00 Abstinent from drug misuse on maintenance replacement 
13r4.00 Abstinent from drug misuse when receiving blocking therapy 
T85y.00 Accid. poisoning by other drugs acting on nervous system OS 
T842000 Accidental poisoning by amphetamine 
T841000 Accidental poisoning by cannabis derivatives 
T852000 Accidental poisoning by cocaine 
T801.00 Accidental poisoning by methadone 
1V22.00 Age at starting drug misuse 
1V0D.00 Am spent per day on drug habit 
Z1Q6312 Amphetamine maintenance prescribing 
Z1Q6311 Amphetamine maintenance scripting 
E244.00 Amphetamine or other psychostimulant dependence 
E244z00 Amphetamine or psychostimulant dependence NOS 
E244300 Amphetamine or psychostimulant dependence in remission 
E244100 Amphetamine or psychostimulant dependence, continuous 
E244200 Amphetamine or psychostimulant dependence, episodic 
E244000 Amphetamine or psychostimulant dependence, unspecified 
SL97011 Amphetamine poisoning 
E241.13 Benzodiazepine dependence 
8BAo.00 Benzodiazepine dependence detoxification 
1V62.00 Buying drugs 
ZR3Z.11 CAAP - Cocaine abuse assessment profile 
E243300 Cannabis dependence in remission 
E243100 Cannabis dependence, continuous 
E243200 Cannabis dependence, episodic 
E243000 Cannabis dependence, unspecified 
E243z00 Cannabis drug dependence NOS 
SL96000 Cannabis poisoning 
E243.00 Cannabis type drug dependence 
SM23z00 Chlorinated hydrocarbon solvent causing toxic effect NOS 
ZR3Z.00 Cocaine abuse assessment profile 
E242300 Cocaine dependence in remission 
E242100 Cocaine dependence, continuous 
E242200 Cocaine dependence, episodic 
E242000 Cocaine dependence, unspecified 
E242z00 Cocaine drug dependence NOS 
SL85000 Cocaine poisoning 
E242.00 Cocaine type drug dependence 
E249z00 Combined drug dependence, excluding opioid, NOS 
E249100 Combined drug dependence, excluding opioid, continuous 
E249200 Combined drug dependence, excluding opioid, episodic 
E249300 Combined drug dependence, excluding opioid, in remission 
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E249000 Combined drug dependence, excluding opioid, unspecified 
E249.00 Combined drug dependence, excluding opioids 
E248.00 Combined opioid with other drug dependence 
E248z00 Combined opioid with other drug dependence NOS 
E248300 Combined opioid with other drug dependence in remission 
E248100 Combined opioid with other drug dependence, continuous 
E248200 Combined opioid with other drug dependence, episodic 
E248000 Combined opioid with other drug dependence, unspecified 
1P31.00 Compulsive drug taking 
1P30.00 Compulsive uncontrollable drug taking 
13cC.00 Continuous use of drugs 
1P60.00 Craves for drugs 
1P6..00 Craving for drugs 
13c7.00 Current drug user 
13cK.00 Current non recreational drug user 
ZRBK.11 DAST - Drug abuse screening test 
1V60.00 Dealing with drugs 
9NdN.00 Declined consent for notification of drug misuse 
G801E00 Deep vein thrombosis of leg related to intravenous drug use 
7P22000 Delivery of rehabilitation for drug addiction 
Z192.00 Dependent drug detoxification 
8BA9.00 Detoxification dependence drug 
Z1Q6300 Dexamphetamine maintenance 
E241.14 Diazepam dependence 
1V34.00 Does not inject drugs 
1TF..00 Does not use heroin on top of substitution therapy 
Z1Q6100 Dose equivalent drug substitution 
8AA..00 Drug abuse monitoring 
1V0C.00 Drug addict 
9G2..11 Drug addict notific admin 
9G21.00 Drug addict notific to CMO 
9G23.00 Drug addict re-notif to CMO 
9G22.00 Drug addict re-notific due 
9G24.00 Drug addict-notify local SMR22 
E24..11 Drug addiction 
9G2Z.00 Drug addiction notif NOS 
9G2..00 Drug addiction notification 
E24..00 Drug dependence 
L183000 Drug dependence - unspec whether during pregnancy/puerperium 
E24z.00 Drug dependence NOS 
L183100 Drug dependence during pregnancy - baby delivered 
L183300 Drug dependence during pregnancy - baby not yet delivered 
L183z00 Drug dependence during pregnancy/childbirth/puerperium NOS 
8BAX.00 Drug dependence home detoxification 
8I2N.00 Drug dependence home detoxification contraindicated 
L183.00 Drug dependence in pregnancy, childbirth and the puerperium 
L183400 Drug dependence in puerperium - baby previously delivered 
L183200 Drug dependence in the puerperium - baby delivered 
8BAW.00 Drug dependence self detoxification 
8B23.13 Drug dependence therapy 
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8680.00 Drug desensitisation therapy 
Z192114 Drug detoxification 
8FB0.00 Drug detoxification programme completed 
1V37.00 Drug inject equipment hygiene 
1V3..00 Drug injection behaviour 
4Q1..00 Drug level 
9k52.00 Drug misus trt prim care - ESA 
9k50.00 Drug misuse - enhanced service completed 
9k5..00 Drug misuse - enhanced services administration 
9kS..11 Drug misuse assessment declined 
9kS..00 Drug misuse assessment declined - enhanced services administ 
1V...00 Drug misuse behaviour 
9k52.11 Drug misuse treatment in primary care 
SL...12 Drug poisoning 
1V44.00 Drug priority ov finance oblig 
1V42.00 Drug priority ov social obligs 
1V43.00 Drug priority over family 
E02..00 Drug psychoses 
E02z.00 Drug psychosis NOS 
8FB..00 Drug rehabilitation 
Z1Q6.11 Drug substitution 
13cG.00 Drug tolerance 
13c..00 Drug user 
Z192100 Drug withdrawal regime 
E020.00 Drug withdrawal syndrome 
E02y000 Drug-induced delirium 
E02y100 Drug-induced dementia 
E02y300 Drug-induced depressive state 
E021100 Drug-induced hallucinosis 
E021z00 Drug-induced paranoia or hallucinatory state NOS 
E021.00 Drug-induced paranoia or hallucinatory states 
E021000 Drug-induced paranoid state 
E02y400 Drug-induced personality disorder 
1V6..00 Drug-relat offending behaviour 
1V53.00 Drug-related rituals 
44q9.00 Drugs of abuse screening test 
68U0.00 Drugs of abuse urine screening 
E24A.00 Ecstasy type drug dependence 
1P63.00 Excessive craving for drugs 
146C.00 Failed heroin detoxification 
L255.00 Foetus with drug damage 
L255100 Foetus with drug damage - delivered 
L255z00 Foetus with drug damage NOS 
L255000 Foetus with drug damage unspecified 
L255200 Foetus with drug damage with antenatal problem 
Q007C00 Foetus/neonate affected-plac./breast transfer addictive drug 
4I3e.00 Fluid sample amphetamine level 
1V54.00 Follows drug-related rituals 
1V2..00 Frequency of drug misuse 
1T4..00 H/O amphetamine misuse 
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1T8..00 H/O cannabis misuse 
1T5..00 H/O cocaine misuse 
1T6..00 H/O crack cocaine misuse 
1T40.00 H/O daily amphetamine misuse 
1T80.00 H/O daily cannabis misuse 
1T50.00 H/O daily cocaine misuse 
1T60.00 H/O daily crack cocaine misuse 
1T70.00 H/O daily hallucinogen misuse 
1T00.00 H/O daily heroin misuse 
1T10.00 H/O daily methadone misuse 
1T90.00 H/O daily solvent misuse 
1T7..00 H/O hallucinogen misuse 
1T0..00 H/O heroin misuse 
1T42.00 H/O infrequent amphetamine misuse 
1T82.00 H/O infrequent cannabis misuse 
1T52.00 H/O infrequent cocaine misuse 
1T62.00 H/O infrequent crack cocaine misuse 
1T72.00 H/O infrequent hallucinogen misuse 
1T03.00 H/O infrequent heroin misuse 
1T12.00 H/O infrequent methadone misuse 
1T92.00 H/O infrequent solvent misuse 
1T1..00 H/O methadone misuse 
1T9..00 H/O solvent misuse 
1T41.00 H/O weekly amphetamine misuse 
1T81.00 H/O weekly cannabis misuse 
1T51.00 H/O weekly cocaine misuse 
1T61.00 H/O weekly crack cocaine misuse 
1T71.00 H/O weekly hallucinogen misuse 
1T01.00 H/O weekly heroin misuse 
1T11.00 H/O weekly methadone misuse 
1T91.00 H/O weekly solvent misuse 
146F.00 H/O: drug abuse 
1463.00 H/O: drug dependency 
146E.00 H/O: recreational drug use 
E245.00 Hallucinogen dependence 
E245z00 Hallucinogen dependence NOS 
E245300 Hallucinogen dependence in remission 
E245100 Hallucinogen dependence, continuous 
E245200 Hallucinogen dependence, episodic 
E245000 Hallucinogen dependence, unspecified 
13cL.00 Has never injected drugs 
1V25.00 Has never misused drugs 
13cN.00 Has never shared drug injection equipment 
1V51.00 Has routine of drug activities 
E243.11 Hashish dependence 
1V0E.00 Health prob sec to drug misuse 
E243.12 Hemp dependence 
E240.11 Heroin dependence 
Z1Q6214 Heroin maintenance 
1V65.00 Heroin misuse 
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SL50100 Heroin poisoning 
1V64.00 Illicit drug use 
13c0.00 Injecting drug user 
1V31.00 Injects drugs intramuscularly 
1V30.00 Injects drugs subcutaneously 
13c3.00 Intramuscular drug user 
13c4.00 Intranasal drug user 
13c1.00 Intravenous drug user 
1P64.00 Irresistible craving for drugs 
SL83000 Ketamine poisoning 
E241.15 Librium dependence 
67H3.00 Lifestyle advice regarding drug misuse 
1V01.00 Long-term drug misuser 
Z1Q6211 Low threshold methadone prescribing 
E245.12 Lysergic acid diethylamide dependence 
63C6.00 Maternal drug abuse 
63C6.11 Maternal drug misuse 
E245.13 Mescaline dependence 
E240.12 Methadone dependence 
SL50200 Methadone poisoning 
Z1Q6212 Methadone therapy 
E25z.00 Misuse of drugs NOS 
E259400 Misuse of prescription only drugs 
1V26.00 Misused drugs in past 
1V0..00 Misuses drugs 
13cB.00 Misuses drugs orally 
1V04.00 Misuses drugs rectally 
1V03.00 Misuses drugs sublingually 
1V05.00 Misuses drugs vaginally 
SL76.00 Mixed sedative poisoning NEC 
Q485000 Neonat withdrawal symptom from mat use of drug of addiction 
Q484.00 Newborn drug reaction and intoxication 
Q484z00 Newborn drug reaction or intoxication NOS 
Q485.00 Newborn drug withdrawal syndrome 
1P61.00 No craving for drugs 
46Q1.00 No drug found in urine 
1V40.00 No priority to drug activities 
1V50.00 No routine of drug activities 
9OhB.00 Non-steroidal anti-inflammatory drug risk assessmnt completd 
E25..00 Nondependent abuse of drugs 
E257.00 Nondependent amphetamine or other psychostimulant abuse 
E257z00 Nondependent amphetamine or psychostimulant abuse NOS 
E257200 Nondependent amphetamine or psychostimulant abuse, episodic 
E257300 Nondependent amphetamine/psychostimulant abuse in remission 
E257100 Nondependent amphetamine/psychostimulant abuse, continuous 
E257000 Nondependent amphetamine/psychostimulant abuse, unspecified 
E258.00 Nondependent antidepressant type drug abuse 
E258z00 Nondependent antidepressant type drug abuse NOS 
E258300 Nondependent antidepressant type drug abuse in remission 
E258100 Nondependent antidepressant type drug abuse, continuous 
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E258200 Nondependent antidepressant type drug abuse, episodic 
E258000 Nondependent antidepressant type drug abuse, unspecified 
E252.00 Nondependent cannabis abuse 
E252z00 Nondependent cannabis abuse NOS 
E252300 Nondependent cannabis abuse in remission 
E252100 Nondependent cannabis abuse, continuous 
E252200 Nondependent cannabis abuse, episodic 
E252000 Nondependent cannabis abuse, unspecified 
E256.00 Nondependent cocaine abuse 
E256z00 Nondependent cocaine abuse NOS 
E256300 Nondependent cocaine abuse in remission 
E256100 Nondependent cocaine abuse, continuous 
E256200 Nondependent cocaine abuse, episodic 
E256000 Nondependent cocaine abuse, unspecified 
E259.00 Nondependent mixed drug abuse 
E259z00 Nondependent mixed drug abuse NOS 
E259300 Nondependent mixed drug abuse in remission 
E259100 Nondependent mixed drug abuse, continuous 
E259200 Nondependent mixed drug abuse, episodic 
E259000 Nondependent mixed drug abuse, unspecified 
E25y.00 Nondependent other drug abuse 
E25yz00 Nondependent other drug abuse NOS 
E25y300 Nondependent other drug abuse in remission 
E25y100 Nondependent other drug abuse, continuous 
E25y200 Nondependent other drug abuse, episodic 
E25y000 Nondependent other drug abuse, unspecified 
1V55.00 Not follow drug-relate rituals 
1V3A.00 Not share drug inject equipmen 
1V07.00 Notified addict 
222P.00 O/E - evidence of cessation of drugs 
222N.00 O/E - signs of drug withdrawal 
1V00.00 Occasional drug user 
E240z00 Opioid drug dependence NOS 
E240.00 Opioid type drug dependence 
4I74.00 Oral fluid cocaine level 
4I7..00 Oral fluid drug of abuse level 
4I75.00 Oral fluid methadone level 
SM23.00 Other chlorinated hydrocarbon solvent causing toxic effect 
E02y.00 Other drug psychoses 
E02yz00 Other drug psychoses NOS 
SM2y.00 Other solvents causing toxic effect 
SM2yz00 Other solvents causing toxic effect NOS 
E247.00 Other specified drug dependence 
E247z00 Other specified drug dependence NOS 
E247300 Other specified drug dependence in remission 
E247100 Other specified drug dependence, continuous 
E247200 Other specified drug dependence, episodic 
E247000 Other specified drug dependence, unspecified 
E022.00 Pathological drug intoxication 
Q431100 Perinatal jaundice from maternal transmission drug or toxin 
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13cH.00 Persistent substance misuse 
9k53.11 Pharmacy attended for drug misuse 
9k53.00 Pharmacy attended for drug misuse - enhanced services admin 
1V02.00 Poly-drug misuser 
1V63.00 Possession of drugs 
L183.11 Pregnancy and drug dependence 
13cF.00 Preoccupied with substance misuse 
1T43.00 Previous history of amphetamine misuse 
1T83.00 Previous history of cannabis misuse 
1T53.00 Previous history of cocaine misuse 
1T63.00 Previous history of crack cocaine misuse 
1T73.00 Previous history of hallucinogen misuse 
1T02.00 Previous history of heroin misuse 
1T13.00 Previous history of methadone misuse 
1T93.00 Previous history of solvent misuse 
13cJ.00 Previously injecting drug user 
1V4..00 Priority of drug activity 
1V41.00 Priority to drug activities 
13cE.00 Prolonged high dose use of cannabis 
13c8.00 Reduced drugs misuse 
8HHe.00 Referral to community drug and alcohol team 
8HHL.00 Referral to community drug dependency team 
8H7x.00 Referral to drug abuse counsellor 
8HHd.00 Referral to drug treatment centre 
8Hl5.00 Referral to drugs therapist 
8Hl6.00 Referral to drugs worker 
9N6b.00 Referred by drug non-statutory service 
9N6a.00 Referred by drug statutory service 
1V5..00 Routine drug-related activity 
9K4..00 SMR25a drug misuse initial assessment form 
9K5..00 SMR25b drug misuse follow up assessment form 
1V52.00 Same drug routine every day 
E254.13 Sedative abuse 
E241.16 Sedative dependence 
9N0Z.00 Seen in drug rehabilitation centre 
1V61.00 Selling drugs 
44vB.00 Serum dexamphetamine level 
9k51.11 Shared care drug misuse treatment 
9k51.00 Shared care drug misuse treatment - enhanced services admin 
1V35.00 Shares drug equipment 
1V38.00 Sharing drug inject equipment 
13c9.11 Skin pops drugs 
SL7z.11 Sleeping drug poisoning 
13cA.00 Smokes drugs 
1V08.00 Smokes drugs in cigarette form 
1V09.00 Smokes drugs through a pipe 
1V0B.00 Sniffs drugs 
SM2z.00 Solvents causing toxic effect NOS 
13c9.00 Subcutaneous drug user 
13cM.00 Substance misuse 
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13c6.00 Substance misuse decreased 
13c5.00 Substance misuse increased 
9HC6.00 Substance misuse treatment declined 
9BZ..00 Supply of drugs payment NOS 
9B...00 Supply of drugs payment admin 
1J11.00 Suspected abuse hard drugs 
1J10.00 Suspected abuse soft drugs 
1J1..00 Suspected drug abuse 
1JP..00 Suspected drug overdose 
1V1..00 Time devotd drug rel activties 
1V23.00 Time since stopped drug misuse 
1V10.00 Time spent obtaining drugs 
1V12.00 Time spent recover from drugs 
1V11.00 Time spent taking drugs 
1V24.00 Total time drugs misused 
9NN1.00 Under care of community drug team 
46QO.00 Urine 3,4-methylenedioxyethamphetamine level 
46QA.00 Urine cocaine 
46QH.00 Urine cocaine metabolite screen 
44qP.00 Urine drug metabolite screening test 
46Qu.00 Urine ketamine level 
46Qa.00 Urine methylamphetamine level 
46Qx.00 Urine norbuprenorphine level 
1V06.00 Uses drug paraphernalia 
1TE..00 Uses heroin on top of substitution therapy 
E241.17 Valium dependence 
Q485100 Withdrawal symptoms from therapeutic use of drugs in newborn 
R10B000 [D]Finding of cocaine in blood 
R10B400 [D]Finding of opiate drug in blood 
R10B.00 [D]Findings of drugs & oth subs not norm found in blood 
ZV6D700 [V]Drug abuse counselling and surveillance 
ZV57B00 [V]Drug rehabilitation 
ZV11500 [V]Personal history of drug abuse by injection 
U608312 [X] Adverse reaction to cocaine 
U606312 [X] Adverse reaction to cocaine 
U608212 [X] Adverse reaction to ketamine 
U609612 [X] Adverse reaction to marijuana 
U1A5600 [X]Acc pois/expos narcotic drug indust/construct area 
U1AA600 [X]Acc pois/expos org solvent,halogen hydrocarb,indust area 
U1ADz00 [X]Acc poison by and exposure to amphetamine - unspec places 
U1AD400 [X]Acc poison exposure to amphetamine - street/highway 
U1A5200 [X]Acc poison/expos narcotic drug school/pub admin area 
U1AA200 [X]Acc poison/expos org solvent,halogen hydrocarb, school 
U1AA400 [X]Acc poison/expos org solvent,halogen hydrocarb,in highway 
U1AA700 [X]Acc poison/expos org solvent,halogen hydrocarb,on farm 
U1AA100 [X]Acc poison/expos org solvent,halogen hydrocarb,res instit 
U1AA300 [X]Acc poison/expos org solvent,halogen hydrocarb,sport area 
U1AA500 [X]Acc poison/expos org solvent,halogen hydrocarb,trade area 
U1AD300 [X]Acc poison/expos to amphetamine - sport/athletic area 
U1AD600 [X]Acc poison/exposure to amphetamine - indus/construct area 
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U1AD100 [X]Acc poison/exposure to amphetamine - resident institut 
U1AD500 [X]Acc poison/exposure to amphetamine - trade/service area 
U1AD700 [X]Acc poisoning by and exposure to amphetamine - farm 
U1A5300 [X]Accid pois/expos narcotic drug in sport/athletic area 
U1A5y00 [X]Accid pois/expos to narcotic drug other spec place 
U1A5400 [X]Accid poison/expos narcotic drug in street/highway 
U1A5500 [X]Accid poison/expos narcotic drug trade/service area 
U1AA000 [X]Accid poison/expos organ solvent,halogen hydrocarb, home 
U1A5100 [X]Accid poison/expos to narcotic drug at res institut 
U1A5z00 [X]Accid poison/expos to narcotic drug unspecif place 
U1AA.00 [X]Accid poison/exposure to organ solvent,halogen hydrocarb 
U1A5000 [X]Accident poison/exposure to narcotic drug at home 
U1A5700 [X]Accident poison/exposure to narcotic drug on farm 
U1AD000 [X]Accident poisoning by and exposure to amphetamine - home 
U1A5.00 [X]Accident poisoning/exposure to narcotic drug 
U1AA.11 [X]Accidental poisoning from glue solvent 
Eu12211 [X]Drug addiction - cannabis 
Eu14211 [X]Drug addiction - cocaine 
Eu16211 [X]Drug addiction - hallucinogen 
Eu11211 [X]Drug addiction - opioids 
Eu18211 [X]Drug addiction - solvent 
Eu19211 [X]Drug addiction NOS 
Eu15211 [X]Drug addiction-other stimul 
Ryu8600 [X]Finding of other drugs of addictive potential in blood 
Eu11212 [X]Heroin addiction 
U205600 [X]Int self pois narcotic drug indust/construct area 
U20A600 [X]Int self pois org solvent,halogen hydrocarb,indust area 
U205300 [X]Int self poison narcotic drug in sport/athletic area 
U205y00 [X]Int self poison narcotic drug other spec place 
U205200 [X]Int self poison narcotic drug school/pub admin area 
U20A200 [X]Int self poison org solvent,halogen hydrocarb, school 
U20A400 [X]Int self poison org solvent,halogen hydrocarb,in highway 
U20A700 [X]Int self poison org solvent,halogen hydrocarb,on farm 
U20A100 [X]Int self poison org solvent,halogen hydrocarb,res instit 
U20A300 [X]Int self poison org solvent,halogen hydrocarb,sport area 
U20A500 [X]Int self poison org solvent,halogen hydrocarb,trade area 
U205000 [X]Int self poison/exposure to narcotic drug at home 
U205700 [X]Int self poison/exposure to narcotic drug on farm 
U205400 [X]Intent self pois narcotic drug in street/highway 
U205500 [X]Intent self pois narcotic drug trade/service area 
U20A000 [X]Intent self pois organ solvent,halogen hydrocarb, home 
U205100 [X]Intent self poison narcotic drug at res institut 
U205z00 [X]Intent self poison narcotic drug unspecif place 
U205.00 [X]Intent self poison/exposure to narcotic drug 
U20A.00 [X]Intentional self poison organ solvent,halogen hydrocarb 
Eu12400 [X]Men & beh dis due cannabinds: withdrwl state wth delirium 
Eu14700 [X]Men & beh dis due cocaine: resid & late-onset psychot dis 
Eu16400 [X]Men & beh dis due hallucngns: withdrwl state wth delirium 
Eu18400 [X]Men & beh dis vol solvents: withdrawal state wth delirium 
Eu14400 [X]Men & behav dis due cocaine: withdrawl state wth delirium 
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Eu14y00 [X]Men & behav dis due to use cocaine: oth men & behav dis 
Eu19.00 [X]Men & behav disorder multiple drug use/psychoactive subst 
Eu1A700 [X]Men beh dis due crack cocaine: resid late-onset psych dis 
Eu1A600 [X]Men behav disorders due crack cocaine: amnesic syndrome 
Eu12y00 [X]Men/behav dis due to use cannabinoids: oth men/behav disd 
Eu16y00 [X]Men/behav dis due to use hallucinogens: oth men/behav dis 
Eu18y00 [X]Men/behav dis due to use vol solvents: oth men/behav disd 
Eu14z00 [X]Ment & behav dis due use cocaine: unsp ment & behav dis 
Eu1Az00 [X]Ment behav dis due crack cocaine: unsp ment and behav dis 
Eu1A400 [X]Ment behav dis due crack cocaine: withdraw state delirium 
Eu1A000 [X]Ment behav dis due use crack cocaine: acute intoxication 
Eu1Ay00 [X]Ment behav disord due crack cocaine: other ment behav dis 
Eu19z00 [X]Ment/beh dis multi drug use/oth psy sbs unsp mnt/beh dis 
Eu12z00 [X]Ment/behav dis due use cannabinoids: unsp ment/behav disd 
Eu16z00 [X]Ment/behav dis due use hallucinogens: unsp ment/behav dis 
Eu18z00 [X]Ment/behav dis due use vol solvents: unsp ment/behav dis 
Eu19500 [X]Ment/behav dis mlti drug use/oth psyc sbs: psychotc dis 
Eu16000 [X]Mental & behav dis due hallucinogens: acute intoxicatn 
Eu12500 [X]Mental & behav dis due to cannabinoids: psychotic disordr 
Eu16500 [X]Mental & behav dis due to hallucinogens: psychotic disord 
Eu14000 [X]Mental & behav dis due to use cocaine: acute intoxication 
Eu14500 [X]Mental & behav dis due to use cocaine: psychotic disorder 
Eu18500 [X]Mental & behav dis due to vol solvents: psychotic disordr 
Eu18000 [X]Mental & behav dis due vol solvents: acute intoxication 
Eu18.00 [X]Mental & behav disorders due to use of volatile solvents 
Eu12300 [X]Mental and behav dis due cannabinoids: withdrawal state 
Eu16300 [X]Mental and behav dis due hallucinogens: withdrawal state 
Eu16200 [X]Mental and behav dis due to hallucinogens: dependence syn 
Eu12600 [X]Mental and behav dis due to use cannabinoids: amnesic syn 
Eu14600 [X]Mental and behav dis due to use cocaine: amnesic syndrome 
Eu14200 [X]Mental and behav dis due to use cocaine: dependence syndr 
Eu14300 [X]Mental and behav dis due to use cocaine: withdrawal state 
Eu16100 [X]Mental and behav dis due to use hallucinogens: harmfl use 
Eu14100 [X]Mental and behav dis due to use of cocaine: harmful use 
Eu18600 [X]Mental and behav dis due to use vol solvents: amnesic syn 
Eu18200 [X]Mental and behav dis due to vol solvents: dependence synd 
Eu16600 [X]Mental and behav dis due use hallucinogens: amnesic syndr 
Eu18300 [X]Mental and behav dis due vol solvents: withdrawal state 
Eu18100 [X]Mental and behav dis due volatile solvents: harmful use 
Eu16.00 [X]Mental and behavioural disorders due to use hallucinogens 
Eu14.00 [X]Mental and behavioural disorders due to use of cocaine 
Eu1A.00 [X]Mental and behavioural disorders due use of crack cocaine 
Eu1A500 [X]Mental behav disord due crack cocaine: psychotic disorder 
Eu1A300 [X]Mental behav disord due crack cocaine: withdrawal state 
Eu1A200 [X]Mental behav disorders due use crack cocaine: depend synd 
Eu1A100 [X]Mental behav disorders due use crack cocaine: harmful use 
Eu12700 [X]Mnt/bh dis due cannabinds: resid & late-onset psychot dis 
Eu16700 [X]Mnt/bh dis due hallucngns: resid & late-onset psychot dis 
U205.11 [X]Overdose - heroin 
U405300 [X]Pois/exp ?intent narcotic drug in sport/athletic area 
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U405200 [X]Pois/exp ?intent narcotic drug school/pub admin area 
U40A200 [X]Pois/exp ?intent org solvent,halogen hydrocarb, school 
U40A400 [X]Pois/exp ?intent org solvent,halogen hydrocarb,in highway 
U40A700 [X]Pois/exp ?intent org solvent,halogen hydrocarb,on farm 
U40A100 [X]Pois/exp ?intent org solvent,halogen hydrocarb,res instit 
U40A300 [X]Pois/exp ?intent org solvent,halogen hydrocarb,sport area 
U40A500 [X]Pois/exp ?intent org solvent,halogen hydrocarb,trade area 
U405y00 [X]Pois/exp ?intent to narcotic drug other spec place 
U405400 [X]Pois/expos ?intent narcotic drug in street/highway 
U405600 [X]Pois/expos ?intent narcotic drug indust/construct area 
U405500 [X]Pois/expos ?intent narcotic drug trade/service area 
U40A000 [X]Pois/expos ?intent organ solvent,halogen hydrocarb, home 
U405100 [X]Pois/expos ?intent to narcotic drug at res institut 
U405z00 [X]Pois/expos ?intent to narcotic drug unspecif place 
U40A.00 [X]Pois/exposure,?intent,to organ solvent,halogen hydrocarb 
U405000 [X]Poison/exposure ?intent, to narcotic drug at home 
U405700 [X]Poison/exposure ?intent, to narcotic drug on farm 
U405.00 [X]Poisoning/exposure, ? intent, to narcotic drug 
Eu16711 [X]Post hallucinogen perception disorder 
U20A.11 [X]Self poisoning from glue solvent 
SyuG100 [X]Toxic effect of other organic solvents 
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Appendix 6 
Prescriptions for Opioid Substitution treatment 
Drug code Name of drug 
85255998 BUPRENORPHINE HCl + NALOXONE HCl sublingual tab 2mg + 500micrograms 
85261998 BUPRENORPHINE HCl + NALOXONE HCl sublingual tab 2mg + 500micrograms 
85254998 BUPRENORPHINE HCl + NALOXONE HCl sublingual tab 8mg + 2mg 
85257998 BUPRENORPHINE HCl + NALOXONE HCl sublingual tab 8mg + 2mg 
99070997 BUPRENORPHINE HCl sublingual tab 200micrograms 
95933998 BUPRENORPHINE HCl sublingual tab 200micrograms 
98782998 BUPRENORPHINE HCl sublingual tab 2mg 
92359990 BUPRENORPHINE HCl sublingual tab 2mg 
92593990 BUPRENORPHINE HCl sublingual tab 2mg 
92616990 BUPRENORPHINE HCl sublingual tab 2mg 
88476997 BUPRENORPHINE HCl sublingual tab 2mg 
99070996 BUPRENORPHINE HCl sublingual tab 400micrograms 
92617990 BUPRENORPHINE HCl sublingual tab 400micrograms 
92594990 BUPRENORPHINE HCl sublingual tab 400micrograms 
88476998 BUPRENORPHINE HCl sublingual tab 400micrograms 
92360990 BUPRENORPHINE HCl sublingual tab 400micrograms 
95933996 BUPRENORPHINE HCl sublingual tab 400micrograms 
92615990 BUPRENORPHINE HCl sublingual tab 8mg 
92592990 BUPRENORPHINE HCl sublingual tab 8mg 
98782997 BUPRENORPHINE HCl sublingual tab 8mg 
88476996 BUPRENORPHINE HCl sublingual tab 8mg 
92358990 BUPRENORPHINE HCl sublingual tab 8mg 
96377996 DIHYDROCODEINE mr tab 120mg 
96375996 DIHYDROCODEINE mr tab 120mg 
96377998 DIHYDROCODEINE mr tab 60mg 
96375998 DIHYDROCODEINE mr tab 60mg 
96377997 DIHYDROCODEINE mr tab 90mg 
96375997 DIHYDROCODEINE mr tab 90mg 
97863998 LOFEXIDINE tabs 0.2mg 
97831998 LOFEXIDINE tabs 0.2mg 
97730992 METHADONE 100 MG SUP 
96327992 METHADONE 15 MG SUP 
97733992 METHADONE 20 MG SUP 
97731992 METHADONE 25 MG SUP 
96328992 METHADONE 30 MG SUP 
97732992 METHADONE 40 MG SUP 
97734992 METHADONE 5 MG/ML INJ 
96709992 METHADONE 50 MG SUP 
96497990 METHADONE COLOURANT FOR mix liq 
92008998 METHADONE COLOURANT FOR mix liq 
90004998 METHADONE DILUENT liq 
90005998 METHADONE DILUENT liq 
98733990 METHADONE HCl pwdr 
98321990 METHADONE HCl pwdr 
98303990 METHADONE HCl pwdr 
98714990 METHADONE HCl pwdr 
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98768990 METHADONE HCl pwdr 
84024998 METHADONE caps 
90157998 METHADONE conc oral soln sf 10mg/ml 
90195998 METHADONE conc oral soln sf 10mg/ml 
90157997 METHADONE conc oral soln sf 20mg/ml 
90195997 METHADONE conc oral soln sf 20mg/ml 
84021998 METHADONE impregnatd cigarette 
84022998 METHADONE inj 
93260990 METHADONE inj 10mg/1ml 
85569998 METHADONE inj 10mg/1ml 
85578998 METHADONE inj 10mg/1ml 
93264990 METHADONE inj 10mg/1ml 
93256990 METHADONE inj 10mg/1ml 
93252990 METHADONE inj 10mg/1ml 
85573998 METHADONE inj 10mg/1ml 
99765990 METHADONE inj 10mg/ml 
95878998 METHADONE inj 10mg/ml 
92568998 METHADONE inj 10mg/ml 
97871990 METHADONE inj 10mg/ml 
95879997 METHADONE inj 10mg/ml 
95286990 METHADONE inj 10mg/ml 
96584990 METHADONE inj 10mg/ml 
85572998 METHADONE inj 20mg/2ml 
93259990 METHADONE inj 20mg/2ml 
93251990 METHADONE inj 20mg/2ml 
93263990 METHADONE inj 20mg/2ml 
93255990 METHADONE inj 20mg/2ml 
85568998 METHADONE inj 20mg/2ml 
85577998 METHADONE inj 20mg/2ml 
85571998 METHADONE inj 35mg/3.5ml 
93254990 METHADONE inj 35mg/3.5ml 
93250990 METHADONE inj 35mg/3.5ml 
93258990 METHADONE inj 35mg/3.5ml 
85567998 METHADONE inj 35mg/3.5ml 
85576998 METHADONE inj 35mg/3.5ml 
93262990 METHADONE inj 35mg/3.5ml 
95879996 METHADONE inj 35mg/ml 
87159998 METHADONE inj 50mg/1ml 
91544998 METHADONE inj 50mg/1ml 
93398990 METHADONE inj 50mg/1ml 
87710998 METHADONE inj 50mg/1ml 
87160998 METHADONE inj 50mg/2ml 
87712998 METHADONE inj 50mg/2ml 
87711998 METHADONE inj 50mg/2ml 
93397990 METHADONE inj 50mg/2ml 
93257990 METHADONE inj 50mg/5ml 
93249990 METHADONE inj 50mg/5ml 
93261990 METHADONE inj 50mg/5ml 
85575998 METHADONE inj 50mg/5ml 
85566998 METHADONE inj 50mg/5ml 
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93253990 METHADONE inj 50mg/5ml 
85570998 METHADONE inj 50mg/5ml 
98080998 METHADONE linc 2mg/5ml 
99512989 METHADONE linc 2mg/5ml 
98492990 METHADONE linc 2mg/5ml 
84301998 METHADONE oral liq 
88038997 METHADONE oral soln 1mg/ml 
96882990 METHADONE oral soln 1mg/ml 
97685990 METHADONE oral soln 1mg/ml 
90944998 METHADONE oral soln 1mg/ml 
89287998 METHADONE oral soln 1mg/ml 
98491990 METHADONE oral soln 1mg/ml 
96915990 METHADONE oral soln 1mg/ml 
88045998 METHADONE oral soln 1mg/ml 
84426998 METHADONE oral soln 1mg/ml 
93503998 METHADONE oral soln 1mg/ml 
96635990 METHADONE oral soln 1mg/ml 
99512990 METHADONE oral soln 1mg/ml 
96619990 METHADONE oral soln 1mg/ml 
84424998 METHADONE oral soln 5mg/ml 
84425998 METHADONE oral soln 5mg/ml 
99512988 METHADONE sf oral soln 1mg/ml 
88038998 METHADONE sf oral soln 1mg/ml 
95878996 METHADONE sf oral soln 1mg/ml 
96811990 METHADONE sf oral soln 1mg/ml 
88749998 METHADONE sf oral soln 1mg/ml 
93503997 METHADONE sf oral soln 1mg/ml 
95049990 METHADONE sf oral soln 1mg/ml 
95268990 METHADONE sf oral soln 1mg/ml 
96617990 METHADONE sf oral soln 1mg/ml 
84023998 METHADONE sup 
84025998 METHADONE tabs 
95878997 METHADONE tabs 5mg 
95879998 METHADONE tabs 5mg 
85256998 NALOXONE HCl + BUPRENORPHINE HCl sublingual tab 2mg + 8mg 
85258998 NALOXONE HCl + BUPRENORPHINE HCl sublingual tab 500micrograms + 2mg 
84724998 NALTREXONE HCl tabs 500 micrograms 
94595998 NALTREXONE HCl tabs 50mg 
85122998 NALTREXONE HCl tabs 50mg 
94594998 NALTREXONE HCl tabs 50mg 
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Appendix 7 
Read codes for Opioid substitution treatment 
Read code Description 
13r3.00 Abstinent from drug misuse on maintenance replacement 
13r4.00 Abstinent from drug misuse when receiving blocking therapy 
1T1..00 H/O methadone misuse 
1T10.00 H/O daily methadone misuse 
1T11.00 H/O weekly methadone misuse 
1T12.00 H/O infrequent methadone misuse 
1T13.00 Previous history of methadone misuse 
44u1.00 Serum methadone level 
44uK.00 Plasma methadone level 
44v8.00 Serum buprenorphine level 
44v9.00 Plasma buprenorphine level 
46QB.00 Urine methadone 
46Qf.00 Urine methadone metabolite level 
46Qr.00 Urine buprenorphine level 
46Qx.00 Urine norbuprenorphine level 
4I75.00 Oral fluid methadone level 
8B23.00 Drug addiction therapy 
8B23.11 Drug addictn therap-methadone 
8B23.13 Drug dependence therapy 
8B2M.00 Buprenorphine maintenance therapy 
8B2N.00 Drug addiction detoxification therapy - methadone 
8B2P.00 Drug addiction maintenance therapy - methadone 
8B2Q.00 Drug addiction maintenance therapy - buprenorphine 
8B2R.00 Drug addiction detoxification therapy - buprenorphine 
8BE0.00 Reinduction to methadone maintenance therapy 
8BE1.00 Reinduction to buprenorphine maintenance therapy 
9k51.00 Shared care drug misuse treatment - enhanced services admin 
9k51.11 Shared care drug misuse treatment 
9k52.00 Drug misus trt prim care - ESA 
9k52.11 Drug misuse treatment in primary care 
9k53.00 Pharmacy attended for drug misuse - enhanced services admin 
9k53.11 Pharmacy attended for drug misuse 
E240.12 Methadone dependence 
SL50200 Methadone poisoning 
T801.00 Accidental poisoning by methadone 
Z192.00 Dependent drug detoxification 
Z192100 Drug withdrawal regime 
Z192114 Drug detoxification 
Z1Q6.11 Drug substitution 
Z1Q6100 Dose equivalent drug substitution 
Z1Q6200 Methadone maintenance 
Z1Q6211 Low threshold methadone prescribing 
Z1Q6212 Methadone therapy 
 
  
 370 
 
Appendix 8.1 
Ethics approval from UCL Ethics Committee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 371 
 
UCL RESEARCH ETHICS COMMITTEE   
RADUATE SCHOOL OFFICE  
Dr Fiona Stevenson  
Research Department of Primary Care and Population Health  
UCL    
  
4 June 2014  
  
Dear Dr Stevenson   
  
Notification of Ethical Approval Project ID: 5664/001: What factors determine recording of illicit 
drug use in primary care?  A qualitative study  
  
I am pleased to confirm that in my capacity as Chair of the UCL Research Ethics Committee I have 
approved your project for the duration of the study i.e. until June 2015.  
  
Approval is subject to the following conditions:  
  
1. You must seek Chair’s approval for proposed amendments to the research for which this 
approval has been given. Ethical approval is specific to this project and must not be treated as 
applicable to research of a similar nature.  Each research project is reviewed separately and if 
there are significant changes to the research protocol you should seek confirmation of 
continued ethical approval by completing the ‘Amendment Approval Request Form’.  
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The form identified above can be accessed by logging on to the ethics website homepage: 
http://www.grad.ucl.ac.uk/ethics/ and clicking on the button marked ‘Key Responsibilities of the 
Researcher Following Approval’.  
  
2. It is your responsibility to report to the Committee any unanticipated problems or adverse 
events involving risks to participants or others.  Both non-serious and serious adverse events 
must be reported.    
  
Reporting Non-Serious Adverse Events  
For non-serious adverse events you will need to inform Helen Dougal, Ethics Committee 
Administrator (ethics@ucl.ac.uk), within ten days of an adverse incident occurring and provide a 
full written report that should include any amendments to the participant information sheet 
and study protocol.  The Chair or ViceChair of the Ethics Committee will confirm that the 
incident is non-serious and report to the Committee at the next meeting.  The final view of the 
Committee will be communicated to you.  
  
Reporting Serious Adverse Events  
The Ethics Committee should be notified of all serious adverse events via the Ethics Committee 
Administrator immediately the incident occurs.  Where the adverse incident is unexpected and 
serious, the Chair or ViceChair will decide whether the study should be terminated pending the 
opinion of an independent expert.  The adverse event will be considered at the next Committee 
meeting and a decision will be made on the need to change the information leaflet and/or study 
protocol.    
  
On completion of the research you must submit a brief report (a maximum of two sides of A4) of 
your findings/concluding comments to the Committee, which includes in particular issues relating to 
the ethical implications of the research.   With best wishes for the research.  
  
Yours sincerely   
Professor John Foreman  
Chair of the UCL Research Ethics Committee   
  
Cc:  Hilary Davies, Applicant   
Professor Irwin Nazareth, Head of Department   UCL Research Ethics Committee, c/o The Graduate School, North 
Cloisters, Wilkins Building  University College London Gower Street London WC1E 6BT Tel: +44 (0)20 7679 7844 Fax: +44 (0)20 7679 7043 
ethics@ucl.ac.uk  www.ucl.ac.uk/gradschool  
 373 
 
Appendix 8.2 
Approval of amendment to ethics application 
 374 
 
  
 375 
 
 
 376 
 
Appendix 9 
Information Sheet for participants 
  
 377 
 
  
Information Sheet: 
Title of project: Which factors determine recording of illicit drug use in primary care: A qualitative 
study  
 
You will be given a copy of this information sheet. 
This study has been approved by the UCL Research Ethics Committee (Project ID Number): 5644/100 
Name Hilary Davies 
Work Address Research department of Primary Care and Population Health 
Upper Third Floor 
UCL medical school, Royal Free 
Rowland Hill Street 
NW3 2PF 
Contact Details  02077940500 (extension 31033) 
We would like to invite you to participate in this research project:.             
Details of Study:       
Illicit drug use is a public-health problem with serious health impacts (Madgula et al., 2011a).  In 2009, 
between 149 and 271 million people had used an illicit drug globally (United Nations Office on Drugs and 
Crime, 2014).  The United Kingdom (UK) has one of the highest prevalence of illicit drug use in Europe 
(European Monitoring Centre for Drugs and Drug Addiction, 2013).  According to the Crime survey for 
England and Wales (CSEW), there has been a reduction in reported illicit drug use from 11% in 2001 to 8.2% 
in 2012/13.  Men consistently have higher recording of illicit drug use compared to women, however females 
of childbearing age contribute to the majority of illicit drug use recorded in females (Office for National 
Statistics, 2013b).  Illicit drug use during pregnancy not only impacts the mother, but also the health of the 
foetus and developing child (5).  Accurately estimating the incidence of illicit drug use in pregnancy is difficult: 
international estimates range from 3-5%, but these figures mask the complexity of accessing this patient 
group(Gyarmathy et al., 2009; O’Donnell et al., 2009; van Gelder et al., 2009). 
 
We recently (2013/14) conducted a quantitative study to further investigate recording by GPs of illicit drug use 
LONDON’S GLOBAL UNIVERSITY 
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in primary care in England and Wales.  We used another large primary care database, The Health  
Improvement Network (THIN) (9, 10).  In order to increase our understanding of primary care recording of illicit 
drug use, we first examined the whole population and will subsequently focus on females and pregnant 
women.  To date, we identified 33,508 (22 622 males and 10 886 females) with a first recording of illicit drug 
use and 3412 women who have a recording for one or more pregnancies and at least one recording for illicit 
drug use.  Future work will include examining the timing of the recording in relation to the gestation time of the 
identified women.   
 
It is evident from our quantitative studies that GPs are recording illicit drug use in the total population and 
during pregnancy.  It is however, still unclear as to why and how GPs record illicit drug use and why they may 
use specific methods for different patients.  The main strength of using a large primary care dataset is that it 
provides a large amount of data from real life primary care.  However, meaning and understanding need to be 
incorporated into large datasets (12) .This can be done by using qualitative data to help understand the 
methods, classification and the circumstance for recording (Pope et al., 2014).   
 
This qualitative study therefore aims to complement existing data by exploring the factors which determine 
recording by GPs of illicit drug use in primary care. 
 
We are recruiting GPs from the UK who currently have patients who use illicit drugs (street drugs or any 
opiate based drugs) in their practice.  If you agree to take part in our study, the qualitative interview will take 
approximately 30 minutes.  The interview can take place at your practice and at a time suitable to yourself. 
 
We can send you a final report of the findings after completion of the study.  If it would be beneficial to your 
GP practice, we would be happy to present the findings at a practice meeting. 
 
All data will be collected and stored in accordance with the Data Protection Act 1998.  You will be asked keep 
the identity of the patients that you discuss during the interview anonymous.  Your identity and the identity of 
your practice or health centre will be kept confidential.  A pseudonym will be assigned to you and your 
practice during transcription of the interview.  All recordings will be saved on an encrypted audio file (using 
TrueCrypt software) and subsequently erased from the dictaphone.  Once the interviews have been 
transcribed, they will be saved on an encrypted word file.  After completion of the study, the files will be 
archived and kept on the UCL secure server for 2 years.  After this, the files will be sent and archived to UCL’s 
records office (in accordance with UCL policy).  The research team will need to apply for access to use these 
files.  No one else will have access to these files. 
 
Please discuss the information above with others if you wish or ask us if there is anything that is not clear or if 
you would like more information.  
 
It is up to you to decide whether to take part or not; choosing not to take part will not disadvantage you in any 
way. If you do decide to take part you are still free to withdraw at any time and without giving a reason.   
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If you decide to take part you will be given this information sheet to keep and be asked to sign a consent form. 
You will be given a £30 amazon voucher as a gesture of our appreciation for your valuable time. 
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Appendix 10 
Final topic guide 
Title of project 
What are the factors determining the recording of illicit drug use in primary 
care: A qualitative study. 
 
Fact Sheet 
Name of interviewer: 
 
Name of participant: 
 
Date of interview: 
 
Time of start of interview: 
 
Time of end of interview: 
 
GP Practice or Health Care Centre: 
 
Any other comments: 
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Interview Schedule: 
 
Section 1:  Introduction for participant (5 minutes) 
 Confirm consent 
 Reconfirm permission from the participant that the interview will be audio 
recorded 
 Record name of participant, interviewer, time, date and place verbally (this 
information will also be recorded on the fact sheet) 
 Explain aims of the study 
 Clarify the structure of the interview 
 Clarify the participant of the length of the interview (up to 30 minutes) 
 Advise participant that there will be an opportunity to approve the transcript 
 Confirm that the interview can be stopped at any time and the participant can 
withdraw at any time without reason and without implication. 
 The identity of the participant will be confidential 
 The data will be anonymised 
 Ask the participant if they want any clarifications before stating the interview. 
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Section 2: Semi-structured questions: 
1) I understand that you see patients who use illicit drugs, in the last month can 
you think of an example? 
Prompt: 
Would you enter information about their illicit drug use on the system?   
Prompt: 
If yes, how would you do this, 
If no, what are your reasons for not recording? 
 
2) If you use Read codes, which ones would you use? 
Prompt: does your practice have a template 
 
3) If you use freetext, would you also use Read codes? 
Do you find the software easy to use 
Do you find Read codes easy to use 
4) Can you think of an example of a patient who has asked you not to record 
their illicit drug use? 
Prompt: 
If yes, what did you do in this situation? 
 
5) Can you think of an example of a patient who you suspect is using illicit 
drugs, but does not disclose the information 
Prompt: 
: 
If yes, what did you do in this situation? 
 
 
6) Do you find that you saw more or fewer patients using illicit drugs in the last 
10 years 
Prompt: 
t: treatment more in the community 
7) Do you find that you see more patients who use illicit drugs at certain times of 
the year? 
Prompt: 
:e.g. after big events such as festivals 
8) Can you think of a patient who was pregnant and using illicit drugs during her 
pregnancy? 
Prompt: 
Did you record this patient in the system? 
Prompt: 
If yes, how would you do this? 
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If no, what are your reasons for not recording? 
 
9) Can you think of an example of a patient who is pregnant, using illicit drugs 
during pregnancy and who has asked you not to record? 
Prompt: 
If yes, what did you do in this situation? 
 
10) Can you think of an example of a patient who is pregnant and who you 
suspect is using illicit drugs, but does not disclose the information 
Prompt: 
If yes, what did you do in this situation? 
 
11) If a patient has disclosed that she is using illicit drugs during pregnancy, did 
you refer her to specialized services?   
Prompt: 
If yes, which services? 
If no, what were your reasons? 
If no, what were your reasons for not referring? 
10)  If you know a women has used illicit drugs during pregnancy, do you look 
for neonatal abstinence syndrome in her discharge records? 
Prompt: 
If yes, do you record this? How? 
If yes, do you record this in the mother or the baby’s records? How? 
 
Field notes for interviewer: 
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